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A NOVEL APPROACH TO DEVELOP PREDICTIVE BIOMARKERS 
Prediction of response to anti-EGFR therapy in a large panel of patient-derived colorectal cancer 
xenograft models 
ABSTRACT 
Over the last ten years two major trends have influenced drug development. Instead of cytotoxic, 
non-specific therapies a variety of targeted small molecule agents and monoclonal antibodies 
have been developed. In parallel, higher attention has been paid to the identification and 
validation of predictive markers, which allow the stratification of patients prior to the treatment. 
Hundreds of targeted cancer drugs have been developed, but only a few have been approved. 
Despite these two trends, there is still a high rate of failure in translating promising preclinical 
data obtained with cancer cell lines and xenograft models derived from cancer cell lines into 
positive clinical phase II and phase III data. The goal of the scientific community is to develop 
novel targeted therapies for the majority of solid tumours with unmet clinical need using better 
preclinical tumour models and to link these with the ability to discover effective predictive 
markers that allow efficient stratification of responders from non-responders.  
To bridge the gap between preclinical and clinical development a panel of 133 patients-derived 
CRC xenografts of all four UICC stages was established. As a proof of concept, an efficacy of 
three drugs approved for the treatment of CRC: cetuximab, bevacizumab and oxaliplatin was 
tested in the subset of 67 xenograft models derived of chemonaive CRC patients. In the 
treatment experiment with cetuximab monotherapy an objective response rate of 27% translating 
into 18 responders and 49 non-responders was obtained. This high response rate allowed the use 
the available tumour tissues for evaluating molecular markers for predicting response to the anti-
EGFR antibody in the xenograft models. The accuracy of three mutation markers including 
KRAS, BRAF and PIK3CA was investigated in combination with RNA expression levels of two 
EGFR ligands – amphiregulin and epiregulin. Novel predictive markers panels based on gene 
expression profiling of mRNA and microRNA were also tested and compared with the 
established biomarkers. Successful reconstruction of the clinical situation in the panel of 
xenograft models proves their potential for future use in testing of novel anti-cancer drugs. 
Moreover, their broad molecular characterization allows the simultaneous development of 
predictive biomarkers along with the testing of novel cancer drugs. 
My Ph.D. thesis contributes to the development of novel preclinical tools for cancer drug testing 
and discovery of accompanying predictive markers for patient selection in colorectal cancer.  
EIN NEUARTIGER ANSATZ ZUR ENTWICKLUNG VON PRÄDIKTIVEN 
BIOMARKERN 
Vorhersage der Reaktion auf anti-EGFR-Therapie in einem großen Panel von Patienten- 
stammenden Darmkrebs Xenografts 
ZUSAMMENFASSUNG 
Die Entwicklung von Medikamenten zur Behandlung von Krebserkrankungen wurde in den 
letzten zehn Jahren von zwei großen Trends beeinflusst. Statt zytotoxischer, unspezifischer 
Therapien wie bisher, wurden verschiedene zielgerichtete kleine Moleküle sowie monoklonale 
Antikörper entwickelt. Zudem verstärkten sich die Bemühungen in der Entwicklung und 
Validierung prädiktiver Biomarker (z. B. Marker-Signaturen), die die Stratifizierung von Patienten 
vor der Behandlung ermöglichen. Obwohl hunderte von zielgerichteten Krebsmedikamenten 
entwickelt wurden, erreichten nur wenige davon eine Zulassung. 
Grund hierfür ist die noch hohe Ausfallrate bei der „Übersetzung“ von vielversprechenden 
präklinischen Daten, die mit Krebs-Zelllinien und Xenograft-Modellen von Krebs-Zelllinien 
erlangt wurden, in positive klinische Phase II- und Phase III-Daten. Das Ziel der jüngsten 
Forschung ist es, neue zielgerichtete Therapien mit Hilfe von verbesserten präklinischen 
Tumormodellen für die Mehrzahl der soliden Tumore mit ungedecktem klinischem Bedarf zu 
entwickeln. Mit Hilfe dieser Modelle sollen effektive und prädiktive Marker zur effizienten 
Unterscheidung von Responder und Nicht-Responder entwickelt werden. 
Um die Lücke zwischen präklinischer und klinischer Entwicklung zu überbrücken, wurde unter 
Verwendung von Tumorgewebe von 133 Patienten ein Panel an CRC-Xenograftmodellen aller 
vier UICC-Stadien etabliert. Zur Überprüfung dieses Modells wurde die Wirksamkeit von drei 
Medikamenten getestet, die zur Behandlung von CRC zugelassen sind: Cetuximab, Bevacizumab 
und Oxaliplatin. Für dieses Experiment benutzten wir 67 Xenograft-Modelle, die aus 
chemonaiven CRC-Patienten entwickelt wurden. Die Behandlung mit einer Cetuximab-
Monotherapie ergab eine objektive Ansprechrate von 27% (18 Responder und 49 Non-
Responder). Dank dieser hohen Ansprechrate der Therapie, konnten wir das verfügbare 
Tumorgewebe für die Beurteilung molekularer Marker und zur Vorhersage der Reaktion auf die 
anti EGFR-Antikörper in den Xenograft-Modellen verwenden.  
Wir untersuchten die Genauigkeit von drei Mutations-Markern (KRAS, BRAF und PIK3CA), 
und kombinierten den Mutations-Status dieser drei Gene mit RNA-Expressionsdaten von zwei 
Liganden der epidermalen Wachstumsfaktor-Rezeptor-Familie (Amphiregulin und Epiregulin). 
Weiterhin wurden neue prädiktive Marker-Kombinationen, basierend auf einer mRNA- und 
microRNA- Expressionsanalyse ermittelt.  
Aufgrund der erfolgreichen Nachbildung der klinischen Situation in unserem Panel von 
Xenograft-Modellen, zeigt dieser Modellansatz vielversprechendes Potenzial für eine zukünftige 
Anwendung in der Erprobung neuartiger Krebsmedikamente. Darüber hinaus ermöglicht die 
breite molekulare Charakterisierung der Modelle beides: eine Entwicklung prädiktiver Biomarker 
und eine Erprobung neuartiger Krebsmedikamente. 
Meine Dissertation leistet einen Beitrag zur Entwicklung neuartiger präklinischer Modelle zur 
Testung von Krebsmedikamenten einerseits und zur Entwicklung von prädiktiven Markern zur 
Optimierung der Behandlungsstrategie von Darmkrebspatienten andererseits. 
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Chapter 1 
Introduction 
1.1. BASIC FACTS ABOUT COLORECTAL CANCER 
Colorectal cancer (CRC) forms in the epithelial tissue of the large intestine, which 
includes the caecum, colon, rectum, and anal canal (Fig.1.1; Tab.S1). It is the third most 
common cancer in man and the second most common cancer in women with an 
estimated 1.2 million new cases diagnosed each year worldwide. In fact 10% of all 
cancer patients suffer from colorectal cancer. CRC is the fourth leading cause of cancer-
related deaths. Approximately 600.000 incidents every year account for 8% of all cancer 
deaths (Jemal et al., 2011). 
Germany is among the countries with the highest incidence rate of colorectal cancer with 
more than 71.000 new occurrences annually (71/100.000 in males; 50/100.000 in 
females), and the highest mortality rates with app. 30.000 death cases among CRC 
patients each year (Sieg and Friedrich, 2009).
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Fig.1.1. Anatomy and histology of the large intestine: ascending, transverse, descending, 
sigmoid colon, and rectum (Encyclopedia Britannica, 2003) 
Colorectal cancer is traditionally divided into two categories: sporadic and familial CRC. 
Sporadic colorectal cancer occurs in people who have no family history of the disease and 
familial colorectal cancer is a hereditary syndrome. These are separate diseases both on 
phenotypic and molecular levels. The majority of the CRC patients (app. 75%) suffer 
from sporadic colorectal cancer and all the samples used in this study origin from the 
patients with non-hereditary CRC. The sporadic type of this disease is therefore a focus 
of this work. A number of patients, however, develop CRC as a result of an inherited 
genetic condition. The most common hereditary CRC predisposing syndrome is hereditary 
non-polyposis colorectal cancer (HNPCC/Lynch syndrome) that accounts for app. 3 % of 
all CRC cases. The familial adenomatous polyposis (FAP) syndrome accounts for 
additional 1%. Other, less frequent colon cancer syndromes include Peutz-Jeghers 
syndrome (PJS), Juvenile polyposis syndrome (JPS), hereditary mixed polyposis 
syndrome (MHAP) and Cowden's syndrome. The causes underlying the majority of 
remaining familial CRCs cases are not yet understood (Migliore et al., 2011). 
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1.2. CLINICAL BASIS OF COLORECTAL CANCER 
1.2.1. Clinical Staging 
 At the moment of diagnosis colorectal cancer patients are classified in one out of five 
clinical stages (0-IV) according to the guidelines of the American Joint Committee on 
Cancer (AJCC) and the Union for International Cancer Control (UICC). Clinical stages 
describe the extent of the cancer‟s spread in the body (Fig.1.2) and are based on the 
results of the physical exam, biopsies, imaging tests (computed tomography, magnetic 
resonance imaging scan, x-rays, positron emission tomography, endoscopic or abdominal 
ultrasound) and results of the surgery followed by histopathological diagnosis. In the 
earliest stage 0 the tumour is small in size and limited to the inner layer (mucosa) of the 
colon or rectum (carcinoma in situ). In stage I the cancer has grown through the 
muscularis mucosa into the submucosa or muscularis propria. Stage II colorectal cancers 
are larger and extend through the muscular wall of the colon or rectum. In stage III the 
tumour has spread to one or more nearby lymph nodes. Finally, in the most advance 
stage IV, the tumour metastasized to distant organs, such as liver or lungs (for details, 
see Tab.S2). 
 
 
 
 
 
 
 
 
Fig.1.2. Spread of the tumour through and outside the layers of intestinal wall in CRC stages 
0-IV (image from the National Cancer Institute www.cancer.gov) 
1.2.2. Treatment of CRC Patients 
Clinical stage of colorectal cancer is the foundation on which the treatment 
recommendations are based. For colorectal cancers that have not spread to distant sites 
(stages 0-III), surgery is usually the initial treatment to remove the tumour mass. 
In stage III CRC adjuvant (additional) chemotherapy is generally recommended. The 
FOLFOX (folinic acid, 5-fluorouracil, and oxaliplatin) regimen is still the most common 
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chemotherapy combination. Orally available 5-fluorouracil (5-FU), capecitabine, alone or 
in combination with oxaliplatin (CAPOX) has lately been shown to be equivalent to the 
FOLFOX regimen and is more convenient. Further chemotherapy regimens relevant to 
current clinical practice are based on irinotecan. This topoisomerase inhibitor is used 
typically in combination with other chemotherapeutic drugs: folinic acid and 5-FU 
(FOLFIRI) or with capecitabine (XELIRI). There are no clear recommendations concerning 
adjuvant treatment in stage II CRC. Only stage II patients of high-risk group are, 
therefore, selected for the postoperative adjuvant therapy. 
Although colon and rectal cancer occur anatomically in continuity and have similar 
histopathological features, there is uncertainty regarding the benefits from the adjuvant 
chemotherapy regimens established for colon cancer patients in the group of the patients 
with rectal cancer. For patients with rectum carcinoma of stage II and III adjuvant 
treatment with 5-FU and radiation, followed by resection of the reduced tumour mass, 
represents a valuable alternative to the traditional resection of the primary tumour 
followed by adjuvant chemotherapy. However, recent data demonstrate high long term 
toxicity due to the radiation therapy which needs to be addressed in the future. 
The situation for patients with metastatic stage IV (mCRC) is much more complex and 
cannot be described in detail in this chapter. For short, in the majority of cases there is 
no cure for these patients despite many different treatment options (Van Cutsem et al., 
2010). The clinical cases, in which it is possible to completely remove the primary tumour 
in the colon or rectum and the metastases, are very rare. The majority of patients have a 
metastatic disease that initially is not suitable for surgery. In such cases neoadjuvant 
therapy would be applied to reduce the size of metastases and allow the surgery. 
Treatment of the metastatic disease in CRC patients is extremely challenging as the 
disease in its most advanced stadium often progresses very quickly. Furthermore it is 
often not known which patient will benefit from the treatment. Different therapy options 
are available and can be grouped into first-, second and third-line therapy. In case of a 
patient who does not respond to the standard therapy, another treatment strategy is 
applied (Edwards et al. 2012) (Tab.1.1.). Treatment regimens for mCRC include not only 
cytotoxic chemotherapy but also targeted monoclonal antibodies (mAb): bevacizumab, 
cetuximab and panitumumab. 
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Tab.1.1. A simplified model of the treatment options for the patients with stage IV colorectal 
patients according to the previously administered therapy; KRAS mutation status not 
considered; mAb - monoclonal antibody; 5-FU - 5 fluorouaracil; IRI - irinotecan 
Patients 
 
Therapy 
Chemonaive Pre-treated 
1st line 5-FU + leucovorin 
/FOLFOX/FOLFIRI 
/FOLFOXIRI 
/capecitabine 
/CAPOX 
cetuximab/ 
panitumumab + 
FOLFOX/ 
FOLFIRI  
bevacizumab + 
FOLFOX/ FOLFIRI/ 
CAPOX,  
5-FU/leucovorin 
or capecitabine 
cetuximab/ 
panitumumab 
cetuximab + 
IRI 
2nd line cetuximab/ 
panitumumab +/- 
FOLFIRI 
cetuximab + IRI bevacizumab + 
FOLFOX 
alternative mAb 
3rd line alternative mAb  
+/- FOLFOX/FOLFIRI 
alternative mAb 
1.2.2.1 Monoclonal antibodies in the treatment of metastatic CRC 
Both, cetuximab - a mouse-human chimeric monoclonal antibody and panitumumab - a 
fully human monoclonal antibody bind to the epidermal growth factor receptor (EGFR) 
which is one of the major growth factors in tumourigenesis and disease progression. 
These antibodies are used in first-, second-, and third-line treatment of mCRC (Fig.1.3B). 
Cetuximab and panitumumab bind to the extracellular domain of the EGFR and through 
tertiary structure change of the EGF receptor prevent the binding of the natural ligands: 
EGF, TGF- α, amphiregulin (AREG), epiregulin (EREG), heparin-binding EGF-like growth 
factor (HB-EGF), and β-cellulin to the receptor. Thus, the binding of cetuximab and 
panitumumab prevent ligand-induced activation. By blocking signal transduction 
downstream of EGFR, cetuximab and panitumumab inhibit cell growth, proliferation, 
survival as well as angiogenesis, cell migration and adhesion (van Krieken et al., 2008). 
Mechanism of action of bevacizumab, a mAb which is also approved in first line, second 
line and third line therapy, is completely different. Bevacizumab targets the most potent 
proangiogenic factor identified to date – the vascular endothelial growth factor (VEGF). 
During angiogenesis new tumour vessels are formed. They are necessary to supply the 
tumour with nutrients and oxygen but also allow tumour cells to enter the circulation, 
infiltrate distant organs and establish metastases. By binding to VEGF, bevacizumab 
prevents VEGF from binding to its natural receptor and thus inhibits stimulation of the 
intracellular transduction of proangiogenic signals (Tol and Punt, 2010; Venook, 2005). 
1.2.3. Survival rates in colorectal cancer patients 
In the past 15 years new treatment options for patients with colorectal cancer evolved. 
In 1995 5-fluorouracil used to be the sole treatment option for local defined CRC and for 
advanced disease. Significant advances have been made owing primarily to the 
improvement of surgical methods and pharmaceutical interventions. For example, 
resection of single liver metastases and lung metastases has improved dramatically 
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leading to prolonged survival rates for these patients. However, only a small subgroup 
benefits from the operations (Segal and Saltz, 2009). As described in the previous 
chapter, new antibody-based treatment options and chemotherapeutic agents have been 
introduced. Beside improvements in the progression-free survival (PFS) of patients, one 
of the two common end-points of clinical trials, the long-term overall survival (OS) rates 
remain unsatisfactory, particularly in patients with locally advanced (stage III), or 
metastatic (stage IV) CRC, who represent about 30% and 15% of all CRC patients, 
respectively. 
The 5-year survival rate for CRC patients is greater than 90% when tumours are 
detected at a localized early stage I. The 5-year survival rate refers to the percentage of 
patients who survive at least 5 years after cancer diagnosis. It decreases to app. 80% in 
patients diagnosed with stage II CRC. If the tumour affects local lymph node (stage III 
patients) the 5-year survival rate is only 50-69% despite today‟s standard of care which 
is surgical removal of the tumour followed by adjuvant therapy. Once the tumour has 
spread to distant organs (stage IV patients), a chance to survive the next five years 
drops to 4-12% despite the various new treatment options (O'Connell et al., 2004; Oh et 
al., 2007). This indicates that the approval of targeted antibodies has not led to an 
increase in overall survival, but rather only to a benefit in terms of progression-free 
survival. Although up-to-date long-term survival trends show significant increases, there 
is a large unmet clinical need in advanced, metastatic CRC and for the 20% of patients in 
stage II and 40% of patients in stage III, who will progress despite the standard of care 
(SOC). 
There are several reasons for a poor outcome in a significant number of patients. Lack of 
effective early detection programs in many countries hinders early diagnosis of CRC. 
Because of complexity and heterogeneity of individual tumours, there are also no 
accurate molecular markers that can be applied for prognostic purposes. Moreover, 
despite the variety of treatment options, the response rates remain poor and there are 
no clear guidelines to select patients who may benefit from the therapy. These aspects 
strongly support, but not facilitate, the discovery of cancer biomarkers. 
1.3. BIOMARKERS OF COLORECTAL CANCER 
According to the US National Institutes of Health‟s (NIH) a biomarker is a characteristic 
that is objectively measured and evaluated as an indicator of normal biologic processes, 
pathogenic processes, or pharmacologic responses to a therapeutic intervention (Naylor, 
2003). Statistical measures used to evaluate the accuracy of the biomarker are 
sensitivity (S+) and specificity (S-). Sensitivity relates to the ability of the test to detect 
positive results. It is the proportion of true positives (TP), which are correctly identified 
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as such, among true positives and false negatives (FP) (S+= TP/(TP+FN)). Specificity 
evaluates a test's ability to identify negative results. Specificity measures the ratio of 
true negatives (TN), which are correctly identified among true negatives and false 
positives (FP) (S-=TN/(TN+FP)). 
There are diagnostic, prognostic and predictive biomarkers, grouped with respect to their 
clinical applications. Diagnostic, or early-detection biomarkers, are measurable 
parameters that indicate the presence of cancer in the body of a patient. Diagnostic 
biomarkers can be used for early detection or screening of cancer in a population. 
Another group - prognostic biomarkers, is applied to indicate how the disease will 
develop in an individual case. Standard clinicopathological risk assessment is based on 
the staging system. Stage describes the severity of the cancer and indicates distinct 
treatment recommendations, but even extensive analysis of clinicopathological 
determinants is not always sufficient to predict a patients‟ outcome. Altogether a 
recurrence rate of app. 40-50% is observed in CRC indicating the lack of accurate 
determinants whether to recommend additional treatment. 
1.3.1 Predictive Biomarkers 
While diagnostic and prognostic biomarkers are not yet ready for routine use due to 
challenges in their clinical validation for early disease detection and long-term survival 
improvement, a third group of predictive biomarkers has established position in the 
clinical routine of colorectal cancer. Predictive biomarkers are used to assess, prior to the 
treatment, whether the patient is likely to respond to this particular agent. The purpose 
of a patients‟ stratification is, on the one hand, to increase overall response rate to the 
therapeutic agent and, on the other hand, to decrease unnecessary toxic side effects and 
treatment costs. Predictive biomarkers are particularly important in patients of stage IV 
CRC for whom the consequences of the administration of ineffective treatment are most 
dramatic. A chemotherapy with the most commonly applied regimens of FOLFOX and 
FOLFIRI achieves relatively high response rates in 40% to over 50% (Douillard et al., 
2000; de Gramont et al., 2000) of CRC patients due to their overall non-specific cytotoxic 
effect. In contrary, the molecular mechanism of action of targeted therapies, particularly 
mAb, used in the treatment of advanced colorectal cancer is limited to the selected 
pathway. Any alterations in that pathway may affect efficacy of mAb, therefore 
significantly less patients benefit from the agents directed against a particular target. 
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1.3.2 Biomarkers Discovery and Targeted Therapies 
Such situation is observed in the treatment of mCRC with monoclonal antibodies: 
cetuximab and panitumumab. Cetuximab was the first immunotherapy to treat colorectal 
cancer patients. This mAb was approved in 2004 beside the low overall response rates 
(ORR) observed in 11% of patients treated with single-agent cetuximab and 23% of 
patients treated with cetuximab in combination with irinotecan (Cunningham et al., 
2004). Approval of panitumumab in 2006 was based on even less optimistic efficacy 
data. Only 8% of the patients assigned to panitumumab responded to the treatment. 
Clinical trials that followed the approval of anti-EGFR therapies showed response rates 
between 10% and 20% when single-agents were applied to chemorefractory metastatic 
patients (Amado et al., 2008; Freeman et al., 2008; Karapetis et al., 2008a; Karapetis et 
al., 2008b), while in trials with combination therapy response rates of 20-30% were 
observed (Benvenuti et al., 2007; Di Fiore et al., 2007; De Roock et al., 2008). Anti-
EGFR mAb as first line therapy of metastatic colorectal cancer in chemonaive patients 
showed complete or partial response rate (ORR) of 46-47% when tested in combination 
with FOLFOX and FOLFIRI (Amado et al., 2008; Freeman et al., 2008; Karapetis et al., 
2008a; Van Cutsem et al., 2009). 
Low response rates to anti-EGFR treatment, reported particularly in chemorefractory 
patients, stimulated search for biomarkers that would allow identification of potential 
responders and resistant cases. It took years to learn that neither the mutation status of 
EGFR nor the EGFR expression is an effective biomarker for predicting response. Mutation 
analysis of EGFR in a group of 293 colorectal cancer specimens, revealed that they are 
rare events in colorectal patients and are, therefore, unlikely to be responsible for the 
resistance toward cetuximab as only one mutation was detected in this setting (Barber et 
al., 2004). As well EGFR expression as detected by IHC showed no correlation with 
cetuximab activity (Chung et al., 2005). EGFR – a target for cetuximab and 
panitumumab, failed as predictive biomarker of mAbs effectiveness in colorectal cancer, 
therefore attention was given to the signaling pathways downstream of the EGF receptor. 
1.3.4.1 Mutations in the KRAS gene 
The first one who reported a link between the genetic alterations and the response to the 
targeted treatment was Lievre in 2006. Lievre and colleagues reported that mutations in 
the Kirsten rat sarcoma viral oncogene homolog (KRAS) are responsible for resistance to 
cetuximab (Lievre et al., 2006). Eleven of the 30 patients (37%) enrolled into the study 
responded to cetuximab. Out of seventeen patients with wild-type KRAS status eleven 
(65%) responded to cetuximab, while among the patients who carried mutations in 
Introduction 
9 
 
codon 12 or 13 of the KRAS gene no responders were observed. This association was 
explored by numerous population based studies (Benvenuti et al., 2007; De Roock et al., 
2008; Di Fiore et al., 2007; Lievre and Laurent-Puig, 2009; Maughan et al., 2011) 
confirming that KRAS is a powerful predictive factor in relation to the efficacy of anti-
EGFR treatment. KRAS encodes a 21-kDa signaling G-protein that is a member of the 
small GTPase superfamily and is activated by EGFR. It plays a role in signal transduction 
from the membrane to the cell's nucleus. KRAS is activated as a response to the binding 
of extracellular signals such as growth factors, cytokines, or hormones to the cell surface 
receptors (Fig.1.3A). 
 
Fig.1.3. A) EGFR pathway with its main effectors B) EGFR pathway inhibited by monoclonal 
antibodies that bind the extracellular domain of EGFR C) Mutations in the oncogene KRAS 
cause its permanent activation and stimulate signal transduction downstream of the receptor, 
regardless of a blocking mAb D) BRAF mutations show similar results to those in KRAS 
(image from: Clarient 2011 http://www.clarientinc.com) 
Oncogenic mutations in KRAS impair the hydrolysis of RAS-bound GTP to GDP. KRAS, 
locked in the GTP-bound state, is constitutively activated regardless of EGFR (Fig.1.3C). 
Administration of anti-EGFR agents in patients who harbour KRAS mutations in codon 12 
and 13 is, therefore, of no benefit to the patient. Further studies confirmed the oncogenic 
effect of mutations in codon 61, as well as those in codon 146 (Prenen et al., 2009; 
Loupakis et al., 2009). Nevertheless, resistance to anti-EGFR agents observed in 80-90% 
of treated CRC patients could not be fully explained by mutations in the KRAS gene that 
are found in app. 35-45% of CRC patients (Siena et al., 2009). 
1.3.4.2 Mutations in the BRAF gene 
A direct downstream effector of KRAS in EGFR signaling pathway – the serine/threonine 
kinase V-raf murine sarcoma viral oncogene homolog B1 (BRAF) was therefore 
investigated as a potential biomarker. Mutation analysis conducted in 113 patients 
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treated either with cetuximab or panitumumab revealed that indeed not only KRAS wild-
type status, but as well BRAF wild-type status is required for response to anti-EGFR 
therapy in metastatic colorectal cancer (Di Nicolantonio et al., 2008; Benvenuti et al., 
2007;). The BRAF gene encodes a serine/threonine kinase, which phosphorylates and 
activates the Mitogen-activated protein kinase kinase (MEK). MEK triggers a 
phosphorylation of ERK, which translocates to the nucleus. There it regulates activities of 
several transcription factors, which induce expression of the genes required for survival 
and proliferation (Robinson and Cobb, 1997; Montagut and Settleman, 2009). A 
missense substitution at residue V600E accounts for more than 90% of all mutations in 
the BRAF gene. This alteration mimics phosphorylation by inserting a negatively charged 
residue adjacent to a phosphorylation site. The active conformation of the BRAF protein 
leads to significant elevation of its kinase activity. Mutated BRAF permanently stimulates 
signal transduction in the EGFR pathway, irrespective of the received signal (Fig.1.3D) 
(Davies et al., 2002; Wan et al., 2004; Garnett and Marais, 2004). BRAF mutations as 
mutually exclusive with KRAS mutations, account for additional 10% of resistant cases 
(Tie et al., 2011). 
1.3.4.3 Mutations in the NRAS gene 
The neuroblastoma RAS viral (v-ras) oncogene homolog (NRAS) is closely related to the 
KRAS gene. NRAS encodes a membrane protein that plays role in signal transduction 
between the Golgi apparatus and the plasma membrane. Activating mutations of this 
homologue of KRAS do not occur very frequently and were reported in about 2-4% of 
colorectal cancer patients (Bardelli and Siena, 2010; Maughan et al., 2011). NRAS 
mutations were proven to be associated with lack of response to cetuximab (De Roock et 
al., 2010a) as well as to panitumumab (Peeters M, 2012) in randomized clinical trial 
settings. 
1.3.4.4 Mutations in the PIK3CA gene 
Another gene that drew attention as a potential biomarker is the Phosphoinositide-3-
kinase, catalytic, alpha polypeptide (PIK3CA), but its role in the resistance to anti-EGFR 
agents remains controversial (De Roock et al., 2011; Jhawer et al., 2008; Prenen et al., 
2009; Sartore-Bianchi et al., 2009b). PIK3CA is a critical component of the PI3K/Akt 
signaling pathway downstream of EGFR. It encodes a 110 kDa catalytic subunit of a lipid 
kinase. PIK3CA recruits ATP to phosphorylate 3'OH of the inositol ring of 
phosphoinositides and is involved in a wide variety of cellular processes such as 
proliferation, growth, cell survival, vesicular trafficking or cell migration (Nosho et al., 
2008). Mutations in PIK3CA are found in app. 15 % of colorectal cancer patients and 
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often coexist with KRAS or BRAF mutations (Siena et al., 2009; Pentheroudakis et al., 
2013). The majority of the mutations are reported in two hotspots in exon 9 (E542K; 
E545K) and one hotspot in exon 20 (H1047R). A different biologic effect of mutation in 
codon 9 of PIK3CA, which encodes a helical domain and mutations in exon 20, which 
encodes a kinase domain, has as well been suggested. It was reported that only exon 20 
is a potential biomarker for resistance to anti-EGFR treatment, while mutations in exon 9 
had no significant effect on the response rate (De Roock et al., 2010a). 
Authors of this population-based study suggest the sequential assessment of mutations 
in KRAS, BRAF, NRAS and PIK3CA codon 20 for patients‟ selection prior to EGFR targeted 
therapies. According to their impact on the resistance to anti-EGFR treatment, KRAS 
mutations should be assessed first (36.3% response rate), BRAF second (38.4% 
response rate), NRAS as third (39.9% response rate) and PIK3CA exon 20 as fourth 
(41.2% response rate). Such mutation analysis led to the improvement of response rate 
to cetuximab from 24% in unselected population to 41% in quadruple (KRAS, BRAF, 
NRAS, and PIK3CA exon 20) negative population. App. 60-75% of the resistant cases 
could be recognized by mutation analysis in KRAS, BRAF, PIK3CA exon 20, and NRAS 
genes. 
1.3.4.5 KRAS codon 13 and response to the treatment 
Later on, a meta-analysis of patients enrolled in the CO.17, BOND, MABEL, EMR202600, 
EVEREST, BABEL, and SALVAGE clinical trials raised further doubts regarding the 
patients‟ stratification strategy. It demonstrated that some of the patients who carry 
KRAS mutations in codon 13, which accounts for app. 20% of all KRAS mutations, may 
benefit from treatment with mAb. Results of this meta-analysis suggested that patients 
with mutations in KRAS codon 13, previously considered as linked with resistance to anti-
EGFR, are more likely to benefit from the treatment than those who carry mutations in 
codon 12. These findings were confirmed in vitro by comparing an effect of cetuximab on 
different cell lines. Both, cell line with a wild-type status of KRAS and a cell line, which 
harboured mutation in KRAS codon 13 (G13D) were sensitive to cetuximab, while 
colorectal cells that harboured mutations in KRAS codon 12 (G12V) were insensitive to 
cetuximab (De Roock et al., 2010b). 
Mutation based predictive biomarkers in colorectal cancer turned out to be more complex 
than initially thought. In fact mutation status identifies those patients that are resistant 
to the treatment and does not indicate actual responders. Beside KRAS codon 12 and 
BRAF V600E mutations other hotspots linked with resistance have low frequencies and do 
not improve accuracy of the biomarker substantially. Increasing number of hotspots 
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linked with resistance and heterogeneity of tumour samples lead to technical difficulties. 
Moreover, conflicting data concerning some of the hotspots (e.g. in the PIK3CA exon 9, 
KRAS codon 13) result in challenging interpretation. 
1.3.4.6 Response to anti-EGFR treatment and gene expression signatures 
Another class of biomarkers based on gene expression signatures was, next to the 
mutation markers, under active investigation. An impact of the gene expression pattern 
on the ability to respond to anti-EGFR treatment was first studied on the material from 
metastatic colorectal carcinomas treated with cetuximab monotherapy (Khambata-Ford 
et al., 2007). Gene expression profiling was performed using U133A v2.0 Affymetrix 
GeneChip platform. The analysis revealed that in the group of KRAS wild-type patients, a 
high RNA expression of amphiregulin (AREG) and epiregulin (EREG) was associated with 
disease control under cetuximab. AREG and EREG are members of the epidermal growth 
factor family and ligands of EGF/TGF-alpha receptors. It was speculated that elevated 
gene expression of both ligands may promote tumour growth and survival via an 
autocrine loop. Such a loop may characterize tumours that are EGFR-dependent. That 
would explain particular sensitivity to an anti-EGFR agent that block the ligand-receptor 
interaction. These findings were confirmed by expression analysis of AREG and EREG 
performed by real-time PCR in 220 primary tumours derived from mCRC patients (Jacobs 
et al., 2009). In another real-time PCR - based study the RNA expression of 110 selected 
genes was analyzed in 144 KRAS wild-type primary tumour specimens from mCRC 
patients (Baker et al., 2011). A classifier containing AREG, EREG and two other genes, 
DUSP6 (which encodes dual specificity phosphatase that blocks EGFR pathway by 
dephosphorylation of MAPK) and SLC26A3 (which encodes an intestinal chloride ion 
transporter), was proposed to yield the best predictive scores. 
The attention was drawn as well to the phosphatase and tensin homolog (PTEN), which is 
a downstream regulator of EGFR. This tumour suppressor is a key modulator of the Akt-
mTOR signaling pathway. At first, lack of PTEN expression was associated with resistance 
to cetuximab (Frattini et al., 2007; Sartore-Bianchi et al., 2009). Nevertheless, results of 
the recent CAIRO 2 study denied its predictive value for response to cetuximab, neither 
alone, nor in combination with other markers (Tol et al., 2010). 
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1.4. MOLECULAR BASIS OF COLORECTAL CANCER  
1.4.1 Vogelstein/Fearon Model 
So far only KRAS mutations in codon 12 and 13 are approved as 
a predictive biomarker to select patients eligible for anti-EGFR 
treatment. KRAS mutations are as well one of the first 
alterations associated with development of colorectal cancer 
already included in the Vogelstein/Fearon model for the 
multistep genetic process of colorectal tumourigenesis. In 1990, 
Fearon and Vogelstein presented evidence for the formation of 
colorectal cancer as a process in which a number of distinct 
mutations of the oncogenes and tumour suppressor genes occur 
sequentially over time (Fig.1.4). Their general model describes 
molecular abnormalities that trigger dysplasia or the formation of 
the polyps within the epithelial cells of the mucosa followed by 
one or several malignant transformations and finally metastasis 
of the tumour to distant organs (Fearon and Vogelstein, 1990). 
Fig.1.4. Fearon/Vogelstein genetic model of colorectal cancer tumourigenesis (Strachan and 
Read, 1999; Karp and Morris, 2012) 
Intensive mutational analyses of clinical tumour samples performed by the Cancer 
Genome Atlas Network showed that all three key cancer genes of the model (APC, KRAS 
and TP53), found to be mutated in the same sample, only in app. 20% of all CRCs (The 
Cancer Genome Atlas Network, 2012). An intensive screening for factors involved in 
colorectal tumourigenesis led to identification of additional molecular alterations that are 
accumulated during the neoplastic process. Moreover, it was later shown that a subgroup 
of tumours arising from serrated polyps instead of non-serrated adenomas are mutated 
in the BRAF and not in the KRAS gene and follow an alternative pathway of 
tumourigenesis (Goldstein et al., 2003; Goldstein, 2006). The model proposed by Fearon 
and Vogelstein is, therefore, not representative for the majority of colorectal tumours. 
Over time a more complex model of the genetic events in colorectal cancer along the 
adenoma – carcinoma sequence was proposed (Fig.1.5). It was enriched with a variety of 
factors that were identified to contribute to the CRC carcinogenesis due to intensive 
studies on the molecular basis of colorectal cancer over the past 20 years. Mutations in 
the oncogenes and tumour suppressor genes are still recognized as crucial factor in the 
tumour development. Oncogenes and tumour suppressors most frequently mutated in 
colorectal cancer patients are listed in the Tab.1.2. 
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Fig.1.5. Model of colorectal carcinogenesis by Markowitz and Bertagnolli (2009). The 
question mark indicates that up to date no events were identified to trigger metastasis in the 
progression of CRC 
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Tab.1.2. Oncogenes and tumour suppressor genes altered in colorectal cancer and their potential as biomarkers; frequencies quoted according 
to the Catalogue Of Somatic Mutations In Cancer (COSMIC) database; OS - overall survival, PFS - progression-free survival; resp. - 
responders 
Gene Function Mutations % Potential as a Biomarker 
APC 
Tumour suppressor gene; antagonist of the Wnt pathway 
that plays role in cell migration and adhesion; interacts with 
CTNN ß1 
Wide spectrum of mutations - no hotspots 
of significant frequency; high fraction of 
InDels 
35% - 
BRAF 
Oncogene; serine-threonine kinase that plays role in cell 
growth signal transduction downstream of KRAS 
Activating mutation in V600E accounts for 
90% of all mutations 
11% 
Predictive - anti-EGFR agents; Prognostic - 
associated with lower OS and PFS, older 
age and female gender 
FBXW7 
Tumour suppressor gene; substrate recognition component 
of a SCF E3 ubiquitin-protein ligase complex; mediates the 
ubiquitination and degradation of target proteins 
Hotspots in codons 465 and 479 account 
for app. 37% of reported substitutions 
9% - 
CTNNß1 
Oncogene; transcriptional regulator of genes involved in cell 
proliferation, cell cycle progression, apoptosis and in the 
regulation of cell adhesion 
Hotspots in codons 41 and 45 account for 
~25%, 36% of all mutations resp. 
6% - 
KRAS 
Oncogene; involved in signal transduction downstream of 
EGFR as a response to growth factors, cytokines, hormones 
Hotspots in codon 12, 13, 61, 146 account 
for ~79%, 20%, 1%, 0.4% of all 
mutations resp. 
37% 
Predictive to anti-EGFR agents - approved 
by FDA 
PIK3CA 
Oncogene; lipid kinase that phosphorylates inositols; 
participates in cellular signaling in response to various 
growth factors and plays role in cells proliferation, growth, 
survival and migration 
Hotspots in codon 542, 545, 1047 account 
for 18%, 33%, 26% of all mutations resp. 
13% 
Predictive to anti-EGFR agents - 
contradictory results 
PTEN 
Tumour suppressor gene; dual-specificity protein 
phosphatase and lipid phosphatase; modulator of the 
Akt/mTOR signaling pathway, which plays a role in cell cycle 
progression and cell survival 
No hotspots of significant frequency 7% 
Predictive to anti-EGFR agents - 
contradictory results 
SMAD4 
Tumour suppressor gene; coactivator and mediator of signal 
transduction by TGF-beta, transcriptional regulator 
No hotspots of significant frequency 11% - 
TGFBR 
Tumour suppressor gene; receptor involved in signaling 
pathway mediating cell cycle arrest, cell proliferation and 
differentiation, extracellular matrix production, 
immunosuppression and apoptosis 
No hotspots of significant frequency 3% - 
TP53 
Tumour suppressor gene; transcription factor that induces 
cell cycle arrest, apoptosis and DNA repair 
Wide spectrum of mutations; hotspots in 
codon 175, 248, 273, 282 account for 6%, 
5%, 5% and 4% of all mutations resp. 
44% Predictive - chemotherapy 
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1.4.2. Epigenetic Alterations 
It turned out that cancer is more complex and results not only from the alterations at the 
genetic, but as well at the epigenetic level. One of the epigenetic mechanisms to initiate 
development and growth of colorectal cancer is aberrant methylation in the epithelial 
cells. It is well known that methylation of the CpG islands in the promoter region of the 
gene may lead to epigenetic silencing and inactivating of certain tumour suppressor 
genes (Issa, 2004). Moreover abberant methylation influences gene expression and leads 
to microsatellite instability (MSI) if DNA mismatch repair (MMR) system is affected. 
1.5. INTRATUMOURAL HETEROGENEITY 
A variety of molecular alterations involved in colorectal carcinogenesis was observed 
between individual CRC patients. The difference suggests that there are many alternative 
molecular pathways that lead to colorectal cancer. It has even been suggested that 
colorectal cancer is not a single disease, but a group of diseases with similar symptoms. 
Differences in the molecular structure of the underlying genes are not only observed 
between CRC patients, but as well within different cellular foci of one tumour. KRAS, 
TP53 and chromosomal instability of 5q and 18q were studied in a group of 45 tumour 
specimens in order to analyze the intratumoural heterogeneity of genetic alterations (Losi 
et al., 2005). In each tumour 12-17 areas were distinguished depending on the tumour 
size. Analysis of this four genetic markers revealed that 76% of the primary tumours 
were heterogeneous for at least one of the investigated features. Intratumoural 
heterogeneity was frequent in the early stages of CRC (e.g. for KRAS mutations observed 
in 60% of analyzed cases; for TP53 mutations - in 70% of analyzed cases), reduced in 
advanced stages (KRAS in 20%; TP53 in 20%) and almost absent in colorectal 
metastases (KRAS - 0%; TP53 in 5%). 
1.5.1 Parallel- and Clonal-Evolution Models 
Intratumoural heterogeneity implicates a question of the cancer-evolution model. The 
traditional “clonal-evolution” model postulates that tumour development and progression 
is a result of clonal selection and expansion. Tumour cells that contribute a strong 
selective advantage supplant other tumour cells and give rise to the tumour and 
ultimately to metastasis (Baudot et al., 2009). In an alternative “parallel-evolution” 
model, it was proposed that metastasis occurs early and evolves in parallel to the growth 
of the primary tumour (Gray, 2003). Numerous studies addressed this question and 
analyzed genetic alterations of primary tumours in comparison to matched metastases 
(Artale et al., 2008; Molinari et al., 2009; Baldus et al., 2010). Mutation analysis of key 
genes such as KRAS, BRAF or PIK3CA indicated a concordance of 90-100% between 
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primary tumours and distant metastases. Extensive mutation analysis was conducted in 
10 primary tumours and matched mestases. Out of 233 investigated somatic mutations, 
only seven (3%, CI:0,9=1.5-5,7%) were present in metastasis and could not be found in 
primary tumour from which the metastasis arose (Jones et al., 2008). These findings 
suggest that, in most of the cases, mutations that are necessary to initiate metastasis 
are already present in the primary tumour of which they derive. This is supported by the 
observation that most of the metastases from the same patient have identical molecular 
background. It is possible though, that a small population of cells within the tumour gains 
its capacity to metastasize due to additional mutations. Lack of concordance between 
primary tumours and matched metastases or different metastases from the same patient 
in app. 10% of analyzed patients can be explained by the parallel-evolution model. In 
this model the tumour may originate from only one cancer stem-cell. The tumour may 
also evolve independently using different mechanisms of progression within one tumour 
(Klein, 2009). So far, a general mutation pattern responsible for metastasis has not been 
identified. The heterogeneous pattern of tumour mutations suggests that multiple 
alternative genetic pathways exist. They lead to the formation, growth and recurrence of 
colorectal cancer in individual patients, and probably also within one tumour, which 
reflects the complexity of colorectal cancer development and progression. 
1.6 CLINICAL TRIALS IN COLORECTAL CANCER 
Colorectal cancer is a highly complex disease caused by a combination of modified 
genetic variants and aberrant epigenetic states. The heterogeneous patterns of molecular 
events suggest that multiple alternative genetic and epigenetic pathways to colorectal 
cancer exist. Moreover, differences observed within the lesion of the same tumour 
specimen would support the presence of intratumoural heterozygosity and intratumoural 
subclones. Our growing understanding about cancer resulted in the development of new 
treatment options. These new treatment options have, however, not significantly 
increased 5-year survival rate for the majority of the mCRC patients. Moreover, they are 
beneficial only in a very limited fraction of patients. Predictive biomarkers for patients‟ 
stratification prior to the therapy have become lately a standard procedure, but their 
accuracy is still not satisfying. Thus the current clinical situation stimulates a discussion 
about the standard approach to the clinical trial. 
1.6.1 Clinical and Preclinical Studies - Evolving Strategies in CRC 
To date, the majority of the clinical efficacy data originate from clinical trials conducted in 
heavily pre-treated, chemorefractory metastatic CRC patients. Only a few studies 
investigated efficacy of anti EGFR mAb in first-line treatment (Bokemeyer et al., 2009; 
Van Cutsem et al., 2011) resulting in improved response rates in chemonaive patients. 
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Furthermore the concept of simply moving targeted drugs and biomarkers approved in 
metastatic patients to an adjuvant or early setting has failed, which was shown for two 
major antibodies: cetuximab and bevacizumab. Surprisingly, cetuximab in addition to 
FOLFOX-6 showed no benefit over a FOLFOX-6 regimen in the adjuvant setting of 
colorectal cancer patients in terms of disease-free survival (DSF) and response rates 
(Alberts et al., 2012). The lack of benefit was independent of the mutation status in the 
KRAS gene. Similarly, two population studies CO-8 and AVANT failed to show benefit 
from bevacizumab in CRC patients of stages II and III (Allegra et al., 2011; de Gramont, 
2011). In fact, in the AVANT trial the outcomes of the patients were slightly worse with 
bevacizumab in comparison to the chemotherapy alone. These findings stand in contrast 
to the positive effects of mAb observed in the subset of metastatic colon cancer patients. 
It is not surprising though, that such negative results influenced considerations on a new 
preclinical and clinical trial strategy as it has stayed largely unchanged during the last 30 
years (Doroshow and Parchment, 2008). Clinical trials are focused on large populations 
of patients with poorly characterized disease. They take years to complete, achieving 
little impact on the progress in the treatment strategies.  
Lack of rational clinical trial design affects not only response rates to the drugs that are 
already approved, but raises as well concerns about current anti-cancer drug 
development process (de Bono and Ashworth, 2010). Only 5-10% of potential 
therapeutic molecules, which showes promising preclinical data, progress to phase III 
clinical development. Even fewer targeted agents are approved. That suggests a 
systematic problem already in the preclinical phase, which determines whether the 
experimental agent will, at all, undergo subsequent steps of drug development. One 
reason for failure is the expectation that these new targeted drugs are effective in a large 
fraction of patients recruited to the trials. Recent findings however, indicate that many of 
the targeted drugs show limited benefits, often only in small subgroups of patients. This 
highlights the need to incorporate pharmacogenomic markers of response to drug 
treatment into anti-cancer development, and the discovery and validation of predictive 
biomarkers along with the discovery of novel therapies. Such studies should be 
conducted in tumours that are well characterized concerning their genetic, epigenetic, 
and phenotypic background. Nevertheless, before clinical trials can be initiated to test a 
novel compound in actual patients, researchers need to assess the drug's efficacy and 
safety in the preclinical study. A proper preclinical approach can facilitate the approval in 
the further clinical phases. In vivo as well as in vitro systems served so far in cancer 
modeling for preclinical testing. 
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1.6.2 Mouse Models of Cancer 
Conventional transgenic or knockout mouse models are genetically engineered animals in 
which an existing gene has been inactivated or replaced, or a foreign DNA has been 
integrated into the murine genome. In cancer models they are generated to carry cloned 
oncogenes or to lack tumour suppressor genes. They cannot, however, mimic sporadic 
cancers, because introduced mutations are present in all cells of the body. 
Moreover, certain patterns of alterations characteristic for a particular cancer cannot be 
introduced in the germ line due to their lethal effect. Finally, it is difficult to design a 
mouse predisposed to particular cancer as most mutations are not cancer specific and 
there is no way to predict the effect of mutations introduced in the germline to the 
cancer development in this mouse. The second generation of the transgenic mice – 
conditional models was developed to circumvent embryonic lethality and unwanted 
tumourigenesis. They carry regulatable oncogenes and provide an opportunity to induce 
somatic mutations in tissue-specific and time-controlled fashion (Jonkers and Berns, 
2002). Although conditional mouse models offer an important advantage over 
conventional models, the complexity and diversity of the molecular alterations lead to 
challenges in engineering of such models to mimic the formation of sporadic cancer. 
1.6.3 Xenograft Mouse Models Established from Human Cancer Cell Lines 
Another approach to apply mouse models in cancer drug research was the use of 
immunodeficient mice that carry actual human tumours. Few research groups explored 
such xenograft models derived of human cancer cell lines. Some of them investigated 
pharmacokinetics and efficacy of cetuximab alone or in combination with chemotherapy 
in series of xenograft models established from various human colorectal cell lines (Balin-
Gauthier et al., 2006b; Luo et al., 2005a; Prewett et al., 2007b). Although these 
xenografts models use human cell lines, the method still has numerous limitations. 
Cell lines are adapted to grow in laboratory, often for decades, which can affect their 
behavior. Although it is believed that, on average, cell lines preserve parental genetics 
and histology, significant mutations needed for their immortalization, may as well alter 
their properties and biology. After several passages the cells develop a capability of an 
unlimited division as long as they are supplied with nutrients. Such immortalized cell 
cultures are generated due to the cell selection. They may involve such features as 
reduced cell size and higher cloning efficiency. They may also contain variable 
chromosome number or altered mutation pattern. Therefore culturing may lead to a low 
biological relevance with the organism from which the cell line origins (Sharma et al., 
2010; Caponigro and Sellers 2011). As well the limited number of available cancer cell 
Introduction 
20 
 
lines indicates that they cannot well reflect heterogeneity and individuality of cancer 
patients. 
1.6.4 Xenograft Models of Patient-derived Tumours 
Disadvantages related to the use of cell lines in preclinical trials can be eliminated by 
transplantation of cancer tissues derived directly from the patients. Human tumour 
xenografts, originated directly from cancer patients, represent the heterogeneity and 
individuality of each malignoma. In contrary to the cell-lines-derived models, patient-
derived xenografts retain the properties of the donor tissue in regard to the histology and 
genotype. As well tumour micro-environment and the growth properties are similar to the 
original patients‟ tumour tissue. Well characterized models are of vital importance for 
preclinical research in the development of novel anti-cancer drugs. As the emphasis in 
cancer research has shifted from the “one-fits-all” attitude to personalized medicine, such 
patient-derived xenograft models can be use to individualize the approaches to cancer 
treatment. They allow testing various cancer drugs on the individual patient tumour and 
selecting the most effective therapy. Furthermore, xenograft models provide sufficient 
tissue material for molecular studies of biomarkers that are predictive for 
response/resistance to therapy. 
Such panels of patient-derived models were so far created for cancer types as lung 
cancer, breast cancer and for metastatic colon cancer (Fichtner et al., 2008; Bertotti et 
al., 2011; Reyal et al. 2012). 
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1.7.  OBJECTIVES OF THE STUDY 
- To perform molecular characterization of a panel of 133 xenograft models derived of 
chemonaive primary tumours of colorectal cancer patients across four UICC stages in the 
context of their entity with the original primary tumour 
- To analyze response/resistance towards approved targeted monoclonal antibodies including 
cetuximab and bevacizumab as well as the standard chemotherapy agent - oxaliplatin in a 
subset of 67 xenograft models 
- To validate the best sequential combination of the known predictive biomarkers, such as 
mutations in KRAS or BRAF for anti-EGFR mAb, in relation with the response to the 
administered therapies 
- To identify novel predictive biomarkers on the global expression level of mRNA and miRNA 
or mutation patterns of response/resistance and test their accuracy in comparison to the 
established markers
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Chapter 2 
Patients, Materials, and Methods 
2. 1 EQUIPMENTS AND MATERIALS 
Instuments & Equipment Supplier 
ABI Fast 7500 instrument ABI 
Affymetrix GeneChip Fluidics Station 450 Affymetrix 
Affymetrix GeneChip Scanner 3000 Affymetrix 
Agilent 2100 Bioanalyzer Agilent Technologies 
Analog Vortex Mixer VWR International GmbH 
Bionanalyzer Chip-Priming Station Agilent Technologies 
Canon PowerShot G5 Canon 
Centrifuge 5804R Eppendorf 5804R 
Cryostat Leica CM3050 S Leica 
Drying closet  Memmert 
Electrophoresis Power Supply Source TM 300V VWR International GmbH 
Gel Photo Chamber Biometra 
GeneChip Hybridization Oven 640 Affymetrix 
Laboratory Scale Sartorius analytic 
Microcentrifuge (Conventional/Butterfly rotor) Roth 
Microscope  Leica BM E 
PCR Thermal Cyclers Uno VWR International GmbH 
pH-meter Hanna Instruments 
QIACube robot Qiagen 
Sliding microtome, Shandon Finesse Thermo Fisher Scientific 
Spectrophotometer, Nanodrop GE Healthcare 
Spectrophotometer, Nanovue GE Healthcare 
SubCell GT Electrophoresis system Biorad 
Thermocell Mixing Block BIOER 
Vaccum Pump  Leroy-Somer 
Water Bath Störk-Tronic 
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Kits Supplier 
Agilent RNA Nano 6000 Kit Agilent Technologies 
AllPrep DNA/RNA Mini Kit Qiagen 
FlashTag Biotin HSR RNA Labeling Genisphere 
High Capacity cDNA Reverse Transcription Kit ABI 
Invisorb Spin Blood Maxi Kit Invitek 
Invisorb Spin Tissue Mini Kit Invitek 
Invisorb Spin Tissue Mini Kit Invitek 
MessageAmp™ Premier RNA Amplification Kit  Ambion 
miRNeasy FFPE Mini Kit Qiagen 
miRNeasy Mini Kit Qiagen 
TaqMan Reverse Transcription Reagents ABI 
TwinSpin Cell Mini Kit Invitek 
 
Consumables Supplier 
0,2 µm Cellulose Membrane Filter Roth 
Adhesive Film Sarstedt 
Eppendorf Pipettes 10; 100: 200; 1000µl Eppendorf 
Folded Filters 240mm Roth 
Solidofix, Freezing Spray Roth 
Hypodermic Needles Braun 
Laboratory Glass- and Plasticware Roth 
MicroAmp Fast Optical 96-Well Reaction Plate ABI 
MicroAmp Optical Adhesive Film ABI 
Microscope Glas Slides 76x26 mm Roth 
Microtube Tough-Spots Diversified Biotech 
Multichannel Transferpipettes Brand 0.5-10; 2-20; 20-200uL  Brand 
Multiply Fast PCR Plates Sarstedt 
Pasteur Pipettes Roth 
Reaction Tubes 0,2; 0,5; 1,5; 2 ml Sarstedt 
SafeLock 2 ml tubes Eppendorf 
Sterile Disposable Scalpels Braun 
Tips with Filter 2,5; 10; 100, 1000 µl  Biosphere Sarstedt 
Tissue Freezing Medium Jung 
Tissue Wipers Precision Wipes Kimberly Clark Science 
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Conventional PCR/Electrophoresis Supplier 
Broad Range Agarose Roth 
50 bp DNA Ladder Roth 
6 x Gel Loading Solution Sigma 
1 kb DNA Ladder Sigma 
Ethidium Bromide Roth 
Taq Polymerase Invitek 
PCR Buffer Invitek 
MgCl2  Invitek 
dNTPs 100mM stock solution Invitrogen 
 
  
Chemicals and others Supplier 
100% Acetic acid Roth 
Anti-streptavidin antibody (goat), biotinylated Vector Laboratories 
20x Eucaryotic Hybidization Controls (bioB, bioC, bioD, cre) Affymetrix 
Acid hematoxylin solution Mayer Roth 
Control B2- Oligonucleotides Affymetrix 
Biotinylated Anti-Streptavidin linaris 
Boric Acid Roth 
Bovine Serum Albumin (BSA) Roth 
Dimethyl sulfoxide (DMSO) Sigma 
EDTA Roth 
Eosin G Roth 
Formamide Roth 
Goat IgG Protein Dunnlab 
Herring Sperm DNA Solution Invitrogen 
MES hydrate Sigma 
MES Sodium Salt Sigma 
NaCl Roth 
NaH2PO4 Roth 
NaOH Roth 
Paraformaldehyde Roth 
Phosphate buffered saline, tablets Gibco 
RNaseZap Wipes Invitrogen 
Rotisol Roth 
SAPE (streptavidin, R-phycoerythrin conjugate) Invitrogen 
Sodium Dodecyl Sulfate (SDS) Roth 
Tris Base Roth 
Tween-20 Roth 
Water Gibco 
Xylol Roth 
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Databases and Internet References Web Adress 
Cancer Statistics - Americam Society of Cancer http://www.cancer.org/research/cancerfactsfigures/index 
Cancer Statistics -GLOBOCAN http://globocan.iarc.fr/ 
Clinical Trials - National Cancer Institute http://www.cancer.gov/clinicaltrials 
Clinical Trials - National Institutes of Health http://clinicaltrials.gov/ 
COSMIC Database http://cancer.sanger.ac.uk/cosmic/ 
DAVID http://david.abcc.ncifcrf.gov/ 
Ensembl http://www.ensembl.org/index.html 
IARC TP53 Database http://p53.iarc.fr/ 
miR Disease http://watson.compbio.iupui.edu:8080/miR2Disease/ 
miRBase http://www.mirbase.org/ 
mycancer genome http://www.mycancergenome.org/ 
NCBI http://www.ncbi.nlm.nih.gov/ 
Sequence converter http://www.fr33.net/seqedit.php 
Tumorzentrum Berlin-Brandenburg http://www.tumorzentrum-brandenburg.de 
UCSC Genome Browser http://genome.ucsc.edu/ 
 
  
Software Supplier 
2100 expert Software Agilent Technologies 
7500 Software v2.0.1 ABI 
Chromas Lite 2.1 Technelysium Pty Ltd 
Finch TV Geospiza 
GeneChip Command Console Software (AGCC) Affymetrix 
GraphPad Prism 5 software for Windows GraphPad Software Inc 
Microsoft Office Package Microsoft 
miRNA QC tool (Affymetrix) Affymetrix 
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2.2 PATIENT POPULATION 
2.2.1  MSKK and RVS - Trials in CRC 
Sample source - MSKK Study 
Since 2005 the MSKK study recruited almost 7.000 colorectal cancer patients who 
underwent surgery and received a standard treatment according to the German S3 
guidelines. This multi-center, prospective clinical trial enrolled colorectal cancer patients 
of all four UICC stages from 37 primary care and university hospitals in Germany. From 
most of the patients fresh-frozen and formalin-fixed paraffin-embedded (FFPE) tumour 
specimens as well as several blood samples were collected using a standardized 
procedure. Mutation analysis of KRAS, BRAF and PIK3CA was conducted in a cohort of 
788 patient samples originating from the MSKK study. The 788 patients underwent 
surgical resection in sixteen hospitals between 2005 and 2008. 
Sample source - RVS Study 
A subset of frozen tissue samples assessed in mutation analysis was collected in a 
framework of another clinical trial entitled Retrospective Validation Study (RVS). This 
study enrolled app. 1000 CRC patients of which 172 patient samples were used for 
mutations analysis. These 172 patients underwent surgical resection between 1995 and 
2005 in three hospitals. 
Ethical Principles 
All samples were collected according to the ethical requirements and regulations. In 
parallel, comprehensive individual clinical data were collected by clinical research 
associates using a FDA approved electronic data capturing software. All patients have 
given their written informed consent to participate in the clinical studies. Basic clinical 
and pathological characteristics of the patients are shown in the Tab.3.6. Beside the fact 
that one clinical study was prospective and the other retrospective, a mixture of the two 
studies seems to be a random representation of the patients‟ population according to the 
basic clinicopathological characteristics and distribution of analyzed mutations. 
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2.2.2  Exclusion Criteria and the Final Samples Selection 
Failure of the molecular analysis 
Mutation analysis of KRAS, BRAF and PIK3CA was performed in 960 tumour samples 
originated from the MSKK and the RVS studies. KRAS mutation status could not be 
assigned to 20 samples, BRAF mutation status to 10 samples and PIK3CA analysis failed 
in 22 samples. When an assay did not succeed in one of the analyzed hotspots, such 
sample was omitted in further analyses. In this manner 47 samples were excluded. 
Forty-one (87%) out of the 47 failing DNA samples were isolated from the FFPE tissues 
and only six from the snap-frozen tumour specimens. 
Exclusion of the duplicates 
Altogether, 913 samples remained for further analysis after exclusion of those, in which 
mutation analysis did not succeed. It turned out that in 34 cases more than one tissue 
sample was analyzed per patient. In 22 out of the 34 cases one sample derived from 
FFPE and another from snap-frozen tissue. Analysis of the 22 matched sample pairs 
revealed that in six cases mutation results did not match. Five of the 22 cases were 
patients with synchronous disease (two different tumours). Analysis of another five cases 
with synchronous cancer where two samples were available from each patient revealed, 
however, no differences in mutation status in both tumours (three were wild-type in 
analyzed hotspots, two carried mutations in KRAS: G12D and G13D). Altogether there 
were ten cases of synchronous cancer with two samples of each patient analyzed. In five 
cases both tumours matched the genotype, while in other five, they did not match. For 
statistical analyses only the result of the more advanced tumour was taken under 
consideration. Duplicates were excluded. In one case, a discrepancy was found in the 
mutation status of a patient with no diagnosis of synchronous cancer. According to the 
analysis of fresh frozen tumour this patient was wild-type in analyzed hotspots, while 
DNA isolated from FFPE showed mutations in KRAS (G12D) and PIK3CA (E545K). A 
reason for the discrepancy between frozen and FFPE samples of the same patient might 
be the fact that tissue samples were taken from different regions of the tumour (tumour 
center, invasion front etc.). Of the two, the sample originating from the tissue part that 
was closer to the tumour centre was included in the analysis. 
Pathological and clinical exclusions 
Another six cases were excluded due to the violation of the inclusion criteria of the study. 
Pathological evaluation revealed that additional seven samples represent relapses (5), 
Patients, Materials and Methods 
28 
 
metastasis (1), or biopsy (1) instead of primary tumours. Finally, in two patients, FAP 
was diagnosed resulting in exclusion of these samples from further analysis. Thirty 
patient samples which were analyzed for mutation turned out to originate from patients 
diagnosed, apart from colorectal cancer, with another malignancy. These were not 
excluded from mutation analysis. Also the 42 cases in which tumour samples originated 
from the patients who received neoadjuvant treatment prior to surgery were not 
excluded. 
All tissue samples were analysed for their tumour content, but also for the content of 
other cell types by board certified internal pathologists. This semiquantitative data was 
recorded for each tumour sample in a respective database. In 19 samples tumour 
content in the tissue as evaluated by pathologist was lower than 10%. Most of these 
samples were resected after neoadjuvant treatment or from mucinous tumours, which 
are characterized by low cellularity. Ten mutations were found in eight out of these 
samples, out of which seven mutations were identified in samples with a tumour content 
below 5%. Due to the reasonable mutation rate and in order not to select against 
mucinous tumours, the samples with low tumour content were not excluded from further 
analyses. 
2.3 ESTABLISHMENT OF THE XENOGRAFTS 
NOD/SCID mice (Taconic) 
RPMI-1640 medium containing gentamicin 
 
Two hundred and thirty-nine fresh tumour samples originating from the MSKK study were 
used to establish a panel of patient-derived xenograft models. Shortly after surgery 
original tumour pieces were shipped in RPMI-1640 medium containing gentamicin to the 
collaborating company - Experimentelle Pharmakologie & Onkologie Berlin-Buch GmbH 
(EPO). There, samples were cut into pieces of 3 to 4 mm and transplanted within 30 min. 
to 3 - 6 immunodeficient NOD/SCID mice (Taconic). The gender of recipient mice was 
chosen according to the gender of donor patient. In this manner 239 fresh human 
tumour samples were transplanted into NOD/SCID mice. All transplanted samples were 
collected during two years by a collaborating network of four primary care hospitals. 
Tumours were further passaged until stably growing tumour xenografts developed. 
Hundred and forty-nine out of 239 samples (62%) were successfully engrafted. A quality 
control of the engrafted tumours led to the exclusion of 16 models. Among excluded 
engrafted tissues were metastases originated from other primary tumours and 
adenomas. One of the xenografts was excluded due to withdrawal of informed consent by 
the respective patient. Tumour specimens from patients who had received neoadjuvant 
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treatment were excluded, as one of the goals of the study was to test the efficacy of anti-
cancer compounds in the chemonaive population. Finally, 133 high-quality xenografts 
passed quality control and fulfilled criteria of the study. In this way a panel of 133 stably 
passagable, patient-derived colorectal cancer xenografts could be established as 
permanent tumour models. All animal experiments were done in accordance with the 
United Kingdom Coordinating Committee on Cancer Research regulations for the Welfare 
of Animals and of the German Animal Protection Law and approved by the local 
responsible authorities (Landesamt für Gesundheit und Soziales). 
2.4 TREATMENT EXPERIMENT 
NMRI: nu/nu mice (Charles River) 
Cetuximab (erbitux; Merck), qd 7x2, 50 mg/kg/d, i.v. 
Bevacizumab (avastin; Genentech Inc., South San Francisco, CA, USA), qd 4, 5 mg/kg/d, i.p 
Oxaliplatin (eloxatin, Sanofi-Avensis), 5 mg/kg/d, qd 1-5, i.p. 
 
Sixty-seven of the 133 established xenograft models were used in therapy experiments 
(Fig.2.1). Three well known and approved drugs were tested as single agents: oxaliplatin 
which forms the backbone of the FOLFOX regimen, and two targeted anti-EGFR 
antibodies - cetuximab and bevacizumab. Mice were observed daily for tumour growth. 
At a size of app. 1 cm3, 67 tumours were removed and passaged to naive, male NMRI: 
nu/nu mice (Charles River). Each tumour was transplanted subcutaneously to five mice. 
Treatment was initiated at palpable tumour volume of app. 50-100 mm3. For every out of 
67 human-derived xenograft models, five mice were tested with each drug and five 
additional mice were used as controls. The following drugs and treatment schedules were 
used: cetuximab (Erbitux; Merck) qd 7x2, 50 mg/kg/d, i.v.; bevacizumab (Avastin; 
Genentech Inc., South San Francisco, CA, USA) qd 4, 5 mg/kg/d, i.p.; oxaliplatin 
(Eloxatin, Sanofi-Avensis), 5 mg/kg/d, qd 1-5, i.p. Doses and schedules were chosen 
according to the previous experience in animal experiments and represent the maximum 
tolerated dose of oxaliplatin and the efficient doses of monoclonal antibodies cetuximab 
and bevacizumab (see Tab.3.7). The injection volume was 0.2 mL/20 g body weight. 
Tumour size was measured twice a week with a caliper-like instrument in two 
dimensions. Individual tumour volumes (V) were calculated by the formula: V = (length 
+ [width] 2) / 2 and related to the values at the first day of treatment (relative tumour 
volume). Median treated to control (T/C) value of relative tumour volume was used for 
the evaluation of each treatment modality (Fichtner et al., 2008). 
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Fig.2.1. Workflow scheme of transplantation of the 239 CRC patients tumour tissues, 
engraftment of 149, and treatment of 67 of the engrafted models with cetuximab, bevacizumab 
and oxaliplatin; s.c. - sterility check; QC - quality control 
 
2.5 TISSUE SECTIONS AND PATHOLOGICAL EVALUATION 
4% solution of paraformaldehyde in PBS 
Acid hematoxylin solution Mayer; eosin G 
 
FFPE samples - preparation of the sections 
FFPE blocks were cut using a sliding microtome (Shandon Finesse, Thermo Fisher 
Scientific). Prior to cutting, paraffin-blocks were cooled by a freezing spray (Solidofix). 
First 4 µm primary sections were prepared and placed in the water bath. Afterwards, 
they were collected with a suitable glas slide and left for two hours to dry. Next, sections 
were stained with haematoxylin and eosin (H&E). H&E staining protocol used for the FFPE 
slides is shown in Tab.2.1.A. Pathological evaluation of the primary sections included 
tumour classification according to their morphological and histological features. Content 
of tumour cell and other cell types was estimated in a semiquantitative manner. If 
possible, the areas to be macrodissected were marked. Macrodissection was assessed to 
enrich the content of tumour cells in the sample and to minimize the content of other 
tissues (example - Fig.2.2). Marked tumour region was excised with a needle and 
thereafter only excised fragments were collected into a tube. According to the 
pathologists‟ guidelines, between 2 and 10 sections of 20 μm thick FFPE sections were 
cut for DNA and RNA isolation. Before and after sectioning, additional 4 µm-thick sections 
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were cut and stained with H&E in order to evaluate whether the tissue structure had 
changed depending on the thickness of the FFPE block. 
Snap-frozen samples - preparation of the sections 
Sections of the snap-frozen tissues were prepared using the Leica CM3050 S cryostat. 
Tissues were embedded using a freezing medium (Jung) and transferred to a cryotome (-
20°C). After app. 5 min., tumour tissues were immobilized in the medium and their 
temperature equilibrated to the temperature of the cryostat. Next, sections of the desired 
thickness were cut. Tissue sections were placed on the glass slides and transfered within 
30 min. to the 4% paraformaldehyde solution for app. 5 min. Afterwards snap-frozen 
sections were stained with H&E following the steps listed in Tab.2.1.B. Macrodissection of 
the snap-frozen specimens was assessed with a scalpel. Between 10 and 100 of 4 μm-
thick sections were used for DNA and RNA isolation according to the pathologists‟ 
instructions. Except for the mentioned differences, snap-frozen sections were prepared 
and evaluated by pathologists analogously to FFPE sections. 
Tab.2.1. Hematoxylin & Eosin Staining Protocol 
A. For the FFPE slides 
Step Reagent Duration 
1 Xylol 5 min. 
2 Xylol 5 min. 
3 Xylol 5 min. 
4 100% Ethanol 5 min. 
5 96% Ethanol 5 min. 
6 90% Ethanol 5 min. 
7 80% Ethanol 5 min. 
8 70% Ethanol 5 min. 
9 Distilled Water 5 min. 
10 Haematoxylin (Meyer) 3 min. 
11 Tap Water Wash 
11 Tap Water 15 min.  
12 1% Eosin 3 s 
13 Distilled Water Wash 
14 70% Ethanol Wash 
15 80% Ethanol Wash 
16 90% Ethanol Wash 
17 96% Ethanol Wash 
18 100% Ethanol Wash 
19 Xylol 3min. 
20 Cover the slide - 
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B.  For the snap-frozen slides 
Step Reagent Duration 
1 100% Ethanol 5 min. 
2 96% Ethanol 5 min. 
3 90% Ethanol 5 min. 
4 80% Ethanol 5 min. 
5 70% Ethanol 5 min. 
6 Distilled Water 5 min. 
7 Haematoxylin (Meyer) 4 min. 
8 Tap Water Wash 
9 Tap Water 15 min. 
10 1% Eosin 4 s 
11 Distilled Water Wash 
11 70% Ethanol Wash 
12 80% Ethanol Wash 
13 90% Ethanol Wash 
14 96% Ethanol Wash 
15 100% Ethanol Wash 
16 Xylol 3min. 
17 Cover the slide - 
 
A. B. C. 
Fig.2.2. Example of tumour cell enrichment by macrodissection: [5X] A) Tissue section of 
colonic adenocarcinoma, stained with H&E; epithelial tumour: 20%, smooth muscle: 30%; 
stroma: 20%; normal epithelium: 30% B) Tissue section with areas marked for 
macrodissection C) Tissue section after macrodissection; epithelial tumour: 60%, smooth 
muscle: 20%; stroma 20% (Photos: Dr. I. Klaman) 
2.6 MOLECULAR ANALYSES 
2.6.1 DNA and RNA Extraction 
Paraffin disposal and DNA isolation from FFPE samples 
Verdau-Puffer ( 30mM Tris, 10mM EDTA, 1% SDS, pH 8,0 ); proteinase K; 5M NaCl; 70% ethanol 
Genomic DNA from FFPE tissue was isolated using Invisorb Spin Tissue Mini Kit (Invitek) 
preceded by paraffin disposal. Prior to the isolation, FFPE sections were overnight 
incubated on the thermoshaker at 55˚C with an addition of Proteinase K. After overnight 
digestion, a 30 min. long centrifugation at 4˚C was performed. As a result debris moved 
to the bottom of the tube. Paraffin on the other hand formed a ring in the upper part of 
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the tube, allowing its separation from the supernatant. 5M NaCl was added to the 
supernatant to the final concentration of 100 µM and then DNA was precipitated with 
absolute ethanol. The precipitate was washed with 70% ethanol, dried, and finally 
dissolved in the lysis buffer G. Thereafter, the isolation was conducted according to the 
manufacturer's protocol. 
DNA/RNA isolation from snap-frozen samples 
Genomic DNA from snap-frozen primary tumour tissue was isolated along with the total 
RNA using Invisorb TwinSpin Cell Mini Kit (Invitek) in a spin-filter format. From the 133 
xenograft snap-frozen samples DNA and RNA were simultaneously extracted with AllPrep 
DNA/RNA Mini Kit (Qiagen) using an automated protocol on the QIACube robot (Qiagen) 
according to the manufacturer‟s instructions.  
DNA isolation from blood and cell lines- positive and negative controls 
gDNA that served as a negative control in the mutation analyses was extracted using 
Invisorb Spin Blood Maxi Kit (Invitek) from the blood of healthy patients that underwent 
colonoscopy. DNA that was used as a positive control was extracted from the snap-frozen 
cell lines. It was isolated using Invisorb Spin Tissue Mini Kit (Invitek) according to the 
manufacturer‟s protocol. 
Total RNA isolation from FFPE samples 
RNA from the FFPE tissues of the CRC primary tumours was extracted by automated 
protocol (QIACube) using miRNeasy Mini Kit (Qiagen, Hilden). Total RNA from the control 
tumours of the 67 models used in the treatment experiment was isolated using the 
miRNeasy FFPE Mini Kit (Qiagen, Hilden). 
Quality control in nucleic acid isolation - DNA and RNA concentration measurements 
DNA and RNA concentrations (ng/μl) were measured using UV spectrophotometer 
(Nanovue, GE Healthcare/Nanodrop, Thermo Scientific). One or two μl of eluted 
DNA/RNA were assessed for the measurement with Nanovue and Nanodrop respectively. 
Quality control in nucleic acid isolation - gel electrophoresis 
TAE buffer (4 mM TRIS, 1.2 mM sodium acetate, 4 nM EDTA adjusted with acetic acid to pH 8) 
6 x loading buffer (bromphenol blue (0.25% w/v), xylene cyanole FF (0.25% w/v), sucrose (40% w/v)) 
Quality of isolated DNA was assessed in 1% agarose gel electrophoresis. Agarose gel was 
prepared using 130 ml of TEA buffer, 1.3 mg of broad-range agarose and 4.5 μl of 1% 
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ethidium bromide solution. After placing the comb/combs, app. 30 min. was needed for 
polymeryzation of the gel. During polymeryzation 8-10 μl of isolated DNA was combined 
with 2 μl of 6x concentrated loading buffer. Next, 1 kb DNA ladder (NE Biolabs) was 
loaded on the gel as a control, followed by loading of the isolated samples. 
Electrophoretic separation was performed at a voltage of 75 - 100 V for 1 to 1.5 h. The 
evaluation of DNA quality was made by determination of the intensity and degree of DNA 
fragmentation allowed by visualization of intercalated ethidium bromide under a UV 
lamp. 
Quality control in nucleic acid isolation - RNA integrity 
The integrity of RNA was measured on the Agilent 2100 bioanalyzer (Agilent 
Technologies). Prior to the analysis, all the RNA Nano 6000 reagents were placed for 30 
min. at room temperature. Gel matrix was prepared by filtering through the supplied 
column (centrifugation: 10 min., 4000 rpm) and adding 1 μl of dye to the 65 μl of gel. 
After placing a RNA Nano 6000 chip in the priming station, 9 μl of gel-dye mix was 
pippetted into a G well (black). The priming station was closed and the plunger was 
released after 30 s. Next, the gel-dye mix was pipetted into remaing G wells (grey). Five 
μl of Nano Marker, 2 μl of denatured ladder and 2 μl of analyzed samples were pipetted 
into the chip. The samples were diluted, if the measured concentration was higher than 
200ng/μl. The chip was vortexed for 1 min. at 240 rpm and inserted into bioanalyzer. A 
RIN (RNA integrity number) greater than 4 was required to classify the quality of the RNA 
sample as sufficient for further analyses. 
2.6.2 Mutation Analysis 
Mutation analysis was conducted by allele-specific real-time PCR using custom TaqMan-
MGB allelic discrimination assays (Applied Biosystems). The sequences of the primers 
and probes are listed in the Tab.S3. Every well contained 20 ng of purified gDNA 
template. Samples were run in duplicates in the final volume of 10 μl with TaqMan 
Universal PCR Master Mix (2x) No AmpErase UNG, 40 x working stock of allele-specific 
assays and blocking oligonucleotides (125 nM). Amplification was run in the ABI Fast 
7500 instrument. Standard TaqMan thermocycling conditions were used (10 min - 95˚C, 
40 cycles of 15 s at 92 ˚C, 1 min at 60˚C) for all mutation analyses, except for the BRAF 
anneal/extend step, which was prolonged to 90 s. Every 96-well plate was composed of 
40 patients‟ samples in duplicates, 4 negative controls (WT), 8 positive controls 
(titrations), and 4 non-template controls (NTC). 
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2.6.2.1 The principle of the allele-specific real-time PCR 
Allele-specific real-time PCR was designed to detect DNA sequence variants that differ in 
only one nucleotide. A sequence of interest, investigated for the mutation status, is 
flanked by a pair of primers. Each assay contains two probes: one is labeled with a 
fluorescent dye FAM and another with a fluorescent dye VIC. FAM- labeled probe binds to 
the mutated sequence and VIC-labeled probe detects a wild-type sequence. The process 
of amplification leads to the hydrolysis of the probe by Taq's 5' to 3' exonuclease activity. 
A dye from the matched probe is released and the fluorescent signal is generated. Black 
hole quencher prevents fluorescence of the non-matching probe. Specificity of the assays 
is improved by the minor groove binder (MGB) that forms stable duplexes with the 
single-stranded DNA targets. 
Titration - serial dilution of mutant allele with wild-type gDNA 
Originally, allele-specific real-time end-point assays are designed to generate three types 
of signal. A substantial increase in FAM fluorescence indicates a homozygous mutant, a 
VIC signal indicates a homozygous wild-type, and finally increase in both signals 
indicates heterozygosity and an intermediate signal is generated by the software 
(Fig.2.3). 
Majority of the somatic mutations in cancer is dominant and normally affect only a single 
allele of the gene. Homozygous mutations in cancer genomes occur seldom, in most of 
the cases as a result of the LOH (loss of heterozygosity) in which a germ-line mutation in 
one allele is followed by a subsequent somatic alteration. Therefore, in most of the cases 
both probes are binding and an intermediate signal is generated. Moreover, tumour 
tissue samples are genetically heterogeneous. They often contain, apart from tumour 
cells, a variety of other components such as surrounding stroma or the inflammatory 
cells. Commonly, due to the complicated sample architecture, an adjacent tissue cannot 
be removed by macropreparation. Only tumour cells carry somatic mutations, therefore 
an isolation of DNA from such a cell mixture leads to an increase of wild-type sequence 
fraction. Ultimately, an increase of the VIC signal is observed. Due to the challenging 
interpretation of the allele-specific real-time PCR, an analysis of serial dilutions of the 
mutant samples with the wild-type genomic DNA (titration) was conducted on every 
plate. In order to interpret the results and to decide whether the sample was mutated or 
not, a ratio of the FAM and VIC was analyzed along with the visual analysis of the scatter 
plots and in comparison with the titrations. 
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Fig.2.3. Scatter plot illustrates endpoint 
determined exemplary groups of homozygous 
(mutant and wild-type) and heterozygous samples. 
Each cross represents one analyzed sample. 
Increase in FAM (mutant) signal shifts the samples 
to the upper part of the plot (blue crosses), while 
the fluorescent signal from VIC (wild-type) shift the 
samples to the right (red crosses). An intermediate 
signal generated from both FAM and VIC 
fluorescent signals (green crosses) indicated a 
hezerozygous sample. 
 
2.6.2.2 Blocking non-labeled oligonucleotides 
In some of the cases, during the pilot experiments, more than one mutation was 
detected in the same sample, particularly in codon 12 of the KRAS gene. It was caused 
by the fact that six assays, which were designed to detect different mutations in KRAS 
codon 12, differ in one nucleotide only (Fig.2.4). Such similarity led to the binding in the 
fraction of the imperfectly matched probes and to generation of the unspecific signal. 
This cross-reactivity resulted in the challenging interpretation of the preliminary results. 
In order to prevent nonspecific binding, unlabeled oligonucleotides were added to the 
reactions. These unlabeled oligonucleotides were competitive with the unmatched probes 
and blocked their binding position. They prevented generation of nonspecific fluorescence 
signals that originated from the unspecific mutations in codon 12 of the KRAS gene. The 
combinations of the probes and blocking oligonucleotides are shown in table 2.2. 
Fig.2.4. 
Distribution of 
mutations in codon 
12 and 13 in the 
KRAS gene and 
their frequency in 
the CRC 
population 
(source: COSMIC 
database - 
modified) 
 
 
 
Homozygous mutant AA 
Heterozygous mutant AB 
No amplification 
Wild-type BB 
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Tab.2.2 Combinations of the probes and blocking oligonucleotides 
Assay ID 
Target 
Mutation 
Blocker ID Blocker sequence Blocker(s)used in the reaction 
KRAS_ex2-121a 34 G>A Blocker_121a TAGTTGGAGCTAGTGGCGTAG Blocker_121t 
KRAS_ex2-121t 34 G>T Blocker_121t TAGTTGGAGCTTGTGGCGTAG Blocker_121a 
KRAS_ex2-121c 34 G>C - - Blocker_121a; 121t 
KRAS_ex2-122a 35 G>A Blocker_122a TAGTTGGAGCTGATGGCGTAG Blocker_122t; 122c 
KRAS_ex2-122t 35 G>T Blocker_122t TAGTTGGAGCTGTTGGCGTAG Blocker_122a, ; 122c 
KRAS_ex2-122c 35 G>C Blocker_122c TAGTTGGAGCTGCTGGCGTAG Blocker_122a; 122t 
2.6.3 Direct Sanger Sequencing 
2. 6. 3. 1 Direct Sanger sequencing of KRAS codon 12 and 13 
Sanger dideoxy terminator sequencing was applied to verify the results obtained by the 
real-time PCR. KRAS status in codon 12 and 13 was analyzed by conventional sequencing 
of 304 samples for which allele-specific real-time PCR results were available. The primers 
used for amplification and sequencing were described previously (Finberg et al., 2007; 
Loupakis et al., 2009). Primers have the following sequences: forward - 
GGTGGAGTATTTGATAGTGTATTAACC and reverse - TCATGAAAATGGTCAGAGAAACC.  
For each PCR reaction a master mix containing 0,2uM primers, 1,5mM MgCl2, 250uM 
dNTPs, 1 x reaction buffer and 0.5U/uL Taq Polymerase was combined with DNA sample. 
The thermocycling conditions are described in Tab.2.3. The amplified product has a size 
of 283 bp. Traditional Sanger sequencing of the fragments was performed by LGC 
Genomics GmbH. 
Tab.2.3 Components (A) and conditions (B) of PCR reaction and direct sequencing of KRAS 
codon 12 and 13 
PCR Program Temp. [°C] Time  
Denaturation 94 2min  
Denaturation in cycle 94 30 s 
X 35 cycles Annealing 61 30 s 
Elongation 72 30 s 
Final elongation 72 10 min  
2.6.3.2 Direct Sanger sequencing of KRAS codon 61 
Twenty-nine out of the 67 models used in the treatment experiment were not mutated in 
KRAS and BRAF according to the allele-specific real-time PCR analysis. In these samples 
mutation status in KRAS codon 61 was assessed by Sanger sequencing as reported 
earlier (Loupakis et al., 2009). The fragment of 155 bp was generated by primers of the 
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following sequences: forward - CCAGACTGTGTTTCTCCCTT; and reverse - 
CACAAAGAAAGCCCTCCCCA. The concentrations of the the components used in each 
reaction and the thermal cycling conditions are given in Tab.2.4. The same primer pair 
was used for sequencing of the amplified fragments. Sequencing of the fragments was 
performed by LGC Genomics GmbH. 
Tab.2.4 Components (A) and conditions (B) of PCR reaction and direct sequencing of codon 
61 of the KRAS gene 
A) 
Component Conc. Final conc. 
Reaction buffer 10x 1x 
MgCl2 25mM 1,5mM 
dNTPs 12,5 mM each 250uM 
Primer F 5pmole/uL 0,2uM 
Primer R 5pmole/uL 0,2uM 
H2O  - -  
Invi Taq 5U/uL  0.5U/uL 
Template 20ng/uL  2ng/uL 
B) 
PCR Program Temp. [°C] Time   
Denaturation 95 10 min   
Denaturation in cycle 95 30 s 
X 35 cycles 
 
Annealing 60 30 s  
Elongation 72 30 s  
Final elongation 72 10 min   
2.6.4 Gene Expression Analysis of AREG and EREG by Real-time PCR 
RNA Reverse Transcription - snap-frozen samples 
Reverse transcription on the RNA template extracted from the snap-frozen samples was 
performed with TaqMan Reverse Transcription Reagents (Applied Biosystems). Reverse 
transcription was performed in 10 μl reaction volume. For the synthesis of cDNA 10X RT 
Buffer, 25 mM MgCl2, dNTPs Mixture, Random Hexamers, RNase Inhibitor, and 
MultiScribe Reverse Transcriptase were combined with 500 ng of total RNA. The thermo-
cycling conditions of the reverse transcription are described in Tab.2.5. 
Tab.2.5 Reverse transcription PCR conditionsfor snap-frozen samples 
PCR Program Temp. [°C] Time 
Hexamer Incubation 25 10 min. 
Reverse Transcription 48 60 min. 
Inactivation 95 5 min. 
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RNA Reverse Transcription - FFPE samples 
High Capacity cDNA Reverse Transcription Kit (Applied Biosystems) was used to amplify 
RNA extracted from FFPE specimens. Reverse transcription of the material isolated from 
FFPE samples was performed in 20 μl with a starting amount of 2000 ng. Starting 
amount of total RNA isolated from FFPE samples was higher than in case of the snap-
frozen samples because of much higher rate of RNA degradation in the FFPE tissue 
blocks. In order to perform reverse transcription, RNA was combined with 10X RT Buffer, 
25 mM MgCl2, 100 mM dNTP Mix, Random Primers, RNase Inhibitor, and MultiScribe 
Reverse Transcriptase and processed with the thermo-cycling conditions described in 
Tab.2.6. 
 Tab.2.6 Thermo-cycling conditions of the reverse transcription PCR for FFPE samples 
PCR Program Temp. [°C] Time 
Hexamer Incubation 25 10 min. 
Reverse Transcription 37 120 min. 
Inactivation 85 5 min. 
Specific gene amplification 
Material obtained in the reverse transcription reaction was diluted in proportion 1:5 and 
used in the specific amplification of the selected genes. Expression of AREG, EREG, PTEN, 
DUSP6, SLC26A3, PTPRF and LOC158960 was measured with an assays recommended by 
the supplier (sequences of the primers and probes are listed in Tab.S4). Analysis was 
performed in triplicates, in half of the volume, according to the manufacturer‟s 
instructions with a threshold set on 0.2. 20x TaqMan Gene Expression Assay, 2 x TaqMan 
MasterMix was combined with diluted cDNA template. Tab.2.7 shows the conditions of 
the amplification.  
Tab.2.7 Thermo-cycling conditions of the target-amplification (Gene Expression Assay) for 
FFPE samples 
PCR Program Temp. [°C] Time 
Activation 50 2 min. 
Denaturation 95 10 min. 
Cycling x 40 
95 15 s 
60 1 min. 
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Normalization of the measured expression values 
In order to normalize the results, along with the measurements of the target genes, RNA 
levels of three housekeeping genes: GAPDH, RPLP0, and UBC were included in all 
analyses. All chosen probes were recommended by the manufacturer (Applied 
Biosystems) for the selected genes. The median of the three measurements was 
calculated for each of the genes. For the three housekeeping genes the mean of the 
medians was calculated. As the expression level indicator for every target gene (AREG, 
EREG, DUSP6, SLC26A3, PTPRF, and LOC158960) a difference between the median Ct 
value and the mean of the Ct values for three housekeeping genes (GAPDH, RPLP0, and 
UBC) was calculated. Pearson Correlation Coefficients (PCC) between response to 
cetuximab (as indicated by the T/C ratio) and log-transformed expression measurements 
of AREG, EREG, PTEN, DUSP6 and SLC26A3 were calculated. 
2.6.5 Gene Expression Profiling (GEP) on the U133 Plus 2.0 GeneChip 
1 x Array Holding Buffer (1x 100mM MES, 1M [ Na+ ],  0,01% Tween-20) 
2 x Hybridization Buffer (1x 100mM MES, 1M [ Na+ ], 20mM EDTA, 0,01% Tween-20) 
Hybridization components: BSA, Herring Sperm DNA Solution, Biotinylated Anti-Streptavidin, B2- 
Oligo, Dimethyl sulfoxide (DMSO); Fornmamide; 2 x 2 x Hybridization Buffer 
Wash Buffer A (6x SSPE, 0.01% Tween-20) 
Wash Buffer B (100mM MES, 0,1M [Na+], 0,01% Tween-20)  
Staining Cocktails: Staining Buffer (100mM MES, 1M [Na+ ], 0.05% Tween-20); BSA; Goat IgG 
10ng/μl in 150mM NaCl; SAPE; Biotinylated anti-streptavidin Ab  
Reverse Transcription to Synthesize First-Strand cDNA 
250 ng of total RNA was amplified and labeled using MessageAmp™ Premier RNA 
Amplification Kit following the manufacturer‟s instructions. Reverse transcription led to 
the synthesis of the first strand cDNA containing a T7 promoter sequence. First strand 
synthesis was assessed in 10 μl volume. Total RNA was mixed with the serial dilution of 
Poly-A RNA Control (1:500000), combined with First-Strand Buffer Mix and First-Strand 
Enzyme Mix and incubated for 2 hours at 42 °C. 
Second-Strand cDNA Synthesis  
Synthesis of the second strand converted the single-stranded cDNA into a double-
stranded template for transcription. 20 μl of Second-strand Master Mix (Second-Strand 
Buffer Mix, Second-Strand Enzyme Mix, and Nuclease-free Water) was mixed with the 
single strand cDNA and incubated for 1 hour at 16 °C, followed by 10 minutes at 65 °C. 
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Second-strand cDNA synthesis occurs simultaneously with a degradation of the RNA by 
RNase H. 
In Vitro Transcription to Synthesize Labeled aRNA and aRNA purification 
Next, the IVT Master Mix was prepared by combining IVT Biotin Label, IVT Labeling 
Buffer and IVT Enzyme Mix with the double-stranded cDNA sample. The IVT reaction was 
incubated at 40°C for 16 hours. During In Vitro Transcription step multiple copies of 
biotin-modified aRNA were synthesized and amplified. Generated aRNA copies were then 
purified in order to to remove enzymes, salts, and unincorporated nucleotides and thus 
improve their stability. Purification was performed using RNA Binding Beads. Beads were 
combined with aRNA Binding Buffer Concentrate and the mixture was added to the aRNA 
sample. Next, 120 μL of 100% ethanol was added to each sample. The mixture was 
placed at the plate shaker for app. 2 min. Afterwards it was transferred to the magnetic 
stand for 5 min. in order to capture the beads and discard the supernatant. Next, the 
beads were washed with aRNA Wash Solution and the purified aRNA is eluted with aRNA 
Elution Solution. 
Fragmentation and Hybridization onto GeneChip Array 
aRNA yield was assessed using the Agilent bioanalyzer and RNA 6000 Nano Kit (see 2.6.1 
Quality control in nucleic acid isolation - RNA Integrity) and 15 μg of aRNA was used for 
fragmentation. aRNA was mixed with 5x Array Fragmentation Buffer and nuclease-free 
water. The fragmentation reaction was incubated at 94 ºC for 35 minutes and afterwards 
it was placed on ice. Fragmented and labeled aRNA was combined with BSA, herring 
sperm DNA solution, biotinylated anti-streptavidin, B2-oligonucleotides, DMSO, and the 
hybridization buffer. The hybridization cocktail was heated to 99 °C for 5 minutes and 
then injected on the array. Arrays were incubated with rotation (60 rpm ) for 16 h at 
45°C in the oven to allow hybridization of the fragmented aRNA onto the GeneChip array. 
Washing, staining and detection 
Arrays were washed and stained with streptavidin-phycoerythrin in the Affymetrix 
Fluidics Station 450 using the EukGE WS2v4 protocol. Wash buffer A, wash buffer B, 
array holding buffer, staining cocktails 1 and 2 were applied during the procedure. 
Scanning was performed with the Affymetrix GeneChip Scanner 3000, according to the 
manufacturer‟s protocol. As a control served commercial human brain reference RNA 
(Ambion). 
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Biomarker discovery using GEP data 
An Affymetrix U133 Plus 2.0 arrays approach was also used to develop novel predictive 
biomarkers of response to the therapies. RNA was isolated from tumour tissue of the 
non-treated controls. Out of 67 models that were used in the treatment experiment, RNA 
was available for 66 of them and pooled prior to the hybridization on the array. 18 
responders and 48 non-responders were analyzed in the balanced approach. The FARMS 
condensation left 14.753 informative probesets. Prospective performance during 
balanced discovery was performed as well on the panel of corresponding primary 
tumours (18 responders vs. 43 non-responders). After condensation with FARMS 17.501 
informative probesets were available for a discovery of predictive signature directly in the 
patients‟ tumour tissues. 
Data analysis included feature selection and classification using the random forest 
algorithm and support vector machine (SVM) in a nested bootstrap approach. In every 
loop all samples are randomly split into a training set and a test set. The training set is 
used for signature selection. Performance of each classifier discovered in this manner is 
then evaluated as applied to the test set. Repeated procedure, after a large number of 
loops, allows revealing an average signature of best performance and high stability. Such 
procedure was used to develop RNA signatures discriminating between cetuximab 
responders and the resistant cases. 
2.6.6 microRNA Expression as Measured GeneChip miRNA 2.0 Arrays 
1 x Array Holding Buffer (1x 100mM MES, 1M [ Na+ ],  0,01% Tween-20) 
2 x Hybridization Buffer (1x 100mM MES, 1M [ Na+ ], 20mM EDTA, 0,01% Tween-20) 
Hybridization components: BSA, Herring Sperm DNA Solution, Biotinylated Anti-Streptavidin, B2- 
Oligo, Dimethyl sulfoxide (DMSO); 2 x Hybridization Buffer 
Wash Buffer A (6x SSPE, 0.01% Tween-20) 
Wash Buffer B (100mM MES, 0,1M [Na+], 0,01% Tween-20)  
Staining Cocktails (1, 2): Staining Buffer (100mM MES, 1M [Na+ ], 0.05% Tween-20); BSA; SAPE 
(1); Goat IgG 10ng/μl in 150mM NaCl (2); Biotinylated Antibody(2) 
Flash Tag RNA labeling 
250 ng of total RNA was used as a starting material in the microRNA expression profiling 
experiment performed on the GeneChip miRNA 2.0 arrays (Affymetrix). Reactions were 
performed with the FlashTag Biotin HSR RNA Labeling Kit (Genisphere) according to the 
manufacturer‟s manual. At first 2μl RNA Spike Control Oligos were added to the total 
RNA. Next 1.5μl 10X Reaction Buffer, 1.5μl of 25mM MnCl2, 1.0μl of diluted ATP Mix, and 
Patients, Materials and Methods 
43 
 
1.0μl PAP Enzyme were added to each RNA/Spike Control Oligos mix. During the 15 min. 
incubation at 37°C polyA - tails were added at the 3‟ end of RNA by the Poly(A)-
Polymerase (PAP). In the next step the signal molecule biotin was ligated to the target 
miRNA sample. Four μl of 5X FlashTag Biotin HSR Ligation Mix and 2μl of T4 DNA Ligase 
were added to 15μl of tailed RNA and incubated for 30 min. at RT. The reaction was 
stopped by adding 2.5μl of HSR Stop Solution. 
Hybridization 
The following components: BSA, herring sperm DNA solution, biotinylated anti-
streptavidin, Control B2- oligonucleotides, DMSO, formamide and the hybridization buffer 
were added to the biotin-labeled samples. The hybridization cocktail was incubated in 
99°C for 5 minutes, and then in 45°C for 5 minutes. After injection onto the Affymetrix 
GeneChip, arrays were incubated for 16 h in 48˚C with rotation at 60 rpm. 
Washing, staining and detection 
Microarrays were washed and stained in the Affymetrix GeneChip Fluidics Station 450. 
The FS450_0003 protocol was applied and wash buffer A, wash buffer B, array holding 
buffer, staining cocktails 1 and 2 were used. During this process streptavidin-
phycoerythrin complexes bind to the biotin-labeled miRNAs. Next, the complexes are 
detected during scanning performed with Affymetrix GeneChip Scanner 3000, according 
to the manufacturer‟s protocol. As control served commercial human brain reference RNA 
(Ambion).  
Quality control and normalization 
A quality control was conducted with miRNA QC tool (Affymetrix). It was used for data 
summarization, normalization and probeset detection (greater than 2000). Quality 
control was performed using Spearman correlation of expression values between samples 
(higher than 0.5). The procedure of signature discovery was similar to the one used for 
the analysis of the Affymetrix U133 Plus 2.0 arrays. 
2.7 STATISTICAL ANALYSES 
Data handling and statistical analysis were carried out by GraphPad Prism 5 software for 
Windows (GraphPad Software Inc, San Diego, CA) using Chi-square test. A difference 
was considered statistically significant at p value < 0.05.
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Chapter 3 
Results 
3.1 SELECTION AND ESTABLISHMENT OF THE MUTATION ANALYSIS METHOD 
In order to determine mutation status of the genes most frequently mutated in colorectal 
cancer, a custom allele-specific PCR (Applied Biosystems) was conducted. The method 
was selected after a critical review of mutation detection technologies available at this 
time with respect to its sensitivity. Other advantages of this real-time PCR-based method 
were its easy handling, short time of analysis and relatively low cost. The allele-specific 
assays are, however, not suited for detecting de novo mutations. The target mutations 
need to be defined before the analysis. Moreover the method requires analysis of each 
selected nucleotide exchange in a separate reaction. In the population study, mutation 
analysis was therefore restricted to the KRAS, BRAF, and PIK3CA hotspots which were 
known to be commonly mutated in colorectal cancer patients. Allele-specific assays were 
designed for: 8 substitutions in the KRAS gene (34G>A/G12S, 34G>T/G12C, 
34G>C/G12R, 35G>A/G12D, 35G>T/G12V, 35G>C/G12A, 38 G>A/G13D, and 436 
G>A/A146T), the most frequent mutation in the BRAF gene (1799 T>A/V600E), and 3 
hotspots in the PIK3CA gene (1624G>A/E542K, 1633G>A/E545K, 3140A>G/H1047R). 
Mutation status of additional hotspots in the APC gene (4348 C>T/R1450*), CTNNβ1 
gene (121 A>G/T41A, 134 C>T/S45F) and in the TP53 gene (524 G>A/R175H, 742 
C>T/R248W, 743 G>A/R248Q, 818G>A/R273H, 844 C>T/ R282W) was also determined 
in the panel of 67 samples used in the treatment experiment in addition to the KRAS, 
BRAF and PIK3CA analyses. 
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3.1.1 Titration of the Mutated Cell Line DNA in the Wild-type Genomic DNA 
Serial dilutions of mutant cell lines with the wild-type genomic DNA were performed to 
estimate sensitivity of the allele-specific real-time PCR assays. DNA was extracted from 
cell lines, which harbour mutations of interest (Tab.3.1), and then mixed with the 
genomic DNA (gDNA), isolated from lymphocytes of peripheral blood system from 
healthy controls. Mutated cell line DNA was serially diluted with the wild-type gDNA in 
the following proportions: 1:1 (100% mutated cell line), 1:2 (50% mutated cell line), 1:5 
(20% mutated cell line), 1:10 (10% mutated cell line), 1:20 (5% mutated cell line), 1:50 
(2% mutated cell line), and 1:100 (1% mutated cell line) (an example of the titration 
result is shown in Fig.3.2) and analyzed by allele-specific real-time PCR. Sensitivity of the 
assays was evaluated for all the probes used in mutation analysis of KRAS, BRAF and 
PIK3CA and for the majority of the probes used in the analysis of additional genes (APC, 
CTNNB1, and TP53). 
Tab.3.1. Cell lines that served as positive in mutation analysis and the mutations that they 
harbour. Sensitivity (S+) - content of the mutant alleles in the sample required for reliable 
assessment of the mutation status 
Target gene Target Mutation nt Cell line Cell line zygosity S+ mutant alleles 
KRAS 34 G>A A549 Homozygous 10% 
KRAS 34 G>T NCI-H385 Heterozygous 1% 
KRAS 34 G>C HuP-T3 Heterozygous 5% 
KRAS 35 G>A A427 Heterozygous 2.5% 
KRAS 35 G>T SW620 Homozygous 2% 
KRAS 35 G>C RPMI-8226 Heterozygous 2.5% 
KRAS 37 G>T TOV 21 Heterozygous 2.5% 
KRAS 38 G>A LoVo Heterozygous 5% 
BRAF 1799 T>A HT-29 Heterozygous 2.5% 
KRAS 436 G>A ML-2 Heterozygous 2.5% 
PIK3CA 1624 G>A T84 Heterozygous 1% 
PIK3CA 1633 G>A HCT-15 Heterozygous 5% 
PIK3CA 3140 A>G SKOV-3 Heterozygous 5% 
CTNNB1 134C>T  - - - 
CTNNB1 121A>G A427 Homozygous 10% 
TP53 524 G>A KLE Homozygous 10% 
TP53 742 C>T - - - 
TP53 743 G>A OVCAR-3 Homozygous 10% 
TP53 818 G>A SW620 Homozygous 5% 
TP53 844 C>T HuP-T3 Homozygous 5% 
APC 4348 C>T - - - 
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Results revealed a variety in the sensitivity of different assays from 1% mutant alleles to 
10% mutant alleles required for reliable assessment of the mutation status. The cut-off 
for each of the assays is displayed in Tab.3.1. Such differences in the sensitivity result 
from the affinity of the probe to hybridize, which depends on the local sequence context. 
A general cut-off was set at 10% according to the assays with the worst performance 
limiting the sensitivity of the method. 
3.1.1.2. Addition of the non-labeled oligonucleotides to avoid cross-reactivity of the 
imperfectly matched probes 
Three cell lines: A427, SW620, and RPMI-8226 that carry different mutations in the KRAS 
codon 12 (nucleotide position 35 G>A, 35 G>T, and 35 G>C respectively) were analyzed 
using allele-specific real-time PCR (Fig.3.1). All three cell lines were analyzed with the 
same assay detecting mutation 35 G>A. This assay contains two probes. The probe that 
detects the mutation 35 G>A is labeled with FAM and another probe, which detects the 
wild-type is labeled with VIC. DNA of each cell line was serially diluted with the wild-type 
genomic DNA resulting in the 90%, 50%, and 10% tumour DNA vs. wild-type DNA. If the 
assays were specific, FAM signal would be expected only in the A427 cell line titration. 
Unfortunately, FAM signal was observed in all three cell line titrations (Tab.3.2). In the 
dilution containing 90% of cell line alleles, the FAM fluorescence signal observed during 
the analysis of the unspecific cell lines constituted app. 40% and 75% of the specific 
signal for the SW620 and RPMI-8226 respectively. The unspecific signal resulting from 
the analysis of further dilutions of the RPMI-8226 with the wild-type DNA was even 
higher than the signal detected in the corresponding dilutions of the specific cell line. The 
unspecific signal was a result of the cross-reactivity of the imperfectly matched probes 
(Fig. 3.1 A). To silence this unspecific signal, unlabeled oligonucleotides competing with 
the unmatched probes were added to the reactions. First the oligonucleotide blocking 35 
G>T and G>C were tested in separate reactions (Fig.3.1 B and C). Various 
oligonucleotide concentrations and lengths were tested in order to avoid the unspecific 
signal, but at the same time not to decrease the specific signal from the matched probe 
(data not shown). Finally an equimolar mixture of both blocking oligonucleotides was 
added to the reaction (Fig.3.1 D). The non-labeled oligonucleotides prevented the 
generation of unspecific fluorescence signals. Mean absolute fluorescent values of FAM 
and VIC for the three cell lines are displayed in Tab.3.2.  
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Possible sequence variations in the KRAS nt position 35: AACTTGTGGTAGTTGGAGCTG [G/A/T/C] TGGCGTAGGCAAGAGTGCCTT 
Probe detecting wild-type sequence: TTGGAGCTGGTGGCGTA 
Cell line A427 (35 G>A) sequence: TGTGGTAGTTGGAGCTGATGGCGTAGGCAAGA        Probe detecting 35 G>A: TTGGAGCTGATGGCGTA 
Cell line SW620 (35 G>T) sequence: TGTGGTAGTTGGAGCTGTTGGCGTAGGCAAGA        Oligo blocking 35 G>T: TAGTTGGAGCTTGTGGCGTAG 
Cell line RPMI-8226 (35 G>C) sequence: TGTGGTAGTTGGAGCTGCTGGCGTAGGCAAGA    Oligo blocking 35 G>C: TAGTTGGAGCTCGTGGCGTAG 
Tab.3.2. Mean absolute fluorescent values of FAM (mutant - label) and VIC (wild-type - label) in the experiment testing an assay, which detects 
KRAS mutation 35 G>A in three different cell lines: A427 (specific; mutant 35 G>A); RPMI-8226 (unspecific: mutant 35 G>C); SW620 
(unspecific: mutant 35 G>T). Three different dilutions of the cell line with the wild-type DNA were tested: 90%, 50% and 10% under four 
different conditions: A) Standard - no oligo added to the reaction; B) Oligo blocking 35 G>T added to the reaction C) Oligo blocking 35 G>C 
added to the reaction D) Mix of the two oligo added to the reaction. Ratio - of the FAM fluorescence signal after addition of the blocking 
oligonucleotides in comparison to the FAM fluorescence signal of without blockers 
Cell line A. No oligont. B. + 35 G>T blocker C. + 35 G>C blocker D. + 2 blockers mix 
% Mutation FAM VIC FAM VIC 
Ratio 
(FAM) FAM VIC 
Ratio 
(FAM) FAM VIC 
Ratio 
(FAM) 
A427 10% 35 G>A 0,63 2,32 0,56 2,15 89% 0,51 2,18 81% 0,57 2,15 90% 
A427 50% 35 G>A 1,75 2,00 1,82 1,89 104% 1,87 1,85 107% 2,02 1,80 116% 
A427 90% 35 G>A 3,13 1,65 3,17 1,56 101% 3,01 1,53 96% 3,16 1,59 101% 
RPMI-8226 10% 35 G>C 0,74 2,18 0,38 2,01 51% 0,16 1,88 21% 0,21 1,80 29% 
RPMI-8226 50% 35 G>C 1,85 1,87 1,00 1,77 54% 0,34 1,60 19% 0,36 1,64 19% 
RPMI-8226 90% 35 G>C 2,32 1,84 1,27 1,62 55% 0,40 1,47 17% 0,49 1,57 21% 
SW620 10% 35 G>T 0,60 2,23 0,16 1,90 26% 0,36 1,87 59% 0,27 1,99 44% 
SW620 50% 35 G>T 1,07 2,02 0,41 1,53 38% 0,70 1,58 66% 0,44 1,43 42% 
SW620 90% 35 G>T 1,21 2,01 0,54 1,26 45% 0,73 1,50 61% 0,56 1,25 46% 
Neg. control - 0,18 2,26 0,18 2,26 - 0,15 2,19 - 0,17 2,24 - 
NTC - 0,01 0,16 0,01 0,26 - 0,01 0,17 - 0,02 0,06 - 
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A. No blocking oligo added to the reaction 
 
B. Oligo blocking 35 C >T added to the reaction 
C. Oligo blocking 35 G>C added to the reaction 
 
D. Mix of the two oligo added to the reaction 
 
Fig.3.1. Silencing the unspecific signal by blocking oligonucleotides. Mean absolute fluorescent values of FAM (mutant - label) in the experiment 
testing an assay, which detects KRAS mutation 35 G>A in three different cell lines: A427 (specific); RPMI-8226 (mutant 35 G>C); SW620 
(mutant 35 G>T). Three different dilutions of the cell line in the wild-type DNA were tested: 90%, 50% and 10% under four different conditions: 
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A) Standard - no oligont added to the reaction; B) Oligont blocking 35 G>T added to the reaction C) Oligo blocking 35 G>C added to the 
reaction D) Mix of the two oligont added to the reaction
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3.1.2. Comparison of the Sensitivities of the Allele-specific Real-time PCR 
Assays with Dideoxy Sequencing 
The homozygous SW620 cell line, which harbours G12V KRAS mutation, was mixed with 
the wild-type gDNA to obtain 50%, 20%, 10% and 5% tumour DNA content. Mutation 
status of these samples (titration) was analyzed by allele-specific real-time PCR assays 
and conventional sequencing (Fig.3.2). Allele-specific PCR allowed detection of 2% 
mutant alleles for this specific KRAS assay, while dideoxy chain terminator sequencing 
yielded a sensitivity of 10 - 20%. 
3.1.3 Comparison of Matched FFPE and Snap-frozen Tissues 
Two types of differently preserved tumour tissue specimens were used in the mutation 
study - FFPE and snap-frozen tissues. In order to estimate the variance of the assay 
performance for both types of material, a pilot experiment was conducted in 50 match 
pairs of snap-frozen and FFPE derived DNA samples. KRAS mutation status in codon 12 
was analyzed using two different assays detecting mutations G12D (sensitivity 5%) and 
G12V (sensitivity 2%). 10 mutations (seven G12D and three G12V mutations) were 
detected in both snap-frozen and FFPE derived DNA samples from the 50 matched-pairs. 
These results suggest that both -FFPE blocks and fresh frozen tissue specimens can be 
used with allele-specific real-time PCR. Therefore, in most of the analyses, I proceeded 
with FFPE-DNA as FFPE remains the standard tissue in routine clinical practice.
100% tumour 
DNA 
20% 
50% 
5% 
1% 
10% 
WT 
NTC 
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100%                             10% 
 50% 5% 
 20%                                WT 
Fig.3.2. Comparison of the results obtained by mutation analysis performed by allele-specific real-time PCR and direct sequencing; titration was 
performed by serial dilutions of the homozygous mutant cell line SW620 (KRAS 35 G>T) with the KRAS wild-type genomic DNA and mimics different 
tumour cell content in the sample. On the left: allele-specific real-time PCR X-Y bivariate plot of fluorescence of VIC (G allele, wild-type) and FAM 
(T allele, mutant). Each colored symbol in each panel represents a single sample; every sample was analyzed in duplicate. Red dot: homozygous 
wild-type; blue diamond: homozygous mutant; green triangle: mixture of mutant cell line SW620 with KRAS wild-type genomic DNA; grey squares: 
non-template controls (NTC). On the right: chromatograms obtained by sequencing of particular dilutions
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3.2 THE COHORT OF 864 CRC PATIENTS AS A REPRESENTATION OF THE CRC 
POPULATION IN GERMANY 
The chi-square test was used to assess the distribution of categoric variables within the 
analyzed population of the patients. The results were compared with the statistical data 
from the Tumour Register of the Land Brandenburg (http://www.tumorzentrum-
brandenburg.de), which includes all CRC cases registered between 2000 and 2009 in 
state Brandenburg. Statistical analysis revealed similar distribution of gender (p=0.2117; 
OR: 1.093; 95% CT: 0.9507 to 1.256) and age (p=0.5009; OR: 1.076; 95% CT: 0.8697 
to 1.331). There was a prevalence of colon samples in both populations, stronger in the 
MSKK/RVS study patients (60% vs. 66%; p=0.0011). The 864 samples had the following 
clinical stage distribution: UICC stage I - 18%, stage II - 33%, stage III - 41% and stage 
IV - 8%. The stage distribution in the Tumour Register of the Land Brandenburg is: UICC 
stage I - 22%, stage II - 27%, stage III - 27% and - 18% in stage IV. The difference in 
the distribution of UICC stages is statistically significant (p<0.0001; Chi-square df: 
119.6, 3) and is a result of different classification criteria. In the MSKK as well as in the 
RVS study, only patients with histologically confirmed metastases are registered as stage 
IV, which is not the case in public statistics. Therefore a smaller fraction of stage IV in 
our studies (8% vs. 18%) is compensated by higher frequency of patients registered with 
stage III CRC (41% vs. 27%). 
3.2.1 Mutation Distribution in KRAS, BRAF and PIK3CA in 864 Patients 
Mutation status of three selected oncogenes KRAS, BRAF, and PIK3CA was assessed in 
this subpopulation of 864 patients. The most frequently mutated hotspots that are known 
to contribute to tumourigenesis and resistance to targeted therapies in colorectal cancer 
were selected for the analysis. According to the COSMIC database 9 selected hotspots in 
KRAS gene cover 99% of all mutations found in KRAS in CRC patients, the V600E 
mutation covers over 98% of all substitutions in the BRAF, and 3 hotspots analyzed in 
PIK3CA account for 77% of mutations in this gene (Tab.3.3.). If no mutation was found 
in analyzed hotspots, the sample was considered wild-type for the analyzed gene. 
Six hundred and nine (70%) samples were extracted from FFPE tissues and 255 (30%) 
samples from snap-frozen material. In FFPE samples mutations were detected in 38% 
(KRAS), 10% (BRAF), and 15% (PIK3CA) of the analyzed samples while in snap-frozen 
tissue KRAS mutations were found in 45%, BRAF in 8% and PIK3CA in 15% of the 
samples (Tab.3.4). There was no significant difference in the frequency of mutations 
between the two tissue types (p=0.1731, OR: 1.241; 95% CI: 0.9093 -1.694). 
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Tab.3.3. Comparison of mutation frequencies between the Catalogue of Somatic Mutations in 
Cancer (COSMIC) and MSKK/RVS study 
Gene: Mutations positions: COSMIC database Fraction of 
all mut. 
MSKK/RVS study 
nt aa Frequency Fraction 
of all 
mut. 
found in 
that 
gene 
[%] 
Frequency Fraction 
of all 
mut. 
found in 
that gene 
[%] 
KRAS 
 
34 G>A G12S 2.2% 6.1% 99% 2.8% 6.9% 
34 G>T G12C 3.0% 8.4% 2.3% 5.7% 
34 G>C G12R 0.5% 1.3% 0.2% 0.6% 
35 G>A G12D 12.5% 34.5% 12.6% 31.2% 
35 G>T G12V 8.0% 22.1% 9.8% 24.4% 
35 G>C G12A 2.3% 6.4% 2.4% 6.0% 
37 G>T G13C 0.2% 0.5% 0.1% 0.3% 
38 G>A G13D 7.1% 19.6% 8.0% 19.8% 
436 G>A A146T 0.1% 0.3% 2.2% 5.4% 
BRAF 1799 T>A V600E 10.1% 98% 98% 9.5% 100% 
PIK3CA 1624 G>A E542K 2.2% 18% 77% 3.1% 20.9% 
1633 G>A E545K 4.1% 33% 7.9% 52.7% 
3140 A>G H1047R 3.2% 26% 4.3% 28.7% 
Using the allele-specific assays described in chapter 2, altogether at least one mutation 
was detected in 462 out of 864 patients (53%). Most of the mutations were G <-> A 
transitions (63%), while different transversions account for remaining 37% of the 
mutations. The majority of mutations were observed in the KRAS gene and account for 
more than 60% of all mutations that were found. There were 348 patients (40%) who 
carried mutations in this gene, in two cases double KRAS mutations were detected in the 
same patient (G12C + G12D/ G12S + A146T). Seventy-five percent of all KRAS 
mutations were found in codon 12, 20% in codon 13, and 5% in codon 146. The most 
common mutations was G to A substitution in nucleotide position 35, which affects codon 
12 and results in amino acid change of glycine to aspartic acid (over 30% of all KRAS 
mutations). The second most frequent mutation was G to T exchange in the same 
position, which results in amino acid substitution of glycine to valine and accounts for 
24% of KRAS mutations. Another common KRAS mutation was a substitution 38 G>A, 
which leads to amino acid change of glycine to aspartic acid in codon 13 (20% of all 
KRAS mutations). The distribution of different KRAS mutations in the analyzed hotspots 
is shown in Fig.3.3. 
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Fig.3.3. Distribution of different 
substitutions among all KRAS 
mutations detected in the group 
of 864 CRC patients. The 
majority of mutations were 
detected in codon 12 (75%), 20% 
of mutations were found in codon 
13 and remaining 5% in codon 
146 of the KRAS gene 
 
The frequency in the majority of identified mutations detected among the 864 CRC 
patients is in agreement with the data reported in COSMIC database (Tab.3.3). 
Significant difference was found only in codon 146 (p<0.0001). Our results indicate that 
KRAS A146T substitution occurs with a frequency of over 2% among CRC patients, while 
the frequency reported in COSMIC is 0.1%. 
BRAF mutations were analyzed in one hotspot (V600E) and were found in 82 patients 
(9.5%). This finding stays in concordance with the frequency reported in COSMIC 
database (10%). BRAF mutations were mutually exclusive with KRAS mutations (p≤ 
0.0001) in 80 cases. Two patients showed mutations in both BRAF and KRAS genes. Both 
KRAS mutations coexisting with mutations in BRAF were substitutions in codon 13 
(G13D). One of the two patients had additionally a mutation in the PIK3CA gene. 
Mutations in the PIK3CA gene were assessed in two hotspots in exome 9 (E542K; E545K) 
and one hotspot in exon 20 (H1047R). Altogether alterations in at least one of the 
PIK3CA hotspots were detected in 129 (15%) of the patients. Mutations in exon 9 were 
found in 94 (11%) and in exon 20 in 37 (4%) of analyzed patients. The most common 
mutation was a substitution in nucleotide position 1633 that affects amino acid codon 
545 and leads to a change of glutamic acid to lysine. It accounts for more than 50% of 
all mutations detected in PIK3CA in our setting. The frequency of this mutation is 
substantially higher than reported in COSMIC (Tab.3.3). In three cases two different 
PIK3CA mutations were found in the same tumour (E545K + E542K (P573) / H1047R 
(P172; P267)). 
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Tab.3.4. Comparison of mutational distribution between the samples isolated from the FFPE 
and from the snap-frozen material in the framework of the MSKK and RVS studies 
Gene: Mutations positions: FFPE Snap-frozen 
nt aa Mutation No % Mutation No % 
KRAS 34 G>A G12S 15 2,5% 9 3,5% 
34 G>T G12C 14 2,3% 6 2,4% 
34 G>C G12R 1 0,2% 1 0,4% 
35 G>A G12D 75 12,3% 34 13,3% 
35 G>T G12V 54 8,9% 31 12,2% 
35 G>C G12A 15 2,5% 6 2,4% 
37 G>T G13C 1 0,2% 0 0,0% 
38 G>A G13D 48 7,9% 21 8,2% 
436 G>A A146T 12 2,0% 7 2,7% 
BRAF 1799 T>A V600E 62 10,2% 20 7,8% 
PIK3CA 1624 G>A E542K 22 3,6% 5 2,0% 
1633 G>A E545K 45 7,4% 23 9,0% 
3140 A>G H1047R 25 4,1% 12 4,7% 
There were 96 cases, which had more than one mutation in the analyzed hotspots of the 
three genes: KRAS, BRAF and PIK3CA. In 81 cases mutations in the KRAS gene occur 
concomitantly with mutations in PIK3CA. BRAF and PIK3CA mutations were detected in 
same tumour tissue in only 13 cases. In two cases mutations in BRAF and KRAS were 
found to coexist in the same tumour sample (P224; P286). One of these patients had 
mutations in all three analyzed genes (P286). Detailed information about the mutation 
status of KRAS, BRAF and PIK3CA in individual patients is displayed in Tab.S5. 
3.2.2 Sanger Dideoxy Sequencing and Real-time PCR in Matched 304 Samples 
A subset of 304 samples was analyzed for KRAS mutation by both allele-specific real-
time PCR and Sanger dideoxy-sequencing. The PCR sequencing primers spanned exon 2 
of the KRAS gene allowing detection of mutations in codon 12 and 13. Sequencing results 
of 21 samples were of poor quality. Nineteen of these samples were extracted from the 
FFPE tissue and two from the snap-frozen material. Six of the low quality samples were 
excluded due to the unincorporated dye terminators that formed a dye-blob and 
hampered the interpretation, while the rest of the exclusions resulted from a high 
background noise in the chromatograms of the analyzed samples. Analysis of the 
remaining 283 samples showed five (2%) discrepancies between the two methods (P9; 
P60; P226; P381; P461). Five mutations were found by real-time PCR, but either there 
was no signal from the mutated allele on the sequencing chromatogram or the signal was 
so weak that a prospective interpretation was impossible. Altogether dideoxy sequencing 
failed in 26 cases (21 cases of poor quality and in 5 cases the mutations was not found). 
In 112 samples identical mutations were found by real-time PCR as well as by direct 
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sequencing. An example of the comparison of the dideoxy-sequencing versus allele-
specific real-time PCR performance in mutation analysis is shown in Tab.3.5. All the 117 
chromatograms showing mutations or discrepancies between the two methods are 
displayed in the supplementary table S6. The remaining 166 samples were wild-type in 
KRAS codon 12 and 13 as shown by allele specific real-time PCR and by dideoxy 
sequencing. Ten examples of the wild-type chromatograms are also shown in Tab.S6.
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Tab.3.5. Example of the mutation analysis performed using allele-specific real-time PCR assays and the dideoxy-sequencing. The FAM (mutant 
probe)/VIC (wild-type probe) delta Rn ratios indicate the magnitude of the signal generated in the PCR reactions. The Rn values are displayed 
for the analyzed samples in the first row. Below the Rn values of the controls are presented: negative (wild-type DNA); positive (mutant: 0.5%, 
1%, 2%, 5%, 10%, 20%, 50% and 100%). As positive controls served cell lines that harbour investigated mutations: A549- 34 G>A 
(homozygous); A427- 35 G>A (heterozygous); LoVo - 38 G>A (heterozygous); SW620 - 35 G>T (homozygous) that were serially diluted with 
the wild-type DNA. Red font underlines the sensitivity threshold for each used cell line. Below the table, corresponding chromatograms are 
shown for the analyzed samples. In sample A and B mutation found by real-time PCR (FAM/VIC ratio >cut-off) could not be detected by 
sequencing. In samples C and D the mutations could be found by both methods 
A. B. C. D. 
Sample FAM/VIC Sample FAM/VIC Sample FAM/VIC Sample FAM/VIC 
P60 0,85 P381 0,87 P93 2,57 P833 2,24 
WT 0,21 WT 0,10 WT 0,21 WT 0,11 
A549_0.5% 0,29 A427_0.5% 0,09 LoVo_0.5% 0,20 SW620_0.5% 0,17 
A549_1% 0,29 A427_1% 0,09 LoVo_1% 0,23 SW620_1% 0,19 
A549_2% 0,35 A427_2% 0,15 LoVo_2% 0,26 SW620_2% 0,23 
A549_5% 0,41 A427_5% 0,18 LoVo_5% 0,37 SW620_5% 0,49 
A549_10% 0,44 A427_10% 0,32 LoVo_10% 0,46 SW620_10% 0,77 
A549_20% 0,53 A427_20% 0,49 LoVo_20% 0,98 SW620_20% 1,12 
A549_50% 0,87 A427_50% 1,00 LoVo_50% 1,84 SW620_50% 2,03 
A549_100% 16,36 A427_100% 2,49 LoVo_100% 3,72 SW620_100% 5,45 
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3.2.3 Mutation Status vs. Clinicopathological Characteristics of the Patients 
Next, the mutation status was analyzed in relation to different clinical and pathological characteristics such as gender and age of the 
patient, localization, morphology and stage of the tumour, or number of the lymph nodes in which regional metastases were found 
(Tab.3.6). The mutation status was not analyzed in the context of the outcome of the patients as a 5-year follow-up was not yet 
available. Chi-square test was applied to verify the relation of the various clinical and histological characteristics and the mutation status 
of KRAS, BRAF and PIK3CA. KRAS mutations showed no relation to gender, age, tumour location, UICC-stage, lymph node invasion or 
morphology of the tumour. In contrast, BRAF-mutations were significantly associated with female gender (p<0.0001; OR: 0.2673; 95% 
CI: 0.1626 - 0.4396) and tumour location in the colon (p<0.0001; OR: 6.087; 95% CI: 2.766 - 13.40). In addition, there was a slight but 
statistically not significant association between BRAF mutations and older age (> 60yrs) (p= 0.0632; OR: 0.5281; 95% CI: 0.2665 - 
1.046), and number of positive lymph nodes (p=0.0668; Chi square df: 7.164, 3). Patients, who carried PIK3CA mutations were more 
likely to have colon cancer than rectal cancer (p=0.0569; OR: 1,502; 95% CI: 0.9861 - 2.287) although this association did not reach 
statistical significance. 
Tab.3.6. Clinical and pathological features of 864 patients with respect to the mutation status analyzed in KRAS, BRAF and PIK3CA gene 
Characteristic Total % Any Mut % BRAF Mut % KRAS Mut % PIK3CA Mut % > 1 Mut % 
Total n pts 864 100% 462 53% 82 9% 348 40% 129 15% 96 11% 
Gender 
Male 493 57% 239 48% 24 5% 196 40% 71 14% 52 11% 
Female 361 42% 217 60% 58 16% 147 41% 57 16% 44 12% 
X 10 1% 6 - 0 - 5 - 1 - 0 - 
Age 
≤60 yrs old 172 20% 79 46% 10 6% 61 35% 22 13% 14 8% 
>60 yrs old 688 80% 381 55% 72 10% 286 42% 106 15% 82 12% 
X 4 0% 2 - 0 - 1 - 1 - 0 - 
Localization 
Colon 569 66% 323 57% 74 13% 228 40% 94 17% 72 13% 
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Rectum 292 34% 136 47% 7 2% 119 41% 34 12% 24 8% 
Characteristic Total % Any Mut % BRAF Mut % KRAS Mut % PIK3CA Mut % > 1 Mut % 
X 3 0% 3 - 1 - 1 - 1 - 0 - 
UICC Stage 
I 154 18% 79 51% 14 9% 58 38% 26 17% 19 12% 
II 283 33% 137 48% 20 7% 103 36% 46 16% 32 11% 
III 353 41% 206 58% 41 12% 157 44% 44 12% 35 10% 
IV 69 8% 37 54% 7 10% 28 41% 11 16% 9 13% 
X 5 1% 3 - 0 - 2 - 2 - 1 - 
No Lymph nodes pos. 
0 439 51% 217 49% 34 8% 162 37% 73 17% 52 12% 
1-3 203 23% 116 57% 19 9% 90 44% 31 15% 23 11% 
4-6 97 11% 54 56% 11 11% 41 42% 12 12% 10 10% 
7 or more 106 12% 65 61% 17 16% 47 44% 10 9% 9 8% 
X 19 2% 10 - 1 - 8 - 3 - 2 - 
Morphology 
Adenocarcinoma 623 72% 308 49% 41 7% 245 39% 81 13% 58 9% 
Mucinous carcinoma 70 8% 55 79% 15 21% 37 53% 18 26% 15 21% 
Mixed diff.with mucin 44 5% 39 89% 9 20% 27 61% 11 25% 8 18% 
Rest after neoadj.th. 25 3% 14 56% 0 0% 12 48% 4 16% 2 8% 
Synchronous CRC 42 5% 13 31% 3 7% 9 21% 4 10% 3 7% 
Tumour in adenoma 19 2% 12 63% 4 21% 8 42% 6 32% 6 32% 
Other diff. 30 3% 15 50% 7 22% 7 28% 3 9% 2 7% 
Unusual diff. 11 1% 6 55% 3 25% 3 25% 2 17% 2 18% 
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3.3 CHARACTERISATION OF THE PANEL OF 133 COLORECTAL CANCERS 
XENOGRAFT MODELS 
3.3.1 Results of the Engraftment of 239 Patient-derived Tumour Specimens 
A total of 239 CRC primary tumour specimens were transplanted subcutaneously into 
immunodeficient mice. Transplanted samples derived from the patients of all four UICC 
stages enrolled into the prospective multicenter MSKK study. Out of the 239 tumour 
specimens, 149 passagable xenograft models, deriving from 144 patients, were 
established, resulting in the engraftment rate of 62%. Altogether 90 samples failed to 
engraft. In 22 cases the reason for a failure was an inflammation or an abscess and in 
remaining 68 cases the reason was unknown. Histological analysis and quality control 
(QC) of the clinical data of the 149 models led to the exclusion of 16 xenografts. Some of 
the engrafted samples turned out to be adenomas or metastases originated from other 
primaries. Tumour specimens from the patients who received neoadjuvant treatment 
prior to surgery or who withdrew their informed consent account for remaining 
exclusions. Finally 133 high-quality xenograft models derived from primary tumours of 
130 chemonaive patients remained after assessing the quality control. 
3.3.2 Morphological Entity between Original Patient Tumours and Xenografts 
Histological examination was performed to compare the properties of established 
xenografts with the matching primary tumours. For the majority of the samples a high 
morphological similarity between original patient carcinoma and the xenografts derived 
thereof was observed (Fig.3.4). Hundred twenty-two cases out of 133 were classified 
identically in respect to their histological type. In 11 cases differences were observed 
between the xenograft and matching primary patients‟ tissue. In six cases mucinous 
carcinoma was observed in xenografts and adenocarcinoma in primary tumours, while in 
three cases – in contrary – mucin reported in primary tumour, was no longer observed in 
the matching xenograft. In one case medullary differentiation was observed in the 
primary tumour, while after passaging mixed differentiation with mucin was reported. 
Finally, one adenoma of primary tumour differentiated into squamous cell carcinoma 
(data not shown). 
Sixty seven models were passaged in order to perform drug testing. Each tumour tissue 
was further passaged onto twenty animals out of which five served as controls and were 
examined by the pathologist after the treatment experiment. Differences in the 
histological classification between the first set of passages and further passaged models 
used in the treatment experiment were observed in 8 models (data not shown). In one 
case adenocarcinoma differentiated into both adenocarcinoma and mixed differentiation 
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with mucin, in another case - mixed differentiation with mucin grew further as 
adenocarcinoma and undifferentiated tumour. In six cases mucinous tumours that were 
observed in early passages differentiated into adenocarcinoma. Four of these gained back 
the histological properties of primary tumours. 
 
Fig.3.4. Two examples of 
histopathological evaluation 
and comparison of patient 
tumour (on the left) and the 
xenograft derived thereof (on 
the right). Both xenografts show 
a denser atypical gland packing 
in comparison to the original 
adenocarcinoma. Xenograft B 
shows extensive necroses 
(photo: Dr. Irina Klaman) 
 
 
 
3.3.3 Gene Expression Profiling in Original Patient Tumour and Matched 
Xenograft 
As a part of internal quality control of the xenografts entity between primary tumours 
and the xenografts was analyzed as well on the RNA expression level. Analysis was 
conducted using 254 samples, consisting of 127 pairs, each composed of an original 
sample of a primary colorectal tumour and its xenograft. Gene expression profiling 
revealed that primary tumours and their matched xenografts were more similar to each 
other (Spearman correlation of 0.80) than pairs of primary tumours (Spearman 
correlation of 0.66) or pairs of xenograft tissues (Spearman correlation of 0.69) (data not 
shown). 
3.3.4 Mutations of KRAS, BRAF and PIK3CA in the Panel of 133 Models 
In order to characterize the panel of 133 established xenograft models, mutation status 
was assessed in the most frequently mutated hotspots of KRAS, BRAF and PIK3CA. In 
three patients diagnosed with synchronous cancer two different tumour samples were 
engrafted. Mutation analysis did not reveal differences in mutation status in any of them, 
reducing the number of xenograft models for further statistical analysis to 130. At least 
one mutation was found in 69 (53%) of the analyzed models (Tab.S7). Forty four 
mutations (34%) were reported in codons 12, 13 or 146 of the KRAS gene. Seventeen 
models (13%) harboured BRAF substitution V600E. The same number of models was 
A. B. 
C. D. 
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found to carry PIK3CA mutations with the majority of them (14) found in exon 9. Only 
three models harboured PIK3CA alterations of exon 20 (2%). In 11 out of 17 cases that 
harboured PIK3CA substitutions, additional mutation was observed in KRAS (9 cases) or 
BRAF (2 cases). In one of the models mutation status of PIK3CA could not be assigned. 
KRAS and BRAF mutations were mutually exclusive. Mutation frequency in the MSKK/RVS 
study and in the xenografts was compared in order to evaluate how well the panel of 133 
established models represents the population of patients. Altogether there was no 
difference in the overall mutation frequency in KRAS, BRAF, and PIK3CA (p=0.6804, OR: 
0.9254; 95% CI: 0.6398 - 1.339) between the patients‟ population and the panel of 133 
xenografts. A lower frequency of KRAS mutations of 34% observed in the xenograft 
models versus 40% in the MSKK/RVS study was compensated by BRAF mutations (13% - 
xenograft vs. 9% - MSKK/RVS) that occur only in KRAS wild-type patients. The 
differences in the mutation frequencies in KRAS and BRAF were, however, not 
statistically significant (KRAS: p=0.1171, OR: 1.365, 95% CI: 0.7329 - 1.082; BRAF: 
p=0.2030, OR: 0.670, 95% CI: 0.3988 - 1.218; PIK3CA: p=0.5778, OR: 1.167, 95%CI: 
0.6776 - 2.008). 
3.4 TREATMENT EXPERIMENT WITH CETUXIMAB, BEVACIZUMAB AND 
OXALIPLATIN IN THE 67 XENOGRAFT MODELS 
3.4.1 Response toward Single-agents: Cetuximab, Bevacizumab and Oxaliplatin   
A panel of 67 out of the 133 xenograft models was used to assess the antitumour 
efficacy of three anti-cancer compounds - cetuximab, bevacizumab and oxaliplatin. Each 
of 67 tumour models used in the treatment experiments was engrafted onto 20 mice - 5 
were used for testing of each therapeutic agent, and 5 served as non-treated controls. 
Cetuximab, bevacizumab and oxaliplatin were applied as single-agents (detailed 
treatment scheme: Tab.3.7). Responders were defined by T/C ratio (volume of the 
treated tumour in relation to the non-treated control) of <20%. Non-responder 
(resistant) models were defined with T/C ratios greater than 20%. 
Tab.3.7. Treatment scheme and response rates of the 67 pharmacologically characterized 
xenograft models. Treatment groups consist of 15 and control group of 5 animals each. 
Drug Treatment scheme 
Responder T/C < 20% 
Number % 
Oxaliplatin 
(Eloxatin; Sanofi-Aventis) 
qd 1-5; 5 mg/kg/d, 
i.p. 
4/67 6% 
Cetuximab 
(Erbitux; Merck) 
qd 7x2; 50 mg/kg/d, 
i.v. 
18/67 27% 
Bevacizumab 
(Avastin; Genentech Inc.) 
qd 4; 5 mg/kg/d, i.p. 2/67 3% 
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Altogether 20 models (30%) responded to at least one of the three therapeutic agents. 
Eighteen of 67 models (27%) showed a strong response toward cetuximab monotherapy. 
In contrast, four models (6%) responded to oxaliplatin and only two models (3%) 
responded to bevacizumab. One of the models responded to all three drugs and in two 
models response toward two drugs - cetuximab and oxaliplatin was observed. Detailed 
information on the response to oxaliplatin, cetuximab, and bevacizumab is shown in 
Tab.3.10. A sufficient number of responders were observed only toward single-agent 
cetuximab. Most of the further analyses are, therefore, limited to results of the treatment 
experiment with cetuximab. 
In six models very strong response to cetuximab resulted in almost complete regression 
of the tumour (T/C <5%), further six models responded with reduction in size to 5 - 10% 
of the non-treated control tumour volume, and remaining six responded with a T/C ratio 
of 10 - 20%. Among 49 cetuximab non-responders (73%) there were 8/49 models with 
T/C ratio between 20% - 35%, 12/49 with T/C ratio of 35% - 50% and 29/49 non-
responders with T/C ratio greater than 50% (Tab.3.8). 
Tab.3.8. Distribution of T/C (treated to control) ratios under the treatment with cetuximab in 
the group of 67 xenograft models 
Symbol T/C Ratio Class No of models % 
- > 50 Non-responder 29 43% 
+ 35 - 50 Non-responder 12 18% 
++ 20 - 35 Non-responder 8 12% 
+++ 5 - 20 Responder 12 18% 
++++ < 5 Responder 6 9% 
Total                                                                       n = 67 100% 
Out of 18 events of response to cetuximab 9 occur in the xenograft models originating 
from male patients (n=31) and 9 from female patients (n=36). Among the models 
derived from the patients of 60 years old or younger, there were four responders (4/15), 
while remaining 14 responders represented patients of more than 60 years old (14/52). 
46 out of 67 models were derived from colon cancer and 21 from rectal cancer patients. 
Rectal tumours were more likely to respond toward cetuximab than colon tumours (38% 
vs. 22%). There were 2/8 cetuximab responders of stage I (25%), 8/22 of stage II 
(36%), 4/28 stage III (14%), and 4/9 stage IV (44%; see Tab.3.9). 
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3.4.2 Mutation Distribution in the 67 Xenograft Models 
Altogether at least one KRAS, BRAF or PIK3CA mutation was observed in 41 models 
(61%) out of this subset of 67 xenografts (Tab.3.9.). There were 35 single mutations 
observed: 27 in KRAS, 7 in BRAF and 1 in PIK3CA. In 6 cases (9%) mutations in two 
genes occur concomitantly in KRAS and PIK3CA. Majority of the KRAS mutations (23) 
were observed in codon 12 (70%), 6 mutations were found in codon 13 (18%), and 2 
mutations in each - codon 61 (6%), and codon 146 (6%). Five mutations were detected 
in exon 9 and two in exon 20 of PIK3CA (Fig.3.5). 
 
Fig.3.5. Distribution of mutations detected 
in the hotspots of the KRAS, BRAF and 
PIK3CA genes in the 67 xenograft models 
used as controls in the treatment 
experiments with cetuximab, bevacizumab 
and oxaliplatin 
 
 
A comparison of the mutation profile of the total set of 133 xenograft models (KRAS 
34%; BRAF 13%; PIK3CA 13%) and the subset of 67 xenograft models (KRAS 49%; 
BRAF 10%; PIK3CA 10%) showed no significant differences in the mutation frequency in 
all three genes between the two groups (p=0.1970, OR: 0.6744 95% CI: 0.3701 - 
1.229). If only BRAF and PIK3CA mutations were considered (p=0.5930, OR: 0.7755, 
95% CI: 0.3046 - 1.974), no significant difference was observed between the two sets. If 
one compares the mutation rate in the KRAS gene between the two groups the difference 
is, however, statistically significant (p=0.0271, OR: 1.964, 95% CI: 1.075 - 3.587). The 
higher mutation rate was seen in the 67 models only in codon 12 (p=0.0698), and not in 
codon 13 (p=0.7585) or codon 146 (p=0.9716). In the 67 models used in the treatment 
experiments the mutation status of codon 61 of the KRAS gene was also investigated and 
two additional mutations were identified. The two mutations detected in codon 61 led to 
an overall higher frequency of KRAS mutations in the subset of the 67 xenografts. If one 
compares the frequency of KRAS mutations in the 67 xenograft models with the 
frequency of KRAS mutations in the clinical tumour samples of the MSKK/RVS study, the 
difference does also not achieve statistical significance for all KRAS mutations 
(p=0.3454), nor for mutations in codon 12 in particular (0.4678). 
 
KRAS
40%
BRAF
10%
PIK3CA
1%
KRAS + 
PIK3CA
9%
WT 
39%
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Tab.3.9. Mutation distribution and response to cetuximab in a group of 67 xenograft models 
in respect to the baseline patient characteristics 
Feature Total BRAF 
Mut 
% KRAS 
Mut 
% PIK3CA 
Mut 
% Double 
Mut 
% Resp.p
. 
% 
Total n pts 67 7 10
% 
33 49
% 
7 10
% 
6 9% 18 27
% Gender 
         
  
Male 31 2 6
% 
14 45
% 
3 10
% 
3 10
% 
9 29
% Female 36 5 14
% 
19 53
% 
4 11
% 
3 8% 9 25
% Age 
         
  
≤60 yrs old 15 0 - 7 47
% 
2 13
% 
2 13
% 
4 27
% >60 yrs old 52 7 13
% 
26 50
% 
5 10
% 
4 8% 14 27
% Location 
         
  
Colon 46 7 15
% 
20 43
% 
7 15
% 
6 13
% 
10 22
% Rectum 21 0 - 13 62
% 
0 0% 0 0% 8 38
% UICC Stage 
         
  
I 8 1 13
% 
5 63
% 
1 13
% 
1 13
% 
2 25
% II 22 2 9
% 
7 32
% 
1 5% 1 5% 8 36
% III 28 3 11
% 
18 64
% 
5 18
% 
4 14
% 
4 14
% IV 9 1 11
% 
3 33
% 
0 0% 0 0% 4 44
%  
Among 67 treated models additional mutation analysis was performed in the two 
hotspots of CTNNβ1, the most commonly mutated position in the APC and five hotspots 
of TP53. TP53 point mutations were found in 11 (16%) of the 67 models, out of which six 
harboured additional mutation in KRAS, PIK3CA or BRAF. One mutation was detected in 
the CTNNβ1 gene (S45F) in the model carrying as well KRAS (A146T) and PIK3CA 
(H1047R) mutations. No R1450* mutations were observed in the APC gene in the 
investigated models. 
3.4.3 Mutation Status of the 67 Xenograft Models and Response to Cetuximab 
Mutations of KRAS, BRAF and PIK3CA were already linked with the resistance in the 
patients treated with anti-EGFR mAbs in the large clinical trials (Tab.S12). The mutation 
status of these genes was therefore analyzed in the context of the response to cetuximab 
among the 67 xenograft models. Of the 18 cetuximab responders, 15 responders are 
wild-type in all analyzed hotspots of the three genes (Tab.3.10). The remaining three 
responders carry mutations in the KRAS gene. Two models (M57 and M95) carry 
mutations in codon 13 (Fig.3.6 A and B) and one model (M128) carries a 34 G>A 
mutation in codon 12 (Fig.3.6 C). 
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A. M57 
 
B. M95 
 
C. M128 
 
Fig.3.6. Three xenograft models used in the treatment experiment that were classified as 
cetuximab responders and carry KRAS mutations in codon 13 (M57 - A; M95- B) or in codon 
12 (M128 - C)  
In the non-responder group mutations KRAS codon 12 and 13 gene were found in 26 out 
of 49 of the cases. Additional KRAS mutations in codon 61 in codon 146 were found in 4 
resistant cases. All seven mutations found in BRAF (V600E) were carried by cetuximab 
non-responders. Similarly, all seven PIK3CA mutations were found in the non-responding 
models. There was one CTNNB1 (S45F) mutation found in the model, which was resistant 
to cetuximab. Out of eleven TP53 mutations, detected in the group of the 67 xenografts, 
four were found among responders (4/18) and seven among non-responders (7/49). 
If we apply a standard patient selection procedure, which considers mutations in codon 
12 and 13 to cause resistance to anti-EGFR treatment, 15 out of 18 responders are 
wildtype and would be identified as responder to cetuximab treatment. This corresponds 
to sensitivity (S+) of 83%. In the non-responder group mutations in KRAS codon 12 and 
13 gene were found in 26 out of 49 of the cases resulting in a specificity of 53%. If we 
consider a more sophisticated selection procedure and assume that besides the standard 
KRAS mutations in codon 12 and 13 also KRAS mutations in codon 61 and 146 and 
mutations in BRAF and PIK3CA cause resistance to anti EGFR treatment, the specificity 
increases to 78% as 12 additional resistant cases can be recognized, while the sensitivity 
remains unchanged (83%). 
Results of a recent study (De Roock et al., 2010b) suggest that not all mutations in 
codon 13 of KRAS are associated with resistance to cetuximab. In our data set, we found 
six 38 G>A mutations in codon 13. Two of them were identified in responders and four in 
non-responders. If we link KRAS codon 13 mutations with response to EGFR treatment 
and all other mutations with resistance, a predictor model can be built that is based on 
the combination of wild-type KRAS, BRAF, PIK3CA and KRAS codon 13 mutations. Such a 
predictor achieves an improved sensitivity of 94% (17/18 responders correctly 
recognized). However, its specificity would decrease to 69% as only 34 of the 53 
resistant cases are properly classified. 
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In the subset of the 67 models we investigated additional hotspots in the CTNNß1, APC 
and TP53 genes which are frequently mutated in the CRC patients in order to increase 
the specificity of our predictor model. None of the mutations were linked to response or 
resistance to cetuximab. 
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Tab.3.10. Mutation status of the analyzed hotspots (KRAS, BRAF, PIK3CA, CTNNB1, TP53 and APC) and T/C ratio of response (Resp.) toward cetuximab, 
bevacizumab and oxaliplatin of each of the 67 CRC xenograft samples used in the treatment experiment; T/C - volume of the treated tumour in relation to 
the non-treated control; responders were defined with a T/C ratio of <20%. T/C. *Rating: If T/C: > 50 %: “-”, 36-50 %: “+”, 21-35%: “++”, 6-20 %: 
“+++”, < 5 %: “++++”; NA - not applicable in some of the analyzed hotspots; UICC - Cancer Staging according to the Union for International Cancer 
Control (UICC; see Tab. S.2) 
Models /patients 
Response to the treatment 
Mutation status 
Mut 
No 
UICC 
stage 
Oxaliplatin Cetuximab Bevacizumab 
# 
model- 
ID 
patient- 
ID 
T/C Rated T/C Rated T/C Rated KRAS BRAF PIK3CA CTNNB1 TP53 APC 
1 M128 - 15,9 +++ 1,2 ++++ 20,3 ++ 34 G>A WT WT WT WT WT 1 IV 
2 M76 - 68,3 - 1,7 ++++ 41,0 + WT WT WT WT WT WT 0 II 
3 M88 P812 69,3 - 2,7 ++++ 102,7 - WT WT WT WT WT WT 0 II 
4 M122 - 66,3 - 3,2 ++++ 21,1 ++ WT WT WT WT WT WT 0 II 
5 M82 P792 61,8 - 3,6 ++++ 80 - WT WT WT WT WT WT 0 II 
6 M1 P494 40,9 + 4,5 ++++ 46,7 + WT WT WT WT 524 G>A WT 1 II 
7 M60 P704 35,5 ++ 5,3 +++ 47,4 + WT WT WT WT WT WT 0 III 
8 M112 - 116,7 - 5,3 +++ 63,2 - WT WT WT WT 524 G>A WT 1 IV 
9 M93 P821 19,4 +++ 7 +++ 19,4 +++ WT WT WT WT 743 G>A, NA WT 1 III 
10 M13 - 19,7 +++ 7,6 +++ 39,4 + WT WT WT WT WT WT 0 II 
11 M98 - 37,7 + 8,6 +++ 20,3 ++ WT WT WT WT WT WT 0 III 
12 M29 - 68,4 - 8,9 +++ 31,1 ++ WT WT WT WT WT WT 0 I 
13 M79 P784 40 + 12 +++ 38,7 + WT WT WT WT WT WT 0 IV 
14 M99 - 37,7 + 13,1 +++ 41,4 + WT WT WT WT NA WT 0 II 
15 M84 - 65,5 - 17,2 +++ 43,1 + WT WT WT WT WT WT 0 IV 
16 M95 - 86,4 - 17,3 +++ 34,9 ++ 38 G>A WT WT WT WT WT 1 I 
17 M124 - 61,0 - 17,5 +++ 43,9 + WT WT WT WT WT WT 0 II 
18 M57 P698 84,3 - 19,6 +++ 20,6 ++ 38 G>A WT WT WT 743 G>A, NA WT 2 III 
19 M47 - 22,2 ++ 22 ++ 25,9 ++ 35 G>C WT WT NA WT WT 1 II 
20 M52 - 51,5 + 24,8 ++ 64,6 - 35 G>C WT WT WT WT WT 1 III 
Results 
69 
 
# 
model- 
ID 
patient- 
ID 
T/C Rated T/C Rated T/C Rated KRAS BRAF PIK3CA CTNNB1 TP53 APC No Stage 
21 M85 - 62,2 - 27 ++ 54,5 - 35 G>A WT WT WT WT WT 1 II 
22 M114 - 22,5 ++ 27,1 ++ 35,4 ++ 35 G>C WT WT WT NA WT 1 II 
23 M102 - 4,7 ++++ 28 ++ 24,3 ++ 35 G>T WT WT WT WT WT 1 III 
24 M83 P801 58,1 - 32 ++ 26,7 ++ 35 G>C WT WT WT WT WT 1 III 
25 M117 - 72,2 - 33,8 ++ 48,7 + WT WT 1633 G>A WT NA WT 1 III 
26 M91 - 186,2 - 35,3 ++ 53 - WT WT WT WT WT WT 0 II 
27 M27 P596 42,2 + 36,9 + 16,5 +++ 35 G>A WT WT WT 818 G>A WT 2 III 
28 M72 - 43,9 + 38,1 + 40,4 + WT WT WT WT WT WT 0 II 
29 M75 P775 56,6 - 39,6 + 50,9 - 35 G>C WT WT WT WT WT 1 III 
30 M53 - 25,4 ++ 40,8 + 36,6 + 35 G>A WT WT WT WT WT 1 IV 
31 M80 - 76,6 - 42,4 + 90 - WT WT WT WT WT WT 0 II 
32 M107 - 57,1 - 42,9 + 22,2 ++ 38 G>A WT WT WT WT WT 1 III 
33 M23 - 56,7 - 43,7 + 24,5 ++ WT WT WT WT WT WT 0 IV 
34 M87 P808 52,2 - 45,6 + 108,7 - WT WT WT WT WT WT 0 IV 
35 M94 - 45,2 + 46,7 + 31 ++ WT WT WT WT WT WT 0 II 
36 M129 - 28,6 ++ 47,7 + 52,4 - 35 G>T WT WT WT WT WT 1 IV 
37 M66 P712 45,7 + 48,6 + 41,2 + 183 A>T WT WT WT NA WT 1 II 
38 M132 - 22,3 ++ 49,2 + 21,4 ++ 436 G>A WT 3140 A>G 134 C>T WT WT 3 I 
39 M118 - 61,5 - 51,2 - 58,2 - 35 G>T WT 3140 A>G WT 524 G>A WT 3 III 
40 M104 - 67,7 - 51,6 - 47,4 + 38 G>A WT WT WT WT WT 1 III 
41 M106 - 31,5 ++ 53,2 - 64,3 - 35 G>T WT WT WT WT WT 1 I 
42 M68 P733 68,4 - 55,2 - 57,9 - 35 G>T WT WT WT NA WT 1 III 
43 M55 P692 58,3 - 58,3 - 33,3 ++ WT WT WT WT 844 C>T WT 1 III 
44 M81 P790 37,0 + 60,9 - 57,2 - WT 1799 T>A WT WT WT WT 1 III 
45 M61 P708 93 - 61 - 88,2 - 35 G>T WT WT NA WT WT 1 I 
46 M86 - 53,6 - 62,5 - 50 + 35 G>A WT WT WT WT WT 1 III 
47 M89 - 30,2 ++ 62,5 - 87,5 - WT WT WT WT NA WT 0 III 
48 M123 - 38,8 + 63,4 - 38,4 + WT 1799 T>A WT WT WT WT 1 III 
Results 
70 
 
# 
model- 
ID 
patient- 
ID 
T/C Rated T/C Rated T/C Rated KRAS BRAF PIK3CA CTNNB1 TP53 APC No Stage 
49 M77 - 37,0 + 64,4 - 38 + WT WT WT WT 818 G>A WT 1 II 
50 M101 - 60,9 - 65,7 - 50 + 34 G>A/T WT WT WT WT WT 1 III 
51 M18 P574 72,9 - 67,8 - 103,4 - 35 G>A WT WT WT WT WT 1 II 
52 M121 - 43,2 + 69,3 - 31,8 ++ WT 1799 T>A WT WT WT WT 1 IV 
53 M120 - 48,5 + 69,7 - 54,6 - WT 1799 T>A WT WT WT WT 1 II 
54 M43 P662 61,5 - 72,7 - 66,6 - WT 1799 T>A WT WT WT WT 1 I 
55 M105 - 90 - 73,1 - 56 - WT WT WT WT WT WT 0 III 
56 M92 - 71,4 - 74,7 - 88,7 - 35 G>T WT WT WT WT WT 1 III 
57 M110 - 83,3 - 79,2 - 67,8 - 182 A>T WT 1624 G>A WT WT WT 2 II 
58 M63 P710 34,7 ++ 79,2 - 23,6 ++ 38 G>A WT WT WT WT WT 1 III 
59 M90 - 71 - 79,3 - 82,8 - 35 G>T WT 1633 G>A WT WT WT 2 III 
60 M59 P702 95,3 - 81 - 54,2 - WT 1799 T>A WT WT 742 C>T, NA WT 2 III 
61 M65 - 85,9 - 81,4 - 37,2 + 436 G>A WT 1633 G>A WT 743 G>A, NA WT 3 III 
62 M115 - 77,3 - 82,1 - 54,6 - 38 G>A WT WT WT WT WT 1 II 
63 M56 P693 75 - 88 - 66,7 - 35 G>T WT WT WT WT WT 1 I 
64 M97 - 52,2 - 89,7 - 53,6 - WT WT WT WT WT WT 0 I 
65 M125 - 88,2 - 93 - 34,5 ++ 35 G>T WT WT WT WT WT 1 III 
66 M33 P621 54,7 - 94,7 - 63,8 - WT 1799 T>A WT WT 743 G>A, NA WT 2 II 
67 M96 - 90,3 - 120 - 70,3 - 35 G>T WT 1633 G>A WT WT WT 2 III 
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3.4.4 RNA Expression and Response to Cetuximab 
In addition to mutation markers, RNA expression markers were investigated using 
TaqMan real-time PCR. AREG, EREG and PTEN expression levels were analyzed in the 
RNA isolated from the first set of passages of the 67 treated xenograft models. The 
normalized Ct values are given in the supplementary table S8. A significant correlation 
was found between high expression of AREG and EREG (low Ct values) and response to 
cetuximab. The Pearson Correlation Coefficient (PCC) was calculated between the 
normalized expression values and the T/C ratio, as an indicator of tumour response. PCC 
values indicating association with response to cetuximab were: 0.65 and 0.63 for AREG 
and EREG respectively. PTEN expression was not correlated with cetuximab response 
(PCC=0.06). Correlation calculated for AREG and EREG was even stronger in the group of 
xenograft models with KRAS wild-type (AREG: PCC=0.72; EREG: PCC= 0.75), while the 
PCC value for PTEN (PCC=0.07) did not increase significantly. For 67 cases a PCC greater 
than 0.2 (20%) is significant. DUSP6 and SLC26A3 two candidate genes were additionally 
analyzed in this setting and a correlation between their expression and the T/C values 
was calculated. For SLC26A3 a PCC of 0.38 was obtained and for DUSP6 an inverse 
correlation of PCC=-0.19. Among KRAS wild-type samples SLC26A3 reached a PCC value 
of 0.57 and DUSP6 of -0.36. 
3.4.5 Receiver Operating Characteristic (ROC) Curves of Different Biomarkers 
To verify and compare the accuracy of the classifiers ROC curves were constructed based 
on the assumptions that the following factors are predictive for resistance to cetuximab: 
1. KRAS mutation codon 12 and codon 13 (dashed red); 2. any mutation in KRAS, BRAF 
and PIK3CA (dashed green); 3. any mutation in KRAS, BRAF and PIK3CA without KRAS 
codon 13 mutations (dashed brown); and finally 4. any mutation in KRAS, BRAF and 
PIK3CA without KRAS coding 13 mutations and mean AREG and EREG RNA expression 
(blue; Fig.3.7). 
The area under the curve (AUC) for the four different scenarios is: 0.68, 0.80, 0.82, 
and 0.96 respectively. Tables that served for the construction of the ROC curves and 
that display the potential of the expression values of analyzed genes to recognize 
responders/non-responders are shown in Tab.S9. 
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Fig.3.7. Receiver operating 
characteristic (ROC) curve for prediction 
of patient response to cetuximab as 
measured in the panel of 67 xenograft 
models by: 1:KRAS codon 12 and 13 
mutations (dashed red); 2: all analyzed 
mutations in KRAS, BRAF, and PIK3CA 
(dashed green); 3: by mutations in KRAS 
(excluding codon 13 mutations), BRAF 
and PIK3CA (dashed brown); 4: by 
mutations in KRAS (excluding codon 13 
mutations), BRAF and PIK3CA combined 
with RNA expression of AREG and 
EREG (blue) in the set of 67 xenograft 
models) 
 
 
3.4.6 anti-EGFR Response Prediction by GEP on the U133 Plus 2.0 Arrays 
Encouraged by the correlation observed between the RNA expression level of selected 
genes and response to anti-EGFR mAbs I decided to apply as well genome-wide gene 
expression profiling on the Affymetrix array platform. Affymetrix U133 Plus 2.0 array 
analysis was carried out for 66 out of 67 models that were used in the treatment 
experiment. RNA samples were isolated from the tumour tissues of the non-treated 
xenograft controls. There were five non-treated controls for each model; therefore RNA 
was pooled after completing individual RNA extractions, prior to the hybridization on the 
array. Altogether 18 responders and 48 non-responders were analyzed. First, the raw 
CEL files were normalized using the FARMS program. FARMS condensation identified 
14753 informative probesets out of the 54.000 probesets contained on the U133 2.0 Plus 
array. Then a nested bootstrap method with random forest was applied to the 14753 
probesets for all 66 samples. A signature, which contains 1.800 probesets classified 
responders and non-responders with the highest prospective sensitivity of 89.7% and a 
prospective specificity of 78.1% (Fig.3.8). A short signature of 54 probesets had a 
sensitivity of 85.2% and a specificity of 81.1%.  
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A signature obtained in such manner contains probesets derived from genes coding for 
proteins of known function but also from genes coding for hypothetical proteins. The list 
of 100 best performing probesets and related S+/S- is displayed in the supplementary 
table S10. The first twenty predictive probesets corresponding to 18 genes are listed also 
in Tab.3.11.  
 
Fig.3.8. Prospective performance of the mRNA signatures during balanced discovery on the 
panel of xenografts (18 responders (R) vs. 48 non-responders (NR)); matched primary 
tumours (18 R vs. 43 NR). The plot shows the changes in sensitivity and specificity according 
to the number of best performing probesets included in the classifier 
The probeset with the highest rank belongs to a gene (hypothetical protein LOC158960) 
of unknown function. Among the first twenty probesets are, however, many that were 
previously linked to tumorigenesis and neoplastic processes. The second best classifying 
gene is epiregulin, a ligand of EGFR. Another important ligand of EGFR, amphiregulin B, 
is ranked on the 7th place. The function of the arginine-glutamic acid dipeptide repeats 
(RERE) gene that is ranked on the 3rd place is to repress transcription and to trigger 
apoptosis. The protein tyrosine phosphatase (PTPRF) which plays a role in the Wnt 
signaling pathway appears twice among the twenty best classifying probesets. B-cell 
translocation gene 1 (BTG1), ranked on the 8th place, is a gene which belongs to the 
anti-proliferative gene family that regulates cell growth and differentiation. An inhibitor of 
TNF-induced apoptosis Tax1 (human T-cell leukemia virus type I) binding protein 1 
(TAX1BP1) is listed on place 13. A serine/threonine kinase, which interacts with SMAD 
transcription factors and is involved in the MAPK and TGF-beta signaling pathways, was 
identified on the position 18. Right afterwards another gene that plays a role in signal 
transduction - GNB1 appears in the classification. There were also probesets 
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corresponding to the genes involved in the protein sorting in endoplasmic reticulum 
(KDELR2), regulating membrane traffic to and from trans-Golgi network (TGOLN2) or 
glycosylation in the Golgi apparatus (B3GNT7). Other genes listed among the 20 best 
classifiers are RecQ DNA helicase (RECQL4), protein dpy-19 homolog 1 (DPY19L1) and a 
possible splicing regulator involved in the control of cellular survival (SFRS12IP1). The 
probesets listed on the position 4, 16 and 17 detect genes coding uncharacterized 
proteins. 
Tab.3.11. A list of probesets scoring the 20 best results according to the importance in the 
discrimination between responders and non-responders to cetuximab according to the 
discovery in xenograft models and primary tumours 
  
Affymetrix 
probeset 
Gene 
symbol 
Description 
1 1558685_a_at LOC158960 hypothetical protein BC009467 
2 1569583_at EREG epiregulin 
3 200940_s_at RERE arginine-glutamic acid dipeptide (RE) repeats 
4 1568597_at LOC646762 hypothetical LOC646762 
5 1553581_s_at SFRS12IP1 SFRS12-interacting protein 1 
6 200636_s_at PTPRF protein tyrosine phosphatase 
7 1557285_at AREGB amphiregulin B 
8 200920_s_at BTG1 B-cell translocation gene 1 
9 
200698_at KDELR2 
KDEL (Lys-Asp-Glu-Leu) endoplasmic reticulum protein retention 
receptor 2 
10 1555962_at B3GNT7 UDP-GlcNAc:betaGal beta-1 
11 1553015_a_at RECQL4 RecQ protein-like 4 
12 200921_s_at BTG1 B-cell translocation gene 1 
13 200976_s_at TAX1BP1 Tax1 (human T-cell leukemia virus type I) binding protein 1 
14 1554608_at TGOLN2 trans-golgi network protein 2 
15 1560916_a_at DPY19L1 dpy-19-like 1 (C. elegans) 
16 1558412_at LOC113230 hypothetical protein LOC113230 
17 1559957_a_at LOC642852 hypothetical LOC642852 
18 1552519_at ACVR1C activin A receptor 
19 200745_s_at GNB1 guanine nucleotide binding protein (G protein) 
20 200637_s_at PTPRF protein tyrosine phosphatase 
3.4.7 anti-EGFR Response Prediction and microRNA Expression 
Also microRNA expression signatures were tested in relation to response to cetuximab. 
Total RNA isolated from the tumour tissue of the non-treated controls corresponding to 
the subset of 18 responding xenografts and 19 resistant xenografts was pooled and 
hybridized onto Affymetrix miRNA 2.0. This arrays cover all the miRNAs reported in the 
miRBase V15 (http://www.mirbase.org/) of 131 organisms. Analysis of the best 
discriminating probesets revealed that the signatures of significant predictive benefit 
required at least 100 probesets (sensitivity: 66.7%; specificity: 66.5%; see Fig.3.9). A 
classifier, which contains 250 probesets, performed with a sensitivity of 73% and with a 
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specificity of 67.6%. Accuracy increased with a number of probesets and reached 
77.1%(S+)/66.4%(S-) and 80.7%(S+)/63.6%(S-) for a signature containing 500 and 
1000 probesets respectively. A signature including all 1404 informative probesets had 
the highest sensitivity of 82.3% and a specificity of 73.1%. The list of 100 best 
performing probesets is displayed in the supplementary Tab.S11. Altogether, there were 
probesets corresponding to the genes of 50 different organisms. Interestingly, the 
probesets of human miRNA were rarely the best scoring probesets. Thus, a potential 
signature that contained only human miRNA sequences performed worse than a 
signature which contained miRNA probesets from human and other species. 
  
Fig.3.9. Prospective performance of the miRNA signatures during balanced discovery on the 
panel of xenografts (18 responders (R) vs. 19 non-responders (NR)). Plot shows the changes 
in sensitivity and specificity according to the number of best performing probesets included in 
the classifier 
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Chapter 4 
Discussion 
4.1. UNMET MEDICAL AND DIAGNOSTIC NEED IN COLORECTAL CANCER  
In spite of the many advances in early detection, surgical techniques, therapeutics and 
molecular characterization made over the past decade colorectal cancer remains still a 
major health problem. It is the third most common cancer in man and the second most 
common cancer in women and one of the most aggressive and deadly solid cancers 
(Jemal et al., 2011) with a high, unmet clinical need. 
Improved strategies and new treatment options were developed for colorectal cancer 
patients across different stages of the disease, primarly for patients with advanced 
metastatic colorectal cancer. Although three targeted antibodies including cetuximab, 
panitumumab and bevacizumab were approved since 2004, the 5-year overall survival of 
patients with mCRC remained unchanged and is still dramatically low (4-12%). Why 
targeted therapies do not have a higher impact on survival in mCRC patients? 
One of the reasons for their poor performance is an ability of the tumours to bypass the 
first generation targeted cancer drugs by use of different signaling cascades. Often, after 
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strong initial response, tumours escape the mechanism of action of the therapeutic agent 
and develop resistance. The different escape and resistance mechanisms remain poorly 
understood in most of the cases (Misale et al., 2012). Solid tumours have a high degree 
of intra-heterogeneity and growth signals can be transferred through different signaling 
pathways, therefore targeting a single receptor or a single ligand seems to be 
insufficient. Moreover, the tumour epithelium interacts in a complex way with different 
surrounding cell types also described as tumor microenvironment (TME). These 
interactions are still poorly understood. In addition, tumour epithelial cells have the 
ability to acquire resistance under the selective pressure of cancer drugs (Diaz, Jr. et al., 
2012). 
A second reason for the limited efficacy of targeted therapies is that only a small fraction 
of patients benefit from these drugs. Thus stratification of patients should be carefully 
conducted prior to the treatment. However, responders/resistant cases cannot be 
efficiently preselected as accurate biomarkers are not yet recognized. KRAS mutation 
testing has been established and is mandatory prior to the treatment with cetuximab and 
panitumumab. It is assumed that wildtype KRAS patients benefit from these two anti 
EGFR antibodies while patients with KRAS mutations do not. However, careful analysis of 
tumour samples of patients treated with these two drugs showed that not all KRAS wild-
type patients benefit from the targeted anti-EGFR antibodies. Thus, KRAS alone is not an 
accurate predictive biomarker. For bevacizumab, a mAb directed at the VEGF-A ligand, 
no biomarkers have been identified so far. 
A significant obstacle to the search for predictive biomarkers in patients with mCRC is the 
availability of tumour tissue. Metastasis tissue is accessible prior to treatment in a small 
fraction of patients. For the majority of mCRC patients only primary tumour tissue is 
available for biomarker testing. Primary tumour tissue, however, does not reflect the 
molecular changes which liver or lung metastases have acquired or potential changes 
induced by the drug itself through evolutionary pressure. For majority of the mCRC 
patients who receive neoadjuvant treatment, no current primary tumour tissue is 
available for biomarker testing. 
Preclinical models have been therefore established to provide a tool for an extensive and 
systematic testing of novel drugs. Cancer cell lines and the NCI60 panel in particular 
have been used in many in-vitro studies (Suggitt and Bibby, 2005). Due to the 
disadvantages of the in-vitro approach, such as the limited number of the cancer cell 
lines and their specific properties gained during decades-long cultivation in the 
laboratory, several studies investigated also cancer xenograft models. In most of the 
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cases however, cancer cell lines and not the actual tumour tissues were transplanted on 
the animal (Balin-Gauthier et al., 2006a; Luo et al., 2005b; Prewett et al., 2007a). 
Nevertheless, neither cancer cell lines nor xenograft models derived thereof, reflect the 
heterogeneity and complexity of the tumour (Caponigro and Sellers 2011) and the 
variety of the patients. 
There are also regulatory hurdles in the development process. Current clinical trial 
regulations do not allow testing of novel targeted drugs in chemonaive patients. Novel 
cancer drugs need to be assessed in 3rd or 4th line in heavily pre-treated mCRC patients. 
These patients have already been exposed to adjuvant therapy or have undergone 1st 
line and 2nd line therapy with FOLFOX or FOLFIRI regimens alone or in combination with 
targeted agents. Most of them already showed resistance to the treatment and have 
often only weeks to live, therefore to prove efficacy of a drug and survival benefit in such 
group of patients, is very difficult. 
As we cannot change these clinical regulations, there is a need to develop novel 
preclinical strategies, which allow testing of investigational compounds and establishing 
biomarkers early in the drug discovery process. In this Ph.D. thesis I evaluated a new 
preclinical strategy in which a significant number of xenograft models derived from 
primary colorectal cancer tumour specimens was treated with three drugs approved in 
colorectal cancer: cetuximab, bevacizumab and oxaliplatin. Tumour tissue of the 
xenografts was then used for the molecular characterization on the genetic and 
epigenetic level. Response/resistance data obtained in the treatment experiment with 
xenografts were correlated with the molecular features in order to identify predictive 
biomarkers for drug response to the therapy. 
4.2. MSKK/RVS Clinical Trials as a Representation of the CRC Patients’ 
Population and an Origin of the Engrafted Samples 
4.2.1. Clinicopathological features of the analyzed subset of CRC population 
In order to test whether the sample collection exhibits a random representation of the 
CRC population of all four stages extensive molecular and statistical analyses were 
performed in the subgroup of the 960 patients‟ samples originating from the tumour 
tissue bank. Altogether 96 clinical samples were excluded from the original subgroup of 
960 patients due to clinical, pathological and ethical criteria, leaving a cohort of 864 
patients available for further analyses. Basic clinical and pathological characteristics of 
the 864 patients and tumour samples were compared with the tumour register of the 
state Brandenburg, particularly with patients diagnosed with colorectal cancer in the 
state Brandenburg between 2000 and 2009 (http://www.tumorzentrum-
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brandenburg.de). The comparison of the patients‟ features suggests that the samples 
analyzed in our study constitute a random fraction of the colorectal cancer patient 
population and its balanced representation. 
4.2.2. Mutation distribution in the analyzed subset of CRC population 
Analysis of the mutation distribution in KRAS, BRAF and PIK3CA was conducted by allele-
specific real-time PCR in the group of 864 patients. This approach allowed analyzing nine 
different hotspot mutations in KRAS, the most frequent mutation in BRAF and three 
mutations in PIK3CA. In 53% of patients at least one mutation in the analyzed hotspots 
of KRAS, BRAF and PIK3CA was found. Next, the frequencies of selected mutations were 
compared with the frequencies reported in the COSMIC database (Tab.3.4). The 
distribution of the mutations in the three genes KRAS, BRAF and PIK3CA is in agreement 
with the COSMIC database in most cases. 
A substantial difference in the frequency between our results and the COSMIC database 
was observed in one of the nine analyzed hotspots in the KRAS gene: codon A146T. 
COSMIC displays the A146T at a frequency of 0.1% only, while in the MSKK/RVS study 
this mutation was found in 2.2% of the samples. A reason for this difference may be the 
structure of the COSMIC that screens the information available on the somatic mutations 
in cancer in the published scientific literature and displays it in relation to particular 
human cancers, their morphology, histology or mutated hotspots. Such design of data 
collection leads to a systematic bias. Codons 12 and 13 of the KRAS gene are in the focus 
since these hotspots were associated with resistance to cetuximab in 2006, while other 
KRAS mutations were analyzed less commonly. An oncogenic effect of mutations in 
codon 146 of KRAS was reported later and their influence on the response to the anti-
EGFR monoclonal antibodies has not yet been evaluated in a large clinical trial (Loupakis 
et al., 2009). As a consequence, KRAS codon 146 has been studied less frequently and 
its frequency in the COSMIC database is biased as compared with other hotspots. The 
frequency of the A146T mutation of 2.2% as observed in our setting is, however, in 
agreement with findings of several other studies (Edkins et al., 2006; Loupakis et al., 
2009; Vaughn et al., 2011). 
Also mutations in the PIK3CA gene, E545K in particular, were reported with higher 
frequency among the MSKK/RVS population than in the COSMIC database. A substitution 
of G to A in the nucleotide position 1633 in exon 9 of PIK3CA results in the amino acid 
change E545K and was detected in almost 8% of analyzed patients. These finding are, 
however, in concordance with a population based study conducted in 743 patients (De 
Roock et al., 2010a). 
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There was no significant difference observed in the frequency of V600E BRAF mutation 
between our study (9.5%) and the COSMIC database (10.1%). BRAF mutations were 
also mutually exclusive with KRAS mutations (p≤ 0.0001) (except for two patients) which 
confirms the previous observations (Rajagopalan et al., 2002). 
4.2.3. Correlation of mutations in KRAS, BRAF and PIK3CA with the clinicopathological 
data of the 864 patients  
A statistical analysis of the clinicopathological patient data and the corresponding 
mutation status was performed using the Chi-square test. The results indicated that 
KRAS mutations are not correlated to gender, age, tumour location, or the UICC-stage 
(p>0.1). This observation stays in agreement with most of the published population-
based studies. In contrast, BRAF mutations are linked to the female gender and tumour 
location in colon. There was a trend in the correlation of BRAF mutation and more 
advanced UICC stage (p= 0.0632). Our results support previous reports that BRAF 
mutation status is correlated with specific clinicopathological features and therefore 
identifies a subgroup of colorectal cancers with distinctive clinical and pathological 
characteristics (Li et al., 2006; Zlobec et al., 2010). A weak association of PIK3CA 
mutations and tumour localization in colon, observed in our analysis, was not found in 
other studies (Sartore-Bianchi et al., 2009b; Naguib et al., 2011). The 864 MSKK/RVS 
colorectal cancer samples seem to be in agreement with other population-based studies, 
not only in terms of the distribution of mutations or clinical and pathological features, but 
also in respect to the associations between mutation status and clinical data. 
4.3. SENSITIVITY OF THE ALLELE-SPECIFIC REAL-TIME PCR FOR MUTATION 
DETECTION 
To test the sensitivity of each mutation assay, I performed titrations of mutated DNA 
isolated from the tumour cell lines with wild-type genomic DNA. Most of the allele-specific 
real-time PCR assays detected mutations with a sensitivity of 2.5-5% mutated allele 
content. Some assays, however, had a sensitivity of 10%. A general cut-off at 10% was 
set according to the assays with the lowest sensitivity. Performance of the allele-specific 
real-time PCR method was additionally compared with direct sequencing in KRAS codon 
12 and 13 in a subset of 304 out of 864 samples (35%). In 98% of the patients the 
results are identical. In five cases the mutation was detected only by allele-specific real-
time PCR assays but not by conventional sequencing suggesting that the allele-specific 
PCR assays are more robust in detecting KRAS mutations in tumour samples with lower 
content of mutant allele. Moreover, the short PCR fragments of 80-90 bp used in the 
allele-specific method allow analyses of the samples of poor quality. Such short PCR 
products are not optimal in dideoxy-sequencing and the 283 bp fragment used for 
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dideoxy sequencing led to the failure of 21 additional samples in this setting. Our results 
suggest superiority of the real-time PCR-based assays over direct dideoxy sequencing in 
terms of sensitivity. 
Another research group (Kotoula et al., 2009) compared the allele-specific real-time PCR 
used in our study with a commercially available allele-specific test (TheraScreen® K-RAS 
Mutation Kit, DxS, Manchester, UK) and with conventional sequencing. One hundred 
thirty five diagnostic samples and 75 low-quality samples were analyzed. 109/111 
samples, analyzed by both: allele-specific real-time PCR and sequencing, showed 
matching results. The two discrepant cases were determined as mutants by allele-specific 
real-time PCR and as wild-type by direct sequencing. The results of allele-specific real-
time PCR and the commercial test conducted in the subset of 66 samples were in full 
concordance. In the subset of samples with low quality of DNA the cut-off for the real-
time based methods was set at 10%, which is in concordance with the cut-off applied in 
our study. In comparison, the sensitivity of conventional sequencing was determined at 
the detection threshold of 30% of mutant alleles and could only be applied in the 
samples with relatively well preserved DNA. Furthermore, similar to our observation, in 
some cases more than one mutation was detected in the same tissue sample in KRAS 
codon 12 by allele-specific PCR as well as by the commercial test, suggesting cross-
reactivity of the probes. 
Our results, supported by the findings of other research groups, indicate that allele-
specific real-time PCR assay is a reliable mutation detection method. Due to the high 
sensitivity and the use of short PCR fragments this method can be applied to tissue 
samples with low tumour cell content or to FFPE samples, which exhibit low quality of 
DNA. Allele-specific real-time PCR is more sensitive than the current standard of 
conventional sequencing. Moreover, if blocking oligonucleotides are added to the assays, 
this method has a high accuracy comparable to the performance of more expensive 
commercially available PCR methods. 
4.4. THE PANEL OF XENOGRAFT MODELS AS A REPRESENTATION OF THE CRC 
PATIENTS 
4.4.1. 133 Xenograft Models as a Representation of the CRC Patients’ Population 
The panel of 133 xenograft models derived from patients with colorectal cancer enrolled 
in the MSKK study. Therefore the clinical data of this cohort were investigated with 
respect to the general MSKK patient population. There is no difference in the basic clinical 
characteristics such as age, tumour location or gender in the two cohorts. The 
distribution of UICC stages II, III and IV in the 133 xenograft models is not statistically 
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different (p=0.14) to the stage distribution in a larger clinical cohort of 3.394 patients 
with colorectal cancer of stage II, III and IV that were recruited to the MSKK study. 
However, a statistical difference in UICC stage I was observed. UICC stage I comprise 
T1N0M0 and T2N0M0 tumours. Due to the fact that T1 tumours are very small, there are 
often not enough tumour specimens available for engraftment without compromising the 
histopathological diagnosis. Therefore, T1 tumors are underrepresented in the xenograft 
collection. We also compared the mutation distribution in the 133 xenograft models and 
the cohort of 864 patients of MSKK/RVS study and no significant difference was found in 
the overall mutation frequency in KRAS, BRAF, and PIK3CA. 
Although the mutation rates in the 67 models used for the treatment experiments is in 
agreement with some of the previous studies (Baldus et al., 2010), a comparison with 
the panel of 133 xenograft models revealed that the prevalence of KRAS mutations, 
particularly those in codon 12, is higher among the 67 xenograft models used in the 
treatment experiment. A probable explanation for this bias is that the 133 xenograft 
models exhibit very different growth characteristics and that for the drug treatment 
experiments faster growing tumours were possibly selected. The growth rate of selected 
tumour models could be linked to their greater aggressiveness due to the presence of 
activating oncogenic mutations, indicating that mutations in KRAS codon 12 might be 
responsible for this process. Additional experimental verification is needed to confirm the 
association between different growth rates of some xenografts and particular oncogenic 
mutations. Compared to the overall patient population such difference in the mutation 
frequencies was not observed. 
4.4.2 Xenograft Models as a Representation of Individual Patients’ Tumours 
Regarding the distribution of the mutations in KRAS, BRAF and PIK3CA and the basic 
clinical characteristics of the patients, the panel of 133 xenografts and its treated fraction 
of 67 xenografts reflect the population of CRC patients to a high degree. Subsequently, 
the histology of individual primary tumours resected from the patients and the tumour 
tissue of their matched xenograft models was compared. Histological examination of 133 
samples revealed only eleven discrepancies between the original tumours and the 
corresponding xenograft models. Four of them, however, disappeared within the next set 
of passages. A difference may be a result of the heterogeneity of the original tumour, of 
which the xenograft contains only a part. 
Overall, these results indicate that in the majority of the cases, the panel of 133 
xenograft models preserved the histological properties of the original primary tumours. 
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Finally, the global RNA expression of the 133 xenograft tumours was compared with their 
matched primary tumour tissue using the Affymetrix U133 2.0 Plus array. Results of the 
microarray GEP approach show that the global RNA expression of the xenograft tumours 
is much closer to their respective matched human primary tumours than to other 
xenograft tissues (data not shown). 
4.5. TREATMENT EXPERIMENTS WITH CETUXIMAB, BEVACIZUMAB AND 
OXALIPLATIN 
Three drugs were selected to be tested in the same subgroup of 67 xenograft models: 
oxaliplatin as a standard chemotherapy regime and two mAb: bevacizumab and 
cetuximab. Panitumumab, another targeted mAb was not yet approved in CRC at the 
beginning of the project. Moreover panitumumab, similarly to cetuximab, targets the EGF 
receptor and was therefore not tested in the panel of xenografts. All three tested drugs 
were administered as single-agents to investigate their own cancer suppressive impact 
and to prevent overdoses. 
The size of the treatment experiments was chosen in order to mimic clinical phase II 
studies, which often include 50-100 patients. Efficacy of the three drugs was tested in 
the same 67 xenograft models. Such setting for the comparison of different drugs cannot 
be achieved in clinical practice. Responders were prospectively defined with a T/C ratio of 
<20%. Following this strict criterion response was observed in 27% (18/67) treated with 
cetuximab. Bevacizumab resulted in the response rate of 3% (2/67) only and oxaliplatin 
in the response rate of 6% (4/67). 
4.5.1 Oxaliplatin 
Oxaliplatin is the only platinum agent currently approved in colorectal cancer. It is used 
commonly as a part of the FOLFOX or CAPOX regimens. When evaluated as single-agent 
with untreated CRC patients, oxaliplatin achieved response rates of 18-20% in a phase II 
study (Becouarn and Rougier, 1998; Diaz-Rubio et al., 1998), while in previously treated 
patients an objective response rate of 10% was reported in phase II study (Machover et 
al., 1996). However, the multicenter EFC 4584 trial, which led to the approval of 
oxaliplatin showed that the arm of the study that received oxaliplatin as a single-agent 
resulted in an overall response rate (ORR) of only 1.3% (Rothenberg et al., 2003). In our 
panel of chemonaive xenograft models a moderate response rate of 6% (95% CI: 2%-
15%) was observed which is in between the published data. 
4.5.2 Bevacizumab 
Only 2 of the 67 (3%) xenograft models responded towards bevacizumab (95% CI: 1%-
13%). Nine further xenograft models had a T/C ratio between 0.20 and 0.25 
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corresponding to a response rate of 11/67 (16%). Thus, with less stringent criteria the 
response rate to bevacizumab would be significantly higher. 
In colorectal cancer bevacizumab is approved for use only in combination with 5-FU-
based chemotherapy as a 1st or 2nd line treatment of metastatic colorectal cancer patients 
achieving a response rate of app. 20%. Single-agent bevacizumab used in a treatment of 
advanced disease is inferior to the combination with chemotherapy and shows limited 
efficacy of 3.3% (Cohen et al., 2007), which is comparable with our results of 3%. 
Interestingly, the two xenografts that responded to bevacizumab in our setting are 
derived of stage III patients, while recent results of a phase III clinical trial in patients 
with CRC of UICC stage II or III suggest no benefit from bevacizumab (Allegra et al., 
2011). 
4.5.3 Cetuximab 
Out of three tested drugs only cetuximab showed benefit in a representative subset of 
18/67 (27%) of the xenograft models. Cetuximab is approved in combination with 
chemotherapy (irinotecan or FOLFOX) as well as a single-agent in patients who have 
failed in oxaliplatin- or irinotecan- based chemotherapy. In the original BOND study, 
which led to its approval, a lower response rate for cetuximab monotherapy was 
observed in 11% of 329 treated patients (Cunningham et al. 2004). In this trial however, 
only irinotecan-refractory patients with metastatic disease were treated with cetuximab 
in third line, while in our study xenograft models derived of chemonaive patients of all 
four UICC stages were treated. 
Since 2004 several clinical studies tested performance and efficacy of the anti-EGFR 
agents. A list of clinical trials with cetuximab and panitumumab is shown in 
supplementary table S12. Only a few trials investigated the efficacy of anti-EGFR agents 
as monotherapies and confirmed the results of the BOND study, achieving response rate 
of 8-11% for cetuximab (Giusti et al., 2007; Jonker et al., 2007; Karapetis et al., 2008a). 
In these trials only chemorefractory mCRC patients were enrolled. Recently, randomized 
trials that recruited only chemonaive patients were performed to investigate the benefit 
of adding cetuximab to either FOLFOX (Bokemeyer et al., 2011) or FOLFIRI (Van Cutsem 
et al., 2011). The improvement in overall response rate achieved by adding cetuximab to 
FOLFIRI was 8% and in the population treated with FOLFOX the response rate increased 
by 10%. 
Interestingly, adding anti-EGFR agents to a regimen containing bevacizumab and a 
chemotherapy core did not improve the response rates toward such combination 
therapies (Tol et al., 2009; Hecht et al., 2009). No clinical study investigated the efficacy 
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of anti-EGFR agents as monotherapies in chemonaive CRC patients. Thus our results 
cannot be compared directly with any of the clinical studies. Moreover, clinical studies 
use different criteria to determine response (RECIST criteria) and the quoted response 
rates refer mostly to the overall response rate that includes complete response (CR: 
disappearance of all target lesions) and partial response (PR: at least a 30% decrease in 
the sum of the longest diameter of target lesions) according to the RECIST criteria. A 
comparison of the results obtained in chemonaive xenograft models of all UICC stages 
with clinical trial is, therefore, very challenging. 
4.5.4. Overall Mutation Rate vs. Response to the Treatment 
As discussed in chapter 4.4.1, a prevalence of oncogenic mutations in the treated 
subgroup of 67 models was observed. If analyzed separately, this holds true only for 
KRAS substitutions in codon 12, but not for other mutations in KRAS or alterations found 
in the BRAF or PIK3CA genes. A possible shift resulting in an increased frequency of the 
oncogenic mutations among the treated models would not enrich the treated subset in 
responders. In contrary, analyzed mutations are not only known to be oncogenic, but are 
associated with resistance to EGFR-targeted treatment. Therefore a higher mutation rate 
should result in a larger subset of resistant cases. Nevertheless the response rate of 27% 
obtained with cetuximab monotherapy in the panel of 67 xenograft models derived from 
chemonaive primary tumours of patients with all four UICC stages was higher in 
comparison to clinical studies in which only refractory mCRC patients or chemonaive 
mCRC patients were treated. 
Oxaliplatin and bevacizumab, on the other hand, showed low efficacy in the treatment 
experiments. The response rates of 3% for bevacizumab and 6% for oxaliplatin are 
comparable with those obtained in the reported clinical trials, which tested the effect of 
single-agent therapies. Unfortunately, our understanding of the molecular background of 
resistance to bevacizumab and oxaliplatin is limited. In addition, there are no predictive 
biomarkers for the two agents. Mutations in KRAS, BRAF or PIK3CA that are linked with 
resistance to anti-EGFR treatment have not been connected with the response to 
bevacizumab or oxaliplatin. 
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4.5.5. Benefit from Cetuximab According to the CRC Stages 
Interestingly, there was no association between the response to the anti-EGFR treatment 
and UICC stage of disease (p=0.1955, Chi-square, df: 4.495, 3). To the best of my 
knowledge there are no reports on cetuximab efficacy in patients with colorectal cancer 
of stage I and II. The highest response rate in our setting was achieved in stage IV 
(44%) and the lowest in stage III (14%) (Tab.3.9). However, only nine models derived 
of stage IV patients were included in the set of 67 models, out of these four xenografts 
showed response to cetuximab. In the clinic cetuximab is applied predominantly to 
patients with metastatic colorectal cancer (stage IV), but our representation of this stage 
is not sufficient to draw accurate conclusions.  
Stage III tumours constituted over 40% of the treated xenograft models. No benefit from 
the addition of cetuximab in the adjuvant setting (stage III) could be seen in a large 
randomized phase III clinical trial (N0147) that enrolled 2664 patients. Resistance to 
anti-EGFR treatment in stage III patients was independent of the KRAS mutation status 
(Alberts et al., 2012). The N0147 trial, however, investigated a potential benefit from 
cetuximab added to FOLFOX4 in comparison to the FOLFOX alone and therefore required 
benefit from cetuximab over an established chemotherapy regimen. Cetuximab efficacy 
was, furthermore, tested only in the resected stage III colon cancer patients. Because of 
the microscopic cancer cells that remained after tumour resection, it is challenging to 
prove a benefit from the treatment in such patients. 
4.5.6 Effect of Bevacizumab among Different CRC Stages 
Not only cetuximab, but also bevacizumab failed to maintain its beneficial effect observed 
in patients with metastatic colorectal cancer (stage IV) when tested in the adjuvant 
setting in a large clinical trial. Administered to stage II and III CRC patients, 
bevacizumab showed no improvements in terms of response rates and overall survival in 
two randomized population based studies: CO-8 and AVANT (Allegra et al., 2011; de 
Gramont, 2011). Addition of bevacizumab was actually detrimental to the efficacy of 
chemotherapy alone. Similar to the N0147, trial both of the studies were designed to test 
postoperative efficacy of mAb in patients with stage II and III colon cancer with an aim 
to provide evidence for superiority of bevacizumab addition over chemotherapy regimen 
alone. In our xenograft study by applying a threshold of T/C<20% only two models were 
observed to respond to bevacizumab as monotherapy. Both responder xenografts were 
derived of stage III patients. If we adjust the T/C threshold retrospectively and define 
the responders with T/C ratio <25%, additional nine bevacizumab responders will be 
recognized. Five of them represent stage III tumours. Applying the same retrospective 
adjustment of the T/C ratio threshold in case of cetuximab would clearly result in an 
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increased response rate. Biomarkers established in the clinic would, however, no longer 
apply in our setting of xenograft models. Such shift of the T/C ratio threshold for 
cetuximab is therefore unjustified. Lack of biomarkers associated with the response to 
bevacizumab restrains the retrospective optimization of the chosen threshold for the anti-
VEGF treatment. 
4.5.7 Structural differences of the Four CRC Stages - Impact on the Response to 
the Treatment 
As already discussed, an addition of cetuximab or bevacizumab to the FOLFOX scheme in 
patients with stage II or stage III colorectal cancer did not result in any increase of 
progression free survival or overall survival in large clinical trials. Why a simple 
translation of efficacy of these two targeted antibodies from advanced metastatic 
colorectal cancer into the adjuvant setting did not work? The most probable explanation 
for this failure is a difference in the structure of the tumour in stage II/III versus stage IV 
(Sobrero and Di Benedetto, 2012). In large T4 tumours of stage II, adjuvant treatment is 
applied to remove residual tumour mass after the surgery. In stage III additional 
chemotherapy is used to inhibit the migration of potential microscopic tumour cells and 
the spread of tumour cells from potential positive lymph nodes, which were not removed 
during surgery. In stage IV colorectal cancer the main goal of the treatment is the 
removal of the primary tumour mass by surgery, and if possible, the resection of single 
isolated metastases. In the majority of cases, however, metastases are too large or too 
numerous and the palliative therapy is administered to shrink the metastases mass to 
such extend that resection of the remaining metastases will be possible. Even assuming 
identical genetic and epigenetic background among different CRC stages, the adjuvant 
setting (stage II and III) and stage IV colorectal cancer seem to be mechanistically 
different diseases with a difference in sensitivity of macromestases and micromestases as 
exposed to the treatment. Therefore an assumption that stage II/III and metastatic 
stage IV disease should be treated using similar targeted agents seems incorrect. 
Such considerations indicate a possible limitation of the xenograft models in drug efficacy 
testing. The set of 133 xenografts was derived from primary tumours only. This concept 
is supported by the fact that primary tumour specimen is the only material routinely 
available in the clinical practice. Recently another panel of CRC patients-derived 
xenografts was created (Bertotti et al., 2011). Engrafted tissues were however derived, 
not from primary tumours, but from CRC liver metastases. Forty four of these metastatic 
models were treated with cetuximab resulting in tumour shrinkage in 5 cases (11%), 
disease stabilization in 14 cases, and disease progression in the remaining 28 cases. In 
comparison, a response rate of 27% was achieved in the primary tumours in our panel of 
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models. In the study of Bertotti et al. cetuximab response was defined as regression of at 
least 50% in the tumour volume compared to the baseline tumour volume. Using this 
criterion the response rates were inferior in comparison to the results of our study in 
which more stringent criteria were applied. Moreover, there were no clinical data 
regarding potential previous treatment of the patients (e.g. adjuvant chemotherapy) 
from whom the liver metastases were resected. The differences in the design of the 
study, as well as the limited number of stage IV CRC tumours treated in our setting, 
make a comparison between the two studies difficult. To investigate whether the actual 
origin of the tumour tissue (primary/metastasis) makes a difference in terms of response 
to the treatment, an approach of comparing the response rate in both tissues originating 
from the same patients would be of high interest. Nevertheless, due to the lack of 
primary tumour tissue and matched liver and lung metastases, such treatment 
experiment could not be performed to date. It is, however, possible that the difference in 
the efficacy of cetuximab between the two xenograft panels is caused not by the 
engrafted material, but by the dose and the treatment schedule. In the study performed 
by Bertotti and colleagues cetuximab was administered twice a week at a dose of 20 
mg/kg, while in our setting daily doses of 50 mg/kg were given. 
4.5.8 Response and the Used Doses  
Therapeutic protocols in humans avoid nearly toxic maximum tolerated doses (MTD). For 
the monoclonal antibodies cost-effective doses were established in our study. The use of 
the relatively high dose of cetuximab may be therefore a reason for the high response to 
cetuximab in comparison to the clinic and the study of metastatic xenograft models. It 
could lead to potentially false positive tumour responses in mice and to over-
interpretation of the preclinical activity of cetuximab. That does not hold for the other 
two tested compounds oxaliplatin and bevacizumab. Response to both bevacizumab and 
oxaliplatin was observed in few models only. In xenograft models for majority of the 
agents a significantly higher MTD can be established than in human patients leading 
potentially to larger therapeutic effects in xenografts than in patients. In some cases, 
however, a lower or similar MTD applied to both patients and the models (Kerbel, 2003). 
Due to the different mechanisms of actions of the tested drugs and variety of factors that 
influence their efficacy, a comparison between the three tested agents is impossible. 
There is, therefore, no clear evidence that the doses applied in the treatment experiment 
improved the response rates in our study. 
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4.6 BIOMARKERS OF RESPONSE TO ANTI-EGFR mAb IN THE SET OF 67 TREATED 
XENOGRAFT MODELS 
4.6.1 Mutation Status and Response to the anti-EGFR Treatment 
Possibility of the false positive tumour responses seems to be unlikely as well in the 
context of predictive biomarkers analyzed in the set of 67 treated xenografts. For the two 
tested agents: bevacizumab and oxaliplatin no such approved biomarkers exist, 
moreover underrepresentation in the group of responding models prevented discovery of 
new ones. Due to pragmatic reasons the biomarker evaluation effort of this study was 
focused on cetuximab. KRAS and BRAF mutation were already known markers for 
resistance to cetuximab. Nevertheless, until now mutations in codon 12 and 13 were 
occasionally reported as well within responders to anti-EGFR treatment (Peeters et al., 
2010; Sartore-Bianchi et al., 2009b; Benvenuti et al., 2007; Karapetis et al., 2008a). In 
our panel of 67 treated xenografts, three out of the total of 18 cetuximab responding 
xenograft models (17%, 95% CI: 4-41%) were found to carry KRAS mutations 
(Tab.3.10). Two of them harboured a substitution in codon 13 (G13D; 38G>A), which 
according to the COSMIC database, accounts for app. 20% of all mutations found in the 
KRAS gene. Our observation is in agreement with the clinical data published by De Roock 
et al. indicating that codon 13 mutants may actually benefit from anti-EGFR treatment 
(De Roock et al., 2010b). Functional differences between the mutations in codon 12 and 
13 of the KRAS gene were previously investigated using in vitro approach (Guerrero et 
al., 2000). Specimens carrying the mutation in codon 12 formed colonies of increased 
cell density, induced spontaneous anchorage-independent growth, and demonstrated 
reduced predisposition to enter apoptosis in comparison to the KRAS codon 13 mutants 
(Guerrero et al., 2000). Such differences in the oncogenic effect of KRAS mutations in 
respect to their position support an observation that codon 13 mutants are more 
sensitive to anti-EGFR treatment than KRAS codon 12 mutants. Despite the conflicting 
data for codon 13, KRAS mutations are the only approved biomarkers for predicting 
response to the anti-EGFR treatment to date. 
Nevertheless, most of the clinical data also demonstrate that BRAF mutation V600E is 
associated with resistance to cetuximab treatment. Results of numerous studies as well 
as our findings provide proof that patients harbouring BRAF V600E mutation derive no 
clinical benefit from anti-EGFR targeted agents (Di Nicolantonio et al., 2008; Loupakis et 
al., 2009; De Roock et al., 2010a; De Roock et al., 2011). 
While in case of BRAF, the results are unambiguous, the role of PIK3CA mutations as 
markers of resistance to cetuximab is still controversial. Results of the study conducted 
in 2009 by Prenen and colleagues neglect the correlation between PIK3CA mutation 
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status and the benefit from cetuximab treatment. On the other hand, results of a 
population based study conducted in 773 patients indicate that only PIK3CA exon 20 
mutations and not mutations in exon 9, are significantly associated with resistance to 
anti-EGFR therapy (De Roock et al., 2010a). In this setting only one model carried an 
exclusive PIK3CA mutation in exon 9 (E545K) and was classified as resistant to 
cetuximab with a T/C (treated to control) ratio of 34%. Additional six PIK3CA mutations 
(four in exon 9 and 2 in exon 20) were found in xenograft models that already carried 
KRAS mutations. The second mutation in the PIK3CA gene seems to enhance an 
oncogenic effect of the KRAS mutation that results in the activation of the signaling 
pathway regardless of EGFR blocking. The mean of T/C ratios in the group of non-
responders carrying two mutations, one in KRAS and the second in PIK3CA, was 77% 
(95% CI: 57-89%) in comparison to 57% (95% CI: 48-64%) in the non-responders with 
KRAS mutation only. The T/C ratios in the group of non-responders carrying two 
mutations appear higher than those of non-responders carrying one mutation. The 
difference, however, does not reach statistical significance as the 95% confidence 
intervals overlap. 
Despite the predictive value of the analyzed mutations, there were 11/49 (22% CI: 11-
37%) non-responders that did not harbour a mutation in any of the three genes KRAS, 
BRAF and PIK3CA. Resistance in some of these cases could be explained by the presence 
of other activating mutations that were not investigated in this study. To the current 
knowledge no other common mutations are related with the response to anti-EGFR 
mAbs. Other mutational hotspots in the APC, CTNNB1, and TP53 genes, which are 
frequently mutated among CRC patients, were also assessed. Our data suggested that 
APC, CTNNB1 and TP53 mutations in the analyzed hotspots are not associated with 
responsiveness to cetuximab or were not frequent enough to prove their predictive value 
in the group of 67 xenograft models. Although mutations in NRAS were reported to have 
a similar impact on the efficacy of the anti-EGFR mAb that KRAS mutations, NRAS 
mutations occur relatively rare (2 - 4%) (De Roock et al., 2010a; Maughan et al., 2011). 
Thus NRAS mutations cannot explain every resistant case. 
A classificator composed, additionally to KRAS, BRAF and PIK3CA, of a number of rarely 
mutated genes would require disproportionally more effort in terms of analyses, by a 
chosen method, in comparison to its contribution in the stratification of the patients. 
Moreover, due to the small subset of positive cases, proving efficacy of such rare 
biomarkers requires a great number of samples to reach statistical significance. 
Discussion 
91 
 
4.6.2 RNA Expression and Response to Cetuximab 
We decided to search for potential new biomarkers also on the RNA level using on the 
U133 Plus 2.0 Affymetrix microarrays, which allowed a genome-wide transcript search. 
Discovery effort for classifying RNA expression signatures was performed using a nested 
bootstrap approach. The best RNA expression signature found in xenografts has a 
sensitivity of nearly 90% and a specificity of 85%. A signature obtained by GEP on the 
Affymetrix U133 Plus 2.0 microarrays in the xenograft models confirmed the importance 
of EGFR ligands - AREG and EREG expression in response to cetuximab, observed 
previously in the real-time PCR analyses (AREG: PCC= 0.65; EREG: PCC= 0.63). An 
inverse experiment performed with a purpose of translating results obtained on the array 
into real-time PCR approach failed. Correlation between response and RNA expression of 
LOC158960 (the first among the best classifying genes) achieved a PCC of – 10% and of 
PTPRF (place 6 among the best classifying genes) a PCC of 24% using real-time PCR 
methods. Thus the Affymetrix array results could not be validated by real-time PCR. A 
possible reason is the difference in the binding sites and the number of probes used on 
Affymetrix GeneChip and allele-specific probes for the genes of interest. The overall low 
expression levels of LOC158960 measured by allele-specific probes in the real-time PCR 
approach could also negatively affect the results and influence the difference in 
expression levels by the process of normalization. 
4.6.3 microRNA Expression and Response to Cetuximab 
FFPE is a standard method used in routine pathological practice to preserve tumour 
specimens. It leads, however, to a degradation of nucleic acids. Therefore, microRNAs 
that possess a high degree of stability are an attractive target in the molecular analyses 
of tumour FFPE tissue samples and their potential for predicting response to cetuximab 
was also investigated. This class of short ~22 nucleotide ribonucleic acid molecules plays 
a role in the post-transcriptional regulators that bind to multiple target-mRNAs. Binding 
to the complementary sequences in the 3‟ UTR usually results in translational repression, 
target degradation, and in gene silencing. microRNAs are predicted to regulate app. 60% 
of all human genes. Since their discovery in 1993 more than 1.700 unique mature human 
micro-RNAs have so far been identified (miRBase v18). In 2011 521 new microRNA 
sequences were identified, resulting in the increase in the number of known unique 
mature human miRNA by 43% from 1212 to 1733. This number is growing constantly. 
Bioinformatic analysis showed that the best microRNA signature included all 1404 
informative probesets and reached sensitivity of 82.3% and a specificity of 73.1%. In 
general, shorter microRNA signatures e.g. with 54 probesets had only a limited predictive 
capacity reaching a sensitivity of 63.4% and a specificity of 64.4%. In comparison, a 
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short RNA marker containing signature of 54 probesets generated on the Affymetrix 
U133 Plus 2.0 array had a sensitivity of 85.2% and a specificity of 81.1%. 
It is unlikely that microRNAs are less suitable for response prediction than mRNAs. 
However, it seems that the total number of markers after normalization is critical for 
predicting response to drugs, particularly if absolute differences in expression of 
microRNA or mRNA markers are relatively small between the responder and non-
responder groups. The GeneChip Human Genome U133 Plus 2.0 Array contains 54.000 
probesets representing 47.000 transcripts and variants of only human genes, which is 
app. 20 times the number of probesets contained on the microRNA array.  
Interestingly, taking under account our still limited knowledge and understanding of the 
function of particular microRNAs, surprisingly large fraction of the best performing 
microRNAs was already linked with regulation of either EGFR pathway (miR-125, let-7 
family, miR-99b, miR-143, miR-145) or with other events known to contribute to 
colorectal tumorigenesis like loss of PTEN (miR-195) or TGF-β1 signaling (miR-224) 
(Monzo et al., 2008; Ng et al., 2009; Slaby et al., 2009; Volinia et al., 2006). This 
functional link seems to confirm the potential of microRNA signatures. The greatest 
advantage of the microRNA in comparison to mRNAs is their robustness in degraded RNA 
samples. Therefore microRNAs are of great interest in clinical application that uses 
standard FFPE tissue preservation. 
4.6.4 Combining the Mutation Status with RNA Expression Levels has the 
Highest Accuracy for Predicting Response to Cetuximab 
Neither the mRNA nor the miRNA signature obtained with Affymetrix array technology 
achieved high accuracy. In addition, the efficacy of the mRNA signature could not be 
confirmed in the set of corresponding primary tumours. Among the best classifying genes 
from this mRNA signature were, however, AREG and EREG, previously reported to be 
linked with the response to the anti-EGFR treatment. 
Real-time PCR measurements confirmed a significant association of high expression of 
the two EGFR ligands and sensitivity to cetuximab in the set of xenografts (AREG: 
PCC=0.72; EREG: PCC=0.75). Measurement of the AREG and EREG RNA expression in 
the corresponding snap-frozen and FFPE tissues of original primary tumours indicates 
that the expression level of analyzed genes is to some extent preserved (snap frozen: 
AREG PCC: 0.60; EREG PCC: 0.75; FFPE: AREG PCC: 0.55, EREG PCC: 0.57). Moreover, 
the higher predictive power of AREG and EREG mRNA expression level was observed in 
the models pre-selected by mutation analysis. 
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To avoid further technical challenges a sequential analysis of mutation and mRNA 
expression by real-time PCR was applied. Such combination of the highest accuracy 
seemed also to be preserved in the primary tissue of the matched patients‟ tumours. A 
comparison of the current biomarkers and their possible combinations measured by the 
real-time PCR is shown in Tab. 4.1. 
Tab.4.1. Cross tabulation table shows the relation between response towards cetuximab and -
Predictor 1: mutation status in codon 12 and 13 of KRAS (standard patient selection 
procedure); Predictor 2: all mutation in KRAS, BRAF and PIK3CA; Predictor 3: all 
mutations in KRAS (excluding codon 13 mutations), BRAF and PIK3CA; Predictor 4: all 
mutations in KRAS (excluding codon 13 mutations), BRAF and PIK3CA, combined with RNA 
expression of AREG and EREG. 
 
Predicted Response 
Observed Response 
 
 
Yes No Sums: 
Predictor 1  
WT 15 23 38 
Mut 3 26 29 
Sums: 18 49 67 
Sensitivity/Specificity: 83% (61%-94%) 53% (39%-66%)   
Predictor 2 
WT 15 11 26 
Mut 3 38 41 
Sum 18 49 67 
Sensitivity/Specificity: 83% (61%-94%) 78% (64%-87%)   
Predictor 3 
WT+ c.13 17 15 32 
Mut 1 34 35 
Sum 18 49 67 
Sensitivity/Specificity: 94% (74%-99%) 69% (55%-80%)   
Predictor 4 
WT+ c.13 17 7 24 
Mut + AREG,EREG 1 42 43 
Sum 18 49 67 
Sensitivity/Specificity: 94% (74%-99%) 86% (73%-93%)   
Standard testing is currenty routinely performed only for KRAS mutations in codon 12 
and 13. No mutations in these two KRAS codons were found in the 38 out of the 67 
treated xenograft models. According to the standard approach, anti-EGFR mAb would be 
administered to all of them, while only 15 out of them would respond to cetuximab and 
23 would not. Such patients‟ stratification results in a positive predictive value (PPV) of 
only 0.39 and contributes to the unnecessary toxicity and costs. A negative predictive 
value (NPV) of 26/29 = 0.90 indicates that only three out of potential responders would 
not receive the treatment according to the current guidelines (Tab.4.1, predictor 1). 
If we include in the classifier all the mutations in KRAS, BRAF and PIK3CA, the PPV 
increases to 15/26 = 0.58 (Tab.4.1, predictor 2). A predictive panel composed of all 
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analyzed mutations would recognize additional 12 non-responders and prevent over-
treatment in these patients. Seven of these 12 non-responders carry BRAF V600E 
mutations indicating that this mutation should be now considered, alongside with KRAS 
mutations, as a criterion to exclude the patient from the treatment with anti-EGFR mAbs. 
Four additional KRAS mutations - two in codon 61 and two in codon 146 were found in 
our setting. All of these mutants did not benefit from the treatment with cetuximab. Only 
one model carries a single PIK3CA mutation. Although no response was observed in this 
model, a larger study is needed to decide whether PIK3CA mutations are strongly 
associated with the lack of benefit under anti-EGFR treatment, as the results of clinical 
studies are conflicting. The NPV of the second predictor is 38/41 = 0.93. 
An assumption that KRAS codon 13 mutants benefit from the treatment would lead to the 
further refinement of the classifier and an increase in the NPV to 34/35 = 0.97 (Tab.4.1, 
predictor 3). That means that only one potential responder would not obtain the 
treatment. On the other hand, as four codon 13 mutants showed no response in our 
setting, under such assumption, the PPV drops to 17/32 (0.53). 
A combination of the latter classifier with determination of RNA expression of AREG and 
EREG results in the best potential predictive classifier with a sensitivity of 94% and a 
specificity of 86%. The PPV of this predictor is 17/24=0.71 as the expression level of the 
two EGFR ligands indicates which of the KRAS codon 13 mutants are unlikely to respond 
to cetuximab (Tab.4.1, predictor 4). The resulting NPV is 42/43 =0.98 meaning that only 
one patient recognized by the predictive panel as resistant would be an actual responder 
(Fig.4.1). To my best knowledge, no guideline concerning the AREG and EREG expression 
cut-off exists so far. As measured by real-time PCR, expression data needs normalization 
and as well here no standard procedures were yet established. Such technical difficulties 
lead to the challenges in incorporating of the AREG and EREG in the standard testing 
procedure prior to the therapy, although their clear predictive value was observed by us 
and by others (Baker et al., 2011; Jacobs et al., 2009; Khambata-Ford et al., 2007). 
The retrospective character of this study is manifested i.a. by the optimized selection of 
the cut-off in the expression analysis of AREG and EREG. Such approach may result in a 
higher accuracy of the predictive panel. Although a potential shift in the prevalence of the 
mutated tumours in the subset of 67 treated models seems to have no effect on the 
cetuximab response rate, it may also affect the predictive value of established classifier. 
As analyzed oncogenic mutations are linked with the resistance to anti-EGFR, their high 
frequency could enrich the fraction of recognized non-responders resulting in an 
improved specificity. 
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In spite of the fact that the presented values are found in a retrospective analysis, an 
agreement of our data with the previous findings strongly demonstrates their clinical 
potential. I therefore think it is prudent to adopt a sequential patients‟ stratification 
approach in which mutations in KRAS codons 12, 61 and 146 would be analyzed as first. 
In the group of patients wild-type in these KRAS hotspots, BRAF mutation analysis should 
result in the further identification of the resistant cases. Underrepresentation of single 
PIK3CA mutations in our panel does not allow conclusions about the usefulness of 
PIK3CA in improving sensitivity of the classifier. Although, not analyzed in our setting, 
strong evidence supports consideration of NRAS mutations in the standard protocol to 
select patients prior to the admission of the anti-EGFR mAb. Finally, an effort should be 
made to adjust and include the analysis of AREG and EREG expression and enable 
incorporation of gene expression biomarkers in the last step of the selection procedure. 
Such analysis, performed in the patients that are wild-type in the BRAF, NRAS and codon 
12, 61 and 146 of the KRAS gene should finally enrich the fraction of the recognized non-
responders. In conclusion, adjusting for their retrospective character, our analyses 
deliver an informative value of the priorities that should be set in the standardized 
selection of the CRC patients to be treated with anti-EGFR mAb. 
 
Fig.4.1. A graphic illustration of the population corresponding to the 67 xenograft treated 
with cetuximab and the prediction of response by the biomarkers included in the classifier: 
KRAS, BRAF and PIK3CA mutations and expression level of AREG and EREG 
(modified:Sartore-Bianchi et al., 2009a). 
KRAS mutant 
BRAF mutant 
PIK3CA mutant 
AREG/EREG  
low expression 
Not predicted by classifier 
Responder WT Responder 
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4.7 TRANSLATION OF THE RESULTS OBTAINED IN THE PRECLINICAL 
XENOGRAFT MODELS INTO THE CLINIC 
A five year follow-up of the patients from the MSKK study, from whom the xenografts 
were derived, does not yet exist. Thus a direct comparison of the drug efficacy observed 
in preclinical xenograft models with an actual response of the patients in clinical routine 
is, to date, unfortunately not possible. Consistency between the predictive value of the 
biomarkers established in the clinical trials and the response rates in the panel of 
xenografts has been, however, demonstrated. The panel of 133 patient-derived 
xenografts seems, therefore, to be an attractive model not only as a novel approach for 
the discovery of predictive biomarkers, but also for advanced testing of novel anti-cancer 
agents. 
Although patients-derived xenografts are not ideal models, they have apparent advances 
over the other methods that are in a wide use in the preclinical approach such as in vitro 
and in vivo studies using the cancer cell lines, or transgenic mice (Sausville, E.A. et al.; 
2006). Patient-derived xenografts represent actual, individual, tumours and, although 
they derive from a small part of the neoplastic tissue, these xenografts seem to highly 
resemble the morphologic and molecular characteristics of original primary tumours. On 
the other hand, there are certain limitations concerning the structure of engrafted 
tumours. Substitution of the human stroma by the murine cells and the revascularization 
by penetration of implants with proliferating host blood vessels distinguish engrafted 
tissues from their corresponding primaries. Taking into account the differences between 
human tumours and xenograft models derived from transplantation of human tumour 
tissue, an optimal experimental design needs to be developed to unravel the full potential 
of novel drugs in treatment experiments in a multitude of xenograft models that allow 
mimicking phase II clinical trials.  
A proper treatment plan and dosing scheme are crucial to obtain a sufficient exposure to 
the experimental drug or drug combination and its balanced distribution. Near-toxic 
dosing is undesirable, thus administration of maximum doses to the xenograft models 
may result in the overestimation of the efficacy of tested compounds in humans and lead 
to unnecessary costs. Other important component of the experimental design is a 
number of xenograft models to be used in treatment experiments to reach statistical 
significance and the sufficient number of negative controls. One also needs to be careful 
with determining the proper endpoints of the study as the weight or volume 
measurements, particularly of the small tumours are highly susceptible to the operators‟ 
error (Hollingshead, 2008). 
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Assuming an optimal experimental design under all of mentioned considerations, the 
panel of xenografts is suitable to examine pharmacokinetics, metabolism and mechanism 
of action of the novel therapeutic compounds. The advantage of the approach is that one 
can test a novel targeted compound in any combination with other targeted agents 
without having to prove efficacy of this combination in human clinical trials. The same 
applies to the combination of targeted agents with chemotherapeutics. A minor shift in 
favor of tumours that carry oncogenic mutations, particularly in KRAS codon 12, was 
observed in the 67 models used in the treatment experiment and indicates that a careful 
selection of models should be applied in the future experiments. The panel of 133 
xenograft models can be use in drug development and the development of companion 
diagnostics as they mimic the individual tumours as well as a random subset of the CRC 
patients‟ population. 
Patients‟ selection recently entered the clinical practice with an establishment of such 
predictive biomarkers as KRAS in CRC, HER-2 expression prior to the treatment with 
trastuzumab in breast cancer and EGFR mutation analysis to predict response to EGFR 
tyrosine kinase inhibitors (erlotinib, gefitinib) in non-small cell lung cancer (NSCLC). 
Discovery of predictive biomarkers, so far introduced late in the drug development 
process, is being substituted by the efficacy studies that are in fact driven by the 
biomarker hypothesis. Determination of various genetic and epigenetic alterations such 
as mutations, SNPs, copy-number alterations, altered gene expression or methylation 
patterns etc., that may affect the efficacy of a drug is still needed for our better 
understanding of the mechanism of action of tested compounds. Further molecular 
characterization of the panel of 133 xenograft models is required and is already being 
executed. The panel of 133 CRC patients-derived xenografts is, up to our best 
knowledge, the largest available collection of the primary, chemonaive CRC models. It 
represents patients‟ population, therefore reflects a whole variety of genotypes making 
them suitable for testing of wide spectrum of anti-cancer agents. Patients-derived 
xenografts are an answer to the changing strategy from a „one-size fits all‟ approach to 
the requirements of personalized medicine. 
Not long ago, a concept of engrafting tumour tissue of a patient, testing tumour response 
to the various therapies on the established xenograft model and using the results as an 
actual deciding factor in the choice of the most beneficial therapy for the particular 
patient, seemed to be utopian. Nevertheless, a recent pilot study tested 63 drugs in 232 
treatment regimens in 14 patient-derived xenograft tumours of various indications 
(Hidalgo et al., 2011). For 12 out of 14 patients an effective treatment regimen was 
identified on the basis of the observation of the activity of different drugs in the 
Discussion 
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personalized xenograft generated from the patient‟s resected tumour tissue. The 
treatments selected for each patient were not obvious and would not have been the first 
choice. According to the efficacy data obtained in the xenograft models, patients received 
prospectively guided treatments. An objective response rate of 88% was reported with 
11/14 patients achieving a partial response. Despite such promising results, a broad 
clinical application of such approach needs, however, to overcome several hurdles. High 
cost of such experiments is a potential limiting factor. Moreover, not all tumour tissues 
can be successfully engrafted and even in the best conditions app. 25-30% of implants 
fail. Limitations such as time required for establishing and conducting treatment 
experiments in the model are inevitable, given that particularly advanced cancer stages 
require immediate decisions about the treatment regimen. 
A large panel of 133 xenografts reflects a wide spectrum of tumours. A molecular 
characterization of the panel was already performed in terms of mutation status, mRNA 
and miRNA expression patterns. Further molecular analyses on both: genetic and 
epigenetic levels are under progress in order to provide a detailed characterization of the 
xenograft models. Such deep molecular characterization would allow finding a model 
matching the properties of the particular patients‟ tumour. Results of the treatment 
experiments with various therapeutic regimens performed in the chosen model could 
influence decision making for the patient and, if successful, improve the response rate 
and outcome of the cancer patients. The panel of patient-derived CRC xenograft models 
is, therefore, a potential useful tool that contributes not only to the discovery of novel 
compounds and identification of predictive biomarkers. It has also a potential to influence 
the treatment decisions and so to enable a step toward personalized medicine. 
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Appendix 
Tab.S1. International Statistical Classification of Diseases and Related Health Problems 10th 
Revision (ICD-10) Version for 2010; colorectal cancer classification according to the 
localization of primary tumour 
ICD-10 class Localization of primary tumour 
C18.0 Caecum; ileocaecal valve 
C18.1 Appendix 
C18.2 Ascending colon 
C18.3 Hepatic flexure 
C18.4 Transverse colon 
C18.5 Splenic flexure 
C18.6 Descending colon 
C18.7 Sigmoid colon, excl.: rectosigmoid junction 
C18.8 Overlapping lesion of colon 
C18.9 Colon, unspecified 
C19 Rectosigmoid junction 
C20 Rectum incl.: rectal ampulla 
C21.0 Anus, unspecified 
C21.1 Anal canal, anal sphincter 
C21.2 Cloacogenic zone 
C21.8 Anorectum, anorectal junction 
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Tab.S2. Cancer Staging according to the Seventh Edition of Cancer Staging Manual by 
American Joint Committee on Cancer (AJCC) and the International Union Against Cancer 
(UICC). T0 – no evidence of primary tumour; Tis - carcinoma in situ; T1 - tumour invades 
submucosa; T2 - tumour invades muscularis propia; T3 - Tumour invades through the 
muscularis propria into pericolorectal tissues; T4a - tumour penetrates to the surface of the 
visceral peritoneum; T4b - tumour directly invades or is adherent to other organs or 
structures; N0 - no regional lymph node metastasis; N1 - metastasis in 1–3 regional lymph 
nodes; N1c - tumour deposit(s) in the subserosa, mesentery, or nonperitonealized pericolic or 
perirectal tissues without regional nodal metastasis; N2 - metastasis in 4 or more regional 
lymph nodes; N2a - metastasis in 4–6 regional lymph nodes; N2b - metastasis in 7 or more 
regional lymph nodes; M0 - No distant metastasis; M1a - metastasis confined to one organ or 
site; M1b - metastases in more than one organ/site or the peritoneum 
(http://www.cancerstaging.org) 
Stage T N M 
0 Tis N0 M0 
I T1-2 N0 M0 
IIA T3 N0 M0 
IIB T4a N0 M0 
IIC T4b N0 M0 
IIIA 
T1-2 N1/1c M0 
T1 N2a M0 
IIIB 
T3-4a N1/1c M0 
T2-3 N2a M0 
T1-2 N2b M0 
IIIC 
T4a N2a M0 
T3-4a N2b M0 
T4b N1-2 M0 
IVA Any T Any N M1a 
IVB Any T Any N M1b 
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Tab.S3. Sequences of the primers and probes of the allele-specific assays (Applied Biosystems). Reporters 1 are labeled with VIC and Reporters 
2 are labeled with FAM. All probes use Black Hole Quencher (*due to the courtesy of Prof. S. Tejpar) 
Assay ID 
Target 
Mutation nt 
Target 
Mutation aa 
Forward Primer Seq. Reverse Primer Seq. Reporter 1 Sequence 
Reporter 2 
Sequence 
KRAS_ex2-
121a 
34 G>A G12S (Gly - Ser) AGGCCTGCTGAAAATGACTGAATAT GCTGTATCGTCAAGGCACTCTT 
TTGGAGCTGGTGGCGT
A 
TAGTTGGAGCTAGTGG
CGTA 
KRAS_ex2-
121t 
34 G>T G12C (Gly - Cys) AGGCCTGCTGAAAATGACTGAATAT GCTGTATCGTCAAGGCACTCTT 
TTGGAGCTGGTGGCGT
A 
TTGGAGCTTGTGGCGT
A 
KRAS_ex2-
121c 
34 G>C G12R (Gly - Arg) AGGCCTGCTGAAAATGACTGAATAT GCTGTATCGTCAAGGCACTCTT 
TTGGAGCTGGTGGCGT
A 
TTGGAGCTCGTGGCGT
A 
KRAS_ex2-
122a 
35 G>A G12D (Gly - Asp) AGGCCTGCTGAAAATGACTGAATAT GCTGTATCGTCAAGGCACTCTT 
TTGGAGCTGGTGGCGT
A 
TTGGAGCTGATGGCGT
A 
KRAS_ex2-
122t 
35 G>T G12V (Gly - Val) AGGCCTGCTGAAAATGACTGAATAT GCTGTATCGTCAAGGCACTCTT 
TTGGAGCTGGTGGCGT
A 
TTGGAGCTGTTGGCGT
A 
KRAS_ex2-
122c 
35 G>C G12A (Gly - Ala) AGGCCTGCTGAAAATGACTGAATAT GCTGTATCGTCAAGGCACTCTT 
TTGGAGCTGGTGGCGT
A 
TTGGAGCTGCTGGCGT
A 
KRAS_ex2-
131t 
37 G>T G13C (Gly - Cys) AGGCCTGCTGAAAATGACTGAATAT GCTGTATCGTCAAGGCACTCTT 
TTGGAGCTGGTGGCGT
A 
TTGGAGCTGGTTGCGT
A 
KRAS_132a* 38 G>A G13D (Gly - Asp) AGGCCTGCTGAAAATGACTGAATAT GCTGTATCGTCAAGGCACTCT TGGTGGCGTAGGCA CTGGTGACGTAGGCA 
BRAF 1799 T>A 
V600E (Val - 
Glu) 
CTACTGTTTTCCTTTACTTACTACAC
CTCAGA 
ATCCAGACAACTGTTCAAACTGATG CTAGCTACAGTGAAATC TAGCTACAGAGAAATC 
KRAS_146a 436 G>A 
A146T (Ala - 
Thr) 
GGCTCAGGACTTAGCAAGAAGTTAT 
GCAGAAAACAGATCTGTATTTATTT
CAGTGT 
TCTTGTCTTTGCTGATG
TT 
TCTTGTCTTTGTTGATG
TT 
PIKex9-1624 1624 G>A 
E542K (Glu - 
Lys) 
AGCTCAAAGCAATTTCTACACGAGA
T 
GCACTTACCTGTGACTCCATAGAAA CCTCTCTCTGAAATCA CCTCTCTCTAAAATCA 
PIKex9-1633 1633 G>A 
E545K (Glu - 
Lys) 
TCAAAGCAATTTCTACACGAGATCC
T 
GCACTTACCTGTGACTCCATAGAAA 
CTCTCTGAAATCACTGA
GCAG 
CTCTGAAATCACTAAG
CAG 
PIKex20-
3140 
3140 A>G 
H1047R (His - 
Arg) 
GCAAGAGGCTTTGGAGTATTTCATG 
GCTGTTTAATTGTGTGGAAGATCCA
A 
CCACCATGATGTGCATC CACCATGACGTGCATC 
CTNNex3-
134 
134 C>T  
S45F (Ser -> 
Phe)  
GGAATCCATTCTGGTGCCACTAC CCTCTTCCTCAGGATTGCCTTT CCACTCAGAGAAGGAG CACTCAGAAAAGGAG 
CTNNex3-
121 
121 A>G 
T41A (Thr -> 
Ala) 
CTGGCAGCAACAGTCTTACCT 
GGATTGCCTTTACCACTCAGAGAA
G 
CTGGTGCCACTACCACA TGGTGCCACTGCCACA 
TP53ex5-524 524 G>A 
R175H (Arg -
>His) 
ACAGCACATGACGGAGGTT CTGCTCACCATCGCTATCTGA TGAGGCGCTGCCC TGAGGCACTGCCC 
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TP53ex7-742 742 C>T 
R248W (Arg -> 
Trp) 
AACTACATGTGTAACAGTTCCTGCA
T 
GAGTCTTCCAGTGTGATGATGGT TGGGCCTCCGGTTCA TGGGCCTCCAGTTCA 
TP53ex7-743 743 G>A 
R248Q (Arg -> 
Gln) 
AACTACATGTGTAACAGTTCCTGCA
T 
CCAGTGTGATGATGGTGAGGAT CATGAACCGGAGGCC CATGAACCAGAGGCC 
TP53ex8-818 818 G>A 
R273H (Arg -> 
His) 
CTTGCTTCTCTTTTCCTATCCTGAGT CTGTGCGCCGGTCTCT TGAGGTGCGTGTTTGT 
TTGAGGTGCATGTTTG
T 
TP53ex8-844 844 C>T 
R282W (Arg -> 
Trp) 
GCTTTGAGGTGCGTGTTTGTG GGTGAGGCTCCCCTTTCTTG TGCGCCGGTCTCT TGCGCCAGTCTCT 
APCex16-
4348 
4348 C>T 
R1450* (Arg -> 
*) 
CTCCACCACCTCCTCAAACAG ACTCTCTCTCTTTTCAGCAGTAGGT 
TAGGTACTTCTCGCTTG
GTT 
AGGTACTTCTCACTTG
GTT 
Tab.S4. TaqMan Gene Expression Assays used in the expression analysis of selected target genes: AREG, EREG, PTEN, DUSP6, SLC26A3, 
LOC158960, PTPRF and housekeeping genes: GAPDH, RPLP0 and UBC 
Gene Symbol Assay ID Context Sequence Gene Name 
AREG Hs00950669_m1 AACATGCAAATGTCAGCAAGAATAT amphiregulin 
DUSP6 Hs00737962_m1 CTACCTGGAAGATGAAGCCCGGGGC dual specificity phosphatase 6 
EREG Hs00914313_m1 AGTCAAAACTACTGCAGGTGTGAAG epiregulin 
GAPDH Hs00266705_g1 GGTCGGAGTCAACGGATTTGGTCGT glyceraldehyde-3-phosphate dehydrogenase 
LOC158960 Hs00863860_m1 ACCCTCCCTGATACAGGAGGAGAAA hypothetical protein BC009467 
PTEN Hs02621230_s1 ATGCTGCACAGAAATTTTCAATTTG phosphatase and tensin homolog 
PTPRF Hs00160858_m1 AGCTGCGTTCAGGTGCCTTGCAGAT protein tyrosine phosphatase, receptor type, F 
RPLP0 Hs00420895_gH ACCCAGCTCTGGAGAAACTGCTGCC ribosomal protein, large, P0 
SLC26A3 Hs00995363_m1 TGTATATCGTTGGAACTGATGATGA solute carrier family 26, member 3 
UBC Hs00824723_m1 TGATCGTCACTTGACAATGCAGATC ubiquitin C 
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Tab.S5. Basic clinical (age, gender, tumour localization, stage) and pathological (tumour classification) features of the 864 patients enrolled into MSKK and RVS 
studies and analyzed for mutations in KRAS, BRAF and PIK3CA. Mut No - number of detected mutations; Seq. - result of the dideoxy - sequencing of codon 12 and 
13 of the KRAS gene; ICD-O - colorectal cancer classification according to the localization of primary tumour (see Tab. S2), UICC - cancer staging according to 
the International Union Against Cancer (see Tab. S1); F- female; M- male; WT – wild-type; Mixed Diff.with Mucin – mixed differentiation with mucin; Rest after 
neoadj.th. – Rest after neoadjuvant therapy 
No patient-
ID 
model 
- ID 
Tissue Mut 
No 
BRAF KRAS PIK3CA Seq. Study Age Sex ICD-O UICC Classification 
1 P5 - FFPE 0 WT WT WT WT MSKK 71 F C18.2 III Adenocarcinoma 
2 P6 - FFPE 1 WT 35 G>A WT 35 G>A MSKK 47 F C18.2 I Adenocarcinoma 
3 P10 - Snap-frozen 0 WT WT WT WT MSKK 58 M C20.- II Adenocarcinoma 
4 P11 - FFPE 0 WT WT WT - MSKK 77 F C18.5 II Adenocarcinoma 
5 P12 - FFPE 0 WT WT WT NA MSKK 73 F C20.- I Adenocarcinoma 
6 P13 - FFPE 1 WT WT 1624 G>A - MSKK 71 F C18.2 III Adenocarcinoma 
7 P14 - FFPE 0 WT WT WT - MSKK 72 M C20.- III Adenocarcinoma 
8 P15 - Snap-frozen 1 WT 34 G>T WT 34 G>T MSKK 71 M C18.0 II Adenocarcinoma 
9 P16 - FFPE 1 WT 35 G>A WT 35 G>A MSKK 72 F C18.7 III Adenocarcinoma 
10 P17 - Snap-frozen 0 WT WT WT WT MSKK 75 M C19.9 II Adenocarcinoma 
11 P18 - FFPE 1 WT 436 G>A WT WT MSKK 77 F C19.9 II Adenocarcinoma 
12 P20 - FFPE 1 WT 38 G>A WT - MSKK 85 F C20.- I Tumour in Adenoma 
13 P21 - Snap-frozen 0 WT WT WT WT MSKK 62 F C18.2 III Mucinous Carcinoma 
14 P22 - FFPE 0 WT WT WT - MSKK 46 F C18.4 II Adenocarcinoma 
15 P23 - FFPE 0 WT WT WT - MSKK 72 F C18.2 II Adenocarcinoma 
16 P37 - Snap-frozen 1 WT 34 G>C WT 34 G>C RVS 71 M C18.7 III Adenocarcinoma 
17 P38 - Snap-frozen 1 1799 T>A WT WT - RVS 71 M C18.2 I Adenocarcinoma 
18 P39 - Snap-frozen 1 WT 35 G>T WT 35 G>T RVS 63 M C18.4 III Adenocarcinoma 
19 P40 - Snap-frozen 0 WT WT WT WT RVS 72 F C18.0 III Adenocarcinoma 
20 P41 - Snap-frozen 1 WT 35 G>T WT 35 G>T RVS 47 M C19.- III Adenocarcinoma 
21 P42 - Snap-frozen 1 WT 35 G>T WT 35 G>T RVS 70 M C18.0 II Adenocarcinoma 
22 P44 - Snap-frozen 0 WT WT WT - RVS 73 M C18.7 II Adenocarcinoma 
23 P45 - Snap-frozen 0 WT WT WT WT RVS 57 M C18.5 I Adenocarcinoma 
24 P46 - Snap-frozen 0 WT WT WT - RVS 65 F C18.6 III Adenocarcinoma 
25 P47 - Snap-frozen 0 WT WT WT - RVS 63 M C18.3 II Adenocarcinoma 
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26 P48 - Snap-frozen 1 WT 35 G>A WT 35 G>A RVS 63 M C18.7 III Mixed Diff.with Mucin 
27 P49 - Snap-frozen 0 WT WT WT - RVS 56 M C18.3 II Adenocarcinoma 
28 P50 - Snap-frozen 0 WT WT WT - RVS 46 M C18.3 II Adenocarcinoma 
29 P51 - Snap-frozen 2 WT 38 G>A 3140 A>G - RVS 76 M C18.0 III Adenocarcinoma 
30 P52 - Snap-frozen 1 WT 436 G>A WT WT RVS 60 M C18.2 II Mucinous Carcinoma 
31 P53 - Snap-frozen 0 WT WT WT WT RVS 58 M C20.9 II Adenocarcinoma 
32 P28 - FFPE 1 WT 35 G>A WT - MSKK 77 F C18.7 II Adenocarcinoma 
33 P29 - FFPE 0 WT WT WT WT MSKK 62 M C19.- I Adenocarcinoma 
34 P54 - Snap-frozen 0 WT WT WT - RVS 44 M C18.7 III Adenocarcinoma 
35 P55 - Snap-frozen 0 WT WT WT WT RVS 73 M C18.7 III Adenocarcinoma 
36 P56 - Snap-frozen 0 WT WT WT WT RVS 52 M C18.7 I Adenocarcinoma 
37 P57 - Snap-frozen 0 WT WT WT - RVS 72 F C18.7 II Adenocarcinoma 
38 P59 - Snap-frozen 0 WT WT WT WT RVS 76 F C18.7 II Adenocarcinoma 
39 P60 - Snap-frozen 1 WT 34 G>A WT WT RVS 60 M C18.2 III Adenocarcinoma 
40 P62 - Snap-frozen 1 WT 38 G>A WT - RVS 70 F C18.2 II Adenocarcinoma 
41 P63 - Snap-frozen 1 WT 35 G>T WT 35 G>T RVS 58 F C19.- IV Adenocarcinoma 
42 P65 - Snap-frozen 0 WT WT WT WT RVS 72 M C18.5 III Adenocarcinoma 
43 P66 - Snap-frozen 1 WT 35 G>C WT 35 G>C RVS 50 F C18.7 III Mixed Diff.with Mucin 
44 P30 - FFPE 1 WT 35 G>T WT - MSKK 77 F C19.- III Adenocarcinoma 
45 P26 - FFPE 0 WT WT WT WT MSKK 63 F C18.2 I Adenocarcinoma 
46 P27 - FFPE 0 WT WT WT WT MSKK 70 M C19.9 III Adenocarcinoma 
47 P1 - FFPE 1 1799 T>A WT WT - MSKK 83 F C18.2 III Mucinous Carcinoma 
48 P3 - FFPE 1 WT 35 G>T WT - MSKK 70 F C20.- II Mucinous Carcinoma 
49 P2 - FFPE 1 WT 436 G>A WT - MSKK 85 F C18.2 III Mucinous Carcinoma 
50 P7 - FFPE 1 1799 T>A WT WT NA MSKK 55 F C18.5 III Mucinous Carcinoma 
51 P9 - FFPE 2 WT 35 G>T 3140 A>G WT MSKK 64 M C20.- II Mucinous Carcinoma 
52 P24 - FFPE 2 WT 38 G>A 3140 A>G 38 G>A MSKK 52 F C18.0 I Mixed Diff.with Mucin 
53 P32 - FFPE 0 WT WT WT - MSKK 64 M C18.7 II Adenocarcinoma 
54 P33 - FFPE 0 WT WT WT WT MSKK 53 M C20.- III Adenocarcinoma 
55 P34 - FFPE 0 WT WT WT WT MSKK 64 F C20.- I Adenocarcinoma 
56 P31 - FFPE 0 WT WT WT NA MSKK 26 M C18.7 III Signet-Ring-Cell Ca. 
57 P68 - Snap-frozen 1 WT 35 G>T WT - RVS 64 M C18.0 III Adenocarcinoma 
58 P67 - FFPE 1 1799 T>A WT WT NA MSKK 85 F C18.4 II Mixed Diff.with Mucin 
59 P35 - FFPE 1 WT 38 G>A WT - MSKK 69 F C20.- III Adenocarcinoma 
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60 P36 - FFPE 1 1799 T>A WT WT - MSKK 83 F C18.3 IV Synchronous CRC 
61 P70 - FFPE 1 WT 35 G>A WT 35 G>A MSKK 62 F C18.0 III Signet-Ring-Cell Ca. 
62 P71 - FFPE 0 WT WT WT - MSKK 78 M C18.2 II Mucinous Carcinoma 
63 P72 - FFPE 1 WT 38 G>A WT 38 G>A MSKK 67 F C18.0 III Adenocarcinoma 
64 P73 - FFPE 0 WT WT WT WT MSKK 68 M C19.- II Adenocarcinoma 
65 P75 - Snap-frozen 0 WT WT WT WT MSKK 70 M C18.6 III Signet-Ring-Cell Ca. 
66 P77 - Snap-frozen 0 WT WT WT WT MSKK 73 M C19.- II Adenocarcinoma 
67 P78 - Snap-frozen 0 WT WT WT WT MSKK 52 M C18.7 II Adenocarcinoma 
68 P79 - FFPE 0 WT WT WT WT MSKK 68 M C20.- II Adenocarcinoma 
69 P80 - Snap-frozen 0 WT WT WT WT MSKK 64 F C18.7 III Adenocarcinoma 
70 P81 - Snap-frozen 2 WT 35 G>T 1624 G>A 35 G>T MSKK 72 F C18.5 III Mucinous Carcinoma 
71 P82 - FFPE 0 WT WT WT WT MSKK 84 F C18.7 II Adenocarcinoma 
72 P83 - Snap-frozen 0 WT WT WT WT MSKK 82 M C20.- III Mucinous Carcinoma 
73 P84 - Snap-frozen 0 WT WT WT WT MSKK 53 M C20.- II Adenocarcinoma 
74 P85 - FFPE 1 WT 34 G>A WT 34 G>A MSKK 65 M C18.0 III Adenocarcinoma 
75 P86 - Snap-frozen 1 1799 T>A WT WT WT MSKK 67 M C18.5 II Adenocarcinoma 
76 P87 - Snap-frozen 1 WT 35 G>T WT 35 G>T MSKK 67 M C18.7 III Adenocarcinoma 
77 P89 - Snap-frozen 1 WT 38 G>A WT 38 G>A MSKK 76 F C20.- II Synchronous CRC 
78 P90 - Snap-frozen 1 1799 T>A WT WT - MSKK 75 M C18.7 II Synchronous CRC 
79 P91 - Snap-frozen 0 WT WT WT - MSKK 69 F C20.- I Adenocarcinoma 
80 P92 - Snap-frozen 1 WT 35 G>T WT 35 G>T RVS 69 M C19.- II Adenocarcinoma 
81 P93 - Snap-frozen 1 WT 38 G>A WT 38 G>A RVS 41 F C20.91 III Adenocarcinoma 
82 P94 - Snap-frozen 0 WT WT WT - RVS 55 F C20.91 I Tumour in Adenoma 
83 P95 - Snap-frozen 1 WT 35 G>C WT 35 G>C RVS 60 M C20.91 III Adenocarcinoma 
84 P96 - Snap-frozen 1 WT WT 1624 G>A - RVS 51 F C20.- II Adenocarcinoma 
85 P97 - Snap-frozen 1 WT 35 G>A WT 35 G>A RVS 66 M C20.91 II Adenocarcinoma 
86 P98 - Snap-frozen 1 WT 35 G>A WT - RVS 82 F C20.91 III Adenocarcinoma 
87 P99 - Snap-frozen 1 WT 38 G>A WT - RVS 77 M C20.91 II Mixed Diff.with Mucin 
88 P100 - Snap-frozen 1 1799 T>A WT WT - RVS 73 F C20.- III Tumour in Adenoma 
89 P101 - Snap-frozen 1 1799 T>A WT WT WT RVS 51 M C20.91 III Adenocarcinoma 
90 P102 - Snap-frozen 1 WT 35 G>A WT 35 G>A RVS 67 M C20.- III Adenocarcinoma 
91 P103 - Snap-frozen 0 WT WT WT WT RVS 61 M C20.- III Adenocarcinoma 
92 P104 - Snap-frozen 1 WT 35 G>T WT 35 G>T MSKK 70 F C20.- III Adenocarcinoma 
93 P105 - Snap-frozen 1 WT 35 G>A WT 35 G>A MSKK 66 M C18.7 II Adenocarcinoma 
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94 P106 - Snap-frozen 0 WT WT WT WT MSKK 94 F C20.- II Adenocarcinoma 
95 P107 - Snap-frozen 0 WT WT WT WT MSKK 71 F C18.7 III Adenocarcinoma 
96 P108 - Snap-frozen 0 WT WT WT WT MSKK 66 M C20.- III Adenocarcinoma 
97 P109 - Snap-frozen 0 WT WT WT WT MSKK 50 F C18.4 II Synchronous CRC 
98 P74 - FFPE 1 WT 35 G>A WT - MSKK 61 F C18.0 I Adenocarcinoma 
99 P110 - Snap-frozen 1 WT 35 G>A WT - MSKK 78 F C18.0 III Adenocarcinoma 
100 P111 - Snap-frozen 1 WT 35 G>A WT - MSKK 66 M C19.9 III Adenocarcinoma 
101 P112 - FFPE 1 WT WT 1633 G>A - MSKK 53 M C20.- III Adenocarcinoma 
102 P113 - Snap-frozen 0 WT WT WT WT MSKK 71 M C18.7 I Adenocarcinoma 
103 P114 - Snap-frozen 2 WT 38 G>A 1633 G>A 38 G>A MSKK 79 M C20.- III Adenocarcinoma 
104 P116 - Snap-frozen 0 WT WT WT WT MSKK 79 F C18.0 III Adenocarcinoma 
105 P117 - Snap-frozen 1 1799 T>A WT WT - RVS 53 M C20.- II Adenocarcinoma 
106 P118 - Snap-frozen 1 WT 35 G>T WT - RVS 73 M C20.91 III Adenocarcinoma 
107 P119 - Snap-frozen 1 WT 35 G>T WT - RVS 75 M C20.91 II Adenocarcinoma 
108 P120 - Snap-frozen 2 WT 35 G>A 1633 G>A 35 G>A RVS 59 M C20.- III Adenocarcinoma 
109 P121 - Snap-frozen 0 WT WT WT - RVS 43 F C20.91 I Adenocarcinoma 
110 P122 - Snap-frozen 0 WT WT WT WT RVS 47 M C20.91 III Adenocarcinoma 
111 P123 - Snap-frozen 1 1799 T>A WT WT - RVS 55 M C20.- III Adenocarcinoma 
112 P124 - Snap-frozen 1 WT 35 G>A WT 35 G>A RVS 60 M C20.91 I Adenocarcinoma 
113 P125 - Snap-frozen 0 WT WT WT WT RVS 75 F C20.- III Adenocarcinoma 
114 P126 - Snap-frozen 0 WT WT WT WT MSKK 87 F C20.- I Adenocarcinoma 
115 P127 - Snap-frozen 1 WT 35 G>T WT 35 G>T MSKK 71 M C18.7 III Adenocarcinoma 
116 P128 - Snap-frozen 1 WT 436 G>A WT - MSKK 75 M C18.2 III Mucinous Carcinoma 
117 P129 - Snap-frozen 0 WT WT WT WT MSKK 86 F C18.0 III Adenocarcinoma 
118 P130 - Snap-frozen 0 WT WT WT WT MSKK 67 F C19.9 III Adenocarcinoma 
119 P25 - FFPE 0 WT WT WT - MSKK 74 M C18.7 III Adenocarcinoma 
120 P131 - Snap-frozen 0 WT WT WT WT MSKK 81 F C18.2 II Adenocarcinoma 
121 P132 - Snap-frozen 0 WT WT WT WT MSKK 78 F C18.7 III Adenocarcinoma 
122 P133 - Snap-frozen 1 WT 35 G>T WT 35 G>T MSKK 64 M C20.9 III Adenocarcinoma 
123 P134 - Snap-frozen 1 WT 35 G>A WT 35 G>A MSKK 79 M C20.- III Adenocarcinoma 
124 P135 - Snap-frozen 1 WT 35 G>C WT 35 G>C MSKK 71 F C18.7 III Adenocarcinoma 
125 P136 - Snap-frozen 1 WT 35 G>A WT - MSKK 76 M C20.- II Adenocarcinoma 
126 P137 - Snap-frozen 1 1799 T>A WT WT WT MSKK 84 F C18.2 III Adenocarcinoma 
127 P138 - Snap-frozen 1 WT WT 3140 A>G WT MSKK 53 F C18.5 III Adenocarcinoma 
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128 P139 - Snap-frozen 0 WT WT WT WT MSKK 85 M C20.- II Adenocarcinoma 
129 P140 - Snap-frozen 0 WT WT WT WT MSKK 66 M C18.3 III Adenocarcinoma 
130 P141 - Snap-frozen 1 WT WT 1624 G>A WT MSKK 72 M C18.6 I Adenocarcinoma 
131 P142 - Snap-frozen 0 WT WT WT WT MSKK 60 M C18.7 III Adenocarcinoma 
132 P143 - Snap-frozen 0 WT WT WT WT MSKK 67 M C18.0 III Adenocarcinoma 
133 P145 - FFPE 0 WT WT WT - MSKK 69 F C18.7 I Adenocarcinoma 
134 P146 - Snap-frozen 2 WT 35 G>T 1633 G>A - MSKK 78 M C18.6 III Adenocarcinoma 
135 P147 - Snap-frozen 0 WT WT WT WT MSKK 66 F C20.- III Adenocarcinoma 
136 P148 - FFPE 0 WT WT WT - MSKK 79 M C18.7 I Adenocarcinoma 
137 P149 - Snap-frozen 1 WT 35 G>A WT 35 G>A MSKK 82 F C18.4 III Adenocarcinoma 
138 P8 - FFPE 2 WT 35 G>A 3140 A>G NA MSKK 75 M C18.4 II Adenocarcinoma 
139 P154 - Snap-frozen 0 WT WT WT - MSKK 67 M C18.7 II Adenocarcinoma 
140 P155 - Snap-frozen 0 WT WT WT WT MSKK 68 F C18.7 II Adenocarcinoma 
141 P150 - Snap-frozen 0 WT WT WT WT MSKK 62 M C18.7 I Adenocarcinoma 
142 P144 - FFPE 0 WT WT WT WT MSKK 74 M C18.0 I Synchronous CRC 
143 P152 - FFPE 1 WT 38 G>A WT - MSKK 70 M C20.- III Rest after neoadj.th. 
144 P153 - FFPE 0 WT WT WT - MSKK 68 M C20.- I Adenocarcinoma 
145 P157 - Snap-frozen 2 1799 T>A WT 1633 G>A WT MSKK 67 F C20.- III Adenocarcinoma 
146 P158 - Snap-frozen 0 WT WT WT - MSKK 48 F C20.- III Adenocarcinoma 
147 P159 - FFPE 0 WT WT WT - MSKK 63 M C20.- III Adenocarcinoma 
148 P160 - Snap-frozen 1 WT 35 G>A WT 35 G>A MSKK 46 M C18.4 III Adenocarcinoma 
149 P161 - Snap-frozen 0 WT WT WT - RVS 53 F C19.9 II Adenocarcinoma 
150 P162 - Snap-frozen 1 WT 35 G>A WT 35 G>A RVS 72 M C18.7 II Adenocarcinoma 
151 P163 - Snap-frozen 0 WT WT WT - RVS 82 M C18.7 II Adenocarcinoma 
152 P164 - Snap-frozen 0 WT WT WT WT RVS 65 M C18.9 II Adenocarcinoma 
153 P165 - Snap-frozen 0 WT WT WT WT RVS 52 M C18.7 II Adenocarcinoma 
154 P166 - Snap-frozen 0 WT WT WT WT RVS 61 F C18.0 I Adenocarcinoma 
155 P167 - Snap-frozen 0 WT WT WT WT RVS 66 F C19.- III Adenocarcinoma 
156 P168 - Snap-frozen 1 WT 38 G>A WT 38 G>A RVS 84 F C18.2 I Adenocarcinoma 
157 P169 - Snap-frozen 1 WT 35 G>T WT 35 G>T RVS 64 M C18.0 I Adenocarcinoma 
158 P170 - Snap-frozen 0 WT WT WT WT RVS 71 M C20.- II Adenocarcinoma 
159 P171 - Snap-frozen 1 WT 38 G>A WT - RVS 74 F C18.2 III Adenocarcinoma 
160 P172 - Snap-frozen 1 WT WT 3140 A>G; 
1633 G>A 
WT RVS 69 M C20.- II Adenocarcinoma 
161 P76 - FFPE 1 WT WT 3140 A>G - MSKK 69 M C20.- II Rest after neoadj.th. 
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162 P151 - Snap-frozen 1 1799 T>A WT WT WT MSKK 76 F C18.2 II Adenocarcinoma 
163 P173 - Snap-frozen 0 WT WT WT WT MSKK 63 F C18.6 I Adenocarcinoma 
164 P176 - Snap-frozen 1 WT WT 3140 A>G WT MSKK 64 M C20.- II Adenocarcinoma 
165 P178 - Snap-frozen 0 WT WT WT - MSKK 55 M C20.9 III Adenocarcinoma 
166 P179 - Snap-frozen 1 WT 38 G>A WT 38 G>A MSKK 67 M C18.0 III Adenocarcinoma 
167 P180 - Snap-frozen 2 WT 34 G>T 1624 G>A - MSKK 41 F C18.7 IV Adenocarcinoma 
168 P181 - FFPE 0 WT WT WT WT MSKK 62 M C20.- III Adenocarcinoma 
169 P182 - Snap-frozen 1 WT 38 G>A WT 38 G>A MSKK 71 F C20.- III Adenocarcinoma 
170 P184 - Snap-frozen 0 WT WT WT WT MSKK 49 F C18.7 III Adenocarcinoma 
171 P115 - FFPE 0 WT WT WT - MSKK 56 F C18.2 II Adenocarcinoma 
172 P185 - FFPE 1 WT 34 G>A WT 34 G>A MSKK 63 M C20.- III Adenocarcinoma 
173 P183 - Snap-frozen 1 1799 T>A WT WT - MSKK 84 F C18.0 III Adenocarcinoma 
174 P177 - FFPE 1 WT 35 G>T WT - MSKK 67 F C18.7 III Mixed Differentiation 
175 P187 - Snap-frozen 1 WT 436 G>A WT WT MSKK 64 M C19.- III Adenocarcinoma 
176 P186 - FFPE 0 WT WT WT WT MSKK 71 M C18.0 III Mucinous Carcinoma 
177 P188 - FFPE 2 WT 35 G>C 3140 A>G - MSKK 79 M C18.7 II Mixed Diff.with Mucin 
178 P189 - FFPE 0 WT WT WT - MSKK 81 M C20.- II Adenocarcinoma 
179 P190 - FFPE 1 WT 38 G>A WT - MSKK 83 M C18.3 II Adenocarcinoma 
180 P191 - FFPE 0 WT WT WT NA MSKK 71 M C20.- III Adenocarcinoma 
181 P192 - FFPE 0 WT WT WT - MSKK 71 F C18.7 II Adenocarcinoma 
182 P193 - FFPE 0 WT WT WT - MSKK 76 F C18.2 II Mucinous Carcinoma 
183 P194 - FFPE 2 WT 38 G>A 1624 G>A - MSKK 76 M C18.7 III Synchronous CRC 
184 P196 - FFPE 2 WT 35 G>T 1633 G>A - MSKK 65 M C20.- I Adenocarcinoma 
185 P195 - Snap-frozen 2 WT 34 G>T 1633 G>A 34 G>T MSKK 66 M C20.- III Adenocarcinoma 
186 P197 - Snap-frozen 1 WT 35 G>T WT 35 G>T MSKK 55 M C18.5 III Adenocarcinoma 
187 P198 - Snap-frozen 1 WT 38 G>A WT 38 G>A MSKK 80 F C20.- III Adenocarcinoma 
188 P201 - FFPE 0 WT WT WT - MSKK 46 F C18.5 IV Adenosquamous 
carcinoma 
189 P202 - FFPE 0 WT WT WT WT MSKK 56 F C18.2 III Mucinous Carcinoma 
190 P43 - Snap-frozen 0 WT WT WT WT RVS 75 M C18.6 I Adenocarcinoma 
191 P58 - Snap-frozen 0 WT WT WT WT RVS 54 M C18.3 III Adenocarcinoma 
192 P61 - Snap-frozen 0 WT WT WT - RVS 54 M C18.5 II Adenocarcinoma 
193 P64 - Snap-frozen 0 WT WT WT WT RVS 70 M C20.91 II Adenocarcinoma 
194 P69 - Snap-frozen 0 WT WT WT - RVS 52 M C20.- III Adenocarcinoma 
195 P175 - FFPE 0 WT WT WT - MSKK 74 M C18.7 II Unusual Differentiation 
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196 P174 - FFPE 0 WT WT WT - MSKK 67 M C18.6 II Adenocarcinoma 
197 P204 - FFPE 0 WT WT WT - MSKK 67 M C18.2 III Mixed Diff.with Mucin 
198 P205 - FFPE 0 WT WT WT - MSKK 76 M C18.3 IV Adenocarcinoma 
199 P206 - FFPE 0 WT WT WT - MSKK 67 F C18.2 II Adenocarcinoma 
200 P207 - FFPE 0 WT WT WT - MSKK 36 F C18.7 II Adenocarcinoma 
201 P208 - Snap-frozen 1 WT 34 G>T WT 34 G>T MSKK 75 F C20.- III Adenocarcinoma 
202 P209 - FFPE 0 WT WT WT - MSKK 83 F C19.- II Adenocarcinoma 
203 P210 - Snap-frozen 2 WT 35 G>T 3140 A>G 35 G>T MSKK 69 F C19.- III Adenocarcinoma 
204 P211 - FFPE 0 WT WT WT - MSKK 54 F C18.6 II Adenocarcinoma 
205 P199 - FFPE 0 WT WT WT - MSKK 69 M C20.9 II Rest after neoadj.th. 
206 P212 - Snap-frozen 1 WT 35 G>A WT - RVS 75 M C20.- II Adenocarcinoma 
207 P213 - Snap-frozen 2 WT 35 G>A 1633 G>A NA RVS 70 M C20.- IV Adenocarcinoma 
208 P214 - Snap-frozen 2 WT 35 G>A 1633 G>A NA RVS 69 F C18.7 I Adenocarcinoma 
209 P215 - Snap-frozen 1 WT 35 G>A WT 35 G>A RVS 78 - C18.7 II Adenocarcinoma 
210 P216 - Snap-frozen 0 WT WT WT WT RVS 79 F C18.0 III Adenocarcinoma 
211 P217 - Snap-frozen 0 WT WT WT - RVS - F C18.6 II Adenocarcinoma 
212 P218 - Snap-frozen 1 WT WT 3140 A>G WT RVS 63 M C18.7 III Adenocarcinoma 
213 P219 - Snap-frozen 0 WT WT WT WT MSKK 71 F C18.0 III Adenocarcinoma 
214 P221 - FFPE 1 WT 436 G>A WT - MSKK 77 M C18.4 III Mucinous Carcinoma 
215 P222 - Snap-frozen 0 WT WT WT - MSKK 57 M C18.7 III Adenocarcinoma 
216 P226 - FFPE 1 WT 34 G>T WT WT MSKK 80 M C20.- II Adenocarcinoma 
217 P227 - FFPE 0 WT WT WT - MSKK 69 F C20.9 IV Adenocarcinoma 
218 P228 - Snap-frozen 1 1799 T>A WT WT WT MSKK 86 F C18.2 III Mucinous Carcinoma 
219 P220 - FFPE 1 WT 38 G>A WT - MSKK 77 M C20.- III Mixed Diff.with Mucin 
220 P229 - FFPE 0 WT WT WT - MSKK 58 M C18.0 III Mixed Diff.with Mucin 
221 P230 - FFPE 1 WT 38 G>A WT - MSKK 84 F C20.- II Adenocarcinoma 
222 P231 - FFPE 0 WT WT WT WT MSKK 56 F C20.- III Rest after neoadj.th. 
223 P203 - Snap-frozen 1 WT WT 3140 A>G - MSKK 79 M C18.7 III Adenocarcinoma 
224 P232 - Snap-frozen 1 WT 35 G>C WT 35 G>C MSKK 70 F C18.0 III Adenocarcinoma 
225 P233 - Snap-frozen 0 WT WT WT WT MSKK 66 M C18.6 III Adenocarcinoma 
226 P234 - FFPE 0 WT WT WT - MSKK 56 M C19.9 III Rest after neoadj.th. 
227 P235 - Snap-frozen 0 WT WT WT WT MSKK 73 F C18.7 III Adenocarcinoma 
228 P236 - FFPE 0 WT WT WT - MSKK 83 M C20.- II Adenocarcinoma 
229 P237 - FFPE 0 WT WT WT - MSKK 51 M C19.- III Adenocarcinoma 
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230 P238 - FFPE 1 WT 35 G>T WT - MSKK 65 M C20.- I Rest after neoadj.th. 
231 P239 - FFPE 0 WT WT WT - MSKK 55 M C20.- II Rest after neoadj.th. 
232 P240 - Snap-frozen 0 WT WT WT WT MSKK 82 M C18.3 III Synchronous CRC 
233 P241 - FFPE 1 WT 35 G>A WT - MSKK 51 F C18.2 I Adenocarcinoma 
234 P242 - FFPE 0 WT WT WT - MSKK 73 F C18.0 I Mixed Diff.with Mucin 
235 P243 - Snap-frozen 1 WT 34 G>A WT - MSKK 81 F C20.- III Adenocarcinoma 
236 P244 - FFPE 1 1799 T>A WT WT - MSKK 81 F C18.3 II Medullary Differentitation 
237 P247 - Snap-frozen 2 WT 35 G>A 1633 G>A 35 G>A MSKK 66 M C18.4 III Adenocarcinoma 
238 P248 - FFPE 2 WT 38 G>A 1633 G>A 38 G>A MSKK 66 M C18.2 IV Mixed Diff.with Mucin 
239 P249 - FFPE 1 WT 35 G>T WT - MSKK 80 M C18.3 IV Mucinous Carcinoma 
240 P254 - FFPE 1 WT 35 G>T WT - MSKK 61 M C18.0 I Mixed Diff.with Mucin 
241 P255 - FFPE 0 WT WT WT - MSKK 68 F C20.- III Adenocarcinoma 
242 P258 - FFPE 1 1799 T>A WT WT - MSKK 81 F C18.4 I Mixed Diff.with Mucin 
243 P259 - Snap-frozen 1 WT WT 3140 A>G WT RVS 64 F c18.7 II Adenocarcinoma 
244 P260 - Snap-frozen 1 WT 35 G>A WT 35 G>A RVS 60 M C18.9 I Adenocarcinoma 
245 P261 - Snap-frozen 0 WT WT WT WT RVS 52 M C18.9 II Adenocarcinoma 
246 P262 - Snap-frozen 0 WT WT WT - RVS 71 F C20.- II Adenocarcinoma 
247 P263 - Snap-frozen 1 1799 T>A WT WT - RVS 60 M C20.- III Adenocarcinoma 
248 P264 - Snap-frozen 2 WT 436 G>A 1633 G>A WT RVS 74 M C18.7 II Adenocarcinoma 
249 P265 - Snap-frozen 1 WT 35 G>T WT - RVS 70 F C18.0 III Adenocarcinoma 
250 P266 - Snap-frozen 2 WT 35 G>A 1633 G>A 35 G>A RVS 78 F C18.3 II Adenocarcinoma 
251 P267 - Snap-frozen 1 WT WT 3140 A>G; 
1633 G>A 
WT RVS 65 F C18.7 II Adenocarcinoma 
252 P268 - Snap-frozen 1 WT 35 G>A WT - RVS 76 - C18.9 I Adenocarcinoma 
253 P269 - Snap-frozen 0 WT WT WT WT RVS 34 M C18.7 II Adenocarcinoma 
254 P270 - Snap-frozen 2 WT 34 G>A 1633 G>A 34 G>A RVS 60 M C20.- II Adenocarcinoma 
255 P271 - Snap-frozen 1 WT 35 G>T WT 35 G>T RVS 73 M C20.- I Adenocarcinoma 
256 P272 - Snap-frozen 1 WT WT 1633 G>A - RVS 70 F C18.9 III Adenocarcinoma 
257 P273 - Snap-frozen 1 WT 34 G>A WT 34 G>A RVS 76 F C20.- I Adenocarcinoma 
258 P274 - Snap-frozen 2 WT 38 G>A 1633 G>A 38 G>A RVS 85 M C18.4 II Adenocarcinoma 
259 P275 - Snap-frozen 2 WT 35 G>T 1633 G>A 35 G>T RVS 59 M C18.2 I Adenocarcinoma 
260 P276 - Snap-frozen 1 WT 35 G>T WT 35 G>T RVS 46 F C20.- III Adenocarcinoma 
261 P277 - Snap-frozen 1 WT 436 G>A WT WT RVS 64 M C18.0 I Adenocarcinoma 
262 P278 - Snap-frozen 1 WT 35 G>A WT 35 G>A RVS 41 - C20.9 III Adenocarcinoma 
263 P279 - Snap-frozen 0 WT WT WT WT RVS 59 - C20.- III Adenocarcinoma 
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264 P280 - Snap-frozen 0 WT WT WT WT RVS 67 M C18.2 I Adenocarcinoma 
265 P281 - Snap-frozen 1 WT WT 3140 A>G WT RVS 58 M C20.- III Adenocarcinoma 
266 P282 - FFPE 0 WT WT WT WT MSKK 80 M C18.5 II Adenocarcinoma 
267 P283 - Snap-frozen 1 WT 38 G>A WT 38 G>A MSKK 68 M C18.2 III Mucinous Carcinoma 
268 P284 - Snap-frozen 0 WT WT WT - MSKK 67 M C20.- III Adenocarcinoma 
269 P287 - FFPE 0 WT WT WT NA MSKK 69 M C20.- I Rest after neoadj.th. 
270 P250 - FFPE 1 WT 35 G>A WT - MSKK 78 F C18.7 I Adenocarcinoma 
271 P251 - FFPE 0 WT WT WT - MSKK 66 M C18.7 II Adenocarcinoma 
272 P252 - FFPE 0 WT WT WT - MSKK 64 M C18.7 III Adenocarcinoma 
273 P253 - FFPE 0 WT WT WT - MSKK 79 M C18.0 II Adenocarcinoma 
274 P288 - FFPE 1 1799 T>A WT WT - MSKK 61 F C18.0 IV Adenocarcinoma 
275 P289 - FFPE 0 WT WT WT - MSKK 70 F C18.3 III Undifferentiated 
276 P291 - FFPE 1 WT 35 G>A WT - MSKK 57 F C18.5 III Adenocarcinoma 
277 P292 - FFPE 0 WT WT WT - MSKK 63 F C18.7 II Adenocarcinoma 
278 P293 - FFPE 2 WT 38 G>A 1633 G>A - MSKK 83 F C18.0 III Adenocarcinoma 
279 P294 - FFPE 0 WT WT WT - MSKK 75 M C18.0 II Adenocarcinoma 
280 P295 - FFPE 1 WT 35 G>A WT NA MSKK 75 M C19.9 III Mucinous Carcinoma 
281 P296 - FFPE 1 WT 35 G>A WT - MSKK 67 M C18.0 I Mucinous Carcinoma 
282 P297 - FFPE 1 WT 38 G>A WT - MSKK 37 M C19.9 II Adenocarcinoma 
283 P225 - FFPE 0 WT WT WT - MSKK 72 M C18.7 IV Adenocarcinoma 
284 P223 - FFPE 1 WT 38 G>A WT - MSKK 48 M C18.2 III Adenocarcinoma 
285 P224 - FFPE 2 1799 T>A 38 G>A WT - MSKK 87 F C18.0 II Mixed Diff.with Mucin 
286 P19 - FFPE 0 WT WT WT - MSKK 68 M C18.6 III Adenocarcinoma 
287 P88 - FFPE 2 WT 34 G>T 1624 G>A - MSKK 68 F C18.6 II Adenocarcinoma 
288 P298 - FFPE 0 WT WT WT - MSKK 72 M C18.7 IV Adenocarcinoma 
289 P299 - FFPE 1 WT 34 G>T WT - MSKK 65 M C18.7 II Adenocarcinoma 
290 P300 - FFPE 1 1799 T>A WT WT - MSKK 67 F C20.9 III Adenocarcinoma 
291 P301 - FFPE 0 WT WT WT - MSKK 74 M C18.7 IV Adenocarcinoma 
292 P302 - FFPE 1 WT 35 G>A WT - MSKK 76 M C20.9 II Adenocarcinoma 
293 P290 - FFPE 1 WT 35 G>A WT NA MSKK 68 F C20.- III Adenocarcinoma 
294 P303 - FFPE 1 WT 436 G>A WT - MSKK 88 M C20.- I Adenocarcinoma 
295 P304 - Snap-frozen 0 WT WT WT WT MSKK 67 M C18.7 III Synchronous CRC 
296 P305 - Snap-frozen 0 WT WT WT WT MSKK 76 M C18.2 III Adenocarcinoma 
297 P286 - FFPE 3 1799 T>A 38 G>A 1633 G>A WT MSKK 69 F C18.7 III Adenocarcinoma 
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298 P307 - FFPE 2 WT 35 G>A 1633 G>A - MSKK 75 F C18.7 III Mucinous Carcinoma 
299 P308 - FFPE 1 WT 35 G>A WT - MSKK 68 F C18.2 II Mixed Diff.with Mucin 
300 P309 - FFPE 1 WT 35 G>T WT - MSKK 77 M C18.4 II Adenocarcinoma 
301 P310 - FFPE 1 WT 34 G>A WT - MSKK 64 M C18.6 III Adenocarcinoma 
302 P311 - FFPE 2 WT 35 G>A 3140 A>G - MSKK 48 F C18.3 II Mucinous Carcinoma 
303 P312 - FFPE 0 WT WT WT - MSKK 85 F C18.7 III Adenocarcinoma 
304 P313 - FFPE 0 WT WT WT - MSKK 84 F C19.- I Adenocarcinoma 
305 P314 - FFPE 2 WT 35 G>T 1633 G>A - MSKK 75 M C18.0 III Adenocarcinoma 
306 P315 - FFPE 0 WT WT WT - MSKK 70 M C18.7 III Adenocarcinoma 
307 P316 - FFPE 1 WT 35 G>T WT - MSKK 65 M C18.7 II Mixed Diff.with Mucin 
308 P317 - FFPE 2 WT 34 G>T 3140 A>G - MSKK 76 M C18.2 IV Adenocarcinoma 
309 P318 - FFPE 0 WT WT WT - MSKK 66 M C20.- II Adenocarcinoma 
310 P319 - FFPE 1 WT WT 3140 A>G - MSKK 82 F C18.2 III Adenocarcinoma 
311 P320 - FFPE 0 WT WT WT - MSKK 81 F C18.2 II Mucinous Carcinoma 
312 P321 - FFPE 1 WT 35 G>A WT - MSKK 70 M C18.7 III Adenocarcinoma 
313 P322 - FFPE 1 WT 35 G>A WT - MSKK 62 M C20.- III Rest after neoadj.th. 
314 P323 - FFPE 0 WT WT WT NA MSKK 76 M C20.9 III Adenocarcinoma 
315 P324 - FFPE 0 WT WT WT - MSKK 84 F C19.- II Adenocarcinoma 
316 P325 - FFPE 1 WT 38 G>A WT - MSKK 64 F C20.- III Rest after neoadj.th. 
317 P326 - FFPE 0 WT WT WT - MSKK 72 M C18.7 III Adenocarcinoma 
318 P328 - FFPE 2 WT 35 G>A 3140 A>G - MSKK 71 F C19.- II Rest after neoadj.th. 
319 P329 - Snap-frozen 1 1799 T>A WT WT WT MSKK 79 M C18.0 III Adenocarcinoma 
320 P331 - Snap-frozen 1 WT 35 G>A WT - RVS 69 F C20.- III Adenocarcinoma 
321 P332 - Snap-frozen 0 WT WT WT WT RVS 65 M C18.3 II Adenocarcinoma 
322 P333 - Snap-frozen 0 WT WT WT WT RVS 59 M C18.9 II Adenocarcinoma 
323 P334 - Snap-frozen 0 WT WT WT WT RVS 67 F C20.- II Adenocarcinoma 
324 P335 - Snap-frozen 0 WT WT WT WT RVS 67 - C18.7 I Adenocarcinoma 
325 P336 - Snap-frozen 2 WT 436 G>A 1633 G>A WT RVS 77 F C20.- III Adenocarcinoma 
326 P337 - Snap-frozen 1 WT 35 G>A WT - RVS 64 M C18.0 II Adenocarcinoma 
327 P338 - Snap-frozen 1 WT 35 G>C WT 35 G>C RVS 43 F C20.- III Adenocarcinoma 
328 P339 - Snap-frozen 0 WT WT WT WT RVS 57 M C19.- II Adenocarcinoma 
329 P340 - Snap-frozen 0 WT WT WT WT RVS 46 M C18.7 I Adenocarcinoma 
330 P341 - Snap-frozen 0 WT WT WT WT RVS 61 F C20.- III Adenocarcinoma 
331 P342 - Snap-frozen 1 WT 35 G>T WT 35 G>T RVS 71 M C18.2 III Adenocarcinoma 
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332 P343 - Snap-frozen 1 WT 35 G>T WT 35 G>T RVS 75 F C18.0 II Adenocarcinoma 
333 P344 - Snap-frozen 0 WT WT WT - RVS 66 M C18.9 III Adenocarcinoma 
334 P345 - Snap-frozen 1 WT 35 G>A WT 35 G>A RVS 60 - C20.- III Adenocarcinoma 
335 P346 - Snap-frozen 0 WT WT WT WT RVS 60 M C18.2 III Adenocarcinoma 
336 P347 - Snap-frozen 0 WT WT WT WT RVS 40 F C18.9 II Adenocarcinoma 
337 P348 - Snap-frozen 0 WT WT WT WT RVS - - C20.- II Adenocarcinoma 
338 P349 - Snap-frozen 1 WT 35 G>A WT 35 G>A RVS 66 M C18.0 III Mucinous Carcinoma 
339 P350 - Snap-frozen 1 WT 38 G>A WT - RVS 68 M C20.- I Adenocarcinoma 
340 P351 - Snap-frozen 0 WT WT WT WT RVS 74 M C18.0 II Adenocarcinoma 
341 P352 - Snap-frozen 1 WT 35 G>T WT - RVS 69 M C18.9 I Adenocarcinoma 
342 P353 - Snap-frozen 1 WT 34 G>T WT 34 G>T RVS 77 M C18.0 II Adenocarcinoma 
343 P354 - Snap-frozen 0 WT WT WT WT RVS 59 - C20.- III Adenocarcinoma 
344 P355 - FFPE 0 WT WT WT - MSKK 66 M C18.2 III Adenocarcinoma 
345 P356 - FFPE 0 WT WT WT - MSKK 76 M C20.9 III Rest after neoadj.th. 
346 P306 - FFPE 1 1799 T>A WT WT - MSKK 83 F C18.4 I Mucinous Carcinoma 
347 P357 - FFPE 1 WT 38 G>A WT 38 G>A MSKK 73 M C18.7 I Adenocarcinoma 
348 P359 - FFPE 0 WT WT WT - MSKK 63 M C20.- III Rest after neoadj.th. 
349 P360 - FFPE 1 WT WT 1624 G>A - MSKK 69 F C18.0 II Mucinous Carcinoma 
350 P361 - FFPE 0 WT WT WT - MSKK 76 F C18.0 II Adenocarcinoma 
351 P362 - FFPE 1 WT 35 G>A WT - MSKK 82 F C18.4 II Adenocarcinoma 
352 P363 - FFPE 0 WT WT WT WT MSKK 72 M C18.7 III Adenocarcinoma 
353 P364 - FFPE 0 WT WT WT WT MSKK 77 M C18.3 III Adenocarcinoma 
354 P156 - FFPE 1 WT 38 G>A WT - MSKK 67 M C20.- II Adenocarcinoma 
355 P367 - FFPE 0 WT WT WT - MSKK 65 M C20.- I Rest after neoadj.th. 
356 P368 - Snap-frozen 1 WT 436 G>A WT WT MSKK 87 F C18.7 III Adenocarcinoma 
357 P369 - FFPE 1 1799 T>A WT WT - MSKK 71 F C18.4 III Adenocarcinoma 
358 P370 - FFPE 2 WT 35 G>A 1633 G>A - MSKK 52 F C18.4 I Tumour in Adenoma 
359 P372 - FFPE 0 WT WT WT - MSKK 63 M C20.- II Adenocarcinoma 
360 P373 - FFPE 1 WT 38 G>A WT - MSKK 57 M C18.2 II Adenocarcinoma 
361 P374 - FFPE 0 WT WT WT - MSKK 79 F C18.7 III Adenocarcinoma 
362 P375 - FFPE 1 WT 35 G>A WT - MSKK 79 F C18.0 II Mucinous Carcinoma 
363 P376 - FFPE 1 WT 35 G>A WT - MSKK 83 F C18.7 III Adenocarcinoma 
364 P377 - FFPE 0 WT WT WT WT MSKK 86 F C18.7 II Adenocarcinoma 
365 P358 - Snap-frozen 1 1799 T>A WT WT WT MSKK 66 F C18.4 III Tumour in Adenoma 
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366 P379 - FFPE 1 1799 T>A WT WT - MSKK 52 M C18.2 III Neuroendocrine Diff. 
367 P381 - FFPE 1 WT 35 G>A WT - MSKK 68 M C18.0 III Mucinous Carcinoma 
368 P382 - FFPE 2 WT 35 G>A 1633 G>A - MSKK 82 F C18.6 II Mixed Diff.with Mucin 
369 P383 - FFPE 1 WT 35 G>A WT - MSKK 87 M C18.6 II Adenocarcinoma 
370 P365 - FFPE 1 WT 35 G>A WT - MSKK 73 F C20.9 III Mixed Diff.with Mucin 
371 P366 - FFPE 1 WT 35 G>T WT - MSKK 79 F C18.0 II Adenocarcinoma 
372 P384 - FFPE 2 WT 35 G>T 3140 A>G - MSKK 75 M C18.4 II Adenocarcinoma 
373 P385 - FFPE 1 WT 34 G>A WT - MSKK 80 F C18.0 III Adenocarcinoma 
374 P386 - FFPE 2 1799 T>A WT 1633 G>A - MSKK 62 F C18.2 III Mucinous Carcinoma 
375 P387 - FFPE 0 WT WT WT - MSKK 48 M C19.9 IV Adenocarcinoma 
376 P388 - FFPE 2 WT 35 G>A 1633 G>A - MSKK 55 F C19.9 III Adenocarcinoma 
377 P389 - FFPE 0 WT WT WT - MSKK 70 M C20.9 III Adenocarcinoma 
378 P390 - FFPE 1 WT 35 G>C WT - MSKK 73 M C20.- II Adenocarcinoma 
379 P391 - FFPE 0 WT WT WT - MSKK 62 M C18.0 III Adenocarcinoma 
380 P330 - FFPE 1 WT 35 G>T WT - MSKK 65 M C18.7 II Adenocarcinoma 
381 P394 - FFPE 0 WT WT WT - MSKK 76 F C18.2 II Adenocarcinoma 
382 P395 - FFPE 0 WT WT WT NA MSKK 75 M C20.- II Adenocarcinoma 
383 P396 - FFPE 1 WT 38 G>A WT - MSKK 78 F C19.- III Unusual Differentiation 
384 P397 - FFPE 0 WT WT WT WT MSKK 67 M C20.- I Neuroendocrine Diff. 
385 P398 - FFPE 0 WT WT WT - MSKK 82 F C18.6 II Adenocarcinoma 
386 P399 - FFPE 0 WT WT WT - MSKK 69 M C18.7 IV Adenocarcinoma 
387 P400 - FFPE 0 WT WT WT - MSKK 77 F C18.2 II Mucinous Carcinoma 
388 P401 - FFPE 2 WT 35 G>T 1633 G>A 35 G>T MSKK 65 M C18.2 III Mucinous Carcinoma 
389 P402 - Snap-frozen 1 WT 35 G>A WT 35 G>A MSKK 69 M C18.7 III Adenocarcinoma 
390 P403 - FFPE 0 WT WT WT - MSKK 48 M C19.9 IV Adenocarcinoma 
391 P404 - FFPE 1 WT 35 G>A WT - MSKK 66 M C18.0 III Tumour in Adenoma 
392 P378 - FFPE 0 WT WT WT - MSKK 68 M C18.2 II Mucinous Carcinoma 
393 P406 - FFPE 0 WT WT WT WT MSKK 61 F C18.5 III Adenocarcinoma 
394 P409 - Snap-frozen 0 WT WT WT - MSKK 64 M C20.9 III Adenocarcinoma 
395 P410 - FFPE 0 WT WT WT - MSKK 87 F C20.- II Adenocarcinoma 
396 P411 - FFPE 1 WT 34 G>A WT - MSKK 66 M C20.- I Adenocarcinoma 
397 P380 - FFPE 0 WT WT WT - MSKK 63 F C20.- I Adenocarcinoma 
398 P414 - Snap-frozen 0 WT WT WT WT MSKK 80 F C18.3 III Adenocarcinoma 
399 P415 - Snap-frozen 0 WT WT WT WT MSKK 66 F C18.7 III Adenocarcinoma 
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400 P392 - FFPE 2 1799 T>A WT 1633 G>A - MSKK 65 F C18.4 I Mucinous Carcinoma 
401 P393 - FFPE 0 WT WT WT - MSKK 63 M C20.- III Adenocarcinoma 
402 P416 - FFPE 2 WT 35 G>A 1633 G>A - MSKK 65 M C18.0 I Mixed Diff.with Mucin 
403 P422 - Snap-frozen 1 WT 38 G>A WT 38 G>A MSKK 77 M C19.9 III Adenocarcinoma 
404 P424 - FFPE 1 WT 34 G>A WT - MSKK 76 M C18.7 IV Synchronous CRC 
405 P412 - FFPE 2 WT 35 G>C 1633 G>A - MSKK 84 M C18.3 II Adenocarcinoma 
406 P413 - FFPE 0 WT WT WT WT MSKK 80 M C20.- I Adenocarcinoma 
407 P425 - FFPE 0 WT WT WT - MSKK 58 M C20.- III Unusual Differentiation 
408 P426 - FFPE 1 1799 T>A WT WT WT MSKK 75 M C18.4 III Unusual Differentiation 
409 P427 - FFPE 0 WT WT WT - MSKK 63 M C20.- III Mucinous Carcinoma 
410 P428 - FFPE 2 WT 35 G>T 1624 G>A 35 G>T MSKK 62 M C18.0 II Mixed Diff.with Mucin 
411 P419 - FFPE 1 1799 T>A WT WT - MSKK 82 F C18.7 IV Mixed Diff.with Mucin 
412 P420 - FFPE 1 WT WT 1633 G>A - MSKK 75 M C18.7 II Mixed Diff.with Mucin 
413 P429 - FFPE 1 1799 T>A WT WT - MSKK 72 F C18.0 III Unusual Differentiation 
414 P430 - FFPE 0 WT WT WT - MSKK 63 F C19.- I Tumour in Adenoma 
415 P431 - FFPE 1 WT 35 G>A WT 35 G>A MSKK 52 M C18.0 III Adenocarcinoma 
416 P432 - FFPE 2 WT 35 G>A 1633 G>A - MSKK 82 M C18.2 II Adenocarcinoma 
417 P433 - FFPE 1 1799 T>A WT WT WT MSKK 65 M C18.4 III Adenocarcinoma 
418 P436 - FFPE 1 1799 T>A WT WT - MSKK 67 F C18.0 II Mixed Diff.with Mucin 
419 P437 - FFPE 0 WT WT WT - MSKK 75 M C18.4 IV Adenocarcinoma 
420 P438 - FFPE 1 WT 35 G>A WT - MSKK 82 M C18.2 III Mucinous Carcinoma 
421 P439 - FFPE 1 WT 35 G>T WT - MSKK 58 M C20.- III Adenocarcinoma 
422 P440 - FFPE 0 WT WT WT - MSKK 82 F C18.7 I Adenocarcinoma 
423 P441 - FFPE 0 WT WT WT - MSKK 63 M C18.9 II Adenocarcinoma 
424 P442 - FFPE 1 WT 35 G>A WT - MSKK 82 F C20.- I Adenocarcinoma 
425 P443 - FFPE 0 WT WT WT - MSKK 67 M C18.2 III Adenocarcinoma 
426 P444 - FFPE 1 WT 34 G>A WT - MSKK 73 M C20.- III Adenocarcinoma 
427 P445 - FFPE 1 WT 34 G>T WT 34 G>T MSKK 58 M C18.0 III Adenocarcinoma 
428 P446 - FFPE 1 WT 35 G>T WT - MSKK 77 F C18.- III Synchronous CRC 
429 P447 - FFPE 1 WT 35 G>A WT - MSKK 70 F C18.0 III Unusual Differentiation 
430 P448 - FFPE 2 WT 38 G>A 3140 A>G - MSKK 73 F C20.- III Rest after neoadj.th. 
431 P449 - FFPE 2 WT 35 G>T 1633 G>A - MSKK 77 F C18.3 IV Synchronous CRC 
432 P451 - FFPE 0 WT WT WT - MSKK 80 M C20.- I Adenocarcinoma 
433 P452 - FFPE 0 WT WT WT - MSKK 61 M C20.- I Adenocarcinoma 
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434 P453 - FFPE 2 WT 35 G>A 1624 G>A - MSKK 66 M C18.7 IV Adenocarcinoma 
435 P454 - FFPE 1 WT 436 G>A WT - MSKK 86 M C18.0 III Neuroendocrine Diff. 
436 P455 - FFPE 1 1799 T>A WT WT - MSKK 68 F C18.7 I Adenocarcinoma 
437 P456 - FFPE 1 WT 35 G>T WT 35 G>T MSKK 68 M C18.0 II Adenocarcinoma 
438 P457 - FFPE 2 WT 35 G>A 1633 G>A - MSKK 79 M C18.7 I Adenocarcinoma 
439 P458 - FFPE 0 WT WT WT - MSKK 67 M C20.9 III Rest after neoadj.th. 
440 P459 - FFPE 0 WT WT WT WT MSKK 75 M C20.- II Rest after neoadj.th. 
441 P462 - FFPE 0 WT WT WT NA MSKK 87 F C18.3 III Adenocarcinoma 
442 P463 - FFPE 0 WT WT WT - MSKK 69 F C18.0 II Unusual Differentiation 
443 P464 - FFPE 1 WT 38 G>A WT - MSKK 72 F C18.0 III Mixed Diff.with Mucin 
444 P465 - FFPE 0 WT WT WT - MSKK 52 M C18.7 II Adenocarcinoma 
445 P466 - FFPE 0 WT WT WT - MSKK 64 M C18.7 IV Neuroendocrine Diff. 
446 P467 - FFPE 1 WT 38 G>A WT - MSKK 70 M C20.- III Rest after neoadj.th. 
447 P468 - FFPE 1 WT 35 G>A WT - MSKK 57 M C18.6 II Mucinous Carcinoma 
448 P469 - FFPE 1 WT 35 G>T WT - MSKK 76 M C20.9 I Tumour in Adenoma 
449 P417 - FFPE 0 WT WT WT - MSKK 64 M C20.- I Adenocarcinoma 
450 P473 - FFPE 0 WT WT WT - MSKK 69 M C18.4 II Adenocarcinoma 
451 P475 - FFPE 0 WT WT WT - MSKK 79 M C18.9 II Adenocarcinoma 
452 P408 - FFPE 1 WT 35 G>A WT - MSKK 53 M C18.7 I Adenocarcinoma 
453 P476 - FFPE 1 WT WT 1624 G>A WT MSKK 67 F C18.5 I Adenocarcinoma 
454 P477 - FFPE 0 WT WT WT - MSKK 70 M C20.- II Adenocarcinoma 
455 P478 - FFPE 1 WT 35 G>T WT - MSKK 78 F C18.6 II Adenocarcinoma 
456 P479 - FFPE 0 WT WT WT - MSKK 76 M C18.2 II Adenocarcinoma 
457 P480 - FFPE 1 1799 T>A WT WT - MSKK 79 F C18.2 III Adenocarcinoma 
458 P434 - FFPE 2 WT 34 G>C 3140 A>G - MSKK 80 F C19.- III Mucinous Carcinoma 
459 P435 - FFPE 0 WT WT WT - MSKK 66 M C19.9 II Adenocarcinoma 
460 P481 - FFPE 0 WT WT WT - MSKK 64 M C18.6 II Adenocarcinoma 
461 P482 - FFPE 1 WT 38 G>A WT NA MSKK 78 M C18.3 III Adenocarcinoma 
462 P483 - FFPE 2 WT 35 G>T 3140 A>G - MSKK 72 M C18.2 II Tumour in Adenoma 
463 P484 - FFPE 0 WT WT WT - MSKK 79 F C18.0 III Synchronous CRC 
464 P485 - FFPE 1 WT 35 G>A WT - MSKK 72 M C18.7 I Mucinous Carcinoma 
465 P486 - FFPE 0 WT WT WT - MSKK 72 M C18.2 III Unusual Differentiation 
466 P487 - FFPE 0 WT WT WT - MSKK 75 M C18.2 I Adenocarcinoma 
467 P489 - FFPE 0 WT WT WT - MSKK 56 M C20.- IV Adenocarcinoma 
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468 P490 - FFPE 1 WT WT 1624 G>A - MSKK 66 F C18.7 II Adenocarcinoma 
469 P492 - FFPE 0 WT WT WT - MSKK 39 F C18.7 II Adenocarcinoma 
470 P493 - FFPE 0 WT WT WT NA MSKK 64 M C20.- IV Synchronous CRC 
471 P495 - FFPE 0 WT WT WT - MSKK 60 M C19.- I Adenocarcinoma 
472 P496 - FFPE 0 WT WT WT - MSKK 72 M C18.7 I Adenocarcinoma 
473 P498 - FFPE 0 WT WT WT - MSKK 60 F C18.7 II Adenocarcinoma 
474 P503 - FFPE 0 WT WT WT - MSKK 78 M C18.3 III Mixed Differentiation 
475 P504 - FFPE 0 WT WT WT - MSKK 78 M C18.7 I Adenocarcinoma 
476 P505 - FFPE 0 WT WT WT - MSKK 71 M C18.7 IV Adenocarcinoma 
477 P494 M1 FFPE 0 WT WT WT - MSKK 75 F C18.7 II Adenocarcinoma 
478 P507 - FFPE 0 WT WT WT - MSKK 56 F C20.- III Adenocarcinoma 
479 P488 - FFPE 1 WT 35 G>T WT - MSKK 71 M C20.- I Adenocarcinoma 
480 P508 - FFPE 1 WT WT 1633 G>A - MSKK 74 F C20.9 I Adenocarcinoma 
481 P510 - FFPE 2 1799 T>A WT 3140 A>G - MSKK 63 M C18.2 II Mucinous Carcinoma 
482 P512 - FFPE 0 WT WT WT - MSKK 56 F C18.2 III Adenocarcinoma 
483 P513 - FFPE 1 1799 T>A WT WT - MSKK 76 M C18.3 II Adenocarcinoma 
484 P511 - FFPE 1 WT 38 G>A WT - MSKK 75 F C18.7 II Adenocarcinoma 
485 P472 - FFPE 0 WT WT WT - MSKK 66 M C18.7 IV Adenocarcinoma 
486 P501 - FFPE 0 WT WT WT WT MSKK 72 F C18.7 I Adenocarcinoma 
487 P502 - FFPE 1 WT 34 G>T WT 34 G>T MSKK 81 M C18.4 I Adenocarcinoma 
488 P518 - Snap-frozen 0 WT WT WT WT MSKK 82 M C18.2 III Synchronous CRC 
489 P519 - FFPE 1 WT 35 G>T WT - MSKK 62 M C20.9 IV Adenocarcinoma 
490 P521 - FFPE 0 WT WT WT - MSKK 82 F C18.7 II Adenocarcinoma 
491 P497 - FFPE 0 WT WT WT - MSKK 66 M C20.9 I Adenocarcinoma 
492 P423 - FFPE 0 WT WT WT - MSKK 65 F C18.4 I Adenocarcinoma 
493 P506 - FFPE 0 WT WT WT - MSKK 67 M C18.7 II Adenocarcinoma 
494 P450 - FFPE 0 WT WT WT - MSKK 46 F C18.0 I Tumour in Adenoma 
495 P418 - FFPE 1 WT 35 G>A WT - MSKK 82 F C18.3 III Mucinous Carcinoma 
496 P421 - FFPE 0 WT WT WT WT MSKK 64 M C20.- III Adenocarcinoma 
497 P522 - FFPE 0 WT WT WT - MSKK 52 F C18.7 II Adenocarcinoma 
498 P461 - FFPE 1 WT 35 G>T WT WT MSKK 63 F C20.9 II Rest after neoadj.th. 
499 P460 - FFPE 0 WT WT WT - MSKK 78 M C20.- I Adenocarcinoma 
500 P520 - FFPE 0 WT WT WT - MSKK 74 M C18.7 I Adenocarcinoma 
501 P509 M3 FFPE 1 WT 35 G>C WT - MSKK 56 M C18.6 IV Adenocarcinoma 
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502 P407 - FFPE 1 WT 38 G>A WT - MSKK 77 F C20.- IV Mixed Diff.with Mucin 
503 P524 - FFPE 1 1799 T>A WT WT WT MSKK 81 F C18.4 III Mucinous Carcinoma 
504 P525 M7 FFPE 0 WT WT WT - MSKK 69 M C18.7 II Adenocarcinoma 
505 P526 - FFPE 2 WT 35 G>A 1633 G>A 35 G>A MSKK 73 F C20.- I Mucinous Carcinoma 
506 P527 - FFPE 1 1799 T>A WT WT - MSKK 60 F C18.0 I Adenocarcinoma 
507 P523 - FFPE 1 1799 T>A WT WT - MSKK 77 F C18.0 I Mucinous Carcinoma 
508 P515 - FFPE 1 WT 34 G>A, 436 
G>A 
WT - MSKK 41 F C18.4 III Mucinous Carcinoma 
509 P529 - FFPE 0 WT WT WT - MSKK 58 F C18.0 IV Adenocarcinoma 
510 P532 - FFPE 1 WT 35 G>A WT - MSKK 65 M C18.5 II Adenocarcinoma 
511 P530 - FFPE 0 WT WT WT WT MSKK 76 F C18.2 III Medullary Differentitation 
512 P531 - FFPE 1 WT WT 1633 G>A - MSKK 56 M C18.3 II Mixed Diff.with Mucin 
513 P516 - FFPE 0 WT WT WT - MSKK 73 M C18.7 III Adenocarcinoma 
514 P535 - FFPE 1 WT 35 G>T WT - MSKK 67 F C18.7 II Adenocarcinoma 
515 P536 M10 FFPE 1 1799 T>A WT WT - MSKK 77 M C18.2 III Adenocarcinoma 
516 P537 - FFPE 0 WT WT WT - MSKK 80 F C18.3 II Adenocarcinoma 
517 P538 - FFPE 2 1799 T>A WT 1633 G>A - MSKK 57 F C18.7 III Adenocarcinoma 
518 P539 - FFPE 1 1799 T>A WT WT WT MSKK 77 F C18.2 II Mixed Diff.with Mucin 
519 P540 - FFPE 0 WT WT WT WT MSKK 61 M C18.2 III Adenocarcinoma 
520 P528 - FFPE 0 WT WT WT - MSKK 77 F C20.- IV Adenocarcinoma 
521 P541 - FFPE 0 WT WT WT - MSKK 75 M C19.- III Rest after neoadj.th. 
522 P533 - FFPE 0 WT WT WT - MSKK 65 F C18.4 II Neuroendocrine Diff. 
523 P542 - FFPE 0 WT WT WT - MSKK 62 M C18.7 III Adenocarcinoma 
524 P534 - FFPE 1 1799 T>A WT WT - MSKK 69 F C18.2 III Mixed Diff.with Mucin 
525 P544 - FFPE 0 WT WT WT - MSKK 68 M C18.6 II Adenocarcinoma 
526 P545 - FFPE 1 WT 436 G>A WT - MSKK 70 M C18.7 II Adenocarcinoma 
527 P554 - FFPE 0 WT WT WT - MSKK 62 M C20.- III Synchronous CRC 
528 P546 - FFPE 1 WT 35 G>A WT - MSKK 76 M C18.7 II Mixed Diff.with Mucin 
529 P547 - FFPE 1 WT 35 G>T WT - MSKK 73 M C20.- III Rest after neoadj.th. 
530 P548 - FFPE 1 WT WT 1624 G>A WT MSKK - - - - Mixed Diff.with Mucin 
531 P549 - FFPE 1 WT 38 G>A WT - MSKK - - - - Rest after neoadj.th. 
532 P550 - FFPE 0 WT WT WT - MSKK 73 M C18.7 IV Adenocarcinoma 
533 P551 - FFPE 0 WT WT WT WT MSKK 67 F C18.9 III Adenocarcinoma 
534 P517 - FFPE 1 WT 35 G>T WT - MSKK 70 F C18.7 IV Adenocarcinoma 
535 P405 - FFPE 0 WT WT WT - MSKK 72 F C18.2 II Adenocarcinoma 
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536 P246 - FFPE 2 WT 35 G>A 1624 G>A - MSKK 78 M C18.2 II Adenocarcinoma 
537 P245 - FFPE 1 WT 35 G>A WT - MSKK 73 M C18.5 III Adenocarcinoma 
538 P285 - FFPE 0 WT WT WT - MSKK 81 M C18.2 II Adenocarcinoma 
539 P552 - FFPE 0 WT WT WT - MSKK 66 M c18.0 II Adenocarcinoma 
540 P500 - FFPE 0 WT WT WT - MSKK 69 M C18.6 I Adenocarcinoma 
541 P499 - FFPE 0 WT WT WT - MSKK 81 F C18.0 IV Adenocarcinoma 
542 P553 - FFPE 1 WT 38 G>A WT - MSKK 72 M C18.2 II Mixed Diff.with Mucin 
543 P555 - FFPE 0 WT WT WT - MSKK 47 F C20.- II Adenocarcinoma 
544 P556 - FFPE 0 WT WT WT WT MSKK 61 M C20.- I Rest after neoadj.th. 
545 P557 - FFPE 0 WT WT WT - MSKK 67 M C18.6 III Mucinous Carcinoma 
546 P491 - FFPE 0 WT WT WT - MSKK 72 M C18.7 II Adenocarcinoma 
547 P558 - FFPE 1 WT WT 1633 G>A - MSKK 72 M C18.0 II Mucinous Carcinoma 
548 P559 - FFPE 0 WT WT WT WT MSKK 77 F C18.4 II Adenocarcinoma 
549 P578 - FFPE 1 WT 35 G>A WT - MSKK 64 M C18.0 I Mixed Diff.with Mucin 
550 P561 - FFPE 0 WT WT WT - MSKK 57 M C20.- II Adenocarcinoma 
551 P543 - FFPE 1 WT 34 G>T WT - MSKK 39 F C18.7 III Adenocarcinoma 
552 P474 - FFPE 0 WT WT WT - MSKK 62 M C18.7 III Adenocarcinoma 
553 P371 - FFPE 1 WT WT 1633 G>A - MSKK 44 M C20.- II Rest after neoadj.th. 
554 P327 - FFPE 0 WT WT WT - MSKK 66 F C20.- II Rest after neoadj.th. 
555 P200 - FFPE 0 WT WT WT WT MSKK 68 M C18.2 III Mucinous Carcinoma 
556 P563 - Snap-frozen 1 WT 35 G>T WT 35 G>T MSKK 73 M C18.7 III Synchronous CRC 
557 P564 - FFPE 0 WT WT WT - MSKK 65 M C20.- - Adenocarcinoma 
558 P565 - FFPE 1 1799 T>A WT WT - MSKK 77 F C18.0 I Synchronous CRC 
559 P566 - FFPE 1 WT 35 G>A WT - MSKK 75 M C20.- II Adenocarcinoma 
560 P568 - FFPE 1 WT 35 G>T WT - MSKK 77 M C18.0 II Adenocarcinoma 
561 P569 - FFPE 1 WT 35 G>A WT - MSKK 80 M C18.3 II Adenocarcinoma 
562 P570 - FFPE 0 WT WT WT WT MSKK 78 F C20.- III Adenocarcinoma 
563 P572 - FFPE 2 WT 38 G>A 3140 A>G - MSKK 69 M C18.4 IV Adenocarcinoma 
564 P573 - FFPE 2 WT 35 G>A 1624 G>A; 
1633 G>A 
- MSKK 84 F C18.7 III Synchronous CRC 
565 P575 M19 FFPE 2 1799 T>A WT 3140 A>G - MSKK 68 M C18.2 I Tumour in Adenoma 
566 P576 M20 FFPE 1 1799 T>A WT WT - MSKK 71 M C18.7 IV Adenocarcinoma 
567 P577 - FFPE 0 WT WT WT NA MSKK 79 M C19.- III Adenocarcinoma 
568 P574 M18 FFPE 1 WT 35 G>A WT - MSKK 59 F C18.7 II Adenocarcinoma 
569 P562 - FFPE 0 WT WT WT WT MSKK 77 M C18.7 III Adenocarcinoma 
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570 P582 M21 FFPE 1 1799 T>A WT WT - MSKK 77 F C18.0 III Tumour in Adenoma 
571 P584 - FFPE 1 WT 38 G>A WT - MSKK 65 M C20.9 I Adenocarcinoma 
572 P585 - FFPE 0 WT WT WT WT MSKK 68 M C20.- I Rest after neoadj.th. 
573 P586 - FFPE 2 WT 35 G>A 1624 G>A - MSKK 80 M C18.7 II Adenocarcinoma 
574 P587 - FFPE 0 WT WT WT - MSKK 69 M C20.9 I Tumour in Adenoma 
575 P588 - FFPE 1 WT 35 G>A WT - MSKK 84 F C18.2 III Small Cell Carcinoma 
576 P589 - FFPE 0 WT WT WT - MSKK 74 M C18.0 I Synchronous CRC 
577 P590 M24 FFPE 1 WT 35 G>T WT - MSKK 66 F C20.- III Adenocarcinoma 
578 P591 - FFPE 1 WT 35 G>A WT 35 G>A MSKK 74 M C18.7 I Adenocarcinoma 
579 P592 M25 FFPE 1 WT 34 G>T WT - MSKK 71 F C18.6 II Mixed Diff.with Mucin 
580 P593 - FFPE 1 WT 34 G>T WT - MSKK 69 F C20.- II Mucinous Carcinoma 
581 P594 - FFPE 1 1799 T>A WT WT - MSKK 78 M C18.2 II Undifferentiated 
582 P571 - FFPE 1 1799 T>A WT WT - MSKK 73 F C18.0 III Adenocarcinoma 
583 P583 M22 FFPE 0 WT WT WT - MSKK 82 M C18.7 III Adenocarcinoma 
584 P596 M27 FFPE 1 WT 35 G>A WT - MSKK 56 F C20.- III Adenocarcinoma 
585 P599 - FFPE 2 WT 34 G>A 3140 A>G - MSKK 68 F C19.9 III Adenocarcinoma 
586 P580 - FFPE 1 1799 T>A WT WT - MSKK 83 F - I Neuroendocrine Diff. 
587 P579 - FFPE 0 WT WT WT - MSKK 66 F C19.- II Adenocarcinoma 
588 P601 - FFPE 1 1799 T>A WT WT - MSKK 75 F C18.2 III Adenocarcinoma 
589 P602 - FFPE 0 WT WT WT WT MSKK 65 M C20.- II Rest after neoadj.th. 
590 P560 - FFPE 1 WT 38 G>A WT - MSKK 65 M C18.2 IV Adenocarcinoma 
591 P595 - FFPE 1 WT 35 G>A WT 35 G>A MSKK 74 M C18.7 III Mucinous Carcinoma 
592 P598 M28 FFPE 1 WT 35 G>C WT - MSKK 45 F C20.- I Adenocarcinoma 
593 P606 - FFPE 0 WT WT WT - MSKK 76 M C20.- III Rest after neoadj.th. 
594 P605 - FFPE 0 WT WT WT - MSKK 53 F C18.7 III Adenocarcinoma 
595 P581 - FFPE 0 WT WT WT - MSKK 68 F C20.9 II Adenocarcinoma 
596 P610 - FFPE 1 WT 35 G>T WT 35 G>T MSKK 70 F C20.- I Adenocarcinoma 
597 P611 - FFPE 1 1799 T>A WT WT WT MSKK 66 F C18.6 III Mucinous Carcinoma 
598 P612 - FFPE 2 WT 35 G>T 1633 G>A - MSKK 77 M C18.7 I Adenocarcinoma 
599 P614 - FFPE 0 WT WT WT - MSKK 73 F C18.7 I Adenocarcinoma 
600 P615 - FFPE 1 1799 T>A WT WT - MSKK 72 F C18.3 I Mucinous Carcinoma 
601 P616 M31 FFPE 2 WT 38 G>A 3140 A>G - MSKK 72 F C18.7 I Mucinous Carcinoma 
602 P617 - FFPE 0 WT WT WT - MSKK 56 M C20.9 I Adenocarcinoma 
603 P618 - FFPE 1 WT 35 G>C WT - MSKK 71 M C18.0 III Adenocarcinoma 
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604 P619 - FFPE 1 WT 436 G>A WT - MSKK 74 M C20.9 I Mucinous Carcinoma 
605 P620 - FFPE 1 1799 T>A WT WT - MSKK 58 M C18.0 II Mucinous Carcinoma 
606 P621 M33 FFPE 1 1799 T>A WT WT - MSKK 71 M C18.7 II Adenocarcinoma 
607 P623 - FFPE 1 WT WT 3140 A>G - MSKK 79 M C18.7 I Adenocarcinoma 
608 P624 M34 FFPE 0 WT WT WT - MSKK 68 M C18.7 IV Adenocarcinoma 
609 P625 - FFPE 0 WT WT WT - MSKK 66 F C18.3 II Adenocarcinoma 
610 P626 - FFPE 2 1799 T>A WT 1633 G>A WT MSKK 88 F C18.2 II Unusual Differentiation 
611 P597 - FFPE 0 WT WT WT - MSKK 87 F C20.- - Tumour in Adenoma 
612 P629 - FFPE 2 WT 35 G>T 3140 A>G - MSKK 63 M C20.9 II Adenocarcinoma 
613 P630 - FFPE 0 WT WT WT - MSKK 75 M C18.4 II Adenocarcinoma 
614 P608 - FFPE 0 WT WT WT - MSKK 57 M C20.- I Adenocarcinoma 
615 P609 - FFPE 0 WT WT WT - MSKK 75 M C20.9 I Adenocarcinoma 
616 P632 - FFPE 1 1799 T>A WT WT - MSKK 87 F C18.2 III Adenocarcinoma 
617 P633 M39 FFPE 0 WT WT WT - MSKK 87 F C18.7 II Adenocarcinoma 
618 P634 M40 FFPE 0 WT WT WT - MSKK 68 F C18.7 III Adenocarcinoma 
619 P636 - FFPE 0 WT WT WT - MSKK 73 M C18.7 III Synchronous CRC 
620 P622 - FFPE 1 WT WT 1633 G>A - MSKK 60 M C18.0 I Mixed Diff.with Mucin 
621 P257 - FFPE 1 WT 38 G>A WT - MSKK 51 M C18.4 III Adenocarcinoma 
622 P256 - FFPE 2 1799 T>A WT 3140 A>G - MSKK 81 F C18.4 III Adenocarcinoma 
623 P627 M37 FFPE 1 WT WT 1633 G>A - MSKK 74 M C18.2 IV Adenosquamous 
carcinoma 
624 P628 M38 FFPE 0 WT WT WT - MSKK 64 M C18.2 IV Mixed Diff.with Mucin 
625 P603 - FFPE 1 WT 35 G>A WT - MSKK 85 M C18.4 II Mucinous Carcinoma 
626 P640 - FFPE 1 WT 34 G>A WT - MSKK 67 M C18.0 II Adenocarcinoma 
627 P641 - FFPE 0 WT WT WT - MSKK 71 M C18.2 III Adenocarcinoma 
628 P604 - FFPE 2 WT 35 G>A 1624 G>A - MSKK 57 M C18.0 II Adenocarcinoma 
629 P645 - FFPE 0 WT WT WT WT MSKK 78 M C18.7 II Adenocarcinoma 
630 P471 - FFPE 1 WT 35 G>T WT - MSKK 74 F C20.- II Adenocarcinoma 
631 P607 - FFPE 2 WT 35 G>C 1633 G>A - MSKK 87 M C18.0 II Adenocarcinoma 
632 P647 - FFPE 0 WT WT WT - MSKK 57 M C19.9 III Adenocarcinoma 
633 P648 - FFPE 1 WT 35 G>T WT - MSKK 50 F C18.3 II Adenocarcinoma 
634 P631 - FFPE 1 WT 38 G>A WT 38 G>A MSKK 83 M C18.5 III Mucinous Carcinoma 
635 P651 - FFPE 1 WT 37 G>T WT 37 G>T MSKK 75 M C18.0 III Adenocarcinoma 
636 P653 - FFPE 0 WT WT WT - MSKK 59 F C20.9 III Neuroendocrine Diff. 
637 P654 - FFPE 1 1799 T>A WT WT - MSKK 84 M C18.5 III Neuroendocrine Diff. 
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638 P642 - FFPE 2 WT 35 G>A 1633 G>A - MSKK 50 M C20.9 III Unusual Differentiation 
639 P644 - FFPE 0 WT WT WT - MSKK 52 M C18.4 II Adenocarcinoma 
640 P643 - FFPE 0 WT WT WT - MSKK 84 M C18.4 I Adenocarcinoma 
641 P639 - FFPE 1 1799 T>A WT WT - MSKK 66 F C18.0 II Adenocarcinoma 
642 P600 - FFPE 1 WT 436 G>A WT - MSKK 48 M C18.2 IV Adenosquamous 
carcinoma 
643 P656 - FFPE 0 WT WT WT - MSKK 59 M C20.- II Rest after neoadj.th. 
644 P649 M41 FFPE 0 WT WT WT - MSKK 60 F C18.4 III Signet-Ring-Cell Ca. 
645 P657 - FFPE 1 WT 38 G>A WT - MSKK 84 F C18.4 IV Adenocarcinoma 
646 P658 - FFPE 0 WT WT WT - MSKK 77 M C19.9 II Adenocarcinoma 
647 P659 - FFPE 1 WT WT 1624 G>A - MSKK 67 M C20.- I Mucinous Carcinoma 
648 P652 - FFPE 0 WT WT WT - MSKK 69 M C18.2 II Adenocarcinoma 
649 P470 - FFPE 2 WT 35 G>A 3140 A>G - MSKK 64 M C18.6 - Tumour in Adenoma 
650 P646 - FFPE 1 WT 34 G>A WT - MSKK 75 F C18.7 II Adenocarcinoma 
651 P660 - FFPE 1 1799 T>A WT WT - MSKK 71 F C18.5 III Adenocarcinoma 
652 P662 M43 FFPE 1 1799 T>A WT WT - MSKK 78 F C18.3 I Mixed Diff.with Mucin 
653 P638 - FFPE 0 WT WT WT - MSKK 71 M C20.9 I Adenocarcinoma 
654 P664 M44 FFPE 0 WT WT WT - MSKK 53 F C19.9 I Adenocarcinoma 
655 P635 - FFPE 0 WT WT WT - MSKK 77 F C18.6 I Adenocarcinoma 
656 P665 - FFPE 1 WT WT 1624 G>A   MSKK 82 F C18.6 II Synchronous CRC 
657 P666 - FFPE 1 WT 35 G>A WT - MSKK 82 F C18.0 II Adenocarcinoma 
658 P670 - FFPE 2 WT 35 G>T 1624 G>A - MSKK 80 M C18.7 IV Adenocarcinoma 
659 P672 - FFPE 0 WT WT WT - MSKK 72 F C18.6 II Adenocarcinoma 
660 P661 - FFPE 0 WT WT WT - MSKK 75 M C20.9 III Mucinous Carcinoma 
661 P667 - FFPE 0 WT WT WT - MSKK 75 F C20.9 III Unusual Differentiation 
662 P682 - FFPE 0 WT WT WT - MSKK 68 M C20.- IV Adenocarcinoma 
663 P675 - FFPE 2 WT 34 G>A 1624 G>A - MSKK 74 M C20.- II Mucinous Carcinoma 
664 P676 - FFPE 0 WT WT WT - MSKK 62 M C18.6 II Adenocarcinoma 
665 P687 - FFPE 1 1799 T>A WT WT - MSKK 88 F C18.2 I Adenocarcinoma 
666 P690 - FFPE 0 WT WT WT - MSKK 87 F C18.0 II Adenocarcinoma 
667 P691 - FFPE 0 WT WT WT - MSKK 76 M C20.9 III Adenocarcinoma 
668 P692 M55 FFPE 0 WT WT WT - MSKK 93 M C18.0 III Adenocarcinoma 
669 P679 M50 FFPE 0 WT WT WT - MSKK 73 M C18.7 III Adenocarcinoma 
670 P680 M51 FFPE 1 WT 35 G>A WT 35 G>A MSKK 55 F C18.3 III Adenocarcinoma 
671 P681 - FFPE 0 WT WT WT - MSKK 82 F C18.7 II Adenocarcinoma 
 138 
 
672 P673 M49 FFPE 1 WT 35 G>C WT - MSKK 77 F C18.0 IV Adenocarcinoma 
673 P693 M56 FFPE 1 WT 35 G>T WT - MSKK 55 F C20.9 I Adenocarcinoma 
674 P694 - FFPE 0 WT WT WT WT MSKK 60 M C18.7 II Adenocarcinoma 
675 P688 - FFPE 0 WT WT WT NA MSKK 82 F C18.7 II Adenocarcinoma 
676 P689 - FFPE 1 WT 436 G>A WT WT MSKK 73 M C18.3 IV Adenocarcinoma 
677 P700 - FFPE 0 WT WT WT - MSKK 71 F C18.3 III Neuroendocrine Diff. 
678 P655 - FFPE 0 WT WT WT - MSKK 59 M C18.7 II Adenocarcinoma 
679 P701 M58 FFPE 1 WT WT 1633 G>A - MSKK 71 M C18.7 II Adenocarcinoma 
680 P702 M59 FFPE 1 1799 T>A WT WT - MSKK 75 F C18.3 III Adenocarcinoma 
681 P703 - FFPE 1 WT 38 G>A WT - MSKK 49 F C18.0 III Undifferentiated 
682 P708 M61 FFPE 1 WT 35 G>T WT - MSKK 70 M C18.2 I Adenocarcinoma 
683 P710 M63 FFPE 1 WT 38 G>A WT - MSKK 92 F C18.0 III Adenocarcinoma 
684 P712 M66 FFPE 0 WT WT WT - MSKK 63 M C18.2 II Adenocarcinoma 
685 P709 M62 FFPE 0 WT WT WT - MSKK 68 F C20.9 III Adenocarcinoma 
686 P699 - FFPE 1 WT WT 1624 G>A - MSKK 87 F C18.0 I Adenocarcinoma 
687 P697 - FFPE 2 WT 35 G>A 1633 G>A - MSKK 57 F C18.7 I Tumour in Adenoma 
688 P704 M60 FFPE 0 WT WT WT - MSKK 85 M C20.9 III Adenocarcinoma 
689 P663 - FFPE 1 WT 38 G>A WT - MSKK 71 M C18.2 III Synchronous CRC 
690 P716 - FFPE 0 WT WT WT - MSKK 70 M C18.7 I Mucinous Carcinoma 
691 P683 - FFPE 1 WT 35 G>T WT 35 G>T MSKK 54 M C18.7 III Adenocarcinoma 
692 P684 - FFPE 0 WT WT WT - MSKK 55 M C19.9 II Adenocarcinoma 
693 P686 - FFPE 1 1799 T>A WT WT - MSKK 72 F C18.3 IV Adenocarcinoma 
694 P707 - FFPE 2 1799 T>A WT 3140 A>G - MSKK 76 M C18.5 III Mucinous Carcinoma 
695 P705 - FFPE 1 WT 35 G>A WT - MSKK 78 F C18.0 III Adenocarcinoma 
696 P711 M64 FFPE 1 WT 35 G>A WT - MSKK 65 M C18.0 IV Adenocarcinoma 
697 P719 - FFPE 0 WT WT WT - MSKK 63 F C18.7 I Adenocarcinoma 
698 P721 - FFPE 1 WT 35 G>T WT - MSKK 76 M C20.9 III Rest after neoadj.th. 
699 P723 - FFPE 0 WT WT WT - MSKK 84 M C18.5 II Adenocarcinoma 
700 P724 - FFPE 0 WT WT WT - MSKK 69 M C18.4 III Synchronous CRC 
701 P725 - FFPE 1 WT 35 G>T WT - MSKK 66 M C18.7 I Adenocarcinoma 
702 P726 - FFPE 0 WT WT WT - MSKK 67 M C20.- II Rest after neoadj.th. 
703 P727 - FFPE 0 WT WT WT - MSKK 72 F C20.- I Adenocarcinoma 
704 P714 - FFPE 0 WT WT WT - MSKK 67 F C20.- II Rest after neoadj.th. 
705 P567 M16 FFPE 0 WT WT WT - MSKK 70 M C18.7 IV Adenocarcinoma 
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706 P514 - FFPE 2 WT 35 G>A 1624 G>A - MSKK 73 M C18.7 I Adenocarcinoma 
707 P729 - FFPE 0 WT WT WT - MSKK 67 M C18.4 II Adenocarcinoma 
708 P720 - FFPE 1 WT 34 G>T WT - MSKK 52 F C18.7 III Adenocarcinoma 
709 P730 - FFPE 0 WT WT WT WT MSKK 68 M C18.7 I Adenocarcinoma 
710 P732 - FFPE 0 WT WT WT - MSKK 73 F C18.7 I Adenocarcinoma 
711 P733 M68 FFPE 1 WT 35 G>T WT 35 G>T MSKK 72 M C20.9 III Adenocarcinoma 
712 P734 M69 FFPE 1 WT WT 1624 G>A - MSKK 65 M C18.5 II Adenocarcinoma 
713 P735 - FFPE 1 WT 35 G>T WT 35 G>T MSKK 75 M C18.7 II Adenocarcinoma 
714 P736 - FFPE 1 1799 T>A WT WT WT MSKK 78 F C18.0 II Mucinous Carcinoma 
715 P715 - FFPE 1 WT 34 G>A WT - MSKK 85 F C20.9 II Adenocarcinoma 
716 P717 M67 FFPE 0 WT WT WT - MSKK 72 M C18.7 II Adenocarcinoma 
717 P698 M57 FFPE 1 WT 38 G>A WT - MSKK 87 F C20.- III Adenocarcinoma 
718 P737 M71 FFPE 0 WT WT WT - MSKK 62 M C18.7 III Adenocarcinoma 
719 P713 - FFPE 0 WT WT WT - MSKK 63 M C20.- I Rest after neoadj.th. 
720 P741 - FFPE 1 WT WT 1624 G>A - MSKK 66 M C18.7 IV Adenocarcinoma 
721 P742 - FFPE 2 WT 436 G>A 3140 A>G - MSKK 68 M C18.0 I Adenocarcinoma 
722 P745 - FFPE 0 WT WT WT - MSKK 79 F C20.- I Adenocarcinoma 
723 P746 M73 FFPE 0 WT WT WT - MSKK 73 F C18.7 II Adenocarcinoma 
724 P747 - FFPE 0 WT WT WT - MSKK 64 M C18.2 IV Adenocarcinoma 
725 P748 - FFPE 1 WT 34 G>T WT - MSKK 51 F C18.0 III Adenocarcinoma 
726 P718 - FFPE 0 WT WT WT - MSKK 53 F C20.9 III Rest after neoadj.th. 
727 P706 - FFPE 0 WT WT WT - MSKK 55 F C18.0 III Adenocarcinoma 
728 P728 - FFPE 0 WT WT WT - MSKK 54 M C18.7 III Mixed Diff.with Mucin 
729 P750 - FFPE 0 WT WT WT - MSKK 73 M C19.9 I Adenocarcinoma 
730 P751 - FFPE 1 WT 35 G>T WT - MSKK 72 M C18.0 II Adenocarcinoma 
731 P722 - FFPE 2 WT 35 G>A 1633 G>A - MSKK 68 F C21.8 I Adenocarcinoma 
732 P753 - FFPE 0 WT WT WT - MSKK 69 M C20.9 I Rest after neoadj.th. 
733 P754 - FFPE 1 WT 35 G>A WT - MSKK 73 F C18.0 I Mixed Diff.with Mucin 
734 P738 - FFPE 1 WT 38 G>A WT - MSKK 64 M C20.- II Adenocarcinoma 
735 P740 - FFPE 1 WT 34 G>A WT - MSKK 70 M C18.0 II Mucinous Carcinoma 
736 P739 - FFPE 0 WT WT WT - MSKK 85 M C20.- II Adenocarcinoma 
737 P755 - FFPE 1 WT 35 G>A WT - MSKK 88 F C18.7 III Mixed Diff.with Mucin 
738 P650 - FFPE 0 WT WT WT - MSKK 78 F C20.- I Adenocarcinoma 
739 P671 - FFPE 2 1799 T>A WT 3140 A>G - MSKK 63 F C18.2 I Medullary Differentitation 
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740 P669 - FFPE 0 WT WT WT - MSKK 61 M C20.- I Adenocarcinoma 
741 P678 - FFPE 1 WT 38 G>A WT 38 G>A MSKK 64 F C18.6 II Mucinous Carcinoma 
742 P749 - FFPE 0 WT WT WT - MSKK 58 M C18.4 I Adenocarcinoma 
743 P743 - FFPE 2 WT 35 G>T 1624 G>A - MSKK 75 M C18.0 III Adenocarcinoma 
744 P757 - FFPE 1 WT 35 G>T WT - MSKK 76 M C18.2 III Mucinous Carcinoma 
745 P758 - FFPE 0 WT WT WT NA MSKK 68 M C20.- II Adenocarcinoma 
746 P762 - FFPE 1 WT 35 G>T WT - MSKK 70 M C20.- III Adenocarcinoma 
747 P685 - FFPE 0 WT WT WT - MSKK 75 F C18.7 II Adenocarcinoma 
748 P731 - FFPE 1 WT 34 G>T; 35 
G>A 
WT - MSKK 82 F C18.7 III Mixed Diff.with Mucin 
749 P744 - FFPE 0 WT WT WT - MSKK 51 F C18.0 III Mixed Differentiation 
750 P763 M74 FFPE 0 WT WT WT - MSKK 43 M C18.7 IV Adenocarcinoma 
751 P637 - FFPE 1 1799 T>A WT WT - MSKK 65 F C18.0 III Adenocarcinoma 
752 P674 - FFPE 0 WT WT WT - MSKK 67 F C20.9 III Mucinous Carcinoma 
753 P756 - FFPE 1 WT 35 G>A WT - MSKK 60 M C18.4 II Adenocarcinoma 
754 P769 - FFPE 0 WT WT WT - MSKK 70 M C18.2 III Adenocarcinoma 
755 P770 - FFPE 1 WT 35 G>C WT - MSKK 68 F C18.6 I Adenocarcinoma 
756 P771 - FFPE 0 WT WT WT - MSKK 80 M C18.7 III Adenocarcinoma 
757 P772 - FFPE 0 WT WT WT - MSKK 52 M C20.9 I Rest after neoadj.th. 
758 P773 - FFPE 0 WT WT WT - MSKK 54 F C18.2 I Tumour in Adenoma 
759 P775 M75 FFPE 1 WT 35 G>C WT - MSKK 79 F C18.2 III Adenocarcinoma 
760 P776 - FFPE 0 WT WT WT - MSKK 54 M C18.7 III Adenocarcinoma 
761 P777 - FFPE 2 WT 34 G>T 1633 G>A - MSKK 77 F C18.0 II Adenocarcinoma 
762 P696 - FFPE 1 1799 T>A WT WT - MSKK 67 F C18.2 II Undifferentiated 
763 P779 - FFPE 1 WT 35 G>C WT - MSKK 78 F C18.6 III Adenocarcinoma 
764 P677 - FFPE 0 WT WT WT - MSKK 75 F C18.5 II Adenocarcinoma 
765 P695 - FFPE 0 WT WT WT - MSKK 73 M C18.6 II Adenocarcinoma 
766 P780 - FFPE 2 WT 35 G>C 1633 G>A - MSKK 74 F C20.9 III Adenocarcinoma 
767 P781 - FFPE 1 1799 T>A WT WT WT MSKK 66 M C18.3 IV Mucinous Carcinoma 
768 P668 - FFPE 0 WT WT WT - MSKK 55 M C20.9 III Rest after neoadj.th. 
769 P760 - FFPE 2 WT 35 G>T 1633 G>A 35 G>T MSKK 70 M C18.6 II Adenocarcinoma 
770 P761 - FFPE 0 WT WT WT - MSKK 87 M C18.7 III Adenocarcinoma 
771 P765 - FFPE 0 WT WT WT - MSKK 74 F C18.6 II Adenocarcinoma 
772 P782 - FFPE 0 WT WT WT - MSKK 78 F C18.4 II Adenocarcinoma 
773 P764 - FFPE 1 WT 38 G>A WT - MSKK 65 F C18.2 III Adenocarcinoma 
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774 P783 M78 FFPE 0 WT WT WT WT MSKK 89 F C18.7 II Adenocarcinoma 
775 P784 M79 FFPE 0 WT WT WT - MSKK 77 F C18.2 IV Adenocarcinoma 
776 P785 - FFPE 0 WT WT WT - MSKK 83 M C18.7 I Tumour in Adenoma 
777 P767 - FFPE 1 1799 T>A WT WT - MSKK 68 F C18.4 III Mixed Diff.with Mucin 
778 P768 - FFPE 1 WT 38 G>A WT - MSKK 58 M C20.9 IV Adenocarcinoma 
779 P786 - FFPE 2 WT 34 G>A 1633 G>A - MSKK 74 M C18.2 III Adenocarcinoma 
780 P778 - FFPE 0 WT WT WT - MSKK 70 M C18.6 IV Adenocarcinoma 
781 P789 - FFPE 1 WT 35 G>A WT NA MSKK 70 F C20.9 III Synchronous CRC 
782 P790 M81 FFPE 1 1799 T>A WT WT NA MSKK 74 M C18.7 III Adenocarcinoma 
783 P791 - FFPE 0 WT WT WT - MSKK 59 M C19.9 II Adenocarcinoma 
784 P787 - FFPE 2 1799 T>A WT 1633 G>A - MSKK 70 F C18.7 III Adenocarcinoma 
785 P788 - FFPE 2 WT 436 G>A 1633 G>A - MSKK 78 F C18.0 III Mixed Diff.with Mucin 
786 P774 - FFPE 0 WT WT WT - MSKK 40 M C18.4 IV Adenocarcinoma 
787 P795 - FFPE 2 WT 35 G>A 1633 G>A - MSKK 79 M C20.9 II Mucinous Carcinoma 
788 P794 - FFPE 0 WT WT WT WT MSKK 53 F C20.9 III Adenocarcinoma 
789 P796 - FFPE 2 WT 35 G>T 1633 G>A - MSKK 57 M C19.- I Tumour in Adenoma 
790 P797 - FFPE 0 WT WT WT - MSKK 70 M C18.2 III Adenocarcinoma 
791 P792 M82 FFPE 0 WT WT WT - MSKK 76 M C18.6 I Synchronous CRC 
792 P752 - FFPE 1 WT 35 G>A WT - MSKK 61 F C18.0 IV Adenocarcinoma 
793 P766 - FFPE 1 WT 38 G>A WT - MSKK 70 M C20.- I Rest after neoadj.th. 
794 P793 - FFPE 1 WT 38 G>A WT - MSKK 86 F C18.7 II Adenocarcinoma 
795 P800 - FFPE 1 WT 35 G>T WT - MSKK 68 M C18.7 III Adenocarcinoma 
796 P801 M83 FFPE 1 WT 35 G>C WT - MSKK 68 M C18.7 III Adenocarcinoma 
797 P804 - FFPE 0 WT WT WT - MSKK 67 M C18.2 II Adenocarcinoma 
798 P798 - FFPE 0 WT WT WT - MSKK 70 M C18.7 IV Adenocarcinoma 
799 P799 - FFPE 0 WT WT WT - MSKK 74 M C19.9 II Adenocarcinoma 
800 P803 - FFPE 2 WT 35 G>T 1633 G>A - MSKK 74 F C18.3 IV Neuroendocrine Diff. 
801 P809 - FFPE 0 WT WT WT - MSKK 52 M C20.- II Rest after neoadj.th. 
802 P802 - FFPE 2 WT 35 G>T 1633 G>A - MSKK 72 F C18.2 III Mucinous Carcinoma 
803 P806 - FFPE 0 WT WT WT - MSKK 66 M C19.- III Adenocarcinoma 
804 P808 M87 FFPE 0 WT WT WT WT MSKK 46 F C18.6 IV Adenocarcinoma 
805 P811 - FFPE 1 WT 35 G>C WT - MSKK 65 M C18.7 III Adenocarcinoma 
806 P812 M88 FFPE 0 WT WT WT WT MSKK 69 M C18.4 II Adenocarcinoma 
807 P807 - FFPE 0 WT WT WT - MSKK 71 M C18.3 III Adenocarcinoma 
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808 P810 - FFPE 0 WT WT WT - MSKK 73 M C19.- III Adenocarcinoma 
809 P613 - FFPE 1 WT 38 G>A WT - MSKK 66 F C18.2 I Adenocarcinoma 
810 P759 - FFPE 1 WT 35 G>T WT - MSKK 60 F C20.- II Adenocarcinoma 
811 P813 - FFPE 0 WT WT WT - MSKK 77 M C20.- II Rest after neoadj.th. 
812 P814 - FFPE 1 WT 38 G>A WT 38 G>A MSKK 77 F C19.9 III Mixed Diff.with Mucin 
813 P805 - FFPE 0 WT WT WT - MSKK 72 M C20.- III Rest after neoadj.th. 
814 P815 - FFPE 1 WT 34 G>T WT 34 G>T MSKK 70 M C18.6 II Adenocarcinoma 
815 P816 - FFPE 1 WT 35 G>A WT 35 G>A MSKK 72 F C20.9 III Adenocarcinoma 
816 P817 - FFPE 0 WT WT WT WT MSKK 48 M C20.9 III Rest after neoadj.th. 
817 P818 - FFPE 1 WT 35 G>C WT - MSKK 77 M C18.7 I Adenocarcinoma 
818 P819 - FFPE 0 WT WT WT WT MSKK 76 M C18.7 III Mixed Differentiation 
819 P820 - FFPE 1 WT 38 G>A WT - MSKK 80 F C18.7 II Adenocarcinoma 
820 P821 M93 FFPE 0 WT WT WT - MSKK 55 F C18.7 III Adenocarcinoma 
821 P822 - FFPE 0 WT WT WT - MSKK 76 M C20.- I Adenocarcinoma 
822 P823 - Snap-frozen 1 1799 T>A WT WT - RVS 81 F C18.0 II Adenocarcinoma 
823 P824 - Snap-frozen 1 WT 38 G>A WT 38 G>A RVS 70 M C18.0 III Adenocarcinoma 
824 P825 - Snap-frozen 1 WT 35 G>T WT 35 G>T RVS 65 M C18.0 III Mixed Diff.with Mucin 
825 P826 - Snap-frozen 1 WT 38 G>A WT - RVS 54 M C18.4 I Adenocarcinoma 
826 P827 - Snap-frozen 1 WT 35 G>T WT 35 G>T RVS 74 F C20.9 III Mucinous Carcinoma 
827 P828 - Snap-frozen 0 WT WT WT WT RVS 64 M C20.9 III Adenocarcinoma 
828 P829 - Snap-frozen 1 WT 35 G>T WT 35 G>T RVS 72 F C19.9 II Adenocarcinoma 
829 P830 - Snap-frozen 0 WT WT WT WT RVS 69 M C20.9 III Adenocarcinoma 
830 P831 - Snap-frozen 1 WT 35 G>A WT 35 G>A RVS 66 F C18.7 III Adenocarcinoma 
831 P832 - Snap-frozen 1 WT 35 G>C WT 35 G>C RVS 79 F C19.9 III Adenocarcinoma 
832 P833 - Snap-frozen 2 WT 35 G>T 1633 G>A 35 G>T RVS 64 F C18.7 II Adenocarcinoma 
833 P834 - Snap-frozen 1 WT 38 G>A WT 38 G>A RVS 69 M C18.7 III Adenocarcinoma 
834 P835 - Snap-frozen 0 WT WT WT WT RVS 70 M C18.7 II Adenocarcinoma 
835 P836 - Snap-frozen 0 WT WT WT WT RVS 69 M C19.9 II Adenocarcinoma 
836 P837 - Snap-frozen 0 WT WT WT WT RVS 59 M C18.7 III Adenocarcinoma 
837 P838 - Snap-frozen 2 1799 T>A WT 1633 G>A WT RVS 86 F C18.6 III Adenocarcinoma 
838 P839 - Snap-frozen 0 WT WT WT WT RVS 50 F C20.9 III Adenocarcinoma 
839 P840 - Snap-frozen 1 WT 35 G>A WT 35 G>A RVS 36 F C18.7 II Adenocarcinoma 
840 P841 - Snap-frozen 2 WT 38 G>A 1633 G>A 38 G>A RVS 73 F C18.2 I Adenocarcinoma 
841 P842 - Snap-frozen 1 WT 38 G>A WT 38 G>A RVS 63 F C19.- III Adenocarcinoma 
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842 P843 - Snap-frozen 2 WT 38 G>A 1633 G>A 38 G>A RVS 70 M C20.- III Adenocarcinoma 
843 P844 - Snap-frozen 1 WT 34 G>A WT 34 G>A RVS 62 F C19.- III Adenocarcinoma 
844 P845 - Snap-frozen 2 WT 35 G>A 3140 A>G 35 G>A RVS 79 M C18.7 II Adenocarcinoma 
845 P846 - Snap-frozen 1 WT WT 1633 G>A WT RVS 33 F C20.9 III Adenocarcinoma 
846 P847 - Snap-frozen 1 WT 34 G>T WT 34 G>T RVS 62 M C18.7 II Adenocarcinoma 
847 P848 - Snap-frozen 1 WT 34 G>A WT 34 G>A RVS 55 M C20.9 II Adenocarcinoma 
848 P849 - Snap-frozen 0 WT WT WT WT RVS 67 M C18.4 III Signet-Ring-Cell Ca. 
849 P850 - Snap-frozen 0 WT WT WT - RVS 42 M C20.9 I Adenocarcinoma 
850 P851 - Snap-frozen 1 WT 34 G>A WT - RVS 76 F C20.- III Adenocarcinoma 
851 P852 - Snap-frozen 2 1799 T>A WT 1624 G>A WT RVS 80 F C18.0 II Adenocarcinoma 
852 P853 - Snap-frozen 0 WT WT WT WT RVS 76 F C20.9 II Adenocarcinoma 
853 P854 - Snap-frozen 1 WT 35 G>T WT 35 G>T RVS 67 F C18.7 IV Adenocarcinoma 
854 P855 - Snap-frozen 2 WT 35 G>A 1633 G>A 35 G>A RVS 65 M C18.0 II Adenocarcinoma 
855 P856 - Snap-frozen 1 WT 35 G>A WT 35 G>A RVS 53 M C18.2 IV Adenocarcinoma 
856 P857 - Snap-frozen 1 WT 34 G>A WT 34 G>A RVS 62 M C20.9 III Adenocarcinoma 
857 P858 - Snap-frozen 1 WT 34 G>A WT 34 G>A RVS 71 F C18.7 IV Adenocarcinoma 
858 P859 - Snap-frozen 0 WT WT WT WT RVS 58 M C18.3 II Adenocarcinoma 
859 P860 - Snap-frozen 1 1799 T>A WT WT WT RVS 57 M C18.2 III Adenocarcinoma 
860 P861 - Snap-frozen 0 WT WT WT WT RVS 71 M C20.9 IV Adenocarcinoma 
861 P862 - Snap-frozen 0 WT WT WT WT RVS 62 F C18.7; 
C18.3 
IV Adenocarcinoma 
862 P863 - Snap-frozen 1 WT 35 G>T WT 35 G>T RVS 64 M C18.7 IV Adenocarcinoma 
863 P864 - Snap-frozen 1 1799 T>A WT WT WT RVS 68 F C18.7 IV Adenocarcinoma 
864 P4 - Snap-frozen 2 WT 35 G>A 3140 A>G 35 G>A MSKK 55 F C18.7 III Adenocarcinoma 
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Tab.S6. Sequencing chromatograms of KRAS codon 12 and 13 of the samples with matched 
real-time PCR results 
P4 35 G>A 
 
P6 35 G>A 
 
P15 34 G>T 
 
P16 35 G>A 
 
P37 34 G>C 
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P39 35 G>T 
 
P41 35 G>T 
 
P42 35 G>T 
 
P48 35 G>A 
 
P59 WT 
 
 146 
 
P60 unclear; 
allele-
specific 
PCR: 34 
G>A 
 
 
P63 35 G>T 
 
P66 35 G>C 
 
P9 unclear; 
allele-
specific 
PCR: 35 
G>T 
 
P24 38 G>A 
 
 147 
 
P70 35 G>A 
 
P72 38 G>A 
 
P78 WT 
 
P81 35 G>T 
 
P85 34 G>A 
 
 148 
 
P87 35 G>T 
 
P89 38 G>A 
 
P92 35 G>T 
 
P93 38 G>A 
 
P95 35 G>C 
 
 149 
 
P97 35 G>A 
 
P102 35 G>A 
 
P103 WT 
 
P104 35 G>T 
 
P105 35 G>A 
 
 150 
 
P114 38 G>A 
 
P120 35 G>A 
 
P124 35 G>A 
 
P127 35 G>T 
 
P131 WT 
 
 151 
 
P132 WT 
 
P133 35 G>T 
 
P134 35 G>A 
 
P135 35 G>C 
 
P137 WT 
 
 152 
 
P149 35 G>A 
 
P160 35 G>A 
 
P162 35 G>A 
 
P168 38 G>A 
 
P169 35 G>T 
 
 153 
 
P172 WT 
 
P179 38 G>A 
 
P181 WT 
 
P182 38 G>A 
 
P185 34 G>A 
 
 154 
 
P195 34 G>T 
 
P197 35 G>T 
 
P198 38 G>A 
 
P208 34 G>T 
 
P210 35 G>T 
 
 155 
 
P215 35 G>A 
 
P226 WT; 
allele-
specific 
PCR:  
34 G>T 
 
P232 35 G>C 
 
P247 35 G>A 
 
P248 38 G>A 
 
 156 
 
P260 35 G>A 
 
P266 35 G>A 
 
P270 34 G>A 
 
P271 35 G>T 
 
P273 34 G>A 
 
 157 
 
P274 38 G>A 
 
P275 35 G>T 
 
P276 35 G>T 
 
P278 35 G>A 
 
P283 38 G>A 
 
 158 
 
P338 35 G>C 
 
P340 WT 
 
P342 35 G>T 
 
P343 35 G>T 
 
P345 35 G>A 
 
 159 
 
P349 35 G>A 
 
P353 34 G>T 
 
P357 38 G>A 
 
P381 WT; 
allele-
specific 
PCR:  
35 G>A 
 
P401 35 G>T 
 
 160 
 
P402 35 G>A 
 
P422 38 G>A 
 
P428 35 G>T 
 
P431 35 G>A 
 
P445 34 G>T 
 
 161 
 
P456 35 G>T 
 
P502 34 G>T 
 
P461 unclear; 
allele-
specific 
PCR: 35 
G>T 
 
P526 35 G>A 
 
P563 35 G>T 
 
 162 
 
P591 35 G>A 
 
P595 35 G>A 
 
P610 35 G>T 
 
P631 38 G>A 
 
P651 37 G>T 
 
 163 
 
P680 35 G>A 
 
P683 35 G>T 
 
P733 35 G>T 
 
P735 35 G>T 
 
P678 38 G>A 
 
 164 
 
P760 35 G>T 
 
P814 38 G>A 
 
P815 34 G>T 
 
P816 35 G>A 
 
P824 38 G>A 
 
 165 
 
P825 35 G>T 
 
P827 35 G>T 
 
P829 35 G>T 
 
P831 35 G>A 
 
P832 35 G>C 
 
 166 
 
P833 35 G>T 
 
P834 38 G>A 
 
P840 35 G>A 
 
P841 38 G>A 
 
P842 38 G>A 
 
 167 
 
P843 38 G>A 
 
P844 34 G>A 
 
P845 35 G>A 
 
P846 WT 
 
P847 34 G>T 
 
 168 
 
P848 34 G>A 
 
P854 35 G>T 
 
P855 35 G>A 
 
P856 35 G>A 
 
P857 34 G>A 
 
 169 
 
P858 34 G>A 
 
P860 WT 
 
P863 35 G>T 
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Tab.S7. Mutation status of KRAS, BRAF, and PIK3CA of the 133 successfully engrafted 
xenograft models; Mut No- number of detected mutations; Models M110/M111 derived from 
the same patient. Models M125/M126 also origin from one patient 
No model-ID patient-ID Material type Mut No KRAS BRAF PIK3CA 
1 M25 P592 Snap-frozen Xenograft 1 34 G>A WT WT 
2 M127 - Snap-frozen Xenograft 0 WT WT WT 
3 M19 P575 Snap-frozen Xenograft 1 WT 1799 T>A WT 
4 M132 - Snap-frozen Xenograft 2 436 G>A WT 3140 A>G 
5 M11 - Snap-frozen Xenograft 0 WT WT WT 
6 M120 - Snap-frozen Xenograft 1 WT 1799 T>A WT 
7 M2 - Snap-frozen Xenograft 0 WT WT WT 
8 M20 P576 Snap-frozen Xenograft 1 WT 1799 T>A WT 
9 M17 - Snap-frozen Xenograft 1 38 G>A WT WT 
10 M121 - Snap-frozen Xenograft 1 WT 1799 T>A WT 
11 M78 P783 Snap-frozen Xenograft 0 WT WT WT 
12 M22 P583 Snap-frozen Xenograft 0 WT WT WT 
13 M66 P712 Snap-frozen Xenograft 0 183 A>T WT WT 
14 M10 P536 Snap-frozen Xenograft 1 WT 1799 T>A WT 
15 M102 - Snap-frozen Xenograft 1 35 G>T WT WT 
16 M60 P704 Snap-frozen Xenograft 0 WT WT WT 
17 M90 - Snap-frozen Xenograft 2 35 G>T WT 1633 G>A 
18 M1 P494 Snap-frozen Xenograft 0 WT WT WT 
19 M4 - Snap-frozen Xenograft 1 436 G>A WT WT 
20 M95 - Snap-frozen Xenograft 1 38 G>A WT WT 
21 M73 P746 Snap-frozen Xenograft 0 WT WT WT 
22 M14 - Snap-frozen Xenograft 0 WT WT WT 
23 M109 - Snap-frozen Xenograft 0 WT WT WT 
24 M28 P598 Snap-frozen Xenograft 1 35 G>C WT WT 
25 M113 - Snap-frozen Xenograft 0 WT WT WT 
26 M83 P801 Snap-frozen Xenograft 1 35 G>C WT WT 
27 M35 - Snap-frozen Xenograft 1 WT WT 1633 G>A 
28 M104 - Snap-frozen Xenograft 1 38 G>A WT WT 
29 M59 P702 Snap-frozen Xenograft 1 WT 1799 T>A WT 
30 M74 P763 Snap-frozen Xenograft 0 WT WT WT 
31 M30 - Snap-frozen Xenograft 0 WT WT WT 
32 M53 - Snap-frozen Xenograft 1 35 G>A WT WT 
33 M29 - Snap-frozen Xenograft 0 WT WT WT 
34 M128 - Snap-frozen Xenograft 1 34 G>A WT WT 
35 M72 - Snap-frozen Xenograft 0 WT WT WT 
36 M91 - Snap-frozen Xenograft 0 WT WT WT 
37 M88 P812 Snap-frozen Xenograft 0 WT WT WT 
38 M49 P673 Snap-frozen Xenograft 1 35 G>C WT WT 
39 M57 P698 Snap-frozen Xenograft 1 38 G>A WT WT 
40 M130 - Snap-frozen Xenograft 1 38 G>A WT WT 
41 M37 P627 Snap-frozen Xenograft 1 WT WT 1633 G>A 
42 M51 P680 Snap-frozen Xenograft 1 35 G>A WT WT 
43 M13 - Snap-frozen Xenograft 0 WT WT WT 
44 M131 - Snap-frozen Xenograft 0 WT WT WT 
45 M133 - Snap-frozen Xenograft 1 436 G>A WT WT 
46 M114 - Snap-frozen Xenograft 1 35 G>C WT WT 
47 M84 - Snap-frozen Xenograft 0 WT WT WT 
48 M110 - Snap-frozen Xenograft 1 182 A>T WT 1624 G>A 
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49 M67 P717 Snap-frozen Xenograft 0 WT WT WT 
50 M36 - Snap-frozen Xenograft 0 WT WT WT 
51 M106 - Snap-frozen Xenograft 1 35 G>T WT WT 
52 M123 - Snap-frozen Xenograft 1 WT 1799 T>A WT 
53 M76 - Snap-frozen Xenograft 0 WT WT WT 
54 M40 P634 Snap-frozen Xenograft 0 WT WT WT 
55 M101 - Snap-frozen Xenograft 1 34 G>A, T? WT WT 
56 M12 - Snap-frozen Xenograft 2 WT 1799 T>A WT 
57 M48 - Snap-frozen Xenograft 0 WT WT WT 
58 M27 P596 Snap-frozen Xenograft 1 35 G>A WT WT 
59 M99 - Snap-frozen Xenograft 0 WT WT WT 
60 M87 P808 Snap-frozen Xenograft 0 WT WT WT 
61 M118 - Snap-frozen Xenograft 2 35 G>T WT 3140 A>G 
62 M82 P792 Snap-frozen Xenograft 0 WT WT WT 
63 M94 - Snap-frozen Xenograft 0 WT WT WT 
64 M7 P525 Snap-frozen Xenograft 0 WT WT WT 
65 M24 P590 Snap-frozen Xenograft 2 35 G>T WT 1633 G>A 
66 M3 P509 Snap-frozen Xenograft 1 35 G>C WT WT 
67 M68 P733 Snap-frozen Xenograft 1 35 G>T WT WT 
68 M41 - Snap-frozen Xenograft 0 WT WT WT 
69 M26 - Snap-frozen Xenograft 1 WT 1799 T>A WT 
70 M43 - Snap-frozen Xenograft 1 WT 1799 T>A WT 
71 M64 - Snap-frozen Xenograft 0 WT WT WT 
72 M42 - Snap-frozen Xenograft 1 WT WT 1633 G>A 
73 M18 - Snap-frozen Xenograft 1 35 G>A WT WT 
74 M44 - Snap-frozen Xenograft 0 WT WT WT 
75 M77 - Snap-frozen Xenograft 0 WT WT WT 
76 M115 - Snap-frozen Xenograft 1 38 G>A WT WT 
77 M9 - Snap-frozen Xenograft 2 38 G>A WT 1633 G>A 
78 M96 - Snap-frozen Xenograft 2 35 G>T WT 1633 G>A 
79 M75 - Snap-frozen Xenograft 1 35 G>C WT WT 
80 M81 - Snap-frozen Xenograft 1 WT 1799 T>A WT 
81 M58 - Snap-frozen Xenograft 1 WT WT 1633 G>A 
82 M63 - Snap-frozen Xenograft 1 38 G>A WT WT 
83 M5 - Snap-frozen Xenograft 1 WT 1799 T>A WT 
84 M6 - Snap-frozen Xenograft 0 WT WT WT 
85 M122 - Snap-frozen Xenograft 0 WT WT WT 
86 M107 - Snap-frozen Xenograft 1 38 G>A WT WT 
87 M23 - Snap-frozen Xenograft 0 WT WT WT 
88 M32 - Snap-frozen Xenograft 2 WT 1799 T>A 1633 G>A 
89 M100 - Snap-frozen Xenograft 0 WT WT WT 
90 M97 - Snap-frozen Xenograft 0 WT WT WT 
91 M31 - Snap-frozen Xenograft 2 38 G>A WT 3140 A>G 
92 M119 - Snap-frozen Xenograft 1 WT 1799 T>A WT 
93 M86 - Snap-frozen Xenograft 1 35 G>A WT WT 
94 M56 - Snap-frozen Xenograft 1 35 G>T WT WT 
95 M62 - Snap-frozen Xenograft 0 WT WT WT 
96 M103 - Snap-frozen Xenograft 0 WT WT WT 
97 M89 - Snap-frozen Xenograft 0 WT WT WT 
98 M34 - Snap-frozen Xenograft 0 WT WT WT 
99 M33 - Snap-frozen Xenograft 1 WT 1799 T>A WT 
100 M45 - Snap-frozen Xenograft 2 WT 1799 T>A 1633 G>A 
101 M70 - Snap-frozen Xenograft 0 WT WT WT 
102 M93 - Snap-frozen Xenograft 0 WT WT WT 
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103 M65 - Snap-frozen Xenograft 2 436 G>A WT 1633 G>A 
104 M8 - Snap-frozen Xenograft 0 WT WT WT 
105 M16 - Snap-frozen Xenograft 0 WT WT WT 
106 M79 - Snap-frozen Xenograft 0 WT WT WT 
107 M46 - Snap-frozen Xenograft 0 WT WT WT 
108 M69 - Snap-frozen Xenograft 1 WT WT 1624 G>A 
109 M105 - Snap-frozen Xenograft 0 WT WT WT 
110 M125 - Snap-frozen Xenograft 1 35 G>T WT WT 
111 M129 - Snap-frozen Xenograft 1 35 G>T WT WT 
112 M116 - Snap-frozen Xenograft 0 WT WT WT 
113 M108 - Snap-frozen Xenograft 0 WT WT WT 
114 M80 - Snap-frozen Xenograft 0 WT WT WT 
115 M54 - Snap-frozen Xenograft 0 WT WT WT 
116 M92 - Snap-frozen Xenograft 1 35 G>T WT WT 
117 M52 - Snap-frozen Xenograft 1 35 G>C WT WT 
118 M50 - Snap-frozen Xenograft 0 WT WT WT 
119 M71 - Snap-frozen Xenograft 0 WT WT WT 
120 M47 - Snap-frozen Xenograft 1 35 G>C WT WT 
121 M124 - Snap-frozen Xenograft 0 WT WT WT 
122 M117 - Snap-frozen Xenograft 1 WT WT 1633 G>A 
123 M55 - Snap-frozen Xenograft 0 WT WT WT 
124 M98 - Snap-frozen Xenograft 0 WT WT WT 
125 M61 - Snap-frozen Xenograft 1 35 G>T WT WT 
126 M39 - Snap-frozen Xenograft 0 WT WT WT 
127 M112 - Snap-frozen Xenograft 0 WT WT WT 
128 M14 - Snap-frozen Xenograft 1 35 G>A WT WT 
129 M85 - Snap-frozen Xenograft 1 35 G>A WT WT 
130 M38 - Snap-frozen Xenograft 0 WT WT WT 
131 M21 - Snap-frozen Xenograft 1 WT 1799 T>A NA 
132 M126 - Snap-frozen Xenograft 1 35 G>T WT WT 
133 M111 - Snap-frozen Xenograft 1 182 A>T WT 1624 G>A 
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Tab.S8. Median Ct values indicating expression of the selected genes analyzed in the RNA isolated from the tissue of the xenograft, primary snap-frozen 
tumours, and primary FFPE tissues. HK - housekeeping genes (GAPDH, RPLP0, UBC)which mean of the median Ct values was substracted in order to 
normalized expression data 
Model/Analyzed Gene Xenograft Frozen Corresponding Primary Frozen   
No model-ID Detector Ct Median Ct HK Ct Median - HK Medians Ct Ct HK Medians Ct Median - HK Ct Median Ct HK Ct Median - HK 
1 M1 AREG 28,86 24,67 4,19 24,95 19,86 5,08 30,31 27,60 2,71 
2 M1 EREG 33,85 24,67 9,18 28,26 19,86 8,39 35,51 27,60 7,92 
3 M1 DUSP6 - - - 31,96 19,86 12,10 - - - 
4 M1 SLC26A3 - - - 23,57 19,86 3,71 - - - 
5 M1 PTPRF - - - 25,09 19,86 5,23 - - - 
6 M1 LOC158960 - - - 31,34 19,86 11,48 - - - 
7 M1 PTEN 34,32 24,67 9,65 - - - - - - 
8 M1 GAPDH 24,29 24,67 -0,38 18,96 19,86 -0,91 27,33 27,60 -0,27 
9 M1 RPLP0 22,98 24,67 -1,70 19,32 19,86 -0,55 26,34 27,60 -1,26 
10 M1 UBC 26,75 24,67 2,08 21,32 19,86 1,46 24,04 27,60 -3,56 
11 M18 AREG 30,09 23,11 6,98 31,28 24,04 7,25 35,28 28,38 6,90 
12 M18 EREG 34,13 23,11 11,03 36,29 24,04 12,26 39,62 28,38 11,24 
13 M18 DUSP6 - - - 33,75 24,04 9,71 - - - 
14 M18 SLC26A3 - - - 31,18 24,04 7,14 - - - 
15 M18 PTPRF - - - 28,07 24,04 4,04 - - - 
16 M18 LOC158960 - - - 36,23 24,04 12,20 - - - 
17 M18 PTEN 34,09 23,11 10,98 - - - - - - 
18 M18 GAPDH 22,40 23,11 -0,71 24,13 24,04 0,10 28,03 28,38 -0,35 
19 M18 RPLP0 21,31 23,11 -1,80 22,94 24,04 -1,10 27,25 28,38 -1,13 
20 M18 UBC 25,62 23,11 2,51 25,04 24,04 1,01 29,86 28,38 1,48 
21 M27 AREG 28,28 24,26 4,02 25,86 21,23 4,63 31,01 27,44 3,57 
22 M27 EREG 33,86 24,26 9,60 29,91 21,23 8,68 38,18 27,44 10,74 
23 M27 DUSP6 - - - 30,50 21,23 9,27 - - - 
24 M27 SLC26A3 - - - 29,12 21,23 7,89 - - - 
25 M27 PTPRF - - - 26,32 21,23 5,09 - - - 
26 M27 LOC158960 - - - 34,35 21,23 13,12 - - - 
27 M27 PTEN 35,30 24,26 11,04 - - - - - - 
28 M27 GAPDH 23,27 24,26 -1,00 19,65 21,23 -1,58 26,51 27,44 -0,93 
29 M27 RPLP0 22,12 24,26 -2,14 20,55 21,23 -0,68 26,35 27,44 -1,09 
30 M27 UBC 27,40 24,26 3,14 23,50 21,23 2,27 29,46 27,44 2,02 
31 M52 AREG 27,59 23,23 4,35 25,48 22,40 3,08 37,49 32,90 4,59 
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32 M52 EREG 32,11 23,23 8,88 30,67 22,40 8,27 40,00 32,90 7,10 
33 M52 DUSP6 - - - 31,87 22,40 9,48 - - - 
34 M52 SLC26A3 - - - 29,26 22,40 6,87 - - - 
35 M52 PTPRF - - - 25,73 22,40 3,34 - - - 
36 M52 LOC158960 - - - 34,53 22,40 12,13 - - - 
37 M52 PTEN 34,05 23,23 10,81 - - - - - - 
38 M52 GAPDH 22,63 23,23 -0,61 21,96 22,40 -0,43 34,82 32,90 1,92 
39 M52 RPLP0 22,05 23,23 -1,18 21,86 22,40 -0,54 30,98 32,90 -1,92 
40 M52 UBC 25,03 23,23 1,79 23,36 22,40 0,97 - 32,90 - 
41 M55 AREG 27,16 23,21 3,95 25,23 20,53 4,70 33,78 28,09 5,69 
42 M55 EREG 30,05 23,21 6,84 26,85 20,53 6,32 35,21 28,09 7,12 
43 M55 DUSP6 - - - 31,96 20,53 11,43 - - - 
44 M55 SLC26A3 - - - 23,76 20,53 3,23 - - - 
45 M55 PTPRF - - - 25,18 20,53 4,65 - - - 
46 M55 LOC158960 - - - 31,62 20,53 11,09 - - - 
47 M55 PTEN 36,09 23,21 12,88 - - - - - - 
48 M55 GAPDH 22,50 23,21 -0,71 19,39 20,53 -1,14 28,47 28,09 0,38 
49 M55 RPLP0 22,67 23,21 -0,54 20,14 20,53 -0,39 27,71 28,09 -0,38 
50 M55 UBC 24,47 23,21 1,26 22,06 20,53 1,53 - 28,09 - 
51 M59 AREG 30,37 23,03 7,34 27,95 21,88 6,08 34,00 25,76 8,24 
52 M59 EREG 36,10 23,03 13,06 31,39 21,88 9,51 37,07 25,76 11,31 
53 M59 DUSP6 - - - 31,28 21,88 9,40 - - - 
54 M59 SLC26A3 - - - 33,22 21,88 11,34 - - - 
55 M59 PTPRF - - - 27,33 21,88 5,46 - - - 
56 M59 LOC158960 - - - 32,94 21,88 11,06 - - - 
57 M59 PTEN 33,02 23,03 9,98 - - - - - - 
58 M59 GAPDH 23,24 23,03 0,20 22,73 21,88 0,86 26,46 25,76 0,70 
59 M59 RPLP0 21,43 23,03 -1,60 19,38 21,88 -2,50 25,06 25,76 -0,70 
60 M59 UBC 24,43 23,03 1,40 23,52 21,88 1,64 - 25,76 - 
61 M63 AREG 31,31 23,06 8,25 26,63 20,61 6,02 34,17 27,78 6,39 
62 M63 EREG 35,51 23,06 12,45 31,17 20,61 10,56 39,41 27,78 11,62 
63 M63 DUSP6 - - - 31,63 20,61 11,01 - - - 
64 M63 SLC26A3 - - - 26,65 20,61 6,04 - - - 
65 M63 PTPRF - - - 27,29 20,61 6,68 - - - 
66 M63 LOC158960 - - - 33,10 20,61 12,49 - - - 
67 M63 PTEN 33,36 23,06 10,30 - - - - - - 
68 M63 GAPDH 22,60 23,06 -0,46 20,20 20,61 -0,41 27,20 27,78 -0,58 
69 M63 RPLP0 21,12 23,06 -1,94 19,09 20,61 -1,52 26,58 27,78 -1,20 
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70 M63 UBC 25,45 23,06 2,40 22,54 20,61 1,93 29,56 27,78 1,78 
71 M65 AREG 33,37 26,89 6,48 25,23 21,91 3,32 31,00 27,39 3,61 
72 M65 EREG 37,88 26,89 10,99 29,82 21,91 7,91 34,18 27,39 6,79 
73 M65 DUSP6 - - - 32,62 21,91 10,71 - - - 
74 M65 SLC26A3 - - - 25,22 21,91 3,30 - - - 
75 M65 PTPRF - - - 26,86 21,91 4,95 - - - 
76 M65 LOC158960 - - - 33,85 21,91 11,94 - - - 
77 M65 PTEN 40,00 26,89 13,11 - - - - - - 
78 M65 GAPDH 25,62 26,89 -1,27 21,59 21,91 -0,32 27,40 27,39 0,01 
79 M65 RPLP0 26,00 26,89 -0,89 20,25 21,91 -1,66 25,89 27,39 -1,50 
80 M65 UBC 29,05 26,89 2,16 23,89 21,91 1,98 28,88 27,39 1,50 
81 M66 AREG 27,31 23,16 4,16 24,49 21,12 3,37 31,03 28,25 2,77 
82 M66 EREG 30,78 23,16 7,62 27,61 21,12 6,49 35,73 28,25 7,48 
83 M66 DUSP6 - - - 31,84 21,12 10,72 - - - 
84 M66 SLC26A3 - - - 28,31 21,12 7,19 - - - 
85 M66 PTPRF - - - 26,37 21,12 5,25 - - - 
86 M66 LOC158960 - - - 33,47 21,12 12,35 - - - 
87 M66 PTEN 34,54 23,16 11,39 - - - - - - 
88 M66 GAPDH 22,48 23,16 -0,67 20,26 21,12 -0,86 28,28 28,25 0,03 
89 M66 RPLP0 20,91 23,16 -2,24 19,75 21,12 -1,37 26,16 28,25 -2,10 
90 M66 UBC 26,07 23,16 2,92 23,36 21,12 2,24 30,32 28,25 2,07 
91 M60 AREG 30,26 24,15 6,11 - - - 31,57 29,82 1,75 
92 M60 EREG 31,58 24,15 7,42 - - - 35,34 29,82 5,53 
93 M60 DUSP6 - - - - - - - - - 
94 M60 SLC26A3 - - - - - - - - - 
95 M60 PTPRF - - - - - - - - - 
96 M60 LOC158960 - - - - - - - - - 
97 M60 PTEN 34,37 24,15 10,21 - - - - - - 
98 M60 GAPDH 23,31 24,15 -0,84 - - - 29,11 29,82 -0,71 
99 M60 RPLP0 22,78 24,15 -1,38 - - - 29,59 29,82 -0,23 
100 M60 UBC 26,38 24,15 2,22 - - - 30,76 29,82 0,94 
101 M68 AREG 27,84 23,10 4,74 26,23 21,66 4,57 33,09 29,26 3,83 
102 M68 EREG 30,49 23,10 7,39 27,90 21,66 6,24 35,57 29,26 6,32 
103 M68 DUSP6 - - - 32,06 21,66 10,40 - - - 
104 M68 SLC26A3 - - - 30,19 21,66 8,53 - - - 
105 M68 PTPRF - - - 26,03 21,66 4,37 - - - 
106 M68 LOC158960 - - - 33,20 21,66 11,54 - - - 
107 M68 PTEN 34,15 23,10 11,05 - - - - - - 
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108 M68 GAPDH 22,16 23,10 -0,94 20,62 21,66 -1,04 29,33 29,26 0,07 
109 M68 RPLP0 21,98 23,10 -1,12 21,20 21,66 -0,46 28,18 29,26 -1,08 
110 M68 UBC 25,17 23,10 2,07 23,16 21,66 1,50 30,26 29,26 1,01 
111 M57 AREG 25,17 21,95 3,22 26,26 20,76 5,49 31,56 27,18 4,38 
112 M57 EREG 29,19 21,95 7,24 31,28 20,76 10,52 37,60 27,18 10,42 
113 M57 DUSP6 - - - 31,92 20,76 11,15 - - - 
114 M57 SLC26A3 - - - 21,83 20,76 1,06 - - - 
115 M57 PTPRF - - - 24,40 20,76 3,64 - - - 
116 M57 LOC158960 - - - 32,28 20,76 11,51 - - - 
117 M57 PTEN 32,43 21,95 10,48 - - - - - - 
118 M57 GAPDH 21,02 21,95 -0,93 19,82 20,76 -0,95 27,68 27,18 0,50 
119 M57 RPLP0 20,31 21,95 -1,63 20,35 20,76 -0,42 26,68 27,18 -0,50 
120 M57 UBC 24,51 21,95 2,56 22,13 20,76 1,36 - 27,18 - 
121 M72 AREG 26,76 24,10 2,67 26,45 21,54 4,91 35,22 30,49 4,72 
122 M72 EREG 31,14 24,10 7,04 28,83 21,54 7,29 38,20 30,49 7,71 
123 M72 DUSP6 - - - 33,22 21,54 11,68 - - - 
124 M72 SLC26A3 - - - 28,02 21,54 6,48 - - - 
125 M72 PTPRF - - - 25,84 21,54 4,31 - - - 
126 M72 LOC158960 - - - 32,70 21,54 11,16 - - - 
127 M72 PTEN 35,09 24,10 10,99 - - - - - - 
128 M72 GAPDH 24,05 24,10 -0,05 20,90 21,54 -0,63 31,82 30,49 1,33 
129 M72 RPLP0 22,02 24,10 -2,08 21,07 21,54 -0,47 26,78 30,49 -3,71 
130 M72 UBC 26,22 24,10 2,12 22,64 21,54 1,11 32,87 30,49 2,38 
131 M75 AREG 28,97 22,77 6,20 25,93 20,43 5,49 33,14 29,43 3,71 
132 M75 EREG 33,87 22,77 11,11 30,19 20,43 9,75 39,75 29,43 10,32 
133 M75 DUSP6 - - - 29,85 20,43 9,42 - - - 
134 M75 SLC26A3 - - - 29,53 20,43 9,10 - - - 
135 M75 PTPRF - - - 23,31 20,43 2,87 - - - 
136 M75 LOC158960 - - - 33,20 20,43 12,77 - - - 
137 M75 PTEN 32,27 22,77 9,51 - - - - - - 
138 M75 GAPDH 22,84 22,77 0,08 19,86 20,43 -0,57 30,33 29,43 0,90 
139 M75 RPLP0 20,73 22,77 -2,03 19,28 20,43 -1,16 27,07 29,43 -2,36 
140 M75 UBC 24,72 22,77 1,96 22,17 20,43 1,73 30,88 29,43 1,46 
141 M81 AREG 29,51 22,22 7,29 27,65 19,70 7,95 36,40 30,66 5,75 
142 M81 EREG 32,69 22,22 10,47 30,73 19,70 11,03 40,00 30,66 9,34 
143 M81 DUSP6 - - - 29,55 19,70 9,85 - - - 
144 M81 SLC26A3 - - - 31,70 19,70 11,99 - - - 
145 M81 PTPRF - - - 25,71 19,70 6,01 - - - 
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146 M81 LOC158960 - - - 34,23 19,70 14,53 - - - 
147 M81 PTEN 33,14 22,22 10,91 - - - - - - 
148 M81 GAPDH 21,14 22,22 -1,09 18,56 19,70 -1,14 30,22 30,66 -0,44 
149 M81 RPLP0 21,04 22,22 -1,19 18,79 19,70 -0,92 27,66 30,66 -3,00 
150 M81 UBC 24,49 22,22 2,27 21,76 19,70 2,06 34,09 30,66 3,43 
151 M80 AREG 31,25 24,67 6,58 26,53 22,41 4,11 38,30 32,04 6,26 
152 M80 EREG 40,00 24,67 15,33 33,20 22,41 10,79 40,00 32,04 7,96 
153 M80 DUSP6 - - - 33,77 22,41 11,36 - - - 
154 M80 SLC26A3 - - - 30,99 22,41 8,58 - - - 
155 M80 PTPRF - - - 26,43 22,41 4,02 - - - 
156 M80 LOC158960 - - - 34,72 22,41 12,31 - - - 
157 M80 PTEN 35,60 24,67 10,93 - - - - - - 
158 M80 GAPDH 23,38 24,67 -1,28 21,62 22,41 -0,80 32,64 32,04 0,59 
159 M80 RPLP0 23,92 24,67 -0,74 21,96 22,41 -0,45 29,41 32,04 -2,64 
160 M80 UBC 26,69 24,67 2,02 23,66 22,41 1,24 34,08 32,04 2,04 
161 M83 AREG 25,59 22,22 3,36 22,06 20,60 1,46 27,32 26,78 0,54 
162 M83 EREG 30,06 22,22 7,84 25,54 20,60 4,94 32,19 26,78 5,41 
163 M83 DUSP6 - - - 32,00 20,60 11,41 - - - 
164 M83 SLC26A3 - - - 30,11 20,60 9,51 - - - 
165 M83 PTPRF - - - 25,28 20,60 4,68 - - - 
166 M83 LOC158960 - - - 31,82 20,60 11,23 - - - 
167 M83 PTEN 32,69 22,22 10,47 - - - - - - 
168 M83 GAPDH 21,77 22,22 -0,46 20,23 20,60 -0,37 27,21 26,78 0,43 
169 M83 RPLP0 20,32 22,22 -1,90 19,36 20,60 -1,24 24,96 26,78 -1,82 
170 M83 UBC 24,58 22,22 2,35 22,21 20,60 1,61 28,17 26,78 1,39 
171 M88 AREG 26,40 22,95 3,45 22,89 19,84 3,05 28,13 26,09 2,04 
172 M88 EREG 29,90 22,95 6,95 26,07 19,84 6,23 30,99 26,09 4,89 
173 M88 DUSP6 - - - 31,13 19,84 11,29 - - - 
174 M88 SLC26A3 - - - 25,85 19,84 6,01 - - - 
175 M88 PTPRF - - - 28,55 19,84 8,71 - - - 
176 M88 LOC158960 - - - 32,13 19,84 12,29 - - - 
177 M88 PTEN 32,14 22,95 9,19 - - - - - - 
178 M88 GAPDH 22,00 22,95 -0,95 18,77 19,84 -1,07 26,00 26,09 -0,09 
179 M88 RPLP0 21,78 22,95 -1,17 19,02 19,84 -0,82 24,60 26,09 -1,49 
180 M88 UBC 25,07 22,95 2,12 21,73 19,84 1,89 27,67 26,09 1,58 
181 M86 AREG 27,89 21,59 6,30 25,75 21,41 4,34 38,31 34,16 4,14 
182 M86 EREG 32,89 21,59 11,29 30,16 21,41 8,74 40,00 34,16 5,84 
183 M86 DUSP6 - - - 32,24 21,41 10,83 - - - 
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184 M86 SLC26A3 - - - 35,18 21,41 13,77 - - - 
185 M86 PTPRF - - - 26,33 21,41 4,92 - - - 
186 M86 LOC158960 - - - 34,87 21,41 13,46 - - - 
187 M86 PTEN 32,41 21,59 10,82 - - - - - - 
188 M86 GAPDH 20,29 21,59 -1,30 20,06 21,41 -1,35 36,89 34,16 2,72 
189 M86 RPLP0 19,37 21,59 -2,23 19,92 21,41 -1,49 26,73 34,16 -7,43 
190 M86 UBC 25,12 21,59 3,53 24,25 21,41 2,84 38,88 34,16 4,71 
191 M89 AREG 28,64 23,45 5,19 23,07 20,63 2,44 28,04 26,86 1,18 
192 M89 EREG 31,75 23,45 8,30 27,08 20,63 6,45 32,79 26,86 5,94 
193 M89 DUSP6 - - - 33,60 20,63 12,98 - - - 
194 M89 SLC26A3 - - - 28,55 20,63 7,93 - - - 
195 M89 PTPRF - - - 25,21 20,63 4,59 - - - 
196 M89 LOC158960 - - - 34,14 20,63 13,51 - - - 
197 M89 PTEN 33,71 23,45 10,26 - - - - - - 
198 M89 GAPDH 23,08 23,45 -0,37 19,63 20,63 -1,00 26,76 26,86 -0,09 
199 M89 RPLP0 22,16 23,45 -1,29 19,62 20,63 -1,01 25,70 26,86 -1,15 
200 M89 UBC 25,12 23,45 1,67 22,63 20,63 2,01 28,11 26,86 1,25 
201 M91 AREG 27,38 22,57 4,80 24,21 20,53 3,68 27,11 25,19 1,93 
202 M91 EREG 30,23 22,57 7,66 27,13 20,53 6,60 30,05 25,19 4,86 
203 M91 DUSP6 - - - 33,26 20,53 12,73 - - - 
204 M91 SLC26A3 - - - 26,41 20,53 5,88 - - - 
205 M91 PTPRF - - - 24,67 20,53 4,14 - - - 
206 M91 LOC158960 - - - 31,69 20,53 11,16 - - - 
207 M91 PTEN 32,09 22,57 9,51 - - - - - - 
208 M91 GAPDH 22,29 22,57 -0,28 19,88 20,53 -0,65 25,21 25,19 0,02 
209 M91 RPLP0 21,12 22,57 -1,45 20,10 20,53 -0,43 24,13 25,19 -1,06 
210 M91 UBC 24,30 22,57 1,73 21,61 20,53 1,08 26,22 25,19 1,03 
211 M92 AREG 28,09 24,39 3,70 23,92 20,47 3,45 29,10 26,35 2,75 
212 M92 EREG 30,97 24,39 6,58 26,01 20,47 5,54 31,09 26,35 4,73 
213 M92 DUSP6 - - - 30,69 20,47 10,22 - - - 
214 M92 SLC26A3 - - - 26,33 20,47 5,86 - - - 
215 M92 PTPRF - - - 24,42 20,47 3,96 - - - 
216 M92 LOC158960 - - - 32,55 20,47 12,08 - - - 
217 M92 PTEN 34,99 24,39 10,60 - - - - - - 
218 M92 GAPDH 24,36 24,39 -0,03 19,88 20,47 -0,59 26,45 26,35 0,09 
219 M92 RPLP0 22,98 24,39 -1,41 19,63 20,47 -0,84 25,00 26,35 -1,36 
220 M92 UBC 25,83 24,39 1,44 21,90 20,47 1,43 27,62 26,35 1,27 
221 M90 AREG 29,14 23,14 5,99 25,26 21,28 3,98 31,22 27,06 4,15 
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222 M90 EREG 31,75 23,14 8,61 28,42 21,28 7,14 34,15 27,06 7,08 
223 M90 DUSP6 - - - 31,84 21,28 10,56 - - - 
224 M90 SLC26A3 - - - 29,57 21,28 8,29 - - - 
225 M90 PTPRF - - - 26,32 21,28 5,03 - - - 
226 M90 LOC158960 - - - 33,22 21,28 11,94 - - - 
227 M90 PTEN 32,85 23,14 9,71 - - - - - - 
228 M90 GAPDH 21,80 23,14 -1,35 20,47 21,28 -0,82 26,71 27,06 -0,36 
229 M90 RPLP0 21,73 23,14 -1,42 20,19 21,28 -1,09 26,34 27,06 -0,73 
230 M90 UBC 25,91 23,14 2,76 23,18 21,28 1,90 28,15 27,06 1,09 
231 M13 AREG 26,94 23,26 3,68 21,78 20,17 1,61 30,88 29,56 1,32 
232 M13 EREG 30,90 23,26 7,65 26,47 20,17 6,30 36,74 29,56 7,18 
233 M13 DUSP6 - - - 32,17 20,17 12,00 - - - 
234 M13 SLC26A3 - - - 27,39 20,17 7,22 - - - 
235 M13 PTPRF - - - 25,96 20,17 5,79 - - - 
236 M13 LOC158960 - - - 33,03 20,17 12,86 - - - 
237 M13 PTEN 33,92 23,26 10,67 - - - - - - 
238 M13 GAPDH 22,77 23,26 -0,48 19,54 20,17 -0,63 29,55 29,56 -0,02 
239 M13 RPLP0 22,05 23,26 -1,21 18,94 20,17 -1,23 27,41 29,56 -2,15 
240 M13 UBC 24,94 23,26 1,69 22,03 20,17 1,86 31,73 29,56 2,17 
241 M23 AREG 29,45 24,40 5,05 26,19 21,28 4,91 29,97 26,36 3,61 
242 M23 EREG 35,10 24,40 10,70 29,24 21,28 7,96 34,35 26,36 7,99 
243 M23 DUSP6 - - - 33,44 21,28 12,16 - - - 
244 M23 SLC26A3 - - - 24,82 21,28 3,53 - - - 
245 M23 PTPRF - - - 25,40 21,28 4,12 - - - 
246 M23 LOC158960 - - - 31,53 21,28 10,25 - - - 
247 M23 PTEN 33,67 24,40 9,27 - - - - - - 
248 M23 GAPDH 23,86 24,40 -0,54 19,72 21,28 -1,56 25,48 26,36 -0,88 
249 M23 RPLP0 22,26 24,40 -2,14 20,85 21,28 -0,43 25,58 26,36 -0,78 
250 M23 UBC 27,08 24,40 2,68 23,28 21,28 2,00 28,02 26,36 1,66 
251 M43 AREG 29,01 23,36 5,64 27,94 20,53 7,41 36,82 29,97 6,86 
252 M43 EREG 36,44 23,36 13,07 32,55 20,53 12,03 40,00 29,97 10,03 
253 M43 DUSP6 - - - 30,95 20,53 10,42 - - - 
254 M43 SLC26A3 - - - 30,26 20,53 9,74 - - - 
255 M43 PTPRF - - - 25,10 20,53 4,57 - - - 
256 M43 LOC158960 - - - 33,59 20,53 13,07 - - - 
257 M43 PTEN 33,22 23,36 9,86 - - - - - - 
258 M43 GAPDH 22,41 23,36 -0,96 19,54 20,53 -0,98 29,29 29,97 -0,68 
259 M43 RPLP0 23,13 23,36 -0,23 19,91 20,53 -0,62 28,59 29,97 -1,38 
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260 M43 UBC 24,55 23,36 1,19 22,13 20,53 1,60 32,02 29,97 2,05 
261 M53 AREG 30,41 22,85 7,56 28,80 20,60 8,20 40,00 32,73 7,27 
262 M53 EREG 32,77 22,85 9,92 31,07 20,60 10,47 40,00 32,73 7,27 
263 M53 DUSP6 - - - 32,22 20,60 11,62 - - - 
264 M53 SLC26A3 - - - 31,81 20,60 11,21 - - - 
265 M53 PTPRF - - - 26,45 20,60 5,85 - - - 
266 M53 LOC158960 - - - 33,58 20,60 12,98 - - - 
267 M53 PTEN 33,96 22,85 11,10 - - - - - - 
268 M53 GAPDH 21,37 22,85 -1,48 19,62 20,60 -0,98 32,52 32,73 -0,21 
269 M53 RPLP0 21,73 22,85 -1,12 20,18 20,60 -0,43 29,92 32,73 -2,81 
270 M53 UBC 25,45 22,85 2,60 22,01 20,60 1,41 35,75 32,73 3,02 
271 M56 AREG 28,06 23,62 4,45 25,71 23,17 2,54 31,01 28,86 2,15 
272 M56 EREG 32,07 23,62 8,45 29,17 23,17 6,00 36,19 28,86 7,33 
273 M56 DUSP6 - - - 33,05 23,17 9,88 - - - 
274 M56 SLC26A3 - - - 27,01 23,17 3,85 - - - 
275 M56 PTPRF - - - 26,51 23,17 3,34 - - - 
276 M56 LOC158960 - - - 34,98 23,17 11,82 - - - 
277 M56 PTEN 34,14 23,62 10,52 - - - - - - 
278 M56 GAPDH 22,89 23,62 -0,73 22,33 23,17 -0,84 28,36 28,86 -0,50 
279 M56 RPLP0 22,29 23,62 -1,33 22,05 23,17 -1,12 28,00 28,86 -0,86 
280 M56 UBC 25,68 23,62 2,06 25,13 23,17 1,97 30,21 28,86 1,35 
281 M61 AREG 26,18 22,57 3,61 23,57 20,58 2,98 32,47 29,32 3,15 
282 M61 EREG 30,02 22,57 7,45 27,44 20,58 6,86 38,00 29,32 8,68 
283 M61 DUSP6 - - - 31,44 20,58 10,85 - - - 
284 M61 SLC26A3 - - - 28,22 20,58 7,64 - - - 
285 M61 PTPRF - - - 25,23 20,58 4,64 - - - 
286 M61 LOC158960 - - - 31,61 20,58 11,02 - - - 
287 M61 PTEN 32,85 22,57 10,28 - - - - - - 
288 M61 GAPDH 21,88 22,57 -0,69 19,94 20,58 -0,64 28,82 29,32 -0,50 
289 M61 RPLP0 21,10 22,57 -1,47 18,86 20,58 -1,73 28,83 29,32 -0,49 
290 M61 UBC 24,73 22,57 2,16 22,96 20,58 2,37 30,32 29,32 1,00 
291 M29 AREG 25,48 22,82 2,66 23,88 21,05 2,83 29,62 28,03 1,59 
292 M29 EREG 30,31 22,82 7,49 28,07 21,05 7,03 35,81 28,03 7,78 
293 M29 DUSP6 - - - 31,26 21,05 10,21 - - - 
294 M29 SLC26A3 - - - 25,68 21,05 4,64 - - - 
295 M29 PTPRF - - - 25,95 21,05 4,90 - - - 
296 M29 LOC158960 - - - 33,41 21,05 12,36 - - - 
297 M29 PTEN 34,88 22,82 12,06 - - - - - - 
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298 M29 GAPDH 22,38 22,82 -0,44 20,46 21,05 -0,59 27,66 28,03 -0,37 
299 M29 RPLP0 20,85 22,82 -1,97 20,25 21,05 -0,80 26,74 28,03 -1,29 
300 M29 UBC 25,23 22,82 2,41 22,43 21,05 1,38 29,69 28,03 1,66 
301 M76 AREG 27,23 25,17 2,06 22,96 19,82 3,14 27,57 26,05 1,51 
302 M76 EREG 30,49 25,17 5,32 26,27 19,82 6,45 30,61 26,05 4,56 
303 M76 DUSP6 - - - 31,61 19,82 11,79 - - - 
304 M76 SLC26A3 - - - 30,20 19,82 10,37 - - - 
305 M76 PTPRF - - - 24,36 19,82 4,54 - - - 
306 M76 LOC158960 - - - 32,62 19,82 12,80 - - - 
307 M76 PTEN 35,09 25,17 9,91 - - - - - - 
308 M76 GAPDH 24,47 25,17 -0,71 18,87 19,82 -0,95 26,01 26,05 -0,05 
309 M76 RPLP0 24,15 25,17 -1,03 19,01 19,82 -0,81 25,06 26,05 -1,00 
310 M76 UBC 26,91 25,17 1,73 21,59 19,82 1,77 27,10 26,05 1,04 
311 M79 AREG 26,57 22,65 3,92 24,83 20,33 4,50 30,16 26,57 3,58 
312 M79 EREG 30,50 22,65 7,85 28,67 20,33 8,34 35,14 26,57 8,57 
313 M79 DUSP6 - - - 33,96 20,33 13,63 - - - 
314 M79 SLC26A3 - - - 27,42 20,33 7,09 - - - 
315 M79 PTPRF - - - 24,44 20,33 4,11 - - - 
316 M79 LOC158960 - - - 31,32 20,33 10,99 - - - 
317 M79 PTEN 33,38 22,65 10,73 - - - - - - 
318 M79 GAPDH 21,85 22,65 -0,80 19,38 20,33 -0,95 26,63 26,57 0,05 
319 M79 RPLP0 22,26 22,65 -0,39 20,05 20,33 -0,28 25,65 26,57 -0,92 
320 M79 UBC 23,83 22,65 1,19 21,56 20,33 1,23 27,44 26,57 0,87 
321 M77 AREG 29,22 23,84 5,38 27,89 21,74 6,15 33,26 28,53 4,73 
322 M77 EREG 33,78 23,84 9,94 33,57 21,74 11,83 38,60 28,53 10,07 
323 M77 DUSP6 - - - 34,05 21,74 12,31 - - - 
324 M77 SLC26A3 - - - 27,76 21,74 6,02 - - - 
325 M77 PTPRF - - - 27,23 21,74 5,49 - - - 
326 M77 LOC158960 - - - 33,96 21,74 12,22 - - - 
327 M77 PTEN 33,97 23,84 10,13 - - - - - - 
328 M77 GAPDH 23,24 23,84 -0,60 21,10 21,74 -0,64 28,47 28,53 -0,06 
329 M77 RPLP0 22,69 23,84 -1,15 20,91 21,74 -0,83 27,03 28,53 -1,49 
330 M77 UBC 25,60 23,84 1,76 23,20 21,74 1,46 30,08 28,53 1,55 
331 M82 AREG 25,49 23,66 1,83 22,32 19,91 2,41 32,34 28,99 3,35 
332 M82 EREG 29,27 23,66 5,61 25,33 19,91 5,41 37,09 28,99 8,11 
333 M82 DUSP6 - - - 30,21 19,91 10,29 - - - 
334 M82 SLC26A3 - - - 25,40 19,91 5,48 - - - 
335 M82 PTPRF - - - 24,29 19,91 4,37 - - - 
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336 M82 LOC158960 - - - 31,03 19,91 11,11 - - - 
337 M82 PTEN 34,34 23,66 10,68 - - - - - - 
338 M82 GAPDH 23,52 23,66 -0,14 19,15 19,91 -0,76 28,76 28,99 -0,23 
339 M82 RPLP0 21,27 23,66 -2,39 19,15 19,91 -0,76 27,59 28,99 -1,40 
340 M82 UBC 26,20 23,66 2,53 21,44 19,91 1,52 30,62 28,99 1,63 
341 M84 AREG 26,82 24,32 2,49 23,72 21,73 1,99 38,19 35,30 2,89 
342 M84 EREG 29,96 24,32 5,64 27,05 21,73 5,32 40,00 35,30 4,70 
343 M84 DUSP6 - - - 32,02 21,73 10,29 - - - 
344 M84 SLC26A3 - - - 24,21 21,73 2,48 - - - 
345 M84 PTPRF - - - 25,10 21,73 3,37 - - - 
346 M84 LOC158960 - - - 32,27 21,73 10,53 - - - 
347 M84 PTEN 33,41 24,32 9,09 - - - - - - 
348 M84 GAPDH 22,97 24,32 -1,35 20,27 21,73 -1,46 36,40 35,30 1,10 
349 M84 RPLP0 23,18 24,32 -1,14 20,44 21,73 -1,29 31,16 35,30 -4,14 
350 M84 UBC 26,82 24,32 2,49 24,48 21,73 2,75 38,33 35,30 3,04 
351 M87 AREG 29,70 22,80 6,89 24,49 20,51 3,98 29,64 27,27 2,37 
352 M87 EREG 33,58 22,80 10,78 29,74 20,51 9,23 35,09 27,27 7,82 
353 M87 DUSP6 - - - 31,10 20,51 10,59 - - - 
354 M87 SLC26A3 - - - 26,19 20,51 5,68 - - - 
355 M87 PTPRF - - - 24,86 20,51 4,35 - - - 
356 M87 LOC158960 - - - 31,91 20,51 11,40 - - - 
357 M87 PTEN 33,27 22,80 10,47 - - - - - - 
358 M87 GAPDH 22,03 22,80 -0,78 19,46 20,51 -1,05 26,68 27,27 -0,59 
359 M87 RPLP0 21,13 22,80 -1,68 19,54 20,51 -0,97 25,45 27,27 -1,82 
360 M87 UBC 25,26 22,80 2,45 22,53 20,51 2,02 29,69 27,27 2,42 
361 M53 AREG 30,41 22,85 7,56 28,80 20,60 8,20 40,00 32,73 7,27 
362 M53 EREG 32,77 22,85 9,92 31,07 20,60 10,47 40,00 32,73 7,27 
363 M53 DUSP6 - - - 32,22 20,60 11,62 - - - 
364 M53 SLC26A3 - - - 31,81 20,60 11,21 - - - 
365 M53 PTPRF - - - 26,45 20,60 5,85 - - - 
366 M53 LOC158960 - - - 33,58 20,60 12,98 - - - 
367 M53 PTEN 33,96 22,85 11,10 - - - - - - 
368 M53 GAPDH 21,37 22,85 -1,48 19,62 20,60 -0,98 32,52 32,73 -0,21 
369 M53 RPLP0 21,73 22,85 -1,12 20,18 20,60 -0,43 29,92 32,73 -2,81 
370 M53 UBC 25,45 22,85 2,60 22,01 20,60 1,41 35,75 32,73 3,02 
371 M93 AREG 26,13 23,58 2,55 23,25 21,87 1,38 29,55 28,87 0,68 
372 M93 EREG 29,95 23,58 6,36 26,47 21,87 4,60 34,17 28,87 5,29 
373 M93 DUSP6 - - - 34,33 21,87 12,46 - - - 
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374 M93 SLC26A3 - - - 32,62 21,87 10,75 - - - 
375 M93 PTPRF - - - 25,38 21,87 3,51 - - - 
376 M93 LOC158960 - - - 32,84 21,87 10,97 - - - 
377 M93 PTEN 40,00 23,58 16,42 - - - - - - 
378 M93 GAPDH 23,37 23,58 -0,21 21,24 21,87 -0,63 28,23 28,87 -0,64 
379 M93 RPLP0 21,74 23,58 -1,84 21,73 21,87 -0,14 28,48 28,87 -0,40 
380 M93 UBC 25,64 23,58 2,05 22,64 21,87 0,77 29,91 28,87 1,04 
381 M94 AREG 28,87 24,44 4,43 26,33 22,38 3,95 33,23 29,54 3,69 
382 M94 EREG 33,01 24,44 8,58 29,75 22,38 7,37 38,50 29,54 8,96 
383 M94 DUSP6 - - - 34,17 22,38 11,79 - - - 
384 M94 SLC26A3 - - - 30,78 22,38 8,40 - - - 
385 M94 PTPRF - - - 25,18 22,38 2,80 - - - 
386 M94 LOC158960 - - - 32,87 22,38 10,50 - - - 
387 M94 PTEN 34,81 24,44 10,37 - - - - - - 
388 M94 GAPDH 24,21 24,44 -0,23 21,72 22,38 -0,66 29,33 29,54 -0,21 
389 M94 RPLP0 22,77 24,44 -1,66 21,26 22,38 -1,12 27,74 29,54 -1,80 
390 M94 UBC 26,33 24,44 1,89 24,15 22,38 1,78 31,55 29,54 2,01 
391 M95 AREG 27,99 24,35 3,64 24,01 20,86 3,15 38,25 33,98 4,27 
392 M95 EREG 32,69 24,35 8,34 28,19 20,86 7,34 40,00 33,98 6,02 
393 M95 DUSP6 - - - 31,44 20,86 10,58 - - - 
394 M95 SLC26A3 - - - 31,12 20,86 10,26 - - - 
395 M95 PTPRF - - - 24,93 20,86 4,07 - - - 
396 M95 LOC158960 - - - 31,41 20,86 10,55 - - - 
397 M95 PTEN 33,40 24,35 9,05 - - - - - - 
398 M95 GAPDH 24,06 24,35 -0,29 20,16 20,86 -0,70 35,42 33,98 1,44 
399 M95 RPLP0 22,98 24,35 -1,37 20,11 20,86 -0,74 27,28 33,98 -6,70 
400 M95 UBC 26,02 24,35 1,67 22,30 20,86 1,44 39,23 33,98 5,26 
401 M96 AREG 29,34 22,76 6,58 24,68 20,34 4,34 40,00 34,00 6,00 
402 M96 EREG 38,56 22,76 15,80 28,97 20,34 8,63 40,00 34,00 6,00 
403 M96 DUSP6 - - - 31,35 20,34 11,01 - - - 
404 M96 SLC26A3 - - - 34,92 20,34 14,58 - - - 
405 M96 PTPRF - - - 25,23 20,34 4,89 - - - 
406 M96 LOC158960 - - - 32,78 20,34 12,43 - - - 
407 M96 PTEN 33,40 22,76 10,64 - - - - - - 
408 M96 GAPDH 22,00 22,76 -0,76 19,17 20,34 -1,17 36,64 34,00 2,64 
409 M96 RPLP0 21,17 22,76 -1,58 19,44 20,34 -0,91 26,58 34,00 -7,42 
410 M96 UBC 25,10 22,76 2,34 22,42 20,34 2,08 38,77 34,00 4,77 
411 M97 AREG 29,14 23,72 5,42 25,75 20,60 5,15 30,92 28,19 2,73 
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412 M97 EREG 37,01 23,72 13,30 30,84 20,60 10,24 36,29 28,19 8,11 
413 M97 DUSP6 - - - 31,61 20,60 11,00 - - - 
414 M97 SLC26A3 - - - 32,53 20,60 11,93 - - - 
415 M97 PTPRF - - - 25,37 20,60 4,77 - - - 
416 M97 LOC158960 - - - 34,08 20,60 13,48 - - - 
417 M97 PTEN 34,59 23,72 10,87 - - - - - - 
418 M97 GAPDH 23,06 23,72 -0,66 19,37 20,60 -1,23 27,28 28,19 -0,91 
419 M97 RPLP0 21,87 23,72 -1,85 19,29 20,60 -1,32 26,91 28,19 -1,28 
420 M97 UBC 26,22 23,72 2,51 23,15 20,60 2,55 30,38 28,19 2,19 
421 M98 AREG 26,73 23,81 2,92 22,60 20,31 2,30 31,16 29,29 1,87 
422 M98 EREG 30,28 23,81 6,47 24,96 20,31 4,65 36,12 29,29 6,83 
423 M98 DUSP6 - - - 32,41 20,31 12,11 - - - 
424 M98 SLC26A3 - - - 27,10 20,31 6,79 - - - 
425 M98 PTPRF - - - 27,59 20,31 7,28 - - - 
426 M98 LOC158960 - - - 31,08 20,31 10,78 - - - 
427 M98 PTEN 34,10 23,81 10,29 - - - - - - 
428 M98 GAPDH 23,75 23,81 -0,06 19,85 20,31 -0,45 29,25 29,29 -0,04 
429 M98 RPLP0 21,85 23,81 -1,96 18,59 20,31 -1,71 27,23 29,29 -2,05 
430 M98 UBC 25,83 23,81 2,02 22,48 20,31 2,17 31,38 29,29 2,09 
431 M99 AREG 25,69 23,34 2,35 21,53 19,49 2,04 30,74 27,81 2,93 
432 M99 EREG 29,51 23,34 6,18 25,33 19,49 5,84 35,10 27,81 7,30 
433 M99 DUSP6 - - - 32,02 19,49 12,53 - - - 
434 M99 SLC26A3 - - - 20,92 19,49 1,43 - - - 
435 M99 PTPRF - - - 23,92 19,49 4,43 - - - 
436 M99 LOC158960 - - - 31,86 19,49 12,37 - - - 
437 M99 PTEN 33,92 23,34 10,58 - - - - - - 
438 M99 GAPDH 23,31 23,34 -0,03 18,71 19,49 -0,77 27,77 27,81 -0,03 
439 M99 RPLP0 21,85 23,34 -1,49 18,60 19,49 -0,88 26,46 27,81 -1,35 
440 M99 UBC 24,86 23,34 1,52 21,14 19,49 1,66 29,18 27,81 1,38 
441 M101 AREG 27,69 23,06 4,63 24,85 21,41 3,44 40,00 32,71 7,29 
442 M101 EREG 30,78 23,06 7,72 27,14 21,41 5,73 40,00 32,71 7,29 
443 M101 DUSP6 - - - 31,57 21,41 10,16 - - - 
444 M101 SLC26A3 - - - 30,19 21,41 8,78 - - - 
445 M101 PTPRF - - - 26,31 21,41 4,90 - - - 
446 M101 LOC158960 - - - 33,56 21,41 12,15 - - - 
447 M101 PTEN 33,38 23,06 10,32 - - - - - - 
448 M101 GAPDH 22,47 23,06 -0,59 21,05 21,41 -0,35 38,27 32,71 5,56 
449 M101 RPLP0 21,72 23,06 -1,34 20,26 21,41 -1,15 27,16 32,71 -5,56 
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450 M101 UBC 24,99 23,06 1,93 22,91 21,41 1,50 - 32,71 - 
451 M102 AREG 28,52 22,75 5,77 24,50 20,29 4,21 32,31 28,39 3,93 
452 M102 EREG 32,36 22,75 9,61 28,96 20,29 8,67 36,50 28,39 8,11 
453 M102 DUSP6 - - - 30,92 20,29 10,63 - - - 
454 M102 SLC26A3 - - - 27,57 20,29 7,28 - - - 
455 M102 PTPRF - - - 26,21 20,29 5,92 - - - 
456 M102 LOC158960 - - - 32,58 20,29 12,30 - - - 
457 M102 PTEN 34,53 22,75 11,78 - - - - - - 
458 M102 GAPDH 22,25 22,75 -0,50 19,57 20,29 -0,72 28,00 28,39 -0,39 
459 M102 RPLP0 21,20 22,75 -1,54 18,47 20,29 -1,82 27,11 28,39 -1,27 
460 M102 UBC 24,79 22,75 2,04 22,83 20,29 2,54 30,05 28,39 1,66 
461 M104 AREG 27,13 22,77 4,36 26,50 21,33 5,17 32,22 27,99 4,23 
462 M104 EREG 31,08 22,77 8,31 28,97 21,33 7,65 34,89 27,99 6,90 
463 M104 DUSP6 - - - 32,21 21,33 10,89 - - - 
464 M104 SLC26A3 - - - 29,08 21,33 7,76 - - - 
465 M104 PTPRF - - - 25,13 21,33 3,80 - - - 
466 M104 LOC158960 - - - 33,58 21,33 12,25 - - - 
467 M104 PTEN 33,99 22,77 11,22 - - - - - - 
468 M104 GAPDH 21,74 22,77 -1,04 20,52 21,33 -0,81 27,73 27,99 -0,25 
469 M104 RPLP0 21,23 22,77 -1,54 20,23 21,33 -1,10 26,63 27,99 -1,35 
470 M104 UBC 25,35 22,77 2,58 23,23 21,33 1,91 29,60 27,99 1,61 
471 M105 AREG 33,66 22,81 10,86 27,70 22,64 5,06 33,17 28,33 4,84 
472 M105 EREG 39,02 22,81 16,22 33,28 22,64 10,64 39,22 28,33 10,89 
473 M105 DUSP6 - - - 33,94 22,64 11,30 - - - 
474 M105 SLC26A3 - - - 30,07 22,64 7,43 - - - 
475 M105 PTPRF - - - 28,18 22,64 5,55 - - - 
476 M105 LOC158960 - - - 35,00 22,64 12,36 - - - 
477 M105 PTEN 34,00 22,81 11,20 - - - - - - 
478 M105 GAPDH 21,94 22,81 -0,87 21,70 22,64 -0,93 28,20 28,33 -0,13 
479 M105 RPLP0 20,67 22,81 -2,14 21,29 22,64 -1,35 26,82 28,33 -1,51 
480 M105 UBC 25,81 22,81 3,00 24,92 22,64 2,28 29,97 28,33 1,64 
481 M107 AREG 28,64 24,16 4,49 21,86 19,37 2,48 31,16 28,87 2,29 
482 M107 EREG 32,51 24,16 8,36 24,06 19,37 4,68 35,19 28,87 6,33 
483 M107 DUSP6 - - - 28,42 19,37 9,05 - - - 
484 M107 SLC26A3 - - - 26,87 19,37 7,50 - - - 
485 M107 PTPRF - - - 23,29 19,37 3,92 - - - 
486 M107 LOC158960 - - - 30,23 19,37 10,85 - - - 
487 M107 PTEN 36,17 24,16 12,01 - - - - - - 
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488 M107 GAPDH 24,16 24,16 0,00 18,49 19,37 -0,88 29,42 28,87 0,56 
489 M107 RPLP0 23,06 24,16 -1,09 19,98 19,37 0,60 27,05 28,87 -1,81 
490 M107 UBC 25,25 24,16 1,09 19,65 19,37 0,28 30,12 28,87 1,26 
491 M106 AREG 25,81 22,74 3,07 22,11 19,16 2,95 28,71 27,17 1,54 
492 M106 EREG 30,29 22,74 7,55 26,20 19,16 7,04 34,11 27,17 6,94 
493 M106 DUSP6 - - - 30,93 19,16 11,77 - - - 
494 M106 SLC26A3 - - - 27,33 19,16 8,17 - - - 
495 M106 PTPRF - - - 24,29 19,16 5,13 - - - 
496 M106 LOC158960 - - - 31,14 19,16 11,98 - - - 
497 M106 PTEN 33,21 22,74 10,47 - - - - - - 
498 M106 GAPDH 21,40 22,74 -1,34 17,96 19,16 -1,20 26,60 27,17 -0,57 
499 M106 RPLP0 22,44 22,74 -0,30 18,46 19,16 -0,70 25,85 27,17 -1,32 
500 M106 UBC 24,38 22,74 1,64 21,06 19,16 1,90 29,07 27,17 1,89 
501 M110 AREG 29,90 23,20 6,70 27,19 20,75 6,44 36,34 30,04 6,30 
502 M110 EREG 32,62 23,20 9,42 32,29 20,75 11,54 40,00 30,04 9,96 
503 M110 DUSP6 - - - 31,60 20,75 10,85 - - - 
504 M110 SLC26A3 - - - 28,74 20,75 7,99 - - - 
505 M110 PTPRF - - - 24,00 20,75 3,26 - - - 
506 M110 LOC158960 - - - 32,78 20,75 12,03 - - - 
507 M110 PTEN 33,74 23,20 10,54 - - - - - - 
508 M110 GAPDH 22,31 23,20 -0,89 19,86 20,75 -0,89 30,25 30,04 0,21 
509 M110 RPLP0 21,11 23,20 -2,09 19,25 20,75 -1,50 26,57 30,04 -3,47 
510 M110 UBC 26,18 23,20 2,98 23,13 20,75 2,38 33,30 30,04 3,26 
511 M112 AREG 27,45 23,59 3,86 27,34 24,22 3,12 29,69 27,86 1,83 
512 M112 EREG 31,76 23,59 8,17 32,73 24,22 8,51 34,28 27,86 6,42 
513 M112 DUSP6 - - - 35,44 24,22 11,23 - - - 
514 M112 SLC26A3 - - - 29,26 24,22 5,04 - - - 
515 M112 PTPRF - - - 27,16 24,22 2,95 - - - 
516 M112 LOC158960 - - - 37,41 24,22 13,19 - - - 
517 M112 PTEN 35,28 23,59 11,69 - - - - - - 
518 M112 GAPDH 23,34 23,59 -0,25 24,01 24,22 -0,21 27,71 27,86 -0,15 
519 M112 RPLP0 21,59 23,59 -2,01 23,15 24,22 -1,06 26,76 27,86 -1,10 
520 M112 UBC 25,86 23,59 2,26 25,49 24,22 1,27 29,12 27,86 1,26 
521 M115 AREG 30,75 24,25 6,50 25,75 20,38 5,36 31,23 27,85 3,38 
522 M115 EREG 33,24 24,25 9,00 27,64 20,38 7,26 35,30 27,85 7,44 
523 M115 DUSP6 - - - 32,38 20,38 11,99 - - - 
524 M115 SLC26A3 - - - 31,93 20,38 11,55 - - - 
525 M115 PTPRF - - - 24,93 20,38 4,54 - - - 
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526 M115 LOC158960 - - - 32,34 20,38 11,95 - - - 
527 M115 PTEN 34,04 24,25 9,79 - - - - - - 
528 M115 GAPDH 23,49 24,25 -0,76 19,53 20,38 -0,86 27,89 27,85 0,04 
529 M115 RPLP0 22,74 24,25 -1,51 19,22 20,38 -1,16 26,75 27,85 -1,11 
530 M115 UBC 26,51 24,25 2,27 22,40 20,38 2,02 28,92 27,85 1,07 
531 M117 AREG 30,13 23,66 6,47 28,36 21,70 6,66 30,66 25,64 5,03 
532 M117 EREG 32,61 23,66 8,94 31,69 21,70 9,99 33,47 25,64 7,83 
533 M117 DUSP6 - - - 33,08 21,70 11,38 - - - 
534 M117 SLC26A3 - - - 25,27 21,70 3,56 - - - 
535 M117 PTPRF - - - 25,61 21,70 3,91 - - - 
536 M117 LOC158960 - - - 32,79 21,70 11,08 - - - 
537 M117 PTEN 32,53 23,66 8,86 - - - - - - 
538 M117 GAPDH 23,50 23,66 -0,16 21,40 21,70 -0,31 25,81 25,64 0,17 
539 M117 RPLP0 22,29 23,66 -1,37 21,02 21,70 -0,68 25,01 25,64 -0,63 
540 M117 UBC 25,20 23,66 1,53 22,69 21,70 0,99 26,09 25,64 0,45 
541 M118 AREG 29,82 24,70 5,12 24,31 20,42 3,90 31,32 28,51 2,81 
542 M118 EREG 33,03 24,70 8,33 27,30 20,42 6,88 35,63 28,51 7,12 
543 M118 DUSP6 - - - 31,18 20,42 10,76 - - - 
544 M118 SLC26A3 - - - 27,35 20,42 6,93 - - - 
545 M118 PTPRF - - - 25,28 20,42 4,86 - - - 
546 M118 LOC158960 - - - 33,13 20,42 12,71 - - - 
547 M118 PTEN 33,96 24,70 9,26 - - - - - - 
548 M118 GAPDH 24,42 24,70 -0,28 19,21 20,42 -1,21 28,67 28,51 0,16 
549 M118 RPLP0 23,92 24,70 -0,78 19,81 20,42 -0,61 27,26 28,51 -1,25 
550 M118 UBC 25,76 24,70 1,06 22,23 20,42 1,82 29,59 28,51 1,08 
551 M114 AREG 28,79 24,41 4,38 22,42 20,81 1,60 30,13 27,77 2,36 
552 M114 EREG 32,56 24,41 8,15 26,32 20,81 5,51 34,51 27,77 6,74 
553 M114 DUSP6 - - - 30,77 20,81 9,95 - - - 
554 M114 SLC26A3 - - - 23,29 20,81 2,47 - - - 
555 M114 PTPRF - - - 24,84 20,81 4,02 - - - 
556 M114 LOC158960 - - - 33,68 20,81 12,86 - - - 
557 M114 PTEN 34,30 24,41 9,89 - - - - - - 
558 M114 GAPDH 24,03 24,41 -0,37 19,86 20,81 -0,95 27,81 27,77 0,04 
559 M114 RPLP0 23,69 24,41 -0,72 20,34 20,81 -0,47 27,10 27,77 -0,67 
560 M114 UBC 25,50 24,41 1,09 22,24 20,81 1,43 28,41 27,77 0,64 
561 M122 AREG 26,09 23,90 2,19 20,57 18,44 2,13 29,96 28,92 1,04 
562 M122 EREG 29,87 23,90 5,98 25,07 18,44 6,63 35,96 28,92 7,04 
563 M122 DUSP6 - - - 30,32 18,44 11,88 - - - 
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564 M122 SLC26A3 - - - 23,25 18,44 4,81 - - - 
565 M122 PTPRF - - - 30,47 18,44 12,03 - - - 
566 M122 LOC158960 - - - 31,75 18,44 13,31 - - - 
567 M122 PTEN 33,48 23,90 9,59 - - - - - - 
568 M122 GAPDH 23,84 23,90 -0,06 17,60 18,44 -0,84 28,45 28,92 -0,47 
569 M122 RPLP0 22,02 23,90 -1,87 17,66 18,44 -0,78 27,42 28,92 -1,50 
570 M122 UBC 25,83 23,90 1,93 20,06 18,44 1,62 30,89 28,92 1,97 
571 M123 AREG 28,25 22,63 5,63 25,45 20,66 4,79 33,15 26,87 6,28 
572 M123 EREG 30,23 22,63 7,61 26,48 20,66 5,81 35,33 26,87 8,46 
573 M123 DUSP6 - - - 29,85 20,66 9,19 - - - 
574 M123 SLC26A3 - - - 38,41 20,66 17,75 - - - 
575 M123 PTPRF - - - 25,16 20,66 4,50 - - - 
576 M123 LOC158960 - - - 32,22 20,66 11,55 - - - 
577 M123 PTEN 32,51 22,63 9,88 - - - - - - 
578 M123 GAPDH 21,89 22,63 -0,73 19,16 20,66 -1,51 26,50 26,87 -0,38 
579 M123 RPLP0 20,94 22,63 -1,69 20,00 20,66 -0,67 25,17 26,87 -1,71 
580 M123 UBC 25,05 22,63 2,42 22,84 20,66 2,17 28,96 26,87 2,09 
581 M124 AREG 29,96 24,70 5,25 23,66 20,71 2,95 31,79 29,14 2,65 
582 M124 EREG 30,92 24,70 6,21 26,54 20,71 5,83 36,95 29,14 7,81 
583 M124 DUSP6 - - - 32,29 20,71 11,58 - - - 
584 M124 SLC26A3 - - - 23,86 20,71 3,15 - - - 
585 M124 PTPRF - - - 25,08 20,71 4,37 - - - 
586 M124 LOC158960 - - - 32,11 20,71 11,40 - - - 
587 M124 PTEN 33,63 24,70 8,93 - - - - - - 
588 M124 GAPDH 24,66 24,70 -0,04 20,24 20,71 -0,47 29,77 29,14 0,63 
589 M124 RPLP0 23,58 24,70 -1,12 19,75 20,71 -0,96 27,13 29,14 -2,01 
590 M124 UBC 25,86 24,70 1,16 22,13 20,71 1,43 30,51 29,14 1,37 
591 M120 AREG 28,41 22,93 5,48 27,30 21,31 5,99 31,57 26,40 5,17 
592 M120 EREG 39,04 22,93 16,12 33,95 21,31 12,64 36,06 26,40 9,67 
593 M120 DUSP6 - - - 32,68 21,31 11,37 - - - 
594 M120 SLC26A3 - - - 37,43 21,31 16,12 - - - 
595 M120 PTPRF - - - 25,74 21,31 4,44 - - - 
596 M120 LOC158960 - - - 34,28 21,31 12,98 - - - 
597 M120 PTEN 32,52 22,93 9,60 - - - - - - 
598 M120 GAPDH 22,13 22,93 -0,79 20,76 21,31 -0,55 25,83 26,40 -0,56 
599 M120 RPLP0 21,77 22,93 -1,16 20,02 21,31 -1,29 26,28 26,40 -0,12 
600 M120 UBC 24,88 22,93 1,95 23,15 21,31 1,84 27,08 26,40 0,68 
601 M125 AREG 30,22 22,52 7,70 23,61 21,17 2,43 29,00 27,40 1,60 
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602 M125 EREG 37,85 22,52 15,32 28,44 21,17 7,27 34,32 27,40 6,92 
603 M125 DUSP6 - - - 33,15 21,17 11,98 - - - 
604 M125 SLC26A3 - - - 23,71 21,17 2,54 - - - 
605 M125 PTPRF - - - 26,38 21,17 5,21 - - - 
606 M125 LOC158960 - - - 32,86 21,17 11,69 - - - 
607 M125 PTEN 32,83 22,52 10,31 - - - - - - 
608 M125 GAPDH 22,52 22,52 0,00 20,56 21,17 -0,62 27,10 27,40 -0,30 
609 M125 RPLP0 20,48 22,52 -2,05 19,51 21,17 -1,66 26,10 27,40 -1,31 
610 M125 UBC 24,58 22,52 2,05 23,45 21,17 2,28 29,01 27,40 1,61 
611 M128 AREG 26,16 23,49 2,67 24,96 20,38 4,58 35,10 32,86 2,24 
612 M128 EREG 32,02 23,49 8,53 28,83 20,38 8,45 40,00 32,86 7,14 
613 M128 DUSP6 - - - 30,43 20,38 10,05 - - - 
614 M128 SLC26A3 - - - 25,44 20,38 5,06 - - - 
615 M128 PTPRF - - - 24,22 20,38 3,84 - - - 
616 M128 LOC158960 - - - 33,21 20,38 12,83 - - - 
617 M128 PTEN 36,23 23,49 12,74 - - - - - - 
618 M128 GAPDH 23,04 23,49 -0,45 19,37 20,38 -1,01 32,63 32,86 -0,23 
619 M128 RPLP0 21,26 23,49 -2,23 19,65 20,38 -0,72 30,85 32,86 -2,01 
620 M128 UBC 26,17 23,49 2,68 22,11 20,38 1,73 35,09 32,86 2,24 
621 M129 AREG 27,79 24,21 3,58 24,94 20,89 4,05 30,85 26,82 4,03 
622 M129 EREG 32,40 24,21 8,18 28,20 20,89 7,31 34,36 26,82 7,54 
623 M129 DUSP6 - - - 29,50 20,89 8,61 - - - 
624 M129 SLC26A3 - - - 31,48 20,89 10,58 - - - 
625 M129 PTPRF - - - 24,94 20,89 4,04 - - - 
626 M129 LOC158960 - - - 31,43 20,89 10,54 - - - 
627 M129 PTEN 34,58 24,21 10,37 - - - - - - 
628 M129 GAPDH 24,48 24,21 0,27 20,54 20,89 -0,35 26,79 26,82 -0,03 
629 M129 RPLP0 22,70 24,21 -1,51 20,00 20,89 -0,89 25,58 26,82 -1,25 
630 M129 UBC 25,46 24,21 1,24 22,14 20,89 1,24 28,10 26,82 1,28 
631 M132 AREG 31,39 23,72 7,67 27,31 20,80 6,51 33,30 29,25 4,05 
632 M132 EREG 35,06 23,72 11,34 30,88 20,80 10,09 37,85 29,25 8,61 
633 M132 DUSP6 - - - 31,41 20,80 10,61 - - - 
634 M132 SLC26A3 - - - 30,91 20,80 10,11 - - - 
635 M132 PTPRF - - - 25,31 20,80 4,51 - - - 
636 M132 LOC158960 - - - 33,40 20,80 12,60 - - - 
637 M132 PTEN 33,70 23,72 9,98 - - - - - - 
638 M132 GAPDH 23,07 23,72 -0,65 19,87 20,80 -0,93 28,56 29,25 -0,69 
639 M132 RPLP0 21,91 23,72 -1,81 19,78 20,80 -1,02 27,45 29,25 -1,80 
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640 M132 UBC 26,18 23,72 2,46 22,75 20,80 1,95 31,74 29,25 2,49 
641 M121 AREG 29,35 23,37 5,98 28,21 20,43 7,78 36,50 30,30 6,20 
642 M121 EREG 40,00 23,37 16,63 37,40 20,43 16,97 40,00 30,30 9,70 
643 M121 DUSP6 - - - 30,98 20,43 10,55 - - - 
644 M121 SLC26A3 - - - 36,66 20,43 16,23 - - - 
645 M121 PTPRF - - - 26,44 20,43 6,01 - - - 
646 M121 LOC158960 - - - 32,88 20,43 12,45 - - - 
647 M121 PTEN 34,15 23,37 10,78 - - - - - - 
648 M121 GAPDH 22,51 23,37 -0,86 19,83 20,43 -0,60 30,22 30,30 -0,09 
649 M121 RPLP0 21,84 23,37 -1,53 19,66 20,43 -0,77 29,13 30,30 -1,17 
650 M121 UBC 25,76 23,37 2,39 21,80 20,43 1,37 31,56 30,30 1,26 
651 M33 AREG 30,7 22,65 8,01 28,22 22,6 5,6 - - - 
652 M33 EREG 36,2 22,65 13,51 33,86 22,6 11,3 - - - 
653 M33 DUSP6 - - - 32,856 22,6 10,3 - - - 
654 M33 SLC26A3 - - - 35,523 22,6 12,9 - - - 
655 M33 PTPRF - - - 26,778 22,6 4,2 - - - 
656 M33 LOC158960 - - - 34,299 22,6 11,7 - - - 
657 M33 PTEN 33,8 22,65 11,17 - - - - - - 
658 M33 GAPDH 21,8 22,65 -0,89 22,135 22,6 -0,4 - - - 
659 M33 RPLP0 21,5 22,65 -1,13 21,036 22,6 -1,5 - - - 
660 M33 UBC 24,7 22,65 2,02 24,571 22,6 2,0 - - - 
661 M47 AREG 28,3 22,78 5,56 29,241 24,3 4,9 - - - 
662 M47 EREG 31,6 22,78 8,82 33,138 24,3 8,8 - - - 
663 M47 DUSP6 - - - 34,099 24,3 9,8 - - - 
664 M47 SLC26A3 - - - 28,36 24,3 4,0 - - - 
665 M47 PTPRF - - - 29,229 24,3 4,9 - - - 
666 M47 LOC158960 - - - 36,258 24,3 11,9 - - - 
667 M47 PTEN 32,9 22,78 10,09 - - - - - - 
668 M47 GAPDH 21,9 22,78 -0,92 23,75 24,3 -0,6 - - - 
669 M47 RPLP0 21,7 22,78 -1,03 24,007 24,3 -0,3 - - - 
670 M47 UBC 24,7 22,78 1,95 25,255 24,3 0,9 - - - 
671 M85 AREG 31,3 25,50 5,81 27,619 20,3 7,4 - - - 
672 M85 EREG 39,2 25,50 13,70 33,722 20,3 13,5 - - - 
673 M85 DUSP6 - - - 30,819 20,3 10,6 - - - 
674 M85 SLC26A3 - - - 34,428 20,3 14,2 - - - 
675 M85 PTPRF - - - 24,343 20,3 4,1 - - - 
676 M85 LOC158960 - - - 32,3 20,3 12,0 - - - 
677 M85 PTEN 34,1 25,50 8,59 - - - - - - 
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678 M85 GAPDH 24,7 25,50 -0,79 18,935 20,3 -1,3 - - - 
679 M85 RPLP0 24,5 25,50 -0,99 19,546 20,3 -0,7 - - - 
680 M85 UBC 27,3 25,50 1,77 22,284 20,3 2,0 - - - 
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Tab.S9. Cetuximab responders (R) and non-responders (NR) sorted according to the normalized mean of the Ct expression values of the AREG and EREG 
(Cut-off Value was set at 6); The responders are characterized with lower Ct mean of AREG and EREG (higher expression of the two genes), while non-
responders have higher CT mean of AREG and EREG (lower expression levels); AREG and EREG were measured directly in the xenografts that served as 
controls in the treatment experiment, green - NR, incorrectly classified ba AREG/EREG, but mutated in one of the 3 genes: KRAS; BRAF; PIK3CA; blue - 
NR, correctly classified ba AREG/EREG, and WT in all of the 3 genes: KRAS; BRAF; PIK3CA; orange - R, incorrectly classified by AREG/EREG and WT 
all of the 3 genes: KRAS; BRAF; PIK3CA 
No model-ID AREG Norm EREG  Norm 
AREG + EREG  
Norm 
CE Resp. T/C KRAS BRAF PIK3CA Mut No 
1 M76 2,1 5,3 3,7 R 1,73 ++++ WT WT WT 0 
2 M82 1,8 5,6 3,7 R 3,64 ++++ WT WT WT 0 
3 M84 2,5 5,6 4,1 R 17,24 +++ WT WT WT 0 
4 M122 2,2 6,0 4,1 R 3,19 ++++ WT WT WT 0 
5 M99 2,4 6,2 4,3 R 13,12 +++ WT WT WT 0 
6 M93 2,5 6,4 4,5 R 7 +++ WT WT WT 0 
7 M98 2,9 6,5 4,7 R 8,56 +++ WT WT WT 0 
8 M72 2,7 7,0 4,9 NR 38,1 + WT WT WT 0 
9 M29 2,7 7,5 5,1 R 8,9 +++ WT WT WT 0 
10 M92 3,7 6,6 5,1 NR 74,65 - 35 G>T WT WT 1 
11 M88 3,5 6,9 5,2 R 2,7 ++++ WT WT WT 0 
12 M57 3,2 7,2 5,2 R 19,6 +++ 38 G>A WT WT 1 
13 M106 3,1 7,5 5,3 NR 53,15 - 35 G>T WT WT 1 
14 M55 3,9 6,8 5,4 NR 58,3 - WT WT WT 0 
15 M61 3,6 7,5 5,5 NR 61 - 35 G>T WT WT 1 
16 M128 2,7 8,5 5,6 R 1,19 ++++ 34 G>A WT WT 1 
17 M83 3,4 7,8 5,6 NR 32 ++ 35 G>C WT WT 1 
18 M13 3,7 7,6 5,7 R 7,6 +++ WT WT WT 0 
19 M124 5,3 6,2 5,7 R 17,54 +++ WT WT WT 0 
20 M129 3,6 8,2 5,9 NR 47,71 + 35 G>T WT WT 1 
21 M79 3,9 7,9 5,9 R 12 +++ WT WT WT 0 
22 M66 4,2 7,6 5,9 NR 48,6 + 183 A>T WT WT 1 
23 M95 3,6 8,3 6,0 R 17,31 +++ 38 G>A WT WT 1 
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24 M112 3,9 8,2 6,0 R 5,26 +++ WT WT WT 0 
25 M68 4,7 7,4 6,1 NR 55,2 - 35 G>T WT WT 1 
26 M101 4,6 7,7 6,2 NR 65,71 - 34 G>A, T WT WT 1 
27 M91 4,8 7,7 6,2 NR 35,3 ++ WT WT WT 0 
28 M114 4,4 8,1 6,3 NR 27,08 ++ 35 G>C WT WT 1 
29 M104 4,4 8,3 6,3 NR 51,61 - 38 G>A WT WT 1 
30 M107 4,5 8,4 6,4 NR 42,86 + 38 G>A WT WT 1 
31 M56 4,4 8,4 6,4 NR 88 - 35 G>T WT WT 1 
32 M94 4,4 8,6 6,5 NR 46,67 + WT WT WT 0 
33 M52 4,4 8,9 6,6 NR 24,8 ++ 35 G>C WT WT 1 
34 M123 5,6 7,6 6,6 NR 63,4 - WT 1799 T>A WT 1 
35 M1 4,2 9,2 6,7 R 4,5 ++++ WT WT WT 0 
36 M118 5,1 8,3 6,7 NR 51,16 - 35 G>T WT 3140 A>G 2 
37 M89 5,2 8,3 6,7 NR 62,5 - WT WT WT 0 
38 M60 6,1 7,4 6,8 R 5,26 +++ WT WT WT 0 
39 M27 4,0 9,6 6,8 NR 36,9 + 35 G>A WT WT 1 
40 M47 5,6 8,8 7,2 NR 22 ++ 35 G>C WT WT 1 
41 M90 6,0 8,6 7,3 NR 79,3 - 35 G>T WT 1633 G>A 2 
42 M77 5,4 9,9 7,7 NR 64,41 - WT WT WT 0 
43 M102 5,8 9,6 7,7 NR 27,97 ++ 35 G>T WT WT 1 
44 M117 6,5 8,9 7,7 NR 33,78 ++ WT WT 1633 G>A 1 
45 M115 6,5 9,0 7,7 NR 82,14 - 38 G>A WT WT 1 
46 M23 5,0 10,7 7,9 NR 43,7 + WT WT WT 0 
47 M110 6,7 9,4 8,1 NR 79,17 - 182 A>T WT 1624 G>A 2 
48 M75 6,2 11,1 8,7 NR 39,6 + 35 G>C WT WT 1 
49 M65 6,5 11,0 8,7 NR 81,4 - 436 G>A WT 1633 G>A 2 
50 M53 7,6 9,9 8,7 NR 40,8 + 35 G>A WT WT 1 
51 M86 6,3 11,3 8,8 NR 62,5 - 35 G>A WT WT 1 
52 M87 6,9 10,8 8,8 NR 45,6 + WT WT WT 0 
53 M81 7,3 10,5 8,9 NR 60,87 - WT 1799 T>A WT 1 
54 M18 7,0 11,0 9,0 NR 67,8 - 35 G>A WT WT 1 
55 M43 5,6 13,1 9,4 NR 72,7 - WT 1799 T>A WT 1 
56 M97 5,4 13,3 9,4 NR 89,69 - WT WT WT 0 
57 M132 7,7 11,3 9,5 NR 49,23 + 436 G>A WT 3140 A>G 2 
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58 M85 5,8 13,7 9,8 NR 27 ++ 35 G>A WT WT 1 
59 M59 7,3 13,1 10,2 NR 81 - WT 1799 T>A WT 1 
60 M63 8,3 12,5 10,4 NR 79,2 - 38 G>A WT WT 1 
61 M33 8,0 13,5 10,8 NR 94,7 - WT 1799 T>A WT 1 
62 M120 5,5 16,1 10,8 NR 69,7 - WT 1799 T>A WT 1 
63 M80 6,6 15,3 11,0 NR 42,4 + WT WT WT 0 
64 M96 6,6 15,8 11,2 NR 120 - 35 G>T WT 1633 G>A 2 
65 M121 6,0 16,6 11,3 NR 69,32 - WT 1799 T>A WT 1 
66 M125 7,7 15,3 11,5 NR 93 - 35 G>T WT WT 1 
67 M105 10,9 16,2 13,5 NR 73,1 - WT WT WT 0 
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Tab.S10. A) Performance of the mRNA signature in terms of sensitivity and specificity 
during discovery on the xenografts used in the treatment experiment, sorted according to 
the number of probesets included in the signature; ; mRNA expression analysis 
performed on the Affymetrix U133 Plus 2.0 GeneChip 
Genes No included in the signature Sensitivity Specificity 
genes.1.to.3 76,56% 74,89% 
genes.1.to.4 76,78% 76,24% 
genes.1.to.5 77,33% 77,30% 
genes.1.to.6 77,44% 77,95% 
genes.1.to.7 78,78% 78,90% 
genes.1.to.10 80,56% 80,25% 
genes.1.to.11 80,67% 80,38% 
genes.1.to.12 80,33% 80,74% 
genes.1.to.13 80,44% 80,99% 
genes.1.to.14 81,22% 81,16% 
genes.1.to.20 82,44% 81,28% 
genes.1.to.21 83,44% 81,11% 
genes.1.to.22 83,44% 81,02% 
genes.1.to.23 83,22% 81,36% 
genes.1.to.24 84,22% 81,06% 
genes.1.to.30 83,44% 81,44% 
genes.1.to.31 83,11% 81,35% 
genes.1.to.32 83,67% 81,52% 
genes.1.to.33 84,33% 81,47% 
genes.1.to.34 84,00% 81,57% 
genes.1.to.40 84,00% 81,43% 
genes.1.to.41 84,11% 81,55% 
genes.1.to.42 84,44% 81,52% 
genes.1.to.43 83,78% 81,37% 
genes.1.to.44 83,44% 81,30% 
genes.1.to.50 84,22% 81,08% 
genes.1.to.51 84,78% 80,96% 
genes.1.to.52 84,78% 80,91% 
genes.1.to.53 84,89% 81,05% 
genes.1.to.54 85,22% 81,08% 
genes.1.to.100 84,56% 80,05% 
genes.1.to.101 84,56% 80,04% 
genes.1.to.102 85,00% 79,97% 
genes.1.to.103 84,89% 79,98% 
genes.1.to.104 84,67% 79,96% 
genes.1.to.150 85,78% 79,13% 
genes.1.to.151 85,67% 79,14% 
genes.1.to.152 85,44% 79,21% 
genes.1.to.153 85,56% 79,14% 
genes.1.to.154 85,56% 79,23% 
genes.1.to.200 85,78% 78,77% 
genes.1.to.201 85,56% 78,77% 
genes.1.to.202 85,78% 78,74% 
genes.1.to.203 85,67% 78,69% 
genes.1.to.204 86,00% 78,76% 
genes.1.to.250 86,11% 78,63% 
genes.1.to.251 86,22% 78,64% 
genes.1.to.252 86,22% 78,64% 
genes.1.to.253 86,00% 78,62% 
genes.1.to.254 86,11% 78,64% 
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genes.1.to.300 86,22% 78,32% 
genes.1.to.301 86,00% 78,31% 
genes.1.to.302 86,33% 78,27% 
genes.1.to.303 86,22% 78,35% 
genes.1.to.304 86,78% 78,30% 
genes.1.to.350 86,33% 78,29% 
genes.1.to.351 86,22% 78,33% 
genes.1.to.352 86,00% 78,32% 
genes.1.to.353 86,00% 78,38% 
genes.1.to.354 85,89% 78,25% 
genes.1.to.400 86,89% 78,01% 
genes.1.to.401 86,89% 77,98% 
genes.1.to.402 86,78% 78,05% 
genes.1.to.403 86,44% 78,00% 
genes.1.to.404 86,33% 77,95% 
genes.1.to.450 87,00% 77,74% 
genes.1.to.451 87,33% 77,76% 
genes.1.to.452 87,33% 77,87% 
genes.1.to.453 87,22% 77,78% 
genes.1.to.454 87,11% 77,79% 
genes.1.to.500 86,67% 77,45% 
genes.1.to.501 86,67% 77,39% 
genes.1.to.502 86,56% 77,38% 
genes.1.to.503 86,56% 77,36% 
genes.1.to.504 86,67% 77,37% 
genes.1.to.600 86,44% 77,42% 
genes.1.to.601 86,56% 77,43% 
genes.1.to.602 86,67% 77,36% 
genes.1.to.603 86,67% 77,38% 
genes.1.to.604 86,33% 77,36% 
genes.1.to.700 86,78% 76,93% 
genes.1.to.701 86,56% 76,93% 
genes.1.to.702 86,67% 76,84% 
genes.1.to.703 86,67% 76,83% 
genes.1.to.704 86,67% 76,84% 
genes.1.to.800 86,22% 76,36% 
genes.1.to.801 86,11% 76,35% 
genes.1.to.802 86,56% 76,35% 
genes.1.to.803 86,56% 76,36% 
genes.1.to.804 86,44% 76,34% 
genes.1.to.900 87,67% 76,19% 
genes.1.to.901 87,78% 76,18% 
genes.1.to.902 87,89% 76,10% 
genes.1.to.903 87,89% 76,09% 
genes.1.to.904 87,78% 76,13% 
genes.1.to.1000 88,00% 75,97% 
genes.1.to.1001 88,00% 75,92% 
genes.1.to.1002 87,89% 75,95% 
genes.1.to.1003 87,89% 75,92% 
genes.1.to.1004 88,00% 75,89% 
genes.1.to.1200 87,89% 75,96% 
genes.1.to.1201 88,00% 75,99% 
genes.1.to.1202 88,00% 76,02% 
genes.1.to.1203 88,00% 76,02% 
genes.1.to.1204 88,00% 76,01% 
genes.1.to.1400 88,78% 77,11% 
genes.1.to.1401 88,78% 77,18% 
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genes.1.to.1402 88,89% 77,15% 
genes.1.to.1403 89,00% 77,17% 
genes.1.to.1404 89,00% 77,18% 
genes.1.to.1600 89,00% 77,89% 
genes.1.to.1601 88,78% 77,93% 
genes.1.to.1602 88,78% 77,88% 
genes.1.to.1603 88,89% 77,85% 
genes.1.to.1604 88,89% 77,92% 
genes.1.to.1800 89,67% 78,14% 
genes.1.to.1801 89,56% 78,13% 
genes.1.to.1802 89,44% 78,13% 
genes.1.to.1803 89,44% 78,16% 
genes.1.to.1804 89,44% 78,15% 
genes.1.to.2000 89,44% 78,17% 
genes.1.to.2001 89,44% 78,17% 
genes.1.to.2002 89,44% 78,14% 
genes.1.to.2003 89,44% 78,10% 
genes.1.to.2004 89,22% 78,15% 
 
B) 100 best performing probesets and genes, which they detect sorted according to the 
importance in the contribution to distinguish cetuximab responders and non-responders 
in the xenografts used in the treatment experiment; mRNA expression analysis performed 
on the U133 Plus 2.0 GeneChip 
No Probeset_Affy
metrix 
Gene 
symbol 
Gene name gene.index frequency 
1 1558685_a_at LOC15896
0 
hypothetical protein BC009467 372 100,00% 
2 1569583_at EREG epiregulin 509 100,00% 
3 200940_s_at RERE arginine-glutamic acid dipeptide 
(RE) repeats 
931 100,00% 
4 1568597_at LOC64676
2 
hypothetical LOC646762 476 100,00% 
5 1553581_s_at SFRS12IP
1 
SFRS12-interacting protein 1; 
family with sequence similarity 
159, member B 
67 100,00% 
6 200636_s_at PTPRF protein tyrosine phosphatase, 
receptor type, F 
656 100,00% 
7 1557285_at AREGB amphiregulin; amphiregulin B 318 100,00% 
8 200920_s_at BTG1 B-cell translocation gene 1, anti-
proliferative 
917 100,00% 
9 200698_at KDELR2 KDEL (Lys-Asp-Glu-Leu) 
endoplasmic reticulum protein 
retention receptor 2 
712 100,00% 
10 1555962_at B3GNT7 UDP-GlcNAc:betaGal beta-1,3-N-
acetylglucosaminyltransferase 7 
258 100,00% 
11 1553015_a_at RECQL4 RecQ protein-like 4 46 100,00% 
12 200976_s_at TAX1BP1 Tax1 (human T-cell leukemia virus 
type I) binding protein 1 
965 100,00% 
13 200921_s_at BTG1 B-cell translocation gene 1, anti-
proliferative 
918 100,00% 
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14 1554608_at TGOLN2 trans-golgi network protein 2 168 100,00% 
15 1560916_a_at LOC10013
3317 
dpy-19-like 1 (C. elegans); similar 
to hCG1645499 
427 100,00% 
16 1552519_at ACVR1C activin A receptor, type IC 27 100,00% 
17 1558412_at LOC11323
0 
hypothetical protein LOC113230 361 100,00% 
18 1559957_a_at LOC64285
2 
hypothetical LOC642852 409 100,00% 
19 200745_s_at GNB1 guanine nucleotide binding protein 
(G protein), beta polypeptide 1 
756 100,00% 
20 200637_s_at PTPRF protein tyrosine phosphatase, 
receptor type, F 
657 100,00% 
21 1552954_at C5ORF17 chromosome 5 open reading frame 
17 
45 100,00% 
22 1552628_a_at HERPUD2 HERPUD family member 2 33 100,00% 
23 1553972_a_at CBS cystathionine-beta-synthase 98 100,00% 
24 200612_s_at AP2B1 adaptor-related protein complex 2, 
beta 1 subunit 
632 100,00% 
25 1555963_x_at B3GNT7 UDP-GlcNAc:betaGal beta-1,3-N-
acetylglucosaminyltransferase 7 
259 100,00% 
26 201032_at BLCAP bladder cancer associated protein 1016 100,00% 
27 1556242_a_at LOC72787
2 
hypothetical protein LOC727872 280 100,00% 
28 200062_s_at RPL30 ribosomal protein L30 577 100,00% 
29 200699_at KDELR2 KDEL (Lys-Asp-Glu-Leu) 
endoplasmic reticulum protein 
retention receptor 2 
713 100,00% 
30 1554679_a_at LAPTM4B lysosomal protein transmembrane 
4 beta 
173 100,00% 
31 200647_x_at EIF3CL eukaryotic translation initiation 
factor 3, subunit C-like 
666 100,00% 
32 200638_s_at YWHAZ tyrosine 3-
monooxygenase/tryptophan 
658 100,00% 
33 201066_at CYC1 cytochrome c-1 1044 100,00% 
34 200989_at HIF1A hypoxia inducible factor 1, alpha 
subunit (basic helix-loop-helix 
transcription factor) 
977 100,00% 
35 1554021_a_at ZNF12 postmeiotic segregation increased 
2-like 3; zinc finger protein 12 
116 100,00% 
36 1553589_a_at PDZK1IP1 PDZK1 interacting protein 1 70 100,00% 
37 1557207_s_at LOC28317
7 
hypothetical protein LOC283177 315 100,00% 
38 200640_at YWHAZ tyrosine 3-
monooxygenase/tryptophan 5-
monooxygenase activation protein, 
zeta polypeptide 
660 100,00% 
39 1554576_a_at ETV4 ets variant 4 163 100,00% 
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40 1556228_a_at VCPIP1 valosin containing protein 
(p97)/p47 complex interacting 
protein 1 
279 100,00% 
41 200931_s_at VCL vinculin 925 100,00% 
42 1569110_x_at LOC72861
3 
programmed cell death 6 
pseudogene 
500 100,00% 
43 200090_at FNTA farnesyltransferase, CAAX box, 
alpha 
604 100,00% 
44 1553960_at SNX21 sorting nexin family member 21 96 100,00% 
45 1553709_a_at PRPF38A PRP38 pre-mRNA processing factor 
38 (yeast) domain containing A 
80 100,00% 
46 1568983_a_at - - 496 100,00% 
47 201058_s_at MYL9 myosin, light chain 9, regulatory 1037 100,00% 
48 1561421_a_at MUC3B mucin 3B, cell surface associated 431 100,00% 
49 1552845_at CLDN15 claudin 15 42 100,00% 
50 200975_at PPT1 palmitoyl-protein thioesterase 1 964 100,00% 
51 200608_s_at RAD21 RAD21 homolog (S. pombe) 628 100,00% 
52 200053_at SPAG7 sperm associated antigen 7 568 100,00% 
53 200073_s_at HNRNPD heterogeneous nuclear 
ribonucleoprotein D (AU-rich 
element RNA binding protein 1, 
37kDa) 
588 100,00% 
54 1568807_a_at NDFIP2 Nedd4 family interacting protein 2 492 100,00% 
55 1555370_a_at CAMTA1 calmodulin binding transcription 
activator 1 
203 100,00% 
56 1554436_a_at REG4 regenerating islet-derived family, 
member 4 
149 100,00% 
57 1552691_at ARL11 ADP-ribosylation factor-like 11 35 100,00% 
58 200977_s_at TAX1BP1 Tax1 (human T-cell leukemia virus 
type I) binding protein 1 
966 100,00% 
59 1556429_a_at WDR67 WD repeat domain 67 285 100,00% 
60 1555765_a_at GNG4 guanine nucleotide binding protein 
(G protein), gamma 4 
220 100,00% 
61 201034_at ADD3 adducin 3 (gamma) 1018 100,00% 
62 1567014_s_at NFE2L2 nuclear factor (erythroid-derived 
2)-like 2 
466 100,00% 
63 200948_at MLF2 myeloid leukemia factor 2 939 100,00% 
64 200639_s_at YWHAZ tyrosine 3-
monooxygenase/tryptophan 5-
monooxygenase activation protein, 
zeta polypeptide 
659 100,00% 
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65 1558540_s_at SLC2A11 solute carrier family 2 (facilitated 
glucose transporter), member 11 
366 100,00% 
66 200661_at CTSA cathepsin A 680 100,00% 
67 1558048_x_at - - 341 100,00% 
68 1559910_at PID1 phosphotyrosine interaction 
domain containing 1 
407 100,00% 
69 200620_at TMEM59 transmembrane protein 59 640 100,00% 
70 200691_s_at HSPA9 heat shock 70kDa protein 9 
(mortalin) 
705 100,00% 
71 200903_s_at AHCY adenosylhomocysteinase 901 100,00% 
72 1555841_at TMEFF1 transmembrane protein with EGF-
like and two follistatin-like 
domains 1 
230 100,00% 
73 1568603_at CADPS Ca++-dependent secretion 
activator 
478 100,00% 
74 1555888_at UBR5 similar to E3 ubiquitin protein 
ligase, HECT domain containing, 1 
245 100,00% 
75 200807_s_at HSPD1P6 heat shock 60kDa protein 1 
(chaperonin) pseudogene 6 
813 100,00% 
76 200675_at CD81 CD81 molecule 691 100,00% 
77 200641_s_at YWHAZ tyrosine 3-
monooxygenase/tryptophan 5-
monooxygenase activation protein, 
zeta polypeptide 
661 100,00% 
78 200837_at BCAP31 B-cell receptor-associated protein 
31 
840 100,00% 
79 1560297_at HM13 histocompatibility (minor) 13 419 100,00% 
80 1554003_at RGNEF Rho-guanine nucleotide exchange 
factor 
112 100,00% 
81 200973_s_at TSPAN3 tetraspanin 3 963 100,00% 
82 1555797_a_at ARPC5 actin related protein 2/3 complex, 
subunit 5, 16kDa 
224 100,00% 
83 200645_at GABARAP GABA(A) receptor-associated 
protein 
665 100,00% 
84 1558154_at LLGL2 lethal giant larvae homolog 2 
(Drosophila) 
348 100,00% 
85 200936_at RPL8P2 ribosomal protein L8 pseudogene 
2 
929 100,00% 
86 1556047_s_at MAGEE1 melanoma antigen family E, 1 268 100,00% 
87 1557521_a_at BLCAP bladder cancer associated protein 328 100,00% 
88 1553743_at FAM119A family with sequence similarity 
119, member A 
82 100,00% 
89 201110_s_at THBS1 thrombospondin 1 1082 100,00% 
90 200039_s_at PSMB2 proteasome (prosome, macropain) 
subunit, beta type, 2 
558 100,00% 
 201 
 
91 1555890_at OR2A20P olfactory receptor, family 2, 
subfamily A, member 9 
pseudogene 
247 100,00% 
92 200063_s_at LOC39980
4 
pseudogene 21; hypothetical 
LOC100131044; similar to 
nucleophosmin 1 
578 100,00% 
93 1557522_x_at BLCAP bladder cancer associated protein 329 100,00% 
94 200702_s_at DDX24 DEAD (Asp-Glu-Ala-Asp) box 
polypeptide 24 
716 100,00% 
95 200635_s_at PTPRF protein tyrosine phosphatase, 
receptor type, F 
655 100,00% 
96 201109_s_at THBS1 thrombospondin 1 1081 100,00% 
97 200926_at RPS23 ribosomal protein S23 922 100,00% 
98 1566557_at FLJ90757 hypothetical LOC440465 461 100,00% 
99 1555427_s_at SYNCRIP synaptotagmin binding, 
cytoplasmic RNA interacting 
protein 
204 100,00% 
100 200821_at LAMP2 lysosomal-associated membrane 
protein 2 
826 100,00% 
Tab.S11. A) Performance of the miRNA signature in terms of  sensitivity and specificity 
during discovery on the xenografts used in the treatment experiment, sorted according to the 
number of probesets included in the signature; miRNA expression analysis performed on the 
Affymetrix GeneChip miRNA 2.0  
Genes No included in the signature Sensitivity Specificity 
genes.1.to.3 50,45% 54,73% 
genes.1.to.4 51,59% 56,18% 
genes.1.to.5 51,82% 57,50% 
genes.1.to.6 52,95% 58,50% 
genes.1.to.7 54,55% 58,36% 
genes.1.to.10 53,86% 61,18% 
genes.1.to.11 54,43% 61,91% 
genes.1.to.12 55,00% 61,27% 
genes.1.to.13 57,61% 60,55% 
genes.1.to.14 56,93% 61,09% 
genes.1.to.20 58,30% 60,55% 
genes.1.to.21 58,98% 61,23% 
genes.1.to.22 60,34% 61,27% 
genes.1.to.23 60,91% 62,68% 
genes.1.to.24 61,14% 63,09% 
genes.1.to.30 61,48% 63,86% 
genes.1.to.31 61,36% 64,36% 
genes.1.to.32 61,14% 64,09% 
genes.1.to.33 60,91% 63,73% 
genes.1.to.34 60,91% 63,86% 
genes.1.to.40 61,02% 63,50% 
genes.1.to.41 61,59% 63,68% 
genes.1.to.42 61,36% 64,05% 
genes.1.to.43 60,57% 63,27% 
genes.1.to.44 60,80% 63,36% 
genes.1.to.50 61,70% 63,41% 
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genes.1.to.51 62,84% 63,68% 
genes.1.to.52 62,84% 63,77% 
genes.1.to.53 62,95% 64,27% 
genes.1.to.54 63,41% 64,36% 
genes.1.to.100 66,70% 66,50% 
genes.1.to.101 66,25% 66,68% 
genes.1.to.102 66,02% 66,45% 
genes.1.to.103 66,02% 66,50% 
genes.1.to.104 66,02% 66,77% 
genes.1.to.150 68,07% 67,91% 
genes.1.to.151 68,07% 67,50% 
genes.1.to.152 67,95% 67,55% 
genes.1.to.153 67,84% 67,68% 
genes.1.to.154 68,41% 67,77% 
genes.1.to.200 71,02% 68,23% 
genes.1.to.201 71,14% 68,32% 
genes.1.to.202 71,48% 68,18% 
genes.1.to.203 70,80% 68,23% 
genes.1.to.204 71,02% 68,23% 
genes.1.to.250 72,95% 67,55% 
genes.1.to.251 72,73% 67,32% 
genes.1.to.252 72,73% 67,36% 
genes.1.to.253 72,73% 67,45% 
genes.1.to.254 72,50% 67,50% 
genes.1.to.300 74,89% 67,05% 
genes.1.to.301 75,57% 67,32% 
genes.1.to.302 75,57% 67,36% 
genes.1.to.303 74,89% 67,45% 
genes.1.to.304 74,66% 67,59% 
genes.1.to.350 75,34% 68,00% 
genes.1.to.351 75,57% 67,95% 
genes.1.to.352 75,68% 68,05% 
genes.1.to.353 75,91% 67,91% 
genes.1.to.354 75,91% 67,95% 
genes.1.to.400 75,91% 67,73% 
genes.1.to.401 75,91% 67,73% 
genes.1.to.402 75,80% 67,82% 
genes.1.to.403 75,57% 67,82% 
genes.1.to.404 75,57% 67,73% 
genes.1.to.450 76,59% 67,68% 
genes.1.to.451 76,48% 67,73% 
genes.1.to.452 76,59% 67,59% 
genes.1.to.453 76,59% 67,55% 
genes.1.to.454 76,59% 67,68% 
genes.1.to.500 77,05% 66,36% 
genes.1.to.501 77,16% 66,23% 
genes.1.to.502 77,05% 66,23% 
genes.1.to.503 77,05% 66,23% 
genes.1.to.504 76,93% 66,36% 
genes.1.to.600 78,75% 65,45% 
genes.1.to.601 78,86% 65,50% 
genes.1.to.602 78,98% 65,41% 
genes.1.to.603 78,86% 65,36% 
genes.1.to.604 78,98% 65,36% 
genes.1.to.700 80,45% 64,45% 
genes.1.to.701 80,45% 64,41% 
genes.1.to.702 80,23% 64,41% 
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genes.1.to.703 80,11% 64,50% 
genes.1.to.704 80,11% 64,41% 
genes.1.to.800 80,34% 63,86% 
genes.1.to.801 80,68% 63,82% 
genes.1.to.802 80,80% 63,68% 
genes.1.to.803 80,91% 63,95% 
genes.1.to.804 80,57% 63,86% 
genes.1.to.900 80,68% 63,59% 
genes.1.to.901 80,57% 63,59% 
genes.1.to.902 80,34% 63,59% 
genes.1.to.903 80,34% 63,73% 
genes.1.to.904 80,57% 63,73% 
genes.1.to.1000 80,68% 63,55% 
genes.1.to.1001 80,68% 63,50% 
genes.1.to.1002 80,68% 63,55% 
genes.1.to.1003 80,68% 63,55% 
genes.1.to.1004 80,68% 63,36% 
genes.1.to.1200 81,14% 63,68% 
genes.1.to.1201 81,25% 63,82% 
genes.1.to.1202 81,25% 63,82% 
genes.1.to.1203 81,36% 63,73% 
genes.1.to.1204 81,48% 63,68% 
genes.1.to.1400 82,27% 63,86% 
genes.1.to.1401 82,27% 63,77% 
genes.1.to.1402 82,16% 63,82% 
genes.1.to.1403 82,16% 63,82% 
genes.1.to.1404 82,27% 63,91% 
B) 100 best performing probesets sorted according to the importance in the contribution to 
distinguish cetuximab responders and non-responders in xenografts used in the treatment 
experiment; miRNA expression analysis performed on the Affymetrix GeneChip miRNA 2.0 
 Probeset_Affymetrix gene.index frequency 
1 rno-miR-125a-5p_st 1136 100% 
2 bta-let-7e_st 61 100% 
3 hsa-miR-224_st 550 100% 
4 xtr-miR-125a_st 1361 100% 
5 rno-miR-146b_st 1147 100% 
6 hsa-miR-125a-5p_st 481 100% 
7 mmu-miR-125a-5p_st 844 100% 
8 rno-let-7e_st 1129 100% 
9 fru-miR-125a_st 321 100% 
10 bta-miR-125a_st 70 100% 
11 dre-miR-125a_st 257 100% 
12 bta-miR-151_st 79 100% 
13 cfa-miR-125a_st 147 100% 
14 mml-miR-125a-5p_st 721 100% 
15 ggo-miR-224_st 434 100% 
16 hsa-miR-99b_st 615 100% 
17 hsa-miR-720_st 602 100% 
18 ssc-miR-99b_st 1274 100% 
19 mmu-miR-720_st 940 100% 
20 ppa-miR-30d_st 1030 100% 
21 tni-miR-10b_st 1281 100% 
22 cfa-let-7e_st 139 100% 
23 ppa-miR-224_st 1020 100% 
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24 bta-miR-151-star_st 80 100% 
25 mml-miR-151-5p_st 735 100% 
26 mne-miR-224_st 974 100% 
27 rno-miR-99b_st 1219 100% 
28 cfa-miR-30a_st 192 100% 
29 ptr-miR-224_st 1108 100% 
30 mne-miR-30d_st 984 100% 
31 hsa-miR-182_st 517 100% 
32 hsa-let-7e_st 465 100% 
33 mml-let-7e_st 709 100% 
34 mml-miR-99b_st 824 100% 
35 ssc-miR-224_st 1268 100% 
36 cfa-miR-224_st 181 100% 
37 hsa-miR-143_st 499 100% 
38 cfa-miR-151_st 157 100% 
39 rno-miR-30d_st 1198 100% 
40 cfa-miR-99b_st 214 100% 
41 U48_st 1330 100% 
42 mmu-miR-151-5p_st 857 100% 
43 hsa-miR-151-3p_st 506 100% 
44 mmu-miR-421_st 921 100% 
45 ggo-miR-195_st 424 100% 
46 fru-miR-16_st 325 100% 
47 tni-miR-125a_st 1282 100% 
48 mml-miR-224_st 774 100% 
49 rno-miR-342-3p_st 1204 100% 
50 dre-miR-30d_st 303 100% 
51 mml-miR-151-3p_st 734 100% 
52 ppy-miR-224_st 1068 100% 
53 hsa-miR-483-5p_st 584 100% 
54 rno-miR-361_st 1206 100% 
55 bta-miR-30d_st 118 100% 
56 ppa-miR-195_st 1011 100% 
57 hsa-miR-151-5p_st 507 100% 
58 mmu-miR-361_st 916 100% 
59 mmu-miR-99b_st 947 100% 
60 ptr-miR-30d_st 1119 100% 
61 mmu-let-7e_st 829 100% 
62 bta-miR-150_st 78 100% 
63 cfa-miR-30d_st 195 100% 
64 mmu-miR-195_st 875 100% 
65 fru-miR-30d_st 352 100% 
66 hsa-miR-339-5p_st 570 100% 
67 dre-miR-27b_st 301 100% 
68 cfa-miR-320_st 197 100% 
69 mml-miR-652_st 811 100% 
70 dre-miR-183_st 273 100% 
71 rno-miR-224_st 1184 100% 
72 bta-miR-99b_st 132 100% 
73 mmu-miR-31_st 910 100% 
74 rno-miR-195_st 1166 100% 
75 AFFX-CreX-5_at 3 100% 
76 mdo-miR-143_st 668 100% 
77 cel-miR-72_st 136 100% 
78 mml-miR-320_st 789 100% 
79 bta-miR-139_st 74 100% 
80 ssc-miR-145_st 1258 100% 
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81 mmu-miR-145_st 853 100% 
82 rno-miR-151_st 1149 100% 
83 gga-miR-10b_st 365 100% 
84 rno-miR-652_st 1213 100% 
85 bta-let-7d_st 60 100% 
86 mmu-miR-143_st 852 100% 
87 mdo-miR-10a_st 664 100% 
88 hsa-miR-886-5p_st 608 100% 
89 hsa-miR-320c_st 568 100% 
90 hsa-miR-423-3p_st 579 100% 
91 hsa-miR-320b_st 567 100% 
92 mml-miR-10a_st 717 100% 
93 hsa-miR-30d_st 564 100% 
94 bta-miR-320_st 121 100% 
95 cfa-miR-361_st 201 100% 
96 mmu-miR-483_st 925 100% 
97 ggo-miR-30d_st 443 100% 
98 hsa-miR-1308_st 492 100% 
99 bta-miR-126_st 72 100% 
100 rno-miR-205_st 1176 100% 
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Tab.S12. The largest randomized clinical trials testing efficacy of anti-EGFR mAb (cetuximab or panitumumab) and their effect on the survival 
of the patients 
Reference 
Treatment 
regimens 
Study 
population 
Number 
of 
patients 
Response Rate Survival benefit Findings 
Cunningham 
et al., 2004 
Cetuximab vs. 
Cetuximab + 
irinotecan 
Irinotecan 
refractory, 
Phase III, mCRC 
329 11% vs. 23% 
Median survival time = 6.9 months 
(monotherapy) vs.8.6 (combination 
therapy) (p=0.48). 
No correlation between the 
expression of EGFR (IHC) and 
response to cetuximab 
Monotherapy 
Giusti et al., 
2007 
Best supportive care 
(BSC) vs. 
Best supportive care 
+ panitumumab 
Chemorefractory, 
mCRC 
463  
 
0% vs. 8% 
Median PFS = 51 (BSC) vs. 56 days 
(panitumumab) 
No difference in OS between the two 
study arms 
Amado et 
al., 2008 
Best supportive care 
vs. 
Best supportive care 
+ panitumumab 
Chemorefractory, 
Phase III, mCRC 
427 
0% vs. 17% 
(KRAS WT) 0%; 
(KRAS mut) 
Median PFS = 12.3 weeks 
(panitumumab) vs. 7.3 weeks (BSC) 
in the WT KRAS group 
WT KRAS - required for 
panitumumab efficacy; KRAS 
mutations found in 43% pts 
Karapetis et 
al., 2008 
Best supportive care 
vs. 
Best supportive care 
+ cetuximab;  
NCIC-017 
Chemorefractory, 
Phase III, mCRC 
394 
0% vs. 
12.8%(KRAS 
WT); 1.2% 
(KRAS mut) 
Median OS= 9.5(cetuximab) vs. 4.8 
months (BSC) (P<0.001); Median 
PFS= 3.7 months vs. 1.9 months 
(P<0.001) in the WT KRAS group 
KRAS mutations found in 42% pts - 
confirmed biomarker of resistance 
Van Cutsem 
Best supportive care 
vs. 
Best supportive care 
+ panitumumab 
Chemorefractory, 
phase III, mCRC 
463 (232 
vs. 231)  
0% vs. 10% 
Median PFS = 8 weeks 
(panitumumab) vs. 7.3 weeks (BSC) 
No difference was observed in OS. 
Panitumumab significantly improved 
PFS with manageable toxicity in 
patients with chemorefractory 
colorectal cancer. 
Jonker 
Best supportive care 
vs. 
Best supportive care 
+ cetuximab 
 
Chemorefractory, 
mCRC, mCRC 
572 (285 
vs. 287) 
0% vs. 8% 
Median OS= 6.1 months (cetuximab) 
vs. 4.6 
months (BSC) 
Cetuximab improves OS and PFS in 
chemorefractory pts. 
 
Chemonaive patients – first-line therapy 
Bokemeyer 
et al., 2009 
FOLFOX4 vs. 
FOLFOX4 + 
cetuximab; 
OPUS 
Chemonaïve, 
first line, Phase 
II, mCRC 
315 (KRAS 
status 
assessed 
in 233) 
36% vs. 46% 
(ORR) 
Lower risk of disease progression 
under cetuximab (P = .0163) 
compared with FOLFOX-4 alone in the 
KRAS WT group 
Increased ORR under cetuximab in 
KRAS WT : 61% v 37%, No PFS 
benefit 
Van Cutsem 
et al., 2009 
FOLFIRI vs. 
FOLFIRI + 
cetuximab; 
CRYSTAL 
Chemonaïve, 
first line, Phase 
III, mCRC 
599 vs. 
599 
(KRAS 
status 
assessed 
39% vs. 47% 
(ORR) 
 
PFS hazard ratio in 0.85 (95% 
confidence interval [CI], 0.72 to 0.99; 
P=0.048) (+cetuximab) No difference 
in OS (P=0.31). 
KRAS mutation correlates with 
response (P=0.03) but not with PFS 
(P=0.07) or OS (P=0.44); 
cetuximab + FOLFIRI reduced the 
risk of progression by 15% as 
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in 540) compared with FOLFIRI alone 
Combination therapies of anti-EGFR and bevacizumab 
Tol et 
al.2009 
CAPOX, 
+bevacizumab vs. 
CAPOX, 
+bevacizumab + 
cetuximab 
Chemonaïve, 
first line, mCRC 
378 vs. 
377 
50% vs. 53% 
(ORR) 
 
Median PFS= 10.7 (CAPOX, 
+bevacizumab) vs. 9.4 months 
(CAPOX, +bevacizumab + cetuximab) 
( P=0.01)  
Median OS= 20.3 months vs.19.4 
 (P = 0.16) 
PFS – decreased, toxicity - increased 
after the addition of cetuximab to 
capecitabine, oxaliplatin, and 
bevacizumab; KRAS mutation status 
- predictor of outcome in the 
cetuximab group 
Hecht, 2009 
FOLFOX/FOLFIRI + 
bevacizumab vs. 
FOLFOX/FOLFIRI + 
bevacizumab + 
panitumumab 
First line, phase 
IIIB, mCRC 
1053 (525 
vs. 528) 
46% vs. 48% 
Median PFS=11.4 (control arm) vs. 
10.0 (+panitumumab) Median OS= 
24.5 (control arm) vs. 19.4 
(+panitumumab) 
PFS – decreased, toxicity - increased 
after the addition of panitumumab 
to bevacizumab and oxaliplatin- or 
irinotecan-based 
Saltz et al.  
Cetuximab + 
bevacizumab vs. 
Cetuximab + 
bevacizumab + 
irinotecan 
Chemonaïve, 
mCRC 
40 vs. 43 20% vs. 37% 
Time to tumour progression (TTP)= 
7.3 months (cetuximab + 
bevacizumab) vs. 4.9 months 
(cetuximab + bevacizumab + 
irinotecan) 
The activity of bevacizumab + 
cetuximab (+/-irinotecan) is 
favorable when compared with 
historical controls of cetuximab or 
cetuximab/irinotecan 
Combined with chemotherapy 
Sobrero et 
al. 2008 
Irinotecan vs. 
Irinotecan + 
cetuximab 
Chemorefractory, 
second line, 
mCRC 
1298 4% vs. 16% 
Median OS = 10.0 months (irinotecan) 
vs. 10.7 months (cetuximab + 
irinotecan)  
Median PFS= 2.6 months vs. 4.0 
months (P <or= .0001) 
Cetuximab and irinotecan improved 
PFS and ORR. OS was similar 
between study groups, 
Peeters et 
al. 2010 
FOLFIRI vs. FOLFIRI 
+ cetuximab 
Chemorefractory, 
mCRC 
1186 
(KRAS 
status 
assessed 
in 1083) 
10% vs. 35% 
Median PFS 5.9 months 
(panitumumab + FOLFIRI ) vs. 3.9 
months (FOLFIRI). A nonsignificant 
trend toward increased OS was 
observed. 
Panitumumab plus FOLFIRI 
significantly improved PFS and is 
well-tolerated as second-line 
treatment in patients with WT KRAS 
mCRC. 
Maughan et 
al. 2011 
Chemotherapy vs. 
chemotherapy + 
cetuximab; 
COIN trial 
Chemonaive, 
mCRC 
1630 (815 
vs. 815) 
(Mutation 
status 
assessed 
in 1316) 
57% vs. 64% 
(ORR)(p=0.049) 
OS- no difference between treatment 
groups in KRAS WT OS= 17.9 months 
(control arm) vs.17.0 months (+ 
cetuximab) (p=0.67). 
Median PFS= 8.6 months (control 
arm) vs. 8.6 months (+ cetuximab) 
(p=0·60). 
Cetuximab increases ORR in KRAS 
WT pts, no PFS or OS benefit 
observed 
OS differs by somatic mutation 
status irrespective of treatment: 
BRAF mutant – 9 months; KRAS 
mutant – 14 months; WT- 20 
months 
Trials in stage III CRC 
Alberts et 
al. 2011 
FOLFOX6 vs. 
FOLFOX6 + 
cetuximab; trial 
N0147 
Chemonaive, 
stage III 
1.760 pts 
of stage III 
CRC wild-
type in 
KRAS 
- 
3-yr DFS favored FOLFOX alone (HR 
1.18, 95% CI 0.92-1.52; p=0.33); 
trial closed  
Addition of cetuximab to FOLFOX6 
was of no benefit in resected KRAS 
wild-type pts of stage III CRC 
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Goldberg et 
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FOLFOX6 vs. 
FOLFOX6 + 
cetuximab; trial 
N0147 
Chemonaive, 
stage III 
658 pts of 
stage III 
CRC 
mutated in 
KRAS 
- 
3-yr DFS favored FOLFOX alone (HR 
1.48, 95% CI 1.08-2.03; p=0.02); OS 
favored FOLFOX alone (HR 1.67, CI 
1.00-2.80; p=0.07) 
Addition of cetuximab to FOLFOX6 
resulted in impaired DFS and a 
trend toward impaired OS in KRAS 
mutated CRC pts of stage III 
 
